17,20-lyase deficiency, isolated, 202110 (3)|CYP17A1, CYP17, P450C17|609300|10q24.32
17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3)|CYP17A1, CYP17, P450C17|609300|10q24.32
17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 (3)|HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.22
2-aminoadipic 2-oxoadipic aciduria, 204750 (3)|DHTKD1, KIAA1630, AMOXAD, CMT2Q|614984|10p14
2-methylbutyrylglycinuria, 610006 (3)|ACADSB, SBCAD|600301|10q26.13
3-M syndrome 1, 273750 (3)|CUL7|609577|6p21.1
3-M syndrome 2, 612921 (3)|OBSL1, KIAA0657, 3M2|610991|2q35
3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3)|MCCC1, MCCA|609010|3q27.1
3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3)|MCCC2, MCCB|609014|5q13.2
3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 (3)|HSD3B2|613890|1p12
3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 (3)|HADHSC, SCHAD, HHF4|601609|4q25
3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3)|HIBCH|610690|2q32.2
3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 (3)|SERAC1, MEGDEL|614725|6q25.3
3-methylglutaconic aciduria, type I, 250950 (3)|AUH|600529|9q22.31
3-methylglutaconic aciduria, type III, 258501 (3)|OPA3, MGA3|606580|19q13.32
3-methylglutaconic aciduria, type V, 610198 (3)|DNAJC19, TIM14|608977|3q26.33
3MC syndrome 1, 257920 (3)|MASP1, CRARF, 3MC1|600521|3q27.3
3MC syndrome 2, 265050 (3)|COLEC11, CLK1, 3MC2|612502|2p25.3
3p- syndrome (4)|DEL3pterp25, C3DELpterp25|613792|3pter-p25
3q21q26 syndrome (1)|MECOM, EVI1|165215|3q26.2
46XX sex reversal 1, 400045 (3)|SRY, TDF, TDY, SRXX1, SRXY1|480000|Yp11.31
46XX sex reversal 2 (4)|SRXX2, DUP17q24.3, DEL17q24.3|278850|17q24.3-q25.1
46XX sex reversal 3 (4)|SRXX3|300833|Xq26.3
46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3)|DHH, SRXY7, GDXYM|605423|12q13.12
46XY sex reversal 1, 400044 (3)|SRY, TDF, TDY, SRXX1, SRXY1|480000|Yp11.31
46XY sex reversal 2, dosage-sensitive, 300018 (3)|DAX1, AHC, AHX, NR0B1, SRXY2|300473|Xp21.2
46XY sex reversal 3, 612965 (3)|NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8|184757|9q33.3
46XY sex reversal 4 (4)|DEL9p24.3, C9DELp24.3, SRXY4|154230|9p24.3
46XY sex reversal 5, 613080 (3)|CBX2, M33, SRXY5|602770|17q25.3
46XY sex reversal 6, 613762 (3)|MAP3K1, MEKK1, MEKK, SRXY6|600982|5q11.2
46XY sex reversal 7, 233420 (3)|DHH, SRXY7, GDXYM|605423|12q13.12
46XY sex reversal 8, 614279 (3)|AKR1C2, DDH2, DD2, HAKRD, SRXY8|600450|10p15.1
5-fluorouracil toxicity, 274270 (3)|DPYD, DPD|612779|1p21.3
5-oxoprolinase deficiency, 260005 (3)|OPLAH, OPLAHD|614243|8q24.3
6-mercaptopurine sensitivity, 610460 (3)|TPMT|187680|6p22.3
?ACAT2 deficiency, 614055 (1)|ACAT2|100678|6q25.3
?Abruzzo-Erickson syndrome, 302905 (3)|TBX22, CPX, ABERS|300307|Xq21.1
?Amelogenesis imperfecta-3, hypoplastic type (2)|AIH3|301201|Xq22-q28
?Anal canal carcinoma (2)|ANC|105580|11q22-qter
?Anemia, hypochromic microcytic, with iron overload 2, 615234 (3)|STEAP3, TSAP6, AHMIO2|609671|2q14.2
?Antiphospholipid syndrome, familial (2)|ATPLS|107320|6p21.3
?Arthrogryposis, mental retardation, and seizures, 615553 (3)|SLC35A3, AMRS|605632|1p21.2
?Breast cancer, type 3 (2)|BRCA3, BRCAX|605365|13q21
?Candidiasis, familial, 8, 615527 (3)|TRAF3IP2, C6orf5, ACT1, CIKS, C6orf4, C6orf6, PSORS13, CANDF8|607043|6q21
?Cardiomyopathy, dilated, 1AA, 612158 (3)|ACTN2, CMD1AA|102573|1q43
?Carnitine acetyltransferase deficiency (1)|CRAT, CAT1|600184|9q34.11
?Cataract 41, 116400 (3)|WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41|606201|4p16.1
?Cataract, congenital (2)|SORD, SORD1|182500|15q21.1
?Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4, 615268 (3)|ATP8A2, ATPIB, CAMRQ4|605870|13q12.13
?Ceroid lipofuscinosis, neuronal, 12, 606693 (3)|ATP13A2, PARK9, KRPPD, CLN12|610513|1p36.13
?Charcot-Marie-Tooth disease, X-linked dominant, 6, 300905 (3)|PDK3, CMTX6|300906|Xp22.11
?Charcot-Marie-Tooth disease, type 2R, 615490 (3)|TRIM2, KIAA0517, CMT2R|614141|4q31.3
?Charcot-Marie-Tooth disease, type 4B3, 615284 (3)|SBF1, MTMR5, CMT4B3|603560|22q13.33
?Coffin-Siris syndrome (2)|CSS|135900|7q32-q34
?Colon cancer (1)|SLC26A3, DRA, CLD|126650|7q31.1
?Combined oxidative phosphorylation deficiency 16, 615395 (3)|MRPL44, COXPD16|611849|2q36.1
?Combined oxidative phosphorylation deficiency 19, 615595 (3)|LYRM4, ISD11, C6orf149, COXPD19|613311|6p25.1
?Complement factor B deficiency, 615561 (3)|CFB, BF, GBG, AHUS4, ARMD14, CFBD|138470|6p21.33
?Cone-rod dystrophy (3)|UNC119, HRG4, IMD13|604011|17q11.2
?Congenital disorder of glycosylation, type Iv, 615273 (3)|NGLY1, PNG1, CDG1V|610661|3p24.2
?Congenital disorder of glycosylation, type Iw, 615596 (3)|STT3A, ITM1, TMC|601134|11q24.2
?Congenital disorder of glycosylation, type Ix, 615597 (3)|STT3B, SIMP, CDG1X|608605|3p23
?Corneal intraepithelial dyskeratosis and ectodermal dysplasia, 615225 (3)|NLRP1, NALP1, KIAA0926, DEFCAP, CARD7, SLEV1, VAMAS1, CIDED|606636|17p13.2
?Cortical dysplasia, complex, with other brain malformations 2, 615282 (3)|KIF5C, NKHC2, CDCBM2|604593|2q23.1
?Craniofacioskeletal syndrome (2)|CFSS|300712|Xq26-q27
?Cytochrome c oxidase deficiency, 220110 (3)|COX6B1|124089|19q13.12
?DECR deficiency (2)|DECR1|222745|8q21.3
?Deafness, X-linked 6, 300914 (3)|COL4A6, DELXq22.3, CXDELq22.3, DFNX6|303631|Xq22.3
?Deafness, autosomal recessive 88, 615429 (3)|ELMOD3, RBED1, DFNB88|615427|2p11.2
?Deafness, nonsyndromic (3)|KIAA1199|608366|15q25.1
?Diabetes mellitus, insulin-dependent, neonatal (2)|PBCA|600089|6p21.3
?Diamond-Blackfan anemia 11, 614900 (3)|RPL26, DBA11|603704|17p13.1
?Diamond-Blackfan anemia 12, 615550 (3)|RPL15, DBA12|604174|3p24.2
?Dystonia 23 (2)|DYT23|614860|9q34
?EEC syndrome-1 (2)|EEC1|129900|7q11.2-q21.3
?Ehlers-Danlos syndrome, musculocontractural type 2, 615539 (3)|DSE, SART2, EDSMC2|605942|6q22.1
?Epilepsy, familial adult myoclonic, 5, 615400 (3)|CNTN2, TAX, TAX1, FAME5|190197|1q32.1
?Fanconi renotubular syndrome 3, 615605 (3)|EHHADH, PBFE, LBFP, FRTS3|607037|3q27.2
?Fetal hydantoin syndrome (1)|EPHX1|132810|1q42.12
?Globozoospermia, 102530 (1)|GOPC, PIST, FIG, CAL|606845|6q22.1
?Glycoprotein Ia deficiency, 614200 (1)|ITGA2, CD49B, BR, BDPLT9|192974|5q11.2
?Hairy ears, Y-linked (2)|HEY|425500|Yq
?Hemochromatosis, type 5, 615517 (3)|FTH1, FTHL6, HFE5|134770|11q12.3
?Hepatocellular carcinoma (1)|LCO|165320|2q14-q21
?Heterotaxy, visceral, 3, autosomal (2)|HTX3|606325|6q21
?Hydrocephalus, autosomal dominant (2)|HDCPH1|123155|8q12.2-q21.2
?Hyperimmunoglobulin G1 syndrome (2)|IGHR|144120|14q32.33
?Hyperleucinemia-isoleucinemia or hypervalinemia (1)|BCAT1, BCT1|113520|12p12.1
?Hyperprolactinemia, 615555 (3)|PRLR, MFAB, HPRL|176761|5p13.2
?Hypertension, essential, 145500 (1)|PNMT, PENT|171190|17q12
?Hypertension, salt-resistant (1)|NPR3, ANPRC|108962|5p13.3
?Hypertrichosis universalis congenita, Ambras type (2)|ITC1|145701|8q22
?Hypervalinemia or hyperleucine-isoleucinemia (1)|BCAT2, BCT2|113530|19q13.33
?Immunodeficiency 12, 615468 (3)|MALT1, MLT, IMD12|604860|18q21.32
?Immunodeficiency 13, 615518 (3)|UNC119, HRG4, IMD13|604011|17q11.2
?Immunodeficiency 16, 615593 (3)|TNFRSF4, TXGP1L, OX40, ACT35, IMD16|600315|1p36.33
?Immunodeficiency, common variable, 9, 615559 (3)|PRKCD, CVID9|176977|3p21.1
?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, 615422 (3)|HNRPA2B1, IBMPFD2|600124|7p15.2
?Inclusion body myopathy wtih early-onset Paget disease without frontotemporal dementia 3, 615424 (3)|HNRNPA1, IBMPFD3, ALS20|164017|12q13.13
?Infantile liver failure syndrome 2, 615486 (3)|MARS, MTRNS, METRS|156560|12q13.3
?Isolated growth hormone deficiency due to defect in GHRF (1)|GHRH, GHRF|139190|20q11.23
?Joubert syndrome 22, 615665 (3)|PDE6D, JBTS22|602676|2q37.1
?Keratoderma, palmoplantar, punctate type 3 (2)|PPKP3|101850|2p25-p12
?Klippel-Feil syndrome 2, autosomal recessive (2)|KFS2, KFM|214300|5q11.2
?Laryngeal adductor paralysis (2)|LAP|150270|6p21.3-p21.2
?Lipodystrophy, familial partial, type 5, 615238 (3)|CIDEC, FSP27, CIDE3, FPLD5|612120|3p25.3
?Liver failure, infantile, syndromic, 615438 (3)|LARS, LFIS|151350|5q32
?Lysosomal acid phosphatase deficiency, 200950 (1)|ACP2|171650|11p11.2
?Male infertility (1)|UBE2B, RAD6B|179095|5q31.1
?Male infertility due to acrosin deficiency (2)|ACR|102480|22q13.33
?Male pseudohermaphroditism due to defective LH (1)|LHB|152780|19q13.33
?Megalencephaly, autosomal recessive, 248000 (3)|TBC1D7, PIG51, TBC7, MGCPH|612655|6p24.1
?Melkersson-Rosenthal syndrome (2)|MROS|155900|9p11
?Mental retardation, X-linked 91, 300577 (3)|ZDHHC15, MRX91|300576|Xq13.3
?Mental retardation, X-linked, syndromic 12 (2)|MRXS12|309545|Xp11
?Mental retardation, X-linked, syndromic, Hedera type, 300423 (3)|ATP6AP2, ATP6M8-9, XMRE, MRXSH, XPDS|300556|Xp11.4
?Mental retardation, autosomal dominant 11, 614257 (3)|EPB41L1, MRD11|602879|20q11.23
?Mental retardation, autosomal dominant 22, 612337 (3)|ZBTB18, ZNF238, RP58, MRD22|608433|1q44
?Mental retardation, autosomal recessive, 37, 615493 (3)|ANK3, MRT37|600465|10q21.2
?Microcephaly 11, primary, autosomal recessive, 615414 (3)|PHC1, EDR1, HPH1, RAE28, MCPH11|602978|12p13.31
?Microphthalmia, syndrome 1, 309800 (3)|NAA10, ARD1A, ARD1, TE2, NATD, MCOPS1|300013|Xq28
?Microphthalmia, syndromic 4 (2)|MCOPS4, ANOP1|301590|Xq27-q28
?Microtia with or without hearing impairment (AD), 612290 (3)|HOXA2, MCOHI|604685|7p15.2
?Microtia, hearing impairment, and cleft palate (AR), 612290 (3)|HOXA2, MCOHI|604685|7p15.2
?Mitochondrial complex (ATP synthase) deficiency, nuclear type 4, 615228 (3)|ATP5A1, ATPM, ATP5A, ORM, MC5DN4|164360|18q21.1
?Mitochondrial complex I deficiency, 252010 (3)|NDUFB9, UQOR22|601445|8q24.13
?Mitochondrial complex IV deficiency, 220110 (3)|FASTKD2, KIAA0971|612322|2q33.3
?Mitochondrial complex IV deficiency, 220110 (3)|TACO1, CCDC44|612958|17q23.3
?Moebius syndrome (2)|MBS, MBS1|157900|13q12.2-q13
?Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 (3)|PIGT, NDAP, PNH2, MCAHS3|610272|20q13.12
?Multiple mitochondrial dysfunctions syndrome 3, 615330 (3)|IBA57, C1orf69, MMDS3|615316|1q42.13
?Multiple mitochondrial dysfunctions syndrome 3, 615330 (3)|VTI1A, VTI1RP2, MMDS3|614316|10q25.2
?Muscular dystrophy, limb-girdle, type 2R, 615325 (3)|DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R|125660|2q35
?Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 (3)|SGK196, MDDGA12|615247|8p11.21
?Myofibromatosis, infantile 2, 615293 (3)|NOTCH3, CADASIL, CASIL, IMF2|600276|19p13.12
?N syndrome, 310465 (1)|POLA1|312040|Xp22.1-p21.3
?N-acetylaspartate deficiency, 614063 (3)|NAT8L, CML3, NACED|610647|4p16.3
?Nephronophthisis 9, 613824 (3)|NEK8, JCK, NPHP9, RHPD2|609799|17q11.2
?Nephrotic syndrome, type 8, 615244 (3)|ARHGDIA, GDIA1, NPHS8|601925|17q25.3
?Neuroblastoma (1)|TP73|601990|1p36.32
?Neurodegeneration with optic atrophy, childhood onset, 615491 (3)|UCHL1, PARK5, NDGOA|191342|4p13
?Neutrophil chemotactic repsonse, abnormal (2)|NM, NCR|162820|7q22-qter
?Osteoporosis, involutional, 166710 (1)|VDR|601769|12q13.11
?Otofaciocervical syndrome 2, 615560 (3)|PAX1, OFC2|167411|20p11.22
?Otofaciocervical syndrome, 166780 (3)|EYA1, BOR, BOS1, OFC1|601653|8q13.3
?Paget disease of bone (2)|PDB|167250|6p21.3
?Pancreatic endocrine tumors (1)|ST11, PETS1|602011|3p25
?Parkinsonism with spasticity, X-linked, 300911 (3)|ATP6AP2, ATP6M8-9, XMRE, MRXSH, XPDS|300556|Xp11.4
?Paroxysmal nocturnal hemoglobinuria 2, 615399 (3)|PIGT, NDAP, PNH2, MCAHS3|610272|20q13.12
?Periventricular nodular heterotopia 6, 615544 (3)|ERMARD, C6orf70, PVNH6|615532|6q27
?Phosphoenolpyruvate carboxykinase-1, cytosolic, deficiency, 261680 (1)|PCK1|614168|20q13.31
?Polydactyly, postaxial, type A6, 615226 (3)|ZNF141, D4S90, PAPA6|194648|4p16.3
?Preauricular fistulae, congenital (2)|PAFC|128700|8q11.1-q13.3
?Prinzmetal angina (1)|KCNJ8|600935|12p12.1
?Progesterone resistance, 264080 (2)|PGR|607311|11q22.1
?Ptosis, congenital, 178300 (2)|ZFHX4, ZFH4|606940|8q21.11
?Ragweed sensitivity (2)|RWS|179450|6p21.3
?Renal-hepatic-pancreatic dysplasia 2, 615415 (3)|NEK8, JCK, NPHP9, RHPD2|609799|17q11.2
?Retinal cone dystrophy-1 (2)|RCD1|180020|6q25-q26
?Retinal nonattachment, nonsyndromic congenital, 221900 (3)|ATOH7, RNANC|609875|10q21.3
?Retinitis pigmentosa 23, 300424 (3)|OFD1, CXorf5, SGBS2, JBTS10, RP23|300170|Xp22.2
?Retinitis pigmentosa 66, 615233 (3)|RBP3, RP66|180290|10q11.22
?Retinitis pigmentosa 67, 615565 (3)|NEK2, RP67|604043|1q32.3
?Retinitis pigmentosa, X-linked recessive, 6 (2)|RP6|312612|Xp21.3-p21.2
?Reynolds syndrome, 613471 (3)|LBR, PHA|600024|1q42.12
?Rienhoff syndrome, 615582 (3)|TGFB3, ARVD1, RNHF|190230|14q24.3
?Roifman-Chitayat syndrome (2)|RCHTS|613328|15q11-q21.1
?Sarcoma, synovial, 300813 (3)|SSX1, SSRC|312820|Xp11.23
?Sarcoma, synovial, 300813 (3)|SSX2|300192|Xp11.22
?Seckel syndrome 6, 614728 (3)|CEP63, SCKL6|614724|3q22.2
?Sertoli-cell-only syndrome (1)|DAZ|400003|Yq11.223
?Spastic paraplegia 41, autosomal dominant (2)|SPG41|613364|11p14.1-p11.2
?Spastic paraplegia 43, autosomal recessive, 615043 (3)|C19orf12, NBIA4, SPG43|614297|19q12
?Spastic paraplegia 57, autosomal recessive, 615658 (3)|TFG, HMSNP, SPG57|602498|3q12.2
?Spastic paraplegia 61, autosomal recessive, 615685 (3)|ARL6IP, KIAA0069, SPG61|607669|16p12.3
?Spastic paraplegia 63, 615686 (3)|AMPD2, SPG63|102771|1p13.3
?Spastic paraplegia 72, autosomal dominant, 615625 (3)|REEP2, C5orf19, SPG72|609347|5q31.2
?Spastic paraplegia 72, autosomal recessive, 615625 (3)|REEP2, C5orf19, SPG72|609347|5q31.2
?Spinocerebellar ataxia 26, 609306 (3)|EEF2, EF2, SCA26|130610|19p13.3
?Spinocerebellar ataxia 30 (2)|SCA30|613371|4q34.3-q35.1
?Spinocerebellar ataxia, X-linked 1, 302500 (3)|ATP2B3, PMCA3, SCAX1|300014|Xq28
?Split-hand/foot malformation 1 with sensorineural hearing loss, 220600 (3)|DLX5, SHFM1D|600028|7q21.3
?Spondylocostal dysostosis 5, autosomal dominant, 122600 (3)|TBX6, SCDO5|602427|16p11.2
?Stomatocytosis I, 185000 (1)|EPB72|133090|9q33.2
?Systemic lupus erythematosus, susceptibility to or protection against}, 152700 (2)|C4A, C4S, C4AD|120810|6p21.33
?Testicular anomalies with or without congenital heart disease, 615542 (3)|GATA4, ASD2, VSD1, TACHD|600576|8p23.1
?Testicular microlithiasis, 610441 (3)|SLC34A2|604217|4p15.2
?Tetramelic mirror-image polydactyly (2)|TMIP|135750|14q13
?Thrombocytopenia, Paris-Trousseau type (4)|TCPT|188025|11q23
?Thrombophilia due to decreased release of tissue plasminogen (1)|THPH9|612348|8p12
?Thromboxane synthase deficiency, 614158 (1)|TBXAS1, GHOSAL, CYP5, BDPLT14|274180|7q34
?Tibial hemimelia (2)|THM|275220|8q24.1
?Winchester syndrome, 277950 (3)|MMP14, WNCHRS|600754|14q11.2
?Zimmermann-Laband syndrome (2)|ZLS|135500|3p14.3
?[Birbeck granule deficiency], 613393 (3)|CD207, LANGERIN, CLEC4K|604862|2p13.3
?{Autism susceptibility 16}, 613410 (3)|SLC9A9, AUTS16|608396|3q24
?{Parkinson disease 5, susceptibility to}, 613643 (3)|UCHL1, PARK5, NDGOA|191342|4p13
ABCD syndrome, 600501 (3)|EDNRB, HSCR2, ABCDS, WS4A|131244|13q22.3
ACAD9 deficiency, 611126 (3)|ACAD9|611103|3q21.3
ACTH-independent macronodular adrenal hyperplasia, 219080 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
ADULT syndrome, 103285 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
AICA-ribosiduria due to ATIC deficiency, 608688 (3)|ATIC, PURH, AICAR|601731|2q35
Aarskog-Scott syndrome, 305400 (3)|FGD1, FGDY, AAS, MRXS16|300546|Xp11.22
Abdominal obesity-metabolic syndrome (2)|AOMS1, SYNX|605552|3q27
Abdominal obesity-metabolic syndrome (2)|AOMS2|605572|17p12
Abetalipoproteinemia, 200100 (3)|MTP|157147|4q23
Acampomelic campomelic dysplasia, 114290 (3)|SOX9, CMD1, SRA1|608160|17q24.3
Acatalasemia, 614097 (3)|CAT|115500|11p13
Acetyl-CoA carboxylase deficiency, 613933 (1)|ACACA, ACAC, ACC1, ACACAD|200350|17q12
Achalasia-addisonianism-alacrimia syndrome, 231550 (3)|AAAS, AAA|605378|12q13.13
Acheiropody, 200500 (3)|LMBR1, ACHP, C7orf2, PPD2|605522|7q36.3
Achondrogenesis Ib, 600972 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Achondrogenesis, type IA, 200600 (3)|TRIP11, TRIP230, CEV14, ACG1A|604505|14q32.12
Achondrogenesis, type II or hypochondrogenesis, 200610 (3)|COL2A1|120140|12q13.11
Achondroplasia, 100800 (3)|FGFR3, ACH|134934|4p16.3
Achromatopsia 6, 610024 (3)|PDE6H, RCD3, ACHM6|601190|12p12.3
Achromatopsia-2, 216900 (3)|CNGA3, CNG3, ACHM2|600053|2q11.2
Achromatopsia-3, 262300 (3)|CNGB3, ACHM3, ACHM1|605080|8q21.3
Achromatopsia-4, 613856 (3)|GNAT2, ACHM4|139340|1p13.3
Acid-labile subunit, deficiency of (3)|IGFALS, ALS|601489|16p13.3
Acne inversa, familial, 1, 142690 (3)|NCSTN|605254|1q23.2
Acne inversa, familial, 2, 613736 (3)|PSENEN, PEN2|607632|19q13.12
Acne inversa, familial, 3, 613737 (3)|PSEN1, AD3|104311|14q24.2
Acrocallosal syndrome, 200990 (3)|KIF7, HLS2, ACLS, JBTS12|611254|15q26.1
Acrocapitofemoral dysplasia, 607778 (3)|IHH, BDA1|600726|2q35
Acrodermatitis enteropathica, 201100 (3)|SLC39A4, ZIP4|607059|8q24.3
Acrodysostosis 1, with or without hormone resistance, 101800 (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
Acrodysostosis 2, with or without hormone resistance, 614613 (3)|PDE4D, DPDE3, STRK1, ACRDYS2|600129|5q11.2-q12.1
Acrofacial dysostosis 1, Nager type, 154400 (3)|SF3B4, SF3B49, SAP49, AFD1|605593|1q21.2
Acrokeratosis verruciformis, 101900 (3)|ATP2A2, ATP2B, DAR|108740|12q24.11
Acromegaloid features, overgrowth, cleft palate, and hernia (2)|AOCH|606049|Chr.11
Acromegaly, 102200 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Acromesomelic dysplasia, Maroteaux type, 602875 (3)|NPR2, ANPRB, AMDM|108961|9p13.3
Acromicric dysplasia, 102370 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Acropectoral syndrome (2)|ACRPS|605967|7q36
Acropectorovertebral dysplasia (2)|ACRPV|102510|2q36
Activated PI3K-delta immunodeficiency syndrome, 615513 (3)|PIK3CD, APDS, IMD14|602839|1p36.22
Acute insulin response (2)|AIR|601676|1p31
Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3)|ACADM, MCAD|607008|1p31.1
Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3)|ACADS, SCAD|606885|12q24.31
Adams-Oliver syndrome 1, 100300 (3)|ARHGAP31, CDGAP, KIAA1204, AOS1|610911|3q13.33
Adams-Oliver syndrome 2, 614219 (3)|DOCK6, KIAA1395, AOS2|614194|19p13.2
Adams-Oliver syndrome 3, 614814 (3)|RBPJ, RBPSUH, IGKJRB1, AOS3|147183|4p15.2
Adams-Oliver syndrome 4, 615297 (3)|EOGT, EOGT1, C3orf64, AOS4|614789|3p14.1
Adenine phosphoribosyltransferase deficiency, 614723 (3)|APRT, APRTD|102600|16q24.3
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3)|EGFR|131550|7p11.2
Adenocarcinoma of lung, somatic, 211980 (3)|BRAF, NS7|164757|7q34
Adenocarcinoma of lung, somatic, 211980 (3)|ERBB2, NGL, NEU, HER2|164870|17q12
Adenocarcinoma of lung, somatic, 211980 (3)|PRKN, PARK2, PDJ, LPRS2|602544|6q26
Adenocarcinoma, colonic, somatic (3)|RAD54L, HR54, HRAD54|603615|1p34.1
Adenocarcinoma, ovarian, somatic, 167000 (3)|PRKN, PARK2, PDJ, LPRS2|602544|6q26
Adenoma, periampullary, somatic (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Adenomas, multiple colorectal, 608456 (3)|MUTYH, MYH|604933|1p34.1
Adenomas, salivary gland pleomorphic, 181030 (3)|PLAG1, SGPA, PSA|603026|8q12.1
Adenomatous polyposis coli, 175100 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Adenosine deaminase deficiency, partial, 102700 (3)|ADA|608958|20q13.12
Adenosine triphosphate, elevated, of erythrocytes, 102900 (3)|PKLR, PK1|609712|1q22
Adenylosuccinase deficiency, 103050 (3)|ADSL|608222|22q13.1
Adermatoglyphia, 136000 (3)|SMARCAD1, KIAA1122, ETL1, HEL1, ADERM|612761|4q22.3
Adiponectin deficiency, 612556 (3)|ADIPOQ, APM1, GBP28, ADIPQTL1|605441|3q27.3
Adrenal adenoma, somatic (3)|MEN1|613733|11q13.1
Adrenal cortical carcinoma, 202300 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3)|CYP11B1, P450C11, FHI|610613|8q24.3
Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3)|CYP21A2, CYP21, CA21H|613815|6p21.33
Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3)|DAX1, AHC, AHX, NR0B1, SRXY2|300473|Xp21.2
Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 (3)|CYP11A1, P450SCC|118485|15q24.1
Adrenocortical insufficiency (3)|NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8|184757|9q33.3
Adrenocortical tumor, somatic, (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
Adrenocorticotropic hormone deficiency, 201400 (3)|TBX19|604614|1q24.2
Adrenoleukodystrophy, 300100 (3)|ABCD1, ALD, AMN|300371|Xq28
Adrenomyeloneuropathy, adult, 300100 (3)|ABCD1, ALD, AMN|300371|Xq28
Adult i phenotype without cataract, 110800 (3)|GCNT2, Ii, CTRCT13|600429|6p24.3-p24.2
Advanced sleep phase syndrome, familial, 1, 604348 (3)|PER2, FASPS1, KIAA0347|603426|2q37.3
Advanced sleep-phase syndrome, familial, 2, 615224 (3)|CSNK1D, ASPS, FASPS2|600864|17q25.3
Afibrinogenemia, congenital, 202400 (3)|FGA|134820|4q31.3
Afibrinogenemia, congenital, 202400 (3)|FGB|134830|4q31.3
Agammaglobulinemia 1, 601495 (3)|IGHM, MU, AGM1|147020|14q32.33
Agammaglobulinemia 2, 613500 (3)|IGLL1, IGO, IGL5, VPREB2, AGM2|146770|22q11.23
Agammaglobulinemia 3, 613501 (3)|CD79A, IGA|112205|19q13.2
Agammaglobulinemia 4, 613502 (3)|BLNK, SLP65, AGM4|604515|10q24.1
Agammaglobulinemia 5, 613506 (3)|LRRC8A, KIAA1437, AGM5|608360|9q34.11
Agammaglobulinemia 6, 612692 (3)|CD79B, IGB, B29, AGM6|147245|17q23.3
Agammaglobulinemia 7, autosomal recessive, 615214 (3)|PIK3R1, GRB1, AGM7, SHORT|171833|5q13.1
Agammaglobulinemia and isolated hormone deficiency, 307200 (3)|BTK, AGMX1, IMD1, XLA, AT|300300|Xq22.1
Agammaglobulinemia, X-linked 1, 300755 (3)|BTK, AGMX1, IMD1, XLA, AT|300300|Xq22.1
Agammaglobulinemia, X-linked 2 (2)|AGMX2, XLA2, IMD6|300310|Xp22
Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3)|SLC12A6, KCC3A, KCC3B, KCC3, ACCPN|604878|15q14
Agnathia-otocephaly complex, 202650 (3)|PRRX1, PMX1, PHOX1, AGOTC|167420|1q24.2
Aicardi syndrome (2)|AIC|304050|Xp22
Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3)|TREX1, AGS1, CRV, HERNS|606609|3p21.31
Aicardi-Goutieres syndrome 2, 610181 (3)|RNASEH2B, DLEU8, FLJ11712, AGS2|610326|13q14.3
Aicardi-Goutieres syndrome 3, 610329 (3)|RNASEH2C, AYP1, FLJ20974, AGS3|610330|11q13.1
Aicardi-Goutieres syndrome 4, 610333 (3)|RNASEH2A, RNHIA, AGS4|606034|19p13.2
Aicardi-Goutieres syndrome 5, 612952 (3)|SAMHD1, AGS5, DCIP, CHBL2|606754|20q11.23
Aicardi-Goutieres syndrome 6, 615010 (3)|ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6|146920|1q21.3
Alacrima, achalasia, and mental retardation syndrome, 615510 (3)|GMPPA, AAMR|615495|2q35
Alagille syndrome 2, 610205 (3)|NOTCH2, AGS2, HJCYS|600275|1p12-p11
Alagille syndrome, 118450 (3)|JAG1, AGS, AHD|601920|20p12.2
Aland Island eye disease, 300600 (3)|CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Alazami syndrome, 615071 (3)|LARP7, PIP7S, ALAZS|612026|4q25
Albinism, brown oculocutaneous, 203200 (3)|OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q12-q13
Albinism, oculocutaneous, type IA, 203100 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
Albinism, oculocutaneous, type IB, 606952 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
Albinism, oculocutaneous, type II, 203200 (3)|OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q12-q13
Albinism, oculocutaneous, type III, 203290 (3)|TYRP1, CAS2, GP75, SHEP11|115501|9p23
Albinism, oculocutaneous, type IV, 606574 (3)|SLC45A2, MATP, AIM1, SHEP5, OCA4|606202|5p13.2
Albinism, oculocutaneous, type V (2)|OCA5|615312|4q24
Albinism, oculocutaneous, type VI, 113750 (3)|SLC24A5, NCKX5, SHEP4, OCA6|609802|15q21.1
Albinism, oculocutaneous, type VII, 615179 (3)|C10orf11, OCA7|614537|10q22.2-q22.3
Albinism-deafness syndrome (2)|ADFN, ALDS|300700|Xq24-q26
Alcohol sensitivity, acute, 610251 (3)|ALDH2|100650|12q24.12
Aldosterone to renin ratio raised (3)|CYP11B2|124080|8q24.3
Aldosteronism, glucocorticoid-remediable, 103900 (3)|CYP11B1, P450C11, FHI|610613|8q24.3
Alexander disease, 203450 (3)|GFAP|137780|17q21.31
Alkaptonuria, 203500 (3)|HGD, AKU|607474|3q13.33
Allan-Herndon-Dudley syndrome, 300523 (3)|SLC16A2, DXS128, XPCT|300095|Xq13.2
Alopecia areata 1 (2)|AA1|104000|18p11.3-p11.2
Alopecia areata 2 (2)|AA2|610753|16q11-q22
Alopecia universalis, 203655 (3)|HR, AU, MUHH1|602302|8p21.3
Alopecia, androgenetic, 1 (2)|AFA1, MPB|109200|3q26
Alopecia, androgenetic, 2 (2)|AGA2|300710|Xq11-q12
Alopecia, androgenetic, 3 (2)|AGA3|612421|20p11.22
Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3)|RBM28|612074|7q32.1
Alopecia-mental retardation syndrome 1 (2)|APMR1|203650|3q26.3-q27.3
Alopecia-mental retardation syndrome 2 (2)|APMR2|610422|3q26.2-q26.31
Alopecia-mental retardation syndrome 3 (2)|APMR3|613930|18q11.2-q12.2
Alpha-1-antichymotrypsin deficiency (3)|SERPINA3, AACT, ACT|107280|14q32.13
Alpha-2-macroglobulin deficiency, 614036 (1)|A2M , A2MD|103950|12p13.31
Alpha-2-plasmin inhibitor deficiency, 262850 (3)|PLI, SERPINF2|613168|17p13.3
Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1)|OGDH|613022|7p13
Alpha-methylacetoacetic aciduria, 203750 (3)|ACAT1|607809|11q22.3
Alpha-methylacyl-CoA racemase deficiency, 614307 (3)|AMACR, CBAS4, AMACRD|604489|5p13.2
Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3)|ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq21.1
Alpha-thalassemia/mental retardation syndrome, 301040 (3)|ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq21.1
Alpha-thalassemia/mental retardation syndrome, type 1 (4)|HBHR, ATR1|141750|16pter-p13.3
Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3)|RAG1|179615|11p12
Alport syndrome, 301050 (3)|COL4A5, ATS, ASLN|303630|Xq22.3
Alport syndrome, autosomal dominant, 104200 (3)|COL4A3|120070|2q36.3
Alport syndrome, autosomal recessive, 203780 (3)|COL4A3|120070|2q36.3
Alport syndrome, autosomal recessive, 203780 (3)|COL4A4|120131|2q36.3
Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis (4)|AMMEC, DELXq22.3, CXDELq22.3|300194|Xq22.3
Alstrom syndrome, 203800 (3)|ALMS1, ALSS, KIAA0328|606844|2p13.1
Alternating hemiplegia of childhood 2, 614820 (3)|ATP1A3, DYT12, RDP, AHC2|182350|19q13.2
Alternating hemiplegia of childhood, 104290 (3)|ATP1A2, FHM2, MHP2|182340|1q23.2
Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3)|FOXF1, FKHL5, ACDMPV|601089|16q24.1
Alveolar soft-part sarcoma, 606243 (3)|ASPSCR1, RCC17, ASPL, ASPS|606236|17q25.3
Alzheimer disease 1, familial, 104300 (3)|APP, AAA, CVAP, AD1|104760|21q21.3
Alzheimer disease 17 (2)|AD17|615080|6p21.2
Alzheimer disease 6, 104300 (2)|AD6|605526|10q24
Alzheimer disease 8, 104300 (2)|AD8|607116|20p
Alzheimer disease, type 3, 607822 (3)|PSEN1, AD3|104311|14q24.2
Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3)|PSEN1, AD3|104311|14q24.2
Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3)|PSEN1, AD3|104311|14q24.2
Alzheimer disease-10, 104300 (2)|AD10|609636|7q36
Alzheimer disease-11 (2)|AD11|609790|9p22.1
Alzheimer disease-2, 104310 (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
Alzheimer disease-4, 606889 (3)|PSEN2, AD4, STM2, CMD1V|600759|1q42.13
Alzheimer disease-5, 104300 (2)|AD5|602096|12p11.23-q13.12
Alzheimer disease-7 (2)|AD7|606187|10p13
Amelogenesis imperfecta and gingival fibromatosis syndrome, 614253 (3)|FAM20A, AIGFS|611062|17q24.2
Amelogenesis imperfecta, hypomaturation type, IIA3, 613211 (3)|WDR72, AI2A3|613214|15q21.3
Amelogenesis imperfecta, hypomaturation type, IIA4, 614832 (3)|C4orf26|614829|4q21.1
Amelogenesis imperfecta, hypomaturation-hypoplastic type, with taurodontism, 104510 (3)|DLX3, TDO, AI4|600525|17q21.33
Amelogenesis imperfecta, hypoplastic/hypomaturation type 1E, 301200 (3)|AMELX, AMG, AIH1, AMGX, AI1E|300391|Xp22.2
Amelogenesis imperfecta, type 3, 130900 (3)|FAM83H, AI3|611927|8q24.3
Amelogenesis imperfecta, type IB, 104500 (3)|ENAM, AIH2, AI1C|606585|4q13.3
Amelogenesis imperfecta, type IC, 204650 (3)|ENAM, AIH2, AI1C|606585|4q13.3
Amelogenesis imperfecta, type IIA1, 204700 (3)|KLK4, EMSP1, PRSS17, AI2A1|603767|19q13.41
Amelogenesis imperfecta, type IIA2, 612529 (3)|MMP20, AI2A2|604629|11q22.2
Aminoacylase 1 deficiency, 609924 (3)|ACY1, ACY1D|104620|3p21.2
Amish infantile epilepsy syndrome, 609056 (3)|SIAT9, ST3GALV|604402|2p11.2
Amyloidosis, 3 or more types, 105200 (3)|APOA1|107680|11q23.3
Amyloidosis, Finnish type, 105120 (3)|GSN|137350|9q33.2
Amyloidosis, hereditary renal, 105200 (3)|FGA|134820|4q31.3
Amyloidosis, hereditary, transthyretin-related, 105210 (3)|TTR, PALB|176300|18q12.1
Amyloidosis, primary localized cutaneous, 1, 105250 (3)|OSMR, OSMRB, PLCA1|601743|5p13.1
Amyloidosis, primary localized cutaneous, 2, 613955 (3)|IL31RA, GLMR, GPL, PLCA2|609510|5q11.2
Amyloidosis, renal, 105200 (3)|LYZ|153450|12q15
Amyotrophic lateral sclerosis 1, 105400 (3)|SOD1, ALS1|147450|21q22.11
Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3)|TARDBP, TDP43, ALS10|605078|1p36.22
Amyotrophic lateral sclerosis 11, 612577 (3)|FIG4, KIAA0274, SAC3, ALS11, YVS|609390|6q21
Amyotrophic lateral sclerosis 12, 613435 (3)|OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p13
Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 (3)|VCP, IBMPFD1, ALS14|601023|9p13.3
Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3)|UBQLN2, PLIC2, CHAP1, ALS15|300264|Xp11.21
Amyotrophic lateral sclerosis 16, juvenile, 614373 (3)|SIGMAR1, SRBP, ALS16|601978|9p13.3
Amyotrophic lateral sclerosis 17, 614696 (3)|CHMP2B, DMT1, VPS2B, ALS17|609512|3p11.2
Amyotrophic lateral sclerosis 18, 614808 (3)|PFN1, ALS18|176610|17p13.2
Amyotrophic lateral sclerosis 19, 615515 (3)|ERBB4, HER4, ALS19|600543|2q34
Amyotrophic lateral sclerosis 2, juvenile, 205100 (3)|ALS2, ALSJ, PLSJ, IAHSP|606352|2q33.1
Amyotrophic lateral sclerosis 20, 615426 (3)|HNRNPA1, IBMPFD3, ALS20|164017|12q13.13
Amyotrophic lateral sclerosis 3 (2)|ALS3|606640|18q21
Amyotrophic lateral sclerosis 4, juvenile, 602433 (3)|SETX, SCAR1, AOA2, ALS4|608465|9q34.13
Amyotrophic lateral sclerosis 5, juvenile recessive (2)|ALS5|602099|15q15.1-q21.1
Amyotrophic lateral sclerosis 6, autosomal recessive, with or without frontotemporal dementia, 608030 (3)|FUS, TLS, ALS6, ETM4|137070|16p11.2
Amyotrophic lateral sclerosis 7 (2)|ALS7|608031|20p13
Amyotrophic lateral sclerosis 8, 608627 (3)|VAPB, VAPC, ALS8|605704|20q13.32
Amyotrophic lateral sclerosis 9, 611895 (3)|ANG, RNASE5, ALS9|105850|14q11.2
Amyotrophic lateral sclerosis and/or frontotemporal dementia, 105550 (3)|C9orf72, FTDALS, ALSFTD|614260|9p21.2
Amyotrophy, hereditary neuralgic, 162100 (3)|SEPT9, MSF, MSF1, NAPB|604061|17q25.2-q25.3
Analbuminemia (3)|ALB|103600|4q13.3
Anauxetic dysplasia, 607095 (3)|RMRP, RMRPR, CHH|157660|9p13.3
Andersen syndrome, 170390 (3)|KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9|600681|17q24.3
Androgen insensitivity, 300068 (3)|AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq12
Androgen insensitivity, partial, with or without breast cancer, 312300 (3)|AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq12
Anemia, X-linked, with/without neutropenia and/or platelet abnormalities, 300835 (3)|GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP|305371|Xp11.23
Anemia, hemolytic, Rh-null, regulator type, 268150 (3)|RHAG, RH50A|180297|6p12.3
Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3)|NT5C3A, NT5C3, UMPH1, PSN1|606224|7p14.3
Anemia, hypochromic microcytic, 206100 (3)|NRAMP2|600523|12q13.12
Anemia, neonatal hemolytic, fatal and near-fatal (3)|SPTB, SPH2, EL3, HS2|182870|14q23.3
Anemia, sideroblastic, X-linked, 300751 (3)|ALAS2, ANH1, ASB, XLEPP, XLSA, ANH1|301300|Xp11.21
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)|GLRX5, C14orf87, PRO1238, FLB4739|609588|14q32.13
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)|SLC25A38|610819|3p22.1
Anemia, sideroblastic, with ataxia, 301310 (3)|ABCB7, ABC7, ASAT|300135|Xq13.3
Aneurysm, intracranial berry, 1 (2)|ANIB1|105800|7q11.2
Aneurysm, intracranial berry, 11 (2)|ANIB11|614252|8p22
Aneurysm, intracranial berry, 2 (2)|ANIB2|608542|19q13
Aneurysm, intracranial berry, 3 (2)|ANIB3|609122|1p36.13-p34.3
Aneurysm, intracranial berry, 4 (2)|ANIB4|610213|5p15.2-p14.3
Aneurysm, intracranial berry, 5 (2)|ANIB5|300870|Xp22
Aneurysm, intracranial berry, 5 (2)|ANIB5|610402|2p15-q14
Aneurysm, intracranial berry, 7 (2)|ANIB7|612161|11q24-q25
Aneurysm, intracranial berry, 8 (2)|ANIB8|612162|14q23
Aneurysmal bone cysts (2)|ANBC|606179|16q22
Angelman syndrome, 105830 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Angelman syndrome, 105830 (3)|UBE3A, ANCR|601623|15q11.2
Angelman syndrome-like, 105830 (3)|CDKL5, STK9, ISSX, EIEE2|300203|Xp22.13
Angio serpiginosum (2)|AGSPX|300652|Xp11.3-q12
Angioedema, hereditary, type III, 610618 (3)|F12, HAF, HAE3|610619|5q35.3
Angioedema, hereditary, types I and II, 106100 (3)|C1NH, HAE1, HAE2, SERPING1|606860|11q12.1
Angiofibroma, somatic (3)|MEN1|613733|11q13.1
Angiopathy, hereditary, with nephropathy, aneurysms, and muscle, 611773 (3)|COL4A1, POREN1, HANAC, ICH|120130|13q34
Aniridia, 106210 (3)|PAX6, AN2, MGDA|607108|11p13
Anisomastia (2)|ANMA|605746|16q13-q21
Anonychia congenita, 206800 (3)|RSPO4, CRISTIN4|610573|20p13
Anosmia, isolated congenital (2)|ANIC|107200|18p11.23-q12.2
Anterior segment anomalies with or without cataract, 113650 (3)|EYA1, BOR, BOS1, OFC1|601653|8q13.3
Anterior segment mesenchymal dysgenesis, 107250 (3)|FOXE3, FKHL12, ASMD|601094|1p33
Anterior segment mesenchymal dysgenesis, 107250 (3)|PITX3, CTPP4, CTRCT11|602669|10q24.32
Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3)|POR|124015|7q11.23
Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Aortic aneurysm, ascending, and dissection (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Aortic aneurysm, familial abdominal 1 (2)|AAA1, AAA|100070|19q13
Aortic aneurysm, familial abdominal 2 (2)|AAA2|609782|4q31
Aortic aneurysm, familial abdominal, 4 (2)|AAA4|614375|12q13.3
Aortic aneurysm, familial thoracic 1 (2)|AAT1, FAA1|607086|11q23.3-q24
Aortic aneurysm, familial thoracic 2 (2)|AAT2, FAA2|607087|5q13-q14
Aortic aneurysm, familial thoracic 4, 132900 (3)|MYH11, AAT4, FAA4|160745|16p13.11
Aortic aneurysm, familial thoracic 6, 611788 (3)|ACTA2, ACTSA, AAT6, MYMY5|102620|10q23.31
Aortic aneurysm, familial thoracic 7, 613780 (3)|MYLK, MLCK, AAT7|600922|3q21.1
Aortic aneurysm, familial thoracic 8, 615436 (3)|PRKG1, PRKG1B, PRKGR1B, AAT8|176894|10q11.2-q21.1
Aortic valve disease 2, 614823 (3)|SMAD6, MADH6, AOVD2|602931|15q22.31
Aortic valve disease, 109730 (3)|NOTCH1, TAN1|190198|9q34.3
Apert syndrome, 101200 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Aphakia, congenital primary, 610256 (3)|FOXE3, FKHL12, ASMD|601094|1p33
Aphasia, primary progressive, 607485 (3)|GRN, CLN11|138945|17q21.31
Aplasia cutis congenita, reticulolinear, with mmicrocephaly, facial dysmorphism and other congenital anomalies, 300887 (3)|COX7B, APLCC|300885|Xq21.1
Aplasia of lacrimal and salivary glands, 180920 (3)|FGF10|602115|5p12
Aplastic anemia, 609135 (3)|NBS1, NBS|602667|8q21.3
Apnea, postanesthetic (3)|BCHE, CHE1|177400|3q26.1
ApoA-I and apoC-III deficiency, combined (3)|APOA1|107680|11q23.3
Apolipoprotein A-II deficiency (3)|APOA2|107670|1q23.3
Apparent mineralocorticoid excess, 218030 (3)|HSD11B2, HSD11K, AME|614232|16q22.1
Argininemia, 207800 (3)|ARG1|608313|6q23.2
Argininosuccinic aciduria, 207900 (3)|ASL|608310|7q11.21
Aromatase deficiency, 613546 (3)|CYP19A1, CYP19, ARO|107910|15q21.2
Aromatase excess syndrome, 139300 (3)|CYP19A1, CYP19, ARO|107910|15q21.2
Aromatic L-amino acid decarboxylase deficiency, 608643 (3)|DDC|107930|7p12.1
Arrhythmogenic right ventricular dysplasia 1, 107970 (3)|TGFB3, ARVD1, RNHF|190230|14q24.3
Arrhythmogenic right ventricular dysplasia 10, 610193 (3)|DSG2, ARVD10, ARVC10, CMD1BB|125671|18q12.1
Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3)|DSC2, DSC3, ARVD11|125645|18q12.1
Arrhythmogenic right ventricular dysplasia 11, 610476 (3)|DSC2, DSC3, ARVD11|125645|18q12.1
Arrhythmogenic right ventricular dysplasia 12, 611528 (3)|JUP, DP3, PDGB, ARVD12|173325|17q21.2
Arrhythmogenic right ventricular dysplasia 2, 600996 (3)|RYR2, VTSIP, ARVD2, ARVC2|180902|1q43
Arrhythmogenic right ventricular dysplasia 3 (2)|ARVD3|602086|14q12-q22
Arrhythmogenic right ventricular dysplasia 4 (2)|ARVD4|602087|2q32.1-q32.3
Arrhythmogenic right ventricular dysplasia 5, 604400 (3)|TMEM43, ARVD5, ARVC5, EDMD7|612048|3p25.1
Arrhythmogenic right ventricular dysplasia 6 (2)|ARVD6|604401|10p14-p12
Arrhythmogenic right ventricular dysplasia 8, 607450 (3)|DSP, KPPS2, PPKS2|125647|6p24.3
Arrhythmogenic right ventricular dysplasia 9, 609040 (3)|PKP2, ARVD9|602861|12p11.21
Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3)|CTNNA3, ARVD13|607667|10q21.3
Arterial calcification, generalized, of infancy, 1, 208000 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
Arterial calcification, generalized, of infancy, 2, 614473 (3)|ABCC6, ARA, ABC34, MLP1, PXE, GACI2|603234|16p13.11
Arterial tortuosity syndrome, 208050 (3)|SLC2A10, GLUT10, ATS|606145|20q13.12
Arthrogryposis multiplex congenita, distal, type 1, 108120 (3)|TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.3
Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3)|TNNI2, AMCD2B, DA2B, FSSV|191043|11p15.5
Arthrogryposis multiplex congenita, neurogenic (2)|AMCN, AMCN1|208100|5q35
Arthrogryposis, distal, type 10 (2)|DA10|187370|2q31.3-q32.1
Arthrogryposis, distal, type 1B, 614335 (3)|MYBPC1, LCCS4|160794|12q23.2
Arthrogryposis, distal, type 2A, 193700 (3)|MYH3|160720|17p13.1
Arthrogryposis, distal, type 2B, 601680 (3)|MYH3|160720|17p13.1
Arthrogryposis, distal, type 2B, 601680 (3)|TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.3
Arthrogryposis, distal, type 5, 108145 (3)|PIEZO2, FAM38B, DA5|613629|18p11.22-p11.21
Arthrogryposis, distal, type 5D, 615065 (3)|ECEL1, XCE, DA5D|605896|2q37.1
Arthrogryposis, lethal, with anterior horn cell disease, 611890 (3)|GLE1, GLE1L, LCCS, LCCS1|603371|9q34.11
Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3)|VPS33B|608552|15q26.1
Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3)|VIPAS39, VIPAR, SPE39, C14orf133|613401|14q24.3
Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3)|WISP3, PPAC, PPD|603400|6q21
Arthyrgryposis, distal, type 2B, 601680 (3)|TNNT3, AMCD2B, DA2B, FSSV|600692|11p15.5
Arts syndrome, 301835 (3)|PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22.3
Asparagine synthetase deficiency, 615574 (3)|ASNS, ASNSD|108370|7q21.3
Aspartate aminotransferase, serum level of, QTL1, 614419 (3)|GOT1, ASTQTL1|138180|10q24.2
Aspartylglucosaminuria, 208400 (3)|AGA|613228|4q34.3
Asplenia, isolated congenital, 271400 (3)|LAMR1, LAMBR, ICAS|150370|3p22.1
Asthma and nasal polyps, 208550 (3)|TBX21, TBET|604895|17q21.32
Ataxia with isolated vitamin E deficiency, 277460 (3)|TTPA, TTP1, AVED|600415|8q12.3
Ataxia, cerebellar, Cayman type, 601238 (3)|ATCAY, CLAC, KIAA1872|608179|19p13.3
Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3)|APTX, AOA, AOA1|606350|9p21.1
Ataxia, posterior column, with retinitis pigmentosa, 609033 (3)|FLVCR1, AXPC1, PCARP|609144|1q32.3
Ataxia, sensory, 1, autosomal dominant, 608984 (3)|RNF170, SNAX1|614649|8p11.21
Ataxia, spastic, 4, 613672 (3)|MTPAP, PAPD1, SPAX4|613669|10p11.23
Ataxia, spastic, 5, autosomal recessive, 614487 (3)|AFG3L2, SCA28, SPAX5|604581|18p11.21
Ataxia-ocular apraxia-2, 606002 (3)|SETX, SCAR1, AOA2, ALS4|608465|9q34.13
Ataxia-oculomotor apraxia 3, 615217 (3)|PIK3R5, p101|611317|17p13.1
Ataxia-telangiectasia, 208900 (3)|ATM, ATA, AT1|607585|11q22.3
Ataxia-telangiectasia-like disorder, 604391 (3)|MRE11A, MRE11, ATLD|600814|11q21
Atelosteogenesis II, 256050 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Atelosteogenesis, type I, 108720 (3)|FLNB, SCT, AOI, LRS1|603381|3p14.3
Atelosteogenesis, type III, 108721 (3)|FLNB, SCT, AOI, LRS1|603381|3p14.3
Athabaskan brainstem dysgenesis syndrome, 601536 (3)|HOXA1, HOX1F, BSAS|142955|7p15.2
Atopy, 147050 (3)|SPINK5, LEKTI|605010|5q32
Atransferrinemia, 209300 (3)|TF, TFQTL1|190000|3q22.1
Atrial fibrillation, familial, 1 (2)|ATFB1|608583|10q22-q24
Atrial fibrillation, familial, 10, 614022 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Atrial fibrillation, familial, 11, 614049 (3)|GJA5, CX40, ATFB11|121013|1q21.2
Atrial fibrillation, familial, 12, 614050 (3)|ABCC9, SUR2, CMD1O, ATFB12, CANTU|601439|12p12.1
Atrial fibrillation, familial, 13, 615377 (3)|SCN1B, GEFSP1, BRGDA5, ATFB13|600235|19q13.12
Atrial fibrillation, familial, 14, 615378 (3)|SCN2B, ATFB14|601327|11q23.3
Atrial fibrillation, familial, 2 (2)|ATFB2|608988|6q14-q16
Atrial fibrillation, familial, 3, 607554 (3)|KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5-p15.4
Atrial fibrillation, familial, 4, 611493 (3)|KCNE2, MIRP1, LQT6, ATFB4|603796|21q22.11
Atrial fibrillation, familial, 6, 612201 (3)|NPPA, PND, ANP, ATFB6|108780|1p36.22
Atrial fibrillation, familial, 7, 612240 (3)|KCNA5, ATFB7|176267|12p13.32
Atrial fibrillation, familial, 8 (2)|ATFB8|613055|16q22
Atrial fibrillation, familial, 9, 613980 (3)|KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9|600681|17q24.3
Atrial septal defect 1 (2)|ASD1|108800|5p
Atrial septal defect 2, 607941 (3)|GATA4, ASD2, VSD1, TACHD|600576|8p23.1
Atrial septal defect 3, 614089 (3)|MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3|160710|14q11.2
Atrial septal defect 4, 611363 (3)|TBX20, ASD4|606061|7p14.2
Atrial septal defect 5, 612794 (3)|ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Atrial septal defect 6, 613087 (3)|TLL1, TLL, ASD6|606742|4q32.3
Atrial septal defect 7, with or without AV conduction defects, 108900 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Atrial septal defect 8, 614433 (3)|CITED2, MRG1, P35SRJ, VSD2, ASD8|602937|6q24.1
Atrial septal defect 9, 614475 (3)|GATA6, AVSD5, ASD9, AVSD5, PACHD|601656|18q11.2
Atrial standstill, digenic, 108770 (3)|GJA5, CX40, ATFB11|121013|1q21.2
Atrichia with papular lesions, 209500 (3)|HR, AU, MUHH1|602302|8p21.3
Atrioventricular septal defect 3, 600309 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Atrioventricular septal defect 4, 614430 (3)|GATA4, ASD2, VSD1, TACHD|600576|8p23.1
Atrioventricular septal defect 5, 614474 (3)|GATA6, AVSD5, ASD9, AVSD5, PACHD|601656|18q11.2
Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3)|CRELD1, AVSD2|607170|3p25.3
Atypical mycobacteriosis, familial, X-linked 2, 300645 (3)|CYBB, CGD, AMCBX2|300481|Xp11.4
Auditory neuropathy, autosomal dominant, 1, 609129 (3)|DIAPH3, DIA2, DRF3, AUNA1, NSDAN|614567|13q21.2
Auditory neuropathy, autosomal recessive, 1, 601071 (3)|OTOF, DFNB9, NSRD9, AUNB1|603681|2p23.3
Aural atresia, congenital (2)|CAA|607842|18q22.3-q23
Aural atresia, congenital, 607842 (3)|TSHZ1, TSH1, CAA|614427|18q22.3
Auriculocondylar syndrome 1, 602483 (3)|GNAI3, ARCND1|139370|1p13.3
Auriculocondylar syndrome 2, 614669 (3)|PLCB4, ARCND2|600810|20p12.3-p12.2
Autoimmune disease, syndromic multisystem, 613385 (3)|ITCH, AIP4, NAPP1|606409|20q11.22
Autoimmune lymphoproliferative syndrome type IV, 614470 (3)|NRAS, ALPS4, NS6|164790|1p13.2
Autoimmune lymphoproliferative syndrome, type IA, 601859 (3)|TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q23.31
Autoimmune lymphoproliferative syndrome, type IB, 601859 (3)|TNFSF6, APT1LG1, FASL, ALPS1B|134638|1q24.3
Autoimmune lymphoproliferative syndrome, type II, 603909 (3)|CASP10, MCH4, ALPS2|601762|2q33.1
Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 (3)|AIRE, APECED, APS1|607358|21q22.3
Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 (3)|PLCG2, FCAS3, APLAID|600220|16q23.3
Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 (3)|PSMB8, LMP7, RING10, JMP, NKJO, ALDD|177046|6p21.32
Autonomic nervous system dysfunction (3)|DRD4|126452|11p15.5
Avascular necrosis of the femoral head, 608805 (3)|COL2A1|120140|12q13.11
Axenfeld-Rieger syndrome, type 1, 180500 (3)|PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25
Axenfeld-Rieger syndrome, type 3, 602482 (3)|FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25.3
B-cell non-Hodgkin lymphoma, high-grade (3)|BCL7A, BCL7|601406|12q24.31
BCG and salmonella infection, disseminated, 209950 (1)|IL12B, NKSF2|161561|5q33.3
BCG infection, generalized familial, 209950 (3)|IFNGR1|107470|6q23.3
Bainbridge-Ropers syndrome, 615485 (3)|ASXL3, KIAA1713, BRPS|615115|18q12.1
Baller-Gerold syndrome, 218600 (3)|RECQL4, RTS, RECQ4|603780|8q24.3
Bamforth-Lazarus syndrome, 241850 (3)|FOXE1, FKHL15, TITF2, TTF2|602617|9q22.33
Band-like calcification with simplified gyration and polymicrogyria, 251290 (3)|OCLN, BLCPMG|602876|5q13.2
Bannayan-Riley-Ruvalcaba syndrome, 153480 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Baraitser-Winter syndrome 1, 243310 (3)|ACTB, BRWS1|102630|7p22.1
Baraitser-Winter syndrome 2, 614583 (3)|ACTG1, DFNA20, DFNA26, BRWS2|102560|17q25.3
Bardet-Biedl syndrome 1, 209900 (3)|BBS1|209901|11q13.2
Bardet-Biedl syndrome 10, 209900 (3)|BBS10, C12orf58, FLJ23560|610148|12q21.2
Bardet-Biedl syndrome 11, 209900 (3)|TRIM32, HT2A, LGMD2H, BBS11|602290|9q33.1
Bardet-Biedl syndrome 12, 209900 (3)|BBS12, FLJ35630, C4orf24|610683|4q27
Bardet-Biedl syndrome 13, 209900 (3)|MKS1, MKS, BBS13|609883|17q22
Bardet-Biedl syndrome 14, 209900 (3)|CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.32
Bardet-Biedl syndrome 15, 209900 (3)|C2orf86, BBS15|613580|2p15
Bardet-Biedl syndrome 17, 209900 (3)|LZTFL1, BBS17|606568|3p21.31
Bardet-Biedl syndrome 2, 209900 (3)|BBS2|606151|16q12.2
Bardet-Biedl syndrome 3, 209900 (3)|ARL6, BBS3, RP55|608845|3q11.2
Bardet-Biedl syndrome 4, 209900 (3)|BBS4|600374|15q24.1
Bardet-Biedl syndrome 5, 209900 (3)|BBS5|603650|2q31.1
Bardet-Biedl syndrome 6, 209900 (3)|MKKS, HMCS, KMS, MKS, BBS6|604896|20p12.2
Bardet-Biedl syndrome 7, 209900 (3)|BBS7|607590|4q27
Bardet-Biedl syndrome 8, 209900 (3)|TTC8, BBS8, RP51|608132|14q31.3
Bardet-Biedl syndrome 9, 209900 (3)|PTHB1, BBS9|607968|7p14.3
Bare lymphocyte syndrome, type I, 604571 (3)|TAP1, ABCB2, TAP1, RING4, PSF1|170260|6p21.32
Bare lymphocyte syndrome, type I, 604571 (3)|TAPBP, TPSN|601962|6p21.32
Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3)|TAP2, ABCB3, PSF2, RING11|170261|6p21.32
Bare lymphocyte syndrome, type II, complementation group A, 209920 (3)|MHC2TA, C2TA|600005|16p13.13
Bare lymphocyte syndrome, type II, complementation group C, 209920 (3)|RFX5|601863|1q21.3
Bare lymphocyte syndrome, type II, complementation group D, 209920 (3)|RFXAP|601861|13q13.3
Bare lymphocyte syndrome, type II, complementation group E, 209920 (3)|RFX5|601863|1q21.3
Barrett esophagus/esophageal adenocarcinoma, 614266 (3)|ASCC1, p50|614215|10q22.1
Barrett esophagus/esophageal adenocarcinoma, 614266 (3)|CTHRC1|610635|8q22.3
Barrett esophagus/esophageal adenocarcinoma, 614266 (3)|MSR1, SCARA1, SRA|153622|8p22
Bart-Pumphrey syndrome, 149200 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
Barth syndrome, 302060 (3)|TAZ, EFE2, BTHS, CMD3A, LVNCX|300394|Xq28
Bartter syndrome, type 1, 601678 (3)|SLC12A1, NKCC2|600839|15q21.1
Bartter syndrome, type 2, 241200 (3)|KCNJ1, ROMK1|600359|11q24.3
Bartter syndrome, type 3, 607364 (3)|CLCNKB|602023|1p36.13
Bartter syndrome, type 4a, 602522 (3)|BSND|606412|1p32.3
Bartter syndrome, type 4b, digenic, 613090 (3)|CLCNKA|602024|1p36.13
Bartter syndrome, type 4b, digenic, 613090 (3)|CLCNKB|602023|1p36.13
Basal cell carcinoma, somatic (3)|SMOH, SMO|601500|7q32.1
Basal cell carcinoma, somatic, 605462 (3)|PTCH1, NBCCS, BCNS, HPE7|601309|9q22.32
Basal cell carcinoma, somatic, 605462 (3)|PTCH2|603673|1p34.1
Basal cell carcinoma, somatic, 605462 (3)|RASA1, GAP, CMAVM, PKWS|139150|5q14.3
Basal cell nevus syndrome, 109400 (3)|PTCH1, NBCCS, BCNS, HPE7|601309|9q22.32
Basal ganglia calcification, idiopathic, 2 (2)|IBGC2|606656|2q37
Basal ganglia calcification, idiopathic, 4, 615007 (3)|PDGFRB, PDGFR, IBGC4, IMF1|173410|5q32
Basal ganglia calcification, idiopathic, 5, 615483 (3)|PDGFB, SIS, IBGC5|190040|22q13.1
Basal ganglia cancification, idiopathic, 1, 213600 (3)|SLC20A2, MLVAR, GLVR2, IBGC1|158378|8p11.21
Basal laminar drusen, 126700 (3)|HF1, CFH, HUS, ARMD4, AHUS1|134370|1q31.3
Bazex syndrome (2)|BZX|301845|Xq24-q27
Beare-Stevenson cutis gyrata syndrome, 123790 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Beaulieu-Boycott-Innes syndrome, 613680 (3)|THOC6, FSAP35, BBIS|615403|16p13.3
Becker muscular dystrophy, 300376 (3)|DMD, BMD, CMD3B|300377|Xp21.2-p21.1
Beckwith-Wiedemann syndrome, 130650 (3)|CDKN1C, KIP2, BWS, IMAGE|600856|11p15.4
Beckwith-Wiedemann syndrome, 130650 (3)|H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Beckwith-Wiedemann syndrome, 130650 (3)|KCNQ1OT1, LIT1|604115|11p15.5
Beckwith-Wiedemann syndrome, 130650 (3)|NSD1, ARA267, STO, SOTOS1|606681|5q35.2-q35.3
Bent bone dysplasia syndrome, 614592 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Bernard-Soulier syndrome, type A1 (recessive), 231200 (3)|GP1BA, BSS, BDPLT1, VWDP, BDPLT3|606672|17p13.2
Bernard-Soulier syndrome, type A2 (dominant), 153670 (3)|GP1BA, BSS, BDPLT1, VWDP, BDPLT3|606672|17p13.2
Bernard-Soulier syndrome, type B, 231200 (3)|GP1BB, BS, BDPLT1|138720|22q11.21
Bernard-Soulier syndrome, type C, 231200 (3)|GP9|173515|3q21.3
Best macular dystrophy, 153700 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Bestrophinopathy, 611809 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Beta-2-adrenoreceptor agonist, reduced response to (3)|ADRB2|109690|5q32
Beta-ureidopropionase deficiency, 613161 (3)|UPB1, BUP1|606673|22q11.23
Bethlem myopathy, 158810 (3)|COL6A1, OPLL|120220|21q22.3
Bethlem myopathy, 158810 (3)|COL6A2|120240|21q22.3
Bethlem myopathy, 158810 (3)|COL6A3|120250|2q37.3
Bietti crystalline corneoretinal dystrophy, 210370 (3)|CYP4V2, BCD|608614|4q35.2
Bifid nose with or without anorectal and renal anomalies, 608980 (3)|FREM1, C9orf154, BNAR, MOTA, TRIGNO2|608944|9p22.3
Bile acid malabsorption, primary, 613291 (3)|SLC10A2, NTCP2, PBAM|601295|13q33.1
Bile acid synthesis defect, congenital, 1, 607765 (3)|HSD3B7, CBAS1|607764|16p11.2
Bile acid synthesis defect, congenital, 2, 235555 (3)|AKR1D1, SRD5B1, CBAS2|604741|7q33
Bile acid synthesis defect, congenital, 3, 613812 (3)|CYP7B1, CBAS3, SPG5A|603711|8q12.3
Bile acid synthesis defect, congenital, 4, 214950 (3)|AMACR, CBAS4, AMACRD|604489|5p13.2
Biliary cirrhosis, primary, 1 (2)|PBC1|109720|3p12-q13.2
Biliary cirrhosis, primary, 4 (2)|PBC4|614220|7q32
Biliary cirrhosis, primary, 5 (2)|PBC5|614221|17q12
Biotinidase deficiency, 253260 (3)|BTD|609019|3p25.1
Birk-Barel mental retardation dysmorphism syndrome, 612292 (3)|KCNK9, TASK3|605874|8q24.3
Birt-Hogg-Dube syndrome, 135150 (3)|FLCN, BHD|607273|17p11.2
Bjornstad syndrome, 262000 (3)|BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1|603647|2q35
Bladder cancer, somatic, 109800 (3)|FGFR3, ACH|134934|4p16.3
Bladder cancer, somatic, 109800 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Bladder cancer, somatic, 109800 (3)|RB1|614041|13q14.2
Blau syndrome, 186580 (3)|NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12.1
Bleeding disorder due to P2RX1 defect (3)|P2RX1, P2X1|600845|17p13.2
Bleeding disorder, east Texas type (2)|BDET|605913|1q23
Bleeding disorder, platelet-type, 11, 614201 (3)|GP6, GPIV, BDPLT11|605546|19q13.42
Bleeding disorder, platelet-type, 15, 615193 (3)|ACTN1, BDPLT15|102575|14q24.1
Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3)|ITGA2B, GP2B, CD41B, GT, BDPLT2, BDPLT16|607759|17q21.31
Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3)|ITGB3, GP3A, GT, BDPLT2, BDPLT16|173470|17q21.32
Bleeding disorder, platelet-type, 17, 187900 (3)|GFI1B, BDPLT17|604383|9q34.13
Bleeding disorder, platelet-type, 8, 609821 (3)|P2RY12, P2Y12, BDPLT8|600515|3q25.1
Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3)|FOXL2, BPES, BPES1, PFRK, POF3|605597|3q22.3
Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3)|FOXL2, BPES, BPES1, PFRK, POF3|605597|3q22.3
Blepharophimosis-ptosis-intellectual disability syndrome, 615057 (3)|UBE3B, BPIDS|608047|12q24.11
Blood group--Lutheran inhibitor, 111150 (3)|KLF1, EKLF, INLU, HBFQTL6, CDAN4|600599|19p13.2
Bloom syndrome, 210900 (3)|RECQL3, RECQ2, BLM, BS|604610|15q26.1
Blue cone monochromacy, 303700 (3)|OPN1LW, RCP, CBP, CBBM|300822|Xq28
Blue cone monochromacy, 303700 (3)|OPN1MW, GCP, CBD, CBBM|300821|Xq28
Bohring-Opitz syndrome, 605039 (3)|ASXL1, KIAA0978, BOPS, MDS|612990|20q11.21
Bone marrow failure, familial, 614675 (3)|SRP72, BMFF|602122|4q12
Bone mineral density QTL18, osteoporosis, 300910 (3)|PLS3, BMND18|300131|Xq23
Boomerang dysplasia, 112310 (3)|FLNB, SCT, AOI, LRS1|603381|3p14.3
Bor-Duane hydrocephalus contiguous gene syndrome (4)|DEL8q12q21, C8DELq12q21|600257|8q12.2-q21.2
Borjeson-Forssman-Lehmann syndrome, 301900 (3)|PHF6, BFLS|300414|Xq26.2
Bornholm eye disease (2)|BED|300843|Xq28
Bosley-Salih-Alorainy syndrome, 601536 (3)|HOXA1, HOX1F, BSAS|142955|7p15.2
Bothnia retinal dystrophy, 607475 (3)|RLBP1|180090|15q26.1
Boucher-Neuhauser syndrome, 215470 (3)|PNPLA6, NTE, SPG39, NTEMND, BNHS|603197|19p13.2
Bowen-Conradi syndrome, 211180 (3)|EMG1, NEP1, C2F, BWCNS|611531|12p13.31
Brachiootic syndrome 3, 608389 (3)|SIX1, BOS3, DFNA23|601205|14q23.1
Brachydactyly, type A1, 112500 (2)|BDA1B|607004|5p13.3-p13.2
Brachydactyly, type A1, 112500 (3)|IHH, BDA1|600726|2q35
Brachydactyly, type A1, C, 615072 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Brachydactyly, type A2, 112600 (3)|BMP2, BMP2A, BDA2|112261|20p12.3
Brachydactyly, type A2, 112600 (3)|BMPR1B, ALK6|603248|4q22.3
Brachydactyly, type A2, 112600 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Brachydactyly, type B1, 113000 (3)|ROR2, BDB1, BDB, NTRKR2|602337|9q22.31
Brachydactyly, type B2, 611377 (3)|NOG, SYM1, SYNS1|602991|17q22
Brachydactyly, type C, 113100 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Brachydactyly, type D, 113200 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Brachydactyly, type E, 113300 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Brachydactyly, type E2, 613382 (3)|PTHLH, BDE2|168470|12p11.22
Brachydactyly-mental retardation syndrome, 600430 (3)|HDAC4, HDACA, BDMR, AHO3|605314|2q37.3
Brachydactyly-syndactyly syndrome, 610713 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3)|PAPSS2, ATPSK2, BCYM4|603005|10q23.2-q23.3
Brachyolmia type 3, 113500 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Bradyopsia, 608415 (3)|RGS9, PERRS|604067|17q24.1
Bradyopsia, 608415 (3)|RGS9BP, R9AP, RGS9, PERRS|607814|19q13.11
Brain small vessel disease with Axenfeld-Rieger anomaly, 607595 (3)|COL4A1, POREN1, HANAC, ICH|120130|13q34
Brain small vessel disease with hemorrhage, 607595 (3)|COL4A1, POREN1, HANAC, ICH|120130|13q34
Brain tumor-polyposis syndrome 2, 175100 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 (3)|BCKDK, BDK, BCKDKD|614901|16p11.2
Branchiooculofacial syndrome, 113620 (3)|TFAP2A, AP2TF, BOFS|107580|6p24.3
Branchiootic syndrome 1, 602588 (3)|EYA1, BOR, BOS1, OFC1|601653|8q13.3
Branchiootic syndrome 2 (2)|BOS2|120502|1q31
Branchiootorenal syndrome 1, with or without cataracts, 113650 (3)|EYA1, BOR, BOS1, OFC1|601653|8q13.3
Branchiootorenal syndrome 2, 610896 (3)|SIX5, DMAHP, BOR2|600963|19q13.32
Breast cancer (1)|BCPR|113721|17p13.3
Breast cancer, 114480 (3)|PPM1D, WIP1|605100|17q23.2
Breast cancer, 114480 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Breast cancer, 11:22 translocation associated (1)|BRCATA|600048|11q23
Breast cancer, early-onset, 114480 (3)|BRIP1, BACH1, FANCJ|605882|17q23.2
Breast cancer, somatic, 114480 (3)|AKT1, CWS6|164730|14q32.33
Breast cancer, somatic, 114480 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Breast cancer, somatic, 114480 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Breast cancer, somatic, 114480 (3)|RB1CC1, CC1, KIAA0203|606837|8q11.23
Breast cancer, somatic, 114480 (3)|SLC22A1L, BWSCR1A, IMPT1|602631|11p15.4
Breast cancer, somatic, 114480 (3)|TSG101|601387|11p15.1
Brittle cornea syndrome 2, 614170 (3)|PRDM5, BCS2|614161|4q27
Brittle cornea syndrome, 229200 (3)|ZNF469, KIAA1858, BCS|612078|16q24.2
Brody myopathy, 601003 (3)|ATP2A1, SERCA1|108730|16p11.2
Bronchiectasis with or without elevated sweat chloride 1, 211400 (3)|SCNN1B, BESC1|600760|16p12.2
Bronchiectasis with or without elevated sweat chloride 2, 613021 (3)|SCNN1A, BESC2|600228|12p13.31
Bronchiectasis with or without elevated sweat chloride 3, 613071 (3)|SCNN1G, PHA1, BESC3|600761|16p12.2
Brooke-Spiegler syndrome, 605041 (3)|CYLD, CDMT, EAC, MFT1, KIAA0849, BRSS|605018|16q12.1
Brown-Vialetto-Van Laere syndrome 1, 211530 (3)|SLC52A3, C20orf54, RFT2, BVVLS1|613350|20p13
Brown-Vialetto-Van Laere syndrome 2, 614707 (3)|SLC52A2, GPR172A, GPCR41, PAR1, FLJ11856, BVVLS2|607882|8q24.3
Bruck syndrome 1 (2)|BRKS1|259450|17p12
Bruck syndrome 2, 609220 (3)|PLOD2, LH2, TLH|601865|3q24
Brugada syndrome 1, 601144 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Brugada syndrome 2, 611777 (3)|GPD1L, KIAA0089|611778|3p22.3
Brugada syndrome 3, 611875 (3)|CACNA1C, CACNL1A1, CCHL1A1, TS|114205|12p13.33
Brugada syndrome 4, 611876 (3)|CACNB2|600003|10p12.33-p12.31
Brugada syndrome 5, 612838 (3)|SCN1B, GEFSP1, BRGDA5, ATFB13|600235|19q13.12
Brugada syndrome 6, 613119 (3)|KCNE3, HOKPP, HYPP|604433|11q13.4
Brugada syndrome 7, 613120 (3)|SCN3B, SCNB3|608214|11q24.1
Brugada syndrome 8, 613123 (3)|HCN4, SSS2|605206|15q24.1
Brunner syndrome, 300615 (3)|MAOA|309850|Xp11.3
Burkitt lymphoma, 113970 (3)|MYC|190080|8q24.21
Buschke-Ollendorff syndrome, 166700 (3)|LEMD3, MAN1|607844|12q14.3
C syndrome, 211750 (3)|CD96, TACTILE|606037|3q13.1-q13.2
C1q deficiency, 613652 (3)|C1QA|120550|1p36.12
C1q deficiency, 613652 (3)|C1QB|120570|1p36.12
C1q deficiency, 613652 (3)|C1QC, C1QG|120575|1p36.12
C1r/C1s deficiency, combined, 216950 (1)|C1R|613785|12p13.31
C1s deficiency, 613783 (3)|C1S|120580|12p13.31
C2 deficiency, 217000 (3)|C2, ARMD14|613927|6p21.33
C3 deficiency, 613779 (3)|C3, ARMD9, AHUS5|120700|19p13.3
C4B deficiency, 614379 (3)|C4B, C4F, C4BD|120820|6p21.33
C4a deficiency, 614380 (3)|C4A, C4S, C4AD|120810|6p21.33
C5 deficiency, 609536 (3)|C5|120900|9q33.2
C6 deficiency, 612446 (3)|C6|217050|5p13.1
C7 deficiency, 610102 (3)|C7|217070|5p13.1
C8 deficiency, type I, 613790 (3)|C8A|120950|1p32.2
C8 deficiency, type II, 613789 (3)|C8B|120960|1p32.2
C9 deficiency, 613825 (3)|C9, C9D, ARMD15|120940|5p13.1
CAP myopathy 1, 609284 (3)|TPM3, NEM1, CFTD, CAPM1|191030|1q21.3
CAP myopathy 2, 609285 (3)|TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.3
CARASIL syndrome, 600142 (3)|HTRA1, PRSS11, ARMD7, CARASIL|602194|10q26.13
CATSHL syndrome, 610474 (3)|FGFR3, ACH|134934|4p16.3
CD11C+/CD1C+ dendritic cell deficiency, dominant, 614893 (3)|IRF8, ICSBP1|601565|16q24.1
CD8 deficiency, familial, 608957 (3)|CD8A|186910|2p11.2
CDAGS syndrome (2)|CDAGS|603116|22q12-q13
CHARGE syndrome, 214800 (3)|CHD7, IS3, HH5|608892|8q12.1-q12.2
CHARGE syndrome, 214800 (3)|SEMA3E, SEMAH, KIAA0331|608166|7q21.11
CHILD syndrome, 308050 (3)|NSDHL|300275|Xq28
CHIME syndrome, 280000 (3)|PIGL, CHIME|605947|17p11.2
CINCA syndrome, 607115 (3)|NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
CK syndrome, 300831 (3)|NSDHL|300275|Xq28
CLOVE syndrome, somatic, 612918 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
COACH syndrome, 216360 (3)|CC2D2A, KIAA1345, MKS6|612013|4p15.32
COACH syndrome, 216360 (3)|RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
COACH syndrome, 216360 (3)|TMEM67, MKS3, JBTS6, NPHP11|609884|8q22.1
COPD, rate of decline of lung function in, 606963 (3)|MMP1, CLG|120353|11q22.2
CPT II deficiency, lethal neonatal, 608836 (3)|CPT2, IIAE4|600650|1p32.3
CPT deficiency, hepatic, type IA, 255120 (3)|CPT1A|600528|11q13.3
CPT deficiency, hepatic, type II, 600649 (3)|CPT2, IIAE4|600650|1p32.3
CR1 deficiency (1)|CR1, C3BR|120620|1q32.2
CRASH syndrome, 303350 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
Caffey disease, 114000 (3)|COL1A1|120150|17q21.33
Calcification of joints and arteries, 211800 (3)|NT5E, NT5|129190|6q14.3
Campomelic dysplasia with autosomal sex reversal, 114290 (3)|SOX9, CMD1, SRA1|608160|17q24.3
Campomelic dysplasia, 114290 (3)|SOX9, CMD1, SRA1|608160|17q24.3
Camptodactyly 1 (2)|CAMPD1|114200|3q11.2-q13.12
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3)|PRG4, CACP, MSF, SZP, HAPO|604283|1q31.1
Camurati-Engelmann disease, 131300 (3)|TGFB1, DPD1, CED|190180|19q13.2
Canavan disease, 271900 (3)|ASPA|608034|17p13.2
Candidiasis, familial, 1, autosomal dominant (2)|CANDF1, CMCT|114580|2p22.3-p21
Candidiasis, familial, 2, autosomal recessive, 212050 (3)|CARD9, CANDF2|607212|9q34.3
Candidiasis, familial, 3 (2)|CANDF3, CANDN1, FCNC|607644|11p13-q12
Candidiasis, familial, 4, autosomal recessive, 613108 (3)|CLEC7A, CLECSF12, DECTIN1, CANDF4|606264|12p13.2
Candidiasis, familial, 5, autosomal recessive, 613953 (3)|IL17RA, IL17R, CANDF5|605461|22q11.1
Candidiasis, familial, 6, autosomal dominant, 613956 (3)|IL17F, ML1, CANDF6|606496|6p12.2
Candidiasis, familial, 7, 614162 (3)|STAT1, CANDF7|600555|2q32.2
Capillary malformation-arteriovenous malformation, 608354 (3)|RASA1, GAP, CMAVM, PKWS|139150|5q14.3
Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3)|GNAQ, SWS, CMC1|600998|9q21.2
Capillary malformations, hereditary (2)|CMAL|163000|5q13-q22
Carbamoylphosphate synthetase I deficiency, 237300 (3)|CPS1, PHN|608307|2q34
Carboxylesterase 1 deficiency (3)|CES1, SES1|114835|16q12.2
Carboxypeptidase N deficiency, 212070 (3)|CPN1, SCPN, CPN|603103|10q24.2
Carcinoid tumor of lung (3)|MEN1|613733|11q13.1
Carcinoid tumors, intestinal, 114900 (3)|SDHD, PGL1, CWS3|602690|11q23.1
Cardiac arrhythmia, ankyrin-B-related, 600919 (3)|ANK2, LQT4|106410|4q25-q26
Cardiac conduction defect, nonspecific, 612838 (3)|SCN1B, GEFSP1, BRGDA5, ATFB13|600235|19q13.12
Cardiac valvular dysplasia, X-linked, 314400 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377 (3)|SCO2, CEMCOX1, MYP6|604272|22q13.33
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 (3)|COX15, CEMCOX2|603646|10q24.2
Cardiofaciocutaneous syndrome 2, 615278 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Cardiofaciocutaneous syndrome 3, 615279 (3)|MAP2K1, PRKMK1, MKK1, MEK1, CFC3|176872|15q22.31
Cardiofaciocutaneous syndrome 4, 615280 (3)|MAP2K2, PRKMK2, MEK2, MKK2, CFC4|601263|19p13.3
Cardiofaciocutaneous syndrome, 115150 (3)|BRAF, NS7|164757|7q34
Cardiomyopathy, dilated 1B (2)|CMD1B, CMPD1, FDC|600884|9q13
Cardiomyopathy, dilated 1C, 601493 (3)|LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3, MFM4|605906|10q23.2
Cardiomyopathy, dilated, 1A, 115200 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Cardiomyopathy, dilated, 1BB, 612877 (3)|DSG2, ARVD10, ARVC10, CMD1BB|125671|18q12.1
Cardiomyopathy, dilated, 1CC, 613122 (3)|NEXN, NELIN, CMD1CC, CMH20|613121|1p31.1
Cardiomyopathy, dilated, 1D, 601494 (3)|TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32.1
Cardiomyopathy, dilated, 1DD, 613172 (3)|RBM20|613171|10q25.2
Cardiomyopathy, dilated, 1E, 601154 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Cardiomyopathy, dilated, 1EE, 613252 (3)|MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3|160710|14q11.2
Cardiomyopathy, dilated, 1F and limb-girdle muscular dystrophy type 1D (2)|CMD1F, CDCD3, LGMD1D|602067|6q23
Cardiomyopathy, dilated, 1FF, 613286 (3)|TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.42
Cardiomyopathy, dilated, 1G, 604145 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Cardiomyopathy, dilated, 1GG, 613642 (3)|SDHA, SDH1, SDHF, CMD1GG, PGL5|600857|5p15.33
Cardiomyopathy, dilated, 1H (2)|CMD1H|604288|2q14-q22
Cardiomyopathy, dilated, 1HH, 613881 (3)|BAG3, MFM6|603883|10q26.11
Cardiomyopathy, dilated, 1I, 604765 (3)|DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R|125660|2q35
Cardiomyopathy, dilated, 1II, 615184 (3)|CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2|123590|11q23.1
Cardiomyopathy, dilated, 1J, 605362 (3)|EYA4, DFNA10, CMD1J|603550|6q23.2
Cardiomyopathy, dilated, 1JJ, 615235 (3)|LAMA4, LAMA3, CMD1JJ|600133|6q21
Cardiomyopathy, dilated, 1K (2)|CMD1K|605582|6q12-q16
Cardiomyopathy, dilated, 1KK, 615248 (3)|MYPN, CMD1DD, CMH22, RCM4|608517|10q21.3
Cardiomyopathy, dilated, 1L, 606685 (3)|SGCD, SGD, LGMD2F, CMD1L|601411|5q33.2-q33.3
Cardiomyopathy, dilated, 1LL, 615373 (3)|PRDM16, MEL1, LVNC8, CMD1LL|605557|1p36.32
Cardiomyopathy, dilated, 1M, 607482 (3)|CSRP3, CRP3, CLP, CMD1M, CMH12|600824|11p15.1
Cardiomyopathy, dilated, 1MM, 615396 (3)|MYBPC3, CMH4, CMD1MM, LVNC10|600958|11p11.2
Cardiomyopathy, dilated, 1N, 607487 (3)|TCAP, LGMD2G, CMD1N|604488|17q12
Cardiomyopathy, dilated, 1O, 608569 (3)|ABCC9, SUR2, CMD1O, ATFB12, CANTU|601439|12p12.1
Cardiomyopathy, dilated, 1P, 609909 (3)|PLN, PLB, CMD1P, CMH18|172405|6q22.31
Cardiomyopathy, dilated, 1Q (2)|CMD1Q|609915|7q22.3-q31.1
Cardiomyopathy, dilated, 1R, 613424 (3)|ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Cardiomyopathy, dilated, 1S, 613426 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Cardiomyopathy, dilated, 1T, 613740 (3)|TMPO, LAP2, CMD1T|188380|12q23.1
Cardiomyopathy, dilated, 1U, 613694 (3)|PSEN1, AD3|104311|14q24.2
Cardiomyopathy, dilated, 1V, 613697 (3)|PSEN2, AD4, STM2, CMD1V|600759|1q42.13
Cardiomyopathy, dilated, 1W, 611407 (3)|VCL, CMD1W, CMH15|193065|10q22.2
Cardiomyopathy, dilated, 1X, 611615 (3)|FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31.2
Cardiomyopathy, dilated, 1Y, 611878 (3)|TPM1, CMH3, CMD1Y , LVNC9|191010|15q22.2
Cardiomyopathy, dilated, 1Z, 611879 (3)|TNNC1, CMD1Z, CMH13|191040|3p21.1
Cardiomyopathy, dilated, 2A, 611880 (3)|TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.42
Cardiomyopathy, dilated, 2B, 614672 (3)|GATAD1, ODAG, CMD2B|614518|7q21.2
Cardiomyopathy, dilated, 3B, 302045 (3)|DMD, BMD, CMD3B|300377|Xp21.2-p21.1
Cardiomyopathy, familial hypertrophic 17, 613873 (3)|JPH2, JP2, CMH17|605267|20q13.12
Cardiomyopathy, familial hypertrophic 6, 600858 (3)|PRKAG2, WPWS, CMH6|602743|7q36.1
Cardiomyopathy, familial hypertrophic, 1, 192600 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Cardiomyopathy, familial hypertrophic, 10, 608758 (3)|MYL2, CMH10|160781|12q24.11
Cardiomyopathy, familial hypertrophic, 11, 612098 (3)|ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Cardiomyopathy, familial hypertrophic, 12, 612124 (3)|CSRP3, CRP3, CLP, CMD1M, CMH12|600824|11p15.1
Cardiomyopathy, familial hypertrophic, 13, 613243 (3)|TNNC1, CMD1Z, CMH13|191040|3p21.1
Cardiomyopathy, familial hypertrophic, 14, 613251 (3)|MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3|160710|14q11.2
Cardiomyopathy, familial hypertrophic, 15, 613255 (3)|VCL, CMD1W, CMH15|193065|10q22.2
Cardiomyopathy, familial hypertrophic, 16, 613838 (3)|MYOZ2, CMH16|605602|4q26
Cardiomyopathy, familial hypertrophic, 18, 613874 (3)|PLN, PLB, CMD1P, CMH18|172405|6q22.31
Cardiomyopathy, familial hypertrophic, 19, 613875 (3)|CALR3, CRT2, CMH19|611414|19p13.11
Cardiomyopathy, familial hypertrophic, 192600 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Cardiomyopathy, familial hypertrophic, 2, 115195 (3)|TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32.1
Cardiomyopathy, familial hypertrophic, 20, 613876 (3)|NEXN, NELIN, CMD1CC, CMH20|613121|1p31.1
Cardiomyopathy, familial hypertrophic, 21 (2)|CMH21|614676|7p12.1-q21
Cardiomyopathy, familial hypertrophic, 3, 115196 (3)|TPM1, CMH3, CMD1Y , LVNC9|191010|15q22.2
Cardiomyopathy, familial hypertrophic, 4, 115197 (3)|MYBPC3, CMH4, CMD1MM, LVNC10|600958|11p11.2
Cardiomyopathy, familial hypertrophic, 7, 613690 (3)|TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.42
Cardiomyopathy, familial hypertrophic, 8, 608751 (3)|MYL3, CMH8|160790|3p21.31
Cardiomyopathy, familial hypertrophic, 9, 613765 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Cardiomyopathy, familial restrictive, 115210 (3)|TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.42
Cardiomyopathy, familial restrictive, 2 (2)|RCM2|609578|10q23.3
Cardiomyopathy, familial restrictive, 3, 612422 (3)|TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32.1
Cardiomyopathy, hypertrophic, midventricular, digenic, 192600 (3)|MYLK2, MLCK|606566|20q11.21
Cardiomyopaty, familial restrictive 4, 615248 (3)|MYPN, CMD1DD, CMH22, RCM4|608517|10q21.3
Cardiomypathy, familial hypertrophic, 22, 615248 (3)|MYPN, CMD1DD, CMH22, RCM4|608517|10q21.3
Carney complex variant, 608837 (3)|MYH8|160741|17p13.1
Carney complex, type 1, 160980 (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
Carney complex, type II (2)|CNC2|605244|2p16
Carnitine deficiency, systemic primary, 212140 (3)|SLC22A5, OCTN2, CDSP, SCD|603377|5q31.1
Carnitine-acylcarnitine translocase deficiency, 212138 (3)|SLC25A20, CACT, CAC|613698|3p21.31
Carnosinemia (2)|CNSN|212200|18q21.3
Carotid intimal medial thickness (2)|CIMT|608447|12q24
Carotid intimal medial thickness 1, 609338 (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
Carpal tunnel syndrome, familial, 115430 (3)|TTR, PALB|176300|18q12.1
Carpenter syndrome 2, 614976 (3)|MEGF8, EGFL4, CRPT2|604267|19q13.2
Carpenter syndrome, 201000 (3)|RAB23|606144|6p11.2
Cartilage-hair hypoplasia, 250250 (3)|RMRP, RMRPR, CHH|157660|9p13.3
Cat eye syndrome (4)|CECR, CES|115470|22q11
Cataract 1, multiple types, 116200 (3)|GJA8, CX50, CTRCT1, CZP1, CAE1|600897|1q21.2
Cataract 10, multiple types, 600881 (3)|CRYBA1, CRYB1, CTRCT10|123610|17q11.2
Cataract 11, multiple types, 610623 (3)|PITX3, CTPP4, CTRCT11|602669|10q24.32
Cataract 11, syndromic, 610623 (3)|PITX3, CTPP4, CTRCT11|602669|10q24.32
Cataract 12, multiple types, 611597 (3)|BFSP2, CP49, CP47, CTRCT12|603212|3q22.1
Cataract 13 with adult i phenotype, 110800 (3)|GCNT2, Ii, CTRCT13|600429|6p24.3-p24.2
Cataract 14, multiple types, 601885 (3)|GJA3, CX46, CZP3, CAE3, CTRCT14|121015|13q12.11
Cataract 15, multiple types, 615274 (3)|MIP, AQP0, CTRCT15|154050|12q13.3
Cataract 16, multiple types, 613763 (3)|CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2|123590|11q23.1
Cataract 17, multiple types, 611544 (3)|CRYBB1, CATCN3, CTRCT17|600929|22q12.1
Cataract 18, autosomal recessive, 610019 (3)|FYCO1, CATC2, CTRCT18|607182|3p21.31
Cataract 19, 615277 (3)|LIM2, MP19, CTRCT19|154045|19q13.41
Cataract 2, multiple types, 604307 (3)|CRYGC, CRYG3, CTRCT2, CCL|123680|2q33.3
Cataract 20, multiple types, 116100 (3)|CRYGS, CRYG8, CTRCT20|123730|3q27.3
Cataract 22, autosomal recessive, 609741 (3)|CRYBB3, CRYB3, CATCN2, CTRCT22|123630|22q11.23
Cataract 23, 610425 (3)|CRYBA4, CTRCT23|123631|22q12.1
Cataract 24, anterior polar (2)|CTRCT24, CTAA2|601202|17p13
Cataract 25 (2)|CTRCT25, CCSSO|605728|15q21-q22
Cataract 26, multiple types (2)|CTRCT26, CAAR|605749|9q13-q22
Cataract 27, nuclear progressive (2)|CTRCT27, CCNP|607304|2p12
Cataract 29, coralliform (2)|CTRCT29|115800|2pter-p24
Cataract 3, multiple types, 601547 (3)|CRYBB2, CRYB2, CTRCT3, CCA2|123620|22q11.23
Cataract 30, pulverulent, 116300 (3)|VIM, CTRCT30|193060|10p13
Cataract 31, multiple types, 605387 (3)|CHMP4B, SNF7, CTPP3, CTRCT31|610897|20q11.22
Cataract 32, multiple types (3)|CTRCT32, CTAA1, CAP, CTPP5|115650|14q22-q23
Cataract 33, 611391 (3)|BFSP1, CP115, CTRCT33|603307|20p12.1
Cataract 34, multiple types (2)|CTRCT34, CATC3|612968|1p34.3-p32.2
Cataract 35, congenital nuclear (2)|CTRCT35, CATCN1|609376|19q13
Cataract 36, 613887 (3)|TDRD7, KIAA1529, TRAP, CATC4, CTRCT36|611258|9q22.33
Cataract 37, autosomal dominant (2)|CTRCT37, CCA5|614422|12q24.2-q24.3
Cataract 38, autosomal recessive, 614691 (3)|AGK, MULK, MTDPS10, CATC5, CTRCT38|610345|7q34
Cataract 39, multiple types, autosomal dominant, 615188 (3)|CRYGB, CRYG2, CTRCT39|123670|2q34
Cataract 4, multiple types, 115700 (3)|CRYGD, CRYG4, CTRCT4, CACA, CCA3, PCC|123690|2q33.3
Cataract 40, X-linked, 302200 (3)|NHS, CXN, CTRCT40|300457|Xp22.13
Cataract 5, multiple types, 116800 (3)|HSF4, CTM, CTRCT5|602438|16q22.1
Cataract 6, multiple types, 116600 (3)|EPHA2, ECK, ARCC2, CTPP1, CTPA, ARCC2, CTRCT6|176946|1p36.13
Cataract 7 (2)|CTRCT7, CCA1|115660|17q24
Cataract 8, multiple types (2)|CTRCT8, CCV|115665|1pter-p36.13
Cataract 9, multiple types, 604219 (3)|CRYAA, CRYA1, CTRCT9|123580|21q22.3
Cataract with late-onset corneal dystrophy, 106210 (3)|PAX6, AN2, MGDA|607108|11p13
Cataract, juvenile, with microcornea and glucosuria, 612018 (3)|SLC16A12, MCT12, CJMG|611910|10q23.31
Cataract, pulverulent or cerulean, with or without microcornea, 610202 (3)|MAF, CCA4|177075|16q23.2
Catel-Manzke syndrome (2)|CATMANS|302380|Chr.X
Caudal duplication anomaly, 607864 (3)|AXIN1, AXIN|603816|16p13.3
Caudal regression syndrome, 600145 (3)|VANGL1, STBM2|610132|1p13.1
Cavernous malformations of CNS and retina, 116860 (3)|CCM1, CAM, KRIT1|604214|7q21.2
Cavitary optic disc anomalies (2)|CODA|611543|12q
Cayler cardiofacial syndrome (2)|ACF|125520|22q11
Cenani-Lenz syndactyly syndrome, 212780 (3)|LRP4, MEGF7, CLSS, SOST2|604270|11p11.2
Central core disease, 117000 (3)|RYR1, MHS, CCO|180901|19q13.2
Central hypoventilation syndrome, 209880 (3)|GDNF, HSCR3|600837|5p13.2
Central hypoventilation syndrome, congenital, 209880 (3)|ASCL1, ASH1|100790|12q23.2
Central hypoventilation syndrome, congenital, 209880 (3)|BDNF, BULN2, ANON2|113505|11p14.1
Central hypoventilation syndrome, congenital, 209880 (3)|EDN3, WS4B, HSCR4|131242|20q13.32
Central hypoventilation syndrome, congenital, 209880 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 (3)|PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p13
Centrotemporal epilepsy (2)|ECT, BECTS|117100|11p13
Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3)|RNF216, TRIAD3, ZIN, CAHH|609948|7p22.1
Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3)|CA8, CALS, CARP, CAMRQ3|114815|8q12.1
Cerebellar ataxia, 604290 (3)|CP|117700|3q24-q25
Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 (3)|DNMT1, MCMT, HSN1E, ADCADN|126375|19p13.2
Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 (3)|WDR81, CAMRQ2|614218|17p13.3
Cerebellar ataxia, nonprogressive, with mental retardation, 614756 (3)|CAMTA1, KIAA0833, CANPMR|611501|1p36.31-p36.23
Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3)|VLDLR, CARMQ1|192977|9p24.2
Cerebral amyloid angiopathy, 105150 (3)|CST3, ARMD11|604312|20p11.21
Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 (3)|APP, AAA, CVAP, AD1|104760|21q21.3
Cerebral amyloid angiopathy, PRNP-related, 137440 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 (3)|NOTCH3, CADASIL, CASIL, IMF2|600276|19p13.12
Cerebral cavernous malformations 3, 603285 (3)|PDCD10, TFAR15, CCM3|609118|3q26.1
Cerebral cavernous malformations-1, 116860 (3)|CCM1, CAM, KRIT1|604214|7q21.2
Cerebral cavernous malformations-2, 603284 (3)|C7orf22, CCM2, MGC4067|607929|7p13
Cerebral creatine deficiency syndrome 1, 300352 (3)|SLC6A8, CRTR, CCDS1|300036|Xq28
Cerebral creatine deficiency syndrome 2, 612736 (3)|GAMT, CCDS2|601240|19p13.3
Cerebral creatine deficiency syndrome 3, 612718 (3)|GATM, AGAT, CCDS3|602360|15q21.1
Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3)|SNAP29, CEDNIK|604202|22q11.21
Cerebral palsy, ataxic, autosomal recessive (2)|ACP|605388|9p12-q12
Cerebral palsy, spastic quadriplegic, 1, 603513 (3)|GAD1, SCP, CPSQ1|605363|2q31.1
Cerebral palsy, spastic quadriplegic, 2, 612900 (3)|KANK1, KANK, ANKRD15, KIAA0172, CPSQ2|607704|9p24.3
Cerebral-cerebellar-coloboma syndrome, X-linked (2)|CCCSX|300864|Chr.X
Cerebrooculofacioskeletal syndrome 1, 214150 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
Cerebrooculofacioskeletal syndrome 2, 610756 (3)|ERCC2, EM9, XPD, COFS2|126340|19q13.32
Cerebrooculofacioskeletal syndrome 4, 610758 (3)|ERCC1, UV20, COFS4|126380|19q13.32
Cerebroretinal microangiopathy with calcifications and cysts, 612199 (3)|CTC1, CRMCC, C17orf68, AAF132|613129|17p13.1
Cerebrotendinous xanthomatosis, 213700 (3)|CYP27A1, CYP27, CTX|606530|2q35
Cerebrovascular disease, occlusive (3)|SERPINA3, AACT, ACT|107280|14q32.13
Ceroid lipofuscinosis, neuronal, 1, 256730 (3)|PPT1, CLN1|600722|1p34.2
Ceroid lipofuscinosis, neuronal, 10, 610127 (3)|CTSD, CPSD, CLN10|116840|11p15.5
Ceroid lipofuscinosis, neuronal, 11, 614706 (3)|GRN, CLN11|138945|17q21.31
Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3)|CTSF, CLN13|603539|11q13.2
Ceroid lipofuscinosis, neuronal, 2, 204500 (3)|TPP1, CLN2, SCAR7|607998|11p15.4
Ceroid lipofuscinosis, neuronal, 3, 204200 (3)|CLN3, BTS|607042|16p11.2
Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 (3)|DNAJC5, DNAJC5A, CSP, CLN4B|611203|20q13.33
Ceroid lipofuscinosis, neuronal, 5, 256731 (3)|CLN5|608102|13q22.3
Ceroid lipofuscinosis, neuronal, 6, 601780 (3)|CLN6, CLN4A|606725|15q23
Ceroid lipofuscinosis, neuronal, 7, 610951 (3)|MFSD8, MGC33302, CLN7|611124|4q28.2
Ceroid lipofuscinosis, neuronal, 8, 600143 (3)|CLN8, EPMR|607837|8p23.3
Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3)|CLN8, EPMR|607837|8p23.3
Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 (3)|CLN6, CLN4A|606725|15q23
Cervical cancer, somatic, 603956 (3)|FGFR3, ACH|134934|4p16.3
Cervical carcinoma (2)|ST3|191181|11q13
Chanarin-Dorfman syndrome, 275630 (3)|ABHD5, CGI58, IECN2, NCIE2|604780|3p21.33
Char syndrome, 169100 (3)|TFAP2B, CHAR|601601|6p12.3
Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 (3)|PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22.3
Charcot-Marie-Tooth disease, axonal, type 20, 614228 (3)|DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1|600112|14q32.31
Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3)|HSPB1, HSP27, CMT2F, HMN2B|602195|7q11.23
Charcot-Marie-Tooth disease, axonal, type 2G (2)|CMT2G|608591|12q12-q13.3
Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3)|GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q21.11
Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3)|HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A|608014|12q24.23
Charcot-Marie-Tooth disease, axonal, type 2M, 606482 (3)|DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5|602378|19p13.2
Charcot-Marie-Tooth disease, axonal, type 2N, 613287 (3)|AARS, CMT2N|601065|16q22.1
Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 (3)|DHTKD1, KIAA1630, AMOXAD, CMT2Q|614984|10p14
Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3)|GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q21.11
Charcot-Marie-Tooth disease, dominant intermediate A (2)|CMTDIA|606483|10q24.1-q25.1
Charcot-Marie-Tooth disease, dominant intermediate B, 606482 (3)|DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5|602378|19p13.2
Charcot-Marie-Tooth disease, dominant intermediate C, 608323 (3)|YARS, CMTDIC, TYRRS, YTS, YRS|603623|1p35.1
Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Charcot-Marie-Tooth disease, dominant intermediate E, 614455 (3)|INF2, FSGS5, C14orf173, CMTDIE|610982|14q32.33
Charcot-Marie-Tooth disease, dominant intermediate F, 615185 (3)|GNB4, CMTD1F|610863|3q26.33
Charcot-Marie-Tooth disease, foot deformity of, 192950 (3)|HOXD10, HOX4D|142984|2q31.1
Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3)|PLEKHG5, KIAA0720, DSMA4, CMTRIC|611101|1p36.31
Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3)|GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q21.11
Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 (3)|KARS, CMTRIB, DFNB89|601421|16q23.1
Charcot-Marie-Tooth disease, type 1A, 118220 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Charcot-Marie-Tooth disease, type 1B, 118200 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Charcot-Marie-Tooth disease, type 1C, 601098 (3)|LITAF, CMT1C|603795|16p13.13
Charcot-Marie-Tooth disease, type 1D, 607678 (3)|EGR2, KROX20|129010|10q21.3
Charcot-Marie-Tooth disease, type 1E, 118300 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Charcot-Marie-Tooth disease, type 1F, 607734 (3)|NEFL, CMT2E, CMT1F|162280|8p21.2
Charcot-Marie-Tooth disease, type 2A1, 118210 (3)|KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.22
Charcot-Marie-Tooth disease, type 2A2, 609260 (3)|MFN2, KIAA0214, CMT2A2|608507|1p36.22
Charcot-Marie-Tooth disease, type 2B, 600882 (3)|RAB7, CMT2B, PSN|602298|3q21.3
Charcot-Marie-Tooth disease, type 2B1, 605588 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Charcot-Marie-Tooth disease, type 2B2, 605589 (3)|MED25, PTOV2, ARC92, CMT2B2|610197|19q13.33
Charcot-Marie-Tooth disease, type 2D, 601472 (3)|GARS, SMAD1, CMT2D, HMN5|600287|7p14.3
Charcot-Marie-Tooth disease, type 2E, 607684 (3)|NEFL, CMT2E, CMT1F|162280|8p21.2
Charcot-Marie-Tooth disease, type 2I, 607677 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Charcot-Marie-Tooth disease, type 2J, 607736 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Charcot-Marie-Tooth disease, type 4A, 214400 (3)|GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q21.11
Charcot-Marie-Tooth disease, type 4B1, 601382 (3)|MTMR2, CMT4B1|603557|11q21
Charcot-Marie-Tooth disease, type 4B2, 604563 (3)|SBF2, MTMR13, CMT4B2|607697|11p15.4
Charcot-Marie-Tooth disease, type 4C, 601596 (3)|SH3TC2, KIAA1985, MNMN|608206|5q32
Charcot-Marie-Tooth disease, type 4D, 601455 (3)|NDRG1, HMSNL, CMT4D|605262|8q24.22
Charcot-Marie-Tooth disease, type 4F, 614895 (3)|PRX, CMT4F|605725|19q13.2
Charcot-Marie-Tooth disease, type 4H, 609311 (3)|FGD4, FRABIN, CMT4H|611104|12p11.21
Charcot-Marie-Tooth disease, type 4J, 611228 (3)|FIG4, KIAA0274, SAC3, ALS11, YVS|609390|6q21
Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3)|GJB1, CX32, CMTX1|304040|Xq13.1
Charcot-Marie-Tooth neuropathy, X-linked recessive, 2 (2)|CMTX2|302801|Xp22.2
Charcot-Marie-Tooth neuropathy, X-linked recessive, 3 (2)|CMTX3|302802|Xq26
Charcot-Marie-Toothe disease, axonal, type 2P, 614436 (3)|LRSAM1, TAL, RIFLE, CMT2P|610933|9q33.3
Chediak-Higashi syndrome, 214500 (3)|CHS1, LYST|606897|1q42.3
Cherubism, 118400 (3)|SH3BP2, CRPM|602104|4p16.3
Chilblain lupus 2, 614415 (3)|SAMHD1, AGS5, DCIP, CHBL2|606754|20q11.23
Chilblain lupus, 610448 (3)|TREX1, AGS1, CRV, HERNS|606609|3p21.31
Chloride diarrhea, congenital, Finnish type, 214700 (3)|SLC26A3, DRA, CLD|126650|7q31.1
Choanal atresia and lymphedema, 613611 (3)|PTPN14, PEZ|603155|1q41
Cholangitis, primary sclerosing (2)|PSC|613806|3p21
Cholestasis, benign recurrent intrahepatic, 2, 605479 (3)|ABCB11, BSEP, SPGP, PFIC2, BRIC2|603201|2q31.1
Cholestasis, benign recurrent intrahepatic, 243300 (3)|ATP8B1, FIC1, BRIC, PFIC1, ICP1|602397|18q21.31
Cholestasis, intrahepatic, of pregnancy, 1, 147480 (3)|ATP8B1, FIC1, BRIC, PFIC1, ICP1|602397|18q21.31
Cholestasis, intrahepatic, of pregnancy, 3, 614972 (3)|ABCB4, PGY3, MDR3, ICP3|171060|7q21.12
Cholestasis, progressive canalicular (1)|VIL1|193040|2q35
Cholestasis, progressive familial intrahepatic 1, 211600 (3)|ATP8B1, FIC1, BRIC, PFIC1, ICP1|602397|18q21.31
Cholestasis, progressive familial intrahepatic 2, 601847 (3)|ABCB11, BSEP, SPGP, PFIC2, BRIC2|603201|2q31.1
Cholestasis, progressive familial intrahepatic 3, 602347 (3)|ABCB4, PGY3, MDR3, ICP3|171060|7q21.12
Cholestasis-lymphedema syndrome (2)|LCS1, CHLS|214900|15q
Cholesteryl ester storage disease, 278000 (3)|LIPA, CESD|613497|10q23.31
Chondrocalcinosis 2, 118600 (3)|ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD|605145|5p15.2
Chondrocalcinosis with early-onset osteoarthritis (2)|CCAL1|600668|8q
Chondrodysplasia punctata, X-linked dominant, 302960 (3)|EBP, CDPX2, CPXD, CPX|300205|Xp11.23
Chondrodysplasia punctata, X-linked recessive, 302950 (3)|ARSE, CDPX1, CDPXR|300180|Xp22.33
Chondrodysplasia punctata, rhizomelic, type 2, 222765 (3)|GNPAT, DHAPAT|602744|1q42.2
Chondrodysplasia with joint dislocations, GRAPP type, 614078 (3)|IMPAD1, GPAPP, IMPA3|614010|8q12.1
Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3)|HDAC6, CPBHM|300272|Xp11.23
Chondrodysplasia, Blomstrand type, 215045 (3)|PTHR1, PTHR, PFE|168468|3p21.31
Chondrodysplasia, Grebe type, 200700 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Chondrosarcoma, 215300 (3)|EXT1|608177|8q24.11
Chondrosarcoma, extraskeletal myxoid, 612237 (1)|TAF15, TAF2N, RBP56|601574|17q12
Chondrosarcoma, extraskeletal myxoid, 612237 (1)|TFG, HMSNP, SPG57|602498|3q12.2
Chondrosarcoma, extraskeletal myxoid, 612237 (3)|CSMF|600542|9q22.3-q31.1
Chorea, hereditary benign, 118700 (3)|NKX2-1, TITF1, NKX2A, TTF1|600635|14q13.3
Choreoacanthocytosis, 200150 (3)|VPS13A, CHAC|605978|9q21.2
Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3)|NKX2-1, TITF1, NKX2A, TTF1|600635|14q13.3
Choreoathetosis/spasticity, episodic (2)|CSE, DYT9|601042|1p
Choriodal dystrophy, central areolar 2, 613105 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Chorioretinal atrophy, progressive bifocal (2)|PBCRA, CRAPB|600790|6q14-q16.2
Choroid plexus papilloma, 260500 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Choroidal dystrophy, central areolar 1 (2)|CACD1|215500|17p
Choroideremia, 303100 (3)|CHM, TCD|300390|Xq21.2
Choroideremia, deafness, and mental retardation (4)|DELXq21, CXDELq21|303110|Xq21
Chromosome 10q23 deletion syndrome (4)|DEL10q23, C10DELq23|612242|10q23
Chromosome 10q26 deletion syndrome (4)|DEL10q26, C10q26DEL|609625|10q26
Chromosome 11p15-p14 deletion syndrome (4)|DEL11p15p14, C11DELp15p14|606528|11p15-p14
Chromosome 13q14 deletion syndrome (4)|DEL13q14, C13DELq14|613884|13q14
Chromosome 14q11-q22 deletion syndrome (4)|DEL14q11q22, C14DELq11q22|613457|14q11-q22
Chromosome 15q11.2 deletion syndrome (4)|DEL15q11.2, C15DELq11.2|615656|15q11.2
Chromosome 15q13.3 microdeletion syndrome (4)|DEL15q13.3, MICRODEL15q13.3|612001|15q13.3
Chromosome 15q24 deletion syndrome (4)|DEL15q24, CHR15DELq24|613406|15q24
Chromosome 15q25 deletion syndrome (4)|DEL15q25, C15DELq25|614294|15q25
Chromosome 15q26-qter deletion syndrome (4)|DEL15q26qter, C15DELq26qter|612626|15q26-qter
Chromosome 16p11.2 deletion syndrome, 220kb (4)|BMIQ16, DEL16p.11.2, C16DELp11.2|613444|16p11.2
Chromosome 16p11.2 deletion syndrome, 593kb (4)|DEL16p11.2, C16DELp11.2, AUTS14A|611913|16p11.2
Chromosome 16p11.2 duplication syndrome (4)|DUP16p11.2, C16DUPp11.2, AUTS14B|614671|16p11.2
Chromosome 16p12.1 deletion syndrome, 520kb (4)|DEL16p12.1, C16DELp12.1|136570|16p12
Chromosome 16p12.2-p11.2 deletion syndrome (4)|DEL16p12.1p11.2, C16DELp12.1p11.2|613604|16p12.2-p11.2
Chromosome 16p13.3 deletion syndrome (4)|DEL16p13.3, RSTSS|610543|16p13.3
Chromosome 16p13.3 duplication syndrome (4)|DUP16p13.3, C16DUPq13.3|613458|16p13.3
Chromosome 16q22 deletion syndrome (4)|C16DELq22, DEL16q22|614541|16q22
Chromosome 17p13.1 deletion syndrome (4)|DEL17p13.1, C17DELp13.1|613776|17p13.1
Chromosome 17p13.3 duplication syndrome (4)|DUP17p13.3, C17DUPp13.3|613215|17p13.3
Chromosome 17q11.2 deletion syndrome, 1.4Mb (4)|DEL17q11.2, C17DELq11.2|613675|17q11.2
Chromosome 17q12 deletion syndrome (4)|DEL17q12, C17DELq12|614527|17q12
Chromosome 17q12 duplication syndrome (4)|DUP17q12, C17DUPq12|614526|17q12
Chromosome 17q21.31 duplication syndrome (4)|DUP17q21.31, C17DUPq21.31|613533|17q21.31
Chromosome 17q23.1-q23.2 deletion syndrome (4)|DEL17q23.1q23.2, C17DELq23.1q23.2|613355|17q23.1-q23.2
Chromosome 17q23.1-q23.2 duplication syndrome (4)|DUP17q23.1q23.2, C17DUPq23.1q23.2|613618|17q23.1-q23.2
Chromosome 18 pericentric inversion (4)|DUP18pDEL18q, DUP81qDEL18p|609334|18q22
Chromosome 18p deletion syndrome (4)|DEL18p, C18DELp|146390|18p
Chromosome 18q deletion syndrome (4)|DEL18q|601808|18q
Chromosome 19p13.13 deletion syndrome (4)|DEL19p13.13, C19DELp13.13, DUP19p13.13, C19DUPp13.13|613638|19p13.13
Chromosome 19p13.13 duplication syndrome (4)|DEL19p13.13, C19DELp13.13, DUP19p13.13, C19DUPp13.13|613638|19p13.13
Chromosome 19q13.11 deletion syndrome (4)|DEL19q13.11, C19DELq13.11|613026|19q13.11
Chromosome 1p32-p31 deletion syndrome (4)|DEL1p32p31, C1DELp32p31|613735|1p32-p31
Chromosome 1p36 deletion syndrome (4)|DEL1p36, C1DELp36|607872|1p36
Chromosome 1q21.1 deletion syndrome (4)|DEL1q21, C1DELq21|612474|1q21.1
Chromosome 1q21.1 duplication syndrome (4)|DUP1q21, C1DUPq21|612475|1q21.1
Chromosome 1q41-q42 deletion syndrome (4)|DEL1q41q42, C1DELq41q42|612530|1q41-q42
Chromosome 1q43-q44 deletion syndrome (4)|DEL1q43q44, C1DELq43q44|612337|1q43-q44
Chromosome 22q11.2 deletion syndrome, distal (4)|DEL22q11.2, C22DELq11.2|611867|22q11.2
Chromosome 22q11.2 microduplication syndrome (4)|DUP22q11.2|608363|22q11.2
Chromosome 22q13 duplication syndrome, 615538 (4)|DUP22q13, C22DUPq13|615538|22q13
Chromosome 2p12-p11.2 deletion syndrome (4)|DEL2p12p11.2, C2DELp12p11.2|613564|2p12-p11.2
Chromosome 2p16.1-p15 deletion syndrome (4)|DEL2p16.1-p15, C2DELp161-p15|612513|2p16.1-p15
Chromosome 2q31.1 duplication syndrome (4)|DUP2q31.1, C2DUPq31.1|613681|2q31.1
Chromosome 2q31.2 deletion syndrome (4)|DEL2q31|612345|2q31.2
Chromosome 3q13.31 deletion syndrome (4)|DEL3q13.31, C13DELq13.31|615433|3q13.31
Chromosome 3q29 microdeletion syndrome (4)|DEL3q29, MICRODEL3q29|609425|3q29
Chromosome 3q29 microduplication syndrome (4)|DUP3q29, MICRODUP3q29|611936|3q29
Chromosome 4q21 deletion syndrome (4)|DEL4q21, C4DELq21|613509|4q21
Chromosome 4q32.1-q32.2 triplication syndrome (4)|TRIP4q32.1q32.2, C4TRIPq32.1q32.2|613603|4q32.1-q32.2
Chromosome 5p13 duplication syndrome (4)|DUP5p13, C5DUPp13|613174|5p13
Chromosome 5q12 deletion sydrome (4)|DEL5q12, C5DELq12|615668|5q12
Chromosome 5q14.3 deletion syndrome, 613443 (4)|MEF2C, C5DELq14.3, DEL5q14.3|600662|5q14.3
Chromosome 6pter-p24 deletion syndrome (4)|DEL6pter, C6DELpter|612582|6pter-p24
Chromosome 6q11-q14 deletion syndrome (4)|DEL6q11q14, C6DELq11q14|613544|6q11-q14
Chromosome 6q25-q25 deletion syndrome (4)|DEL6q24q25, C6DELq25q25|612863|6q24-q25
Chromosome 7q11.23 deletion syndrome, distal, 1.2Mb (4)|DEL7q11.23, C7DELq11.23|613729|7q11.23
Chromosome 7q11.23 duplication syndrome (4)|DUP7q11.23, C7DUPq11.23|609757|7q11.23
Chromosome 8p11 myeloproliferative syndrome (4)|SCLL|613523|8p11
Chromosome 8q21.11 deletion syndrome (4)|DEL8q21.11, C8DELq21.11|614230|8q21.11
Chromosome 9p deletion syndrome (4)|DEL9p, C9DELp|158170|9p
Chromosome Xp11.23-p11.22 duplication syndrome (4)|DUPXp11.23p11.22, CXDUPp11.23p11.22|300801|Xp11.23-p11.22
Chromosome Xp11.3 deletion syndrome (4)|DELXp11.3, CXDELp11.3|300578|Xp11.3
Chromosome Xp21 deletion syndrome (4)|DELXp21, CXDELp21|300679|Xp21
Chromosome Xq27.3-q28 duplication syndrome (4)|DUPXq27.3q28, CXDUPq27.3q28|300869|Xq27.3-q28
Chromosome Xq28 duplication syndrome (4)|DUPXq28, CXq28|300815|Xq28
Chrondrodysplasia, acromesomelic, with genital anomalies, 609441 (3)|BMPR1B, ALK6|603248|4q22.3
Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3)|NCF1|608512|7q11.23
Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3)|NCF2|608515|1q25.3
Chronic granulomatous disease, X-linked, 306400 (3)|CYBB, CGD, AMCBX2|300481|Xp11.4
Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3)|CYBA|608508|16q24.3
Chudley-McCullough syndrome, 604213 (3)|GPSM2, LGN, PINS, DFNB82, CMCS|609245|1p13.3
Chylomicron retention disease, 246700 (3)|SAR1B, CMRD, SARA2, ANDD|607690|5q31.1
Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3)|DNAI1, CILD1, ICS, PCD|604366|9p13.3
Ciliary dyskinesia, primary, 10, 612518 (3)|KTU, C14orf104, CILD10|612517|14q21.3
Ciliary dyskinesia, primary, 11, 612649 (3)|RSPH4A, CILD11|612647|6q22.1
Ciliary dyskinesia, primary, 12, 612650 (3)|RSPH9, CILD12|612648|6p21.1
Ciliary dyskinesia, primary, 13, 613193 (3)|LRRC50, ODA7, CILD13|613190|16q23.3-q24.1
Ciliary dyskinesia, primary, 14, 613807 (3)|CCDC39|613798|3q26.33
Ciliary dyskinesia, primary, 15, 613808 (3)|CCDC40, KIAA1640|613799|17q25.3
Ciliary dyskinesia, primary, 16, 614017 (3)|DNAL1, C14orf168, CILD16|610062|14q24.3
Ciliary dyskinesia, primary, 17, 614679 (3)|CCDC103, SMH, PR46B, CILD17|614677|17q21.31
Ciliary dyskinesia, primary, 18, 614874 (3)|HEATR2, CILD18|614864|7p22.3
Ciliary dyskinesia, primary, 19, 614935 (3)|LRRC6, LRTP, CILD19|614930|8q24.22
Ciliary dyskinesia, primary, 2, 606763 (3)|DNAAF3, PF22, DAB1, CILD2|614566|19q13.42
Ciliary dyskinesia, primary, 20, 615067 (3)|CCDC114, CILD20|615038|19q13.33
Ciliary dyskinesia, primary, 21, 615294 (3)|DRC1, CCDC164, C2orf39, CILD21|615288|2p23.3
Ciliary dyskinesia, primary, 22, 615444 (3)|ZMYND10, BLU|607070|3p21.31
Ciliary dyskinesia, primary, 23, 615451 (3)|ARMC4, CILD23|615408|10p12.1
Ciliary dyskinesia, primary, 24, 615481 (3)|RSPH1, TSGA2, TSA2, CILD24|609314|21q22.3
Ciliary dyskinesia, primary, 25, 615482 (3)|DYX1C1, DYXC1, DYX1, CILD25|608706|15q21.3
Ciliary dyskinesia, primary, 26, 615500 (3)|C21ORF59, CILD26|615494|21q22.11
Ciliary dyskinesia, primary, 27, 615504 (3)|CCDC65, CILD27|611088|12q13.12
Ciliary dyskinesia, primary, 28, 615505 (3)|SPAG1, CILD28|603395|8q22.2
Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3)|DNAH5, HL1, PCD, CILD3|603335|5p15.2
Ciliary dyskinesia, primary, 4 (2)|CILD4|608646|15q13.1-q15.1
Ciliary dyskinesia, primary, 5, 608647 (3)|HYDIN, HYDIN1, CILD5|610812|16q22.2
Ciliary dyskinesia, primary, 6, 610852 (3)|NME8, TXNDC3, SPTRX2, CILD6|607421|7p14.1
Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3)|DNAH11, DNAHC11, CILD7, DNAHBL|603339|7p15.3
Ciliary dyskinesia, primary, 8 (2)|CILD8|612274|15q24-q25
Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3)|DNAI2, CILD9|605483|17q25.1
Cirrhosis due to liver phosphorylase kinase deficiency (3)|PHKG2, GSD9C|172471|16p11.2
Cirrhosis, North American Indian childhood type, 604901 (3)|CIRH1A, NAIC, TEX292, KIAA1988|607456|16q22.1
Cirrhosis, cryptogenic, 215600 (3)|KRT18|148070|12q13.13
Cirrhosis, cryptogenic, 215600 (3)|KRT8|148060|12q13.13
Citrullinemia, 215700 (3)|ASS1, ASS|603470|9q34.11
Citrullinemia, adult-onset type II, 603471 (3)|SLC25A13, CTLN2|603859|7q21.3
Citrullinemia, type II, neonatal-onset, 605814 (3)|SLC25A13, CTLN2|603859|7q21.3
Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3)|HVEC, PVRL1, PVRR1, PRR1, ED4, OFC7, CLPED1|600644|11q23.3
Cleft palate with ankyloglossia, 303400 (3)|TBX22, CPX, ABERS|300307|Xq21.1
Cleft palate, isolated, 119540 (2)|UBB|191339|17p11.2
Cleidocranial dysplasia, 119600 (3)|RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD|600211|6p21.1
Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3)|RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD|600211|6p21.1
Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3)|RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD|600211|6p21.1
Clopidogrel, impaired responsiveness to, 609535 (3)|CYP2C, CYP2C19|124020|10q23.33
Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3)|PITX1, PTX1, BFT, POTX, CCF, LBNBG|602149|5q31.1
Cockayne syndrome, type A, 216400 (3)|ERCC8, CKN1, CSA, UVSS2|609412|5q12.1
Cockayne syndrome, type B, 133540 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
Cocoon syndrome, 613630 (3)|CHUK, IKBKA, NFKBIKA, IKKA, IKK1|600664|10q24.31
Coenzyme Q10 deficiency, primary, 1, 607426 (3)|COQ2, COQ10D1, MSA1|609825|4q21.23
Coenzyme Q10 deficiency, primary, 2, 614651 (3)|PDSS1, TPT, COQ1, COQ10D2|607429|10p12.1
Coenzyme Q10 deficiency, primary, 3, 614652 (3)|PDSS2, DLP1, C6orf210, COQ10D3|610564|6q21
Coenzyme Q10 deficiency, primary, 4, 612016 (3)|CABC1, COQ8, ADCK3, SCAR9, ARCA2, COQ10D4|606980|1q42.13
Coenzyme Q10 deficiency, primary, 5, 614654 (3)|COQ9, C16orf49, COQ10D5|612837|16q21
Coenzyme Q10 deficiency, primary, 6, 614650 (3)|COQ6, CGI10, COQ10D6|614647|14q24.3
Coffin-Lowry syndrome, 303600 (3)|RPS6KA3, RSK2, MRX19|300075|Xp22.12
Cognitive impairment with or without cerebellar ataxia, 614306 (3)|SCN8A, CIAT, EIEE13|600702|12q13.13
Cohen syndrome, 216550 (3)|VPS13B, KIAA0532, COH1|607817|8q22.2
Cold-induced autoinflammatory syndrome, familial, 120100 (3)|NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
Cold-induced sweating syndrome 1, 610313 (3)|CLCF1, BSF3, CLC|607672|11q13.2
Cold-induced sweating syndrome, 272430 (3)|CRLF1, CISS|604237|19p13.11
Cole disease, 615522 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
Coloboma of optic nerve, 120430 (3)|PAX6, AN2, MGDA|607108|11p13
Coloboma, ocular, 120200 (3)|PAX6, AN2, MGDA|607108|11p13
Colon cancer, advanced (3)|SRC, ASV, SRC1|190090|20q11.23
Colon cancer, somatic, 114500 (3)|PTPN12, PTPG1|600079|7q11.23
Colon cancer, somatic, 114500 (3)|PTPRJ, DEP1|600925|11p11.2
Colon cancer, somatic, 114500 (3)|RAD54B|604289|8q22.1
Colorblindness, deutan, 303800 (3)|OPN1MW, GCP, CBD, CBBM|300821|Xq28
Colorblindness, protan, 303900 (3)|OPN1LW, RCP, CBP, CBBM|300822|Xq28
Colorblindness, tritan, 190900 (3)|OPN1SW, BCP, CBT|613522|7q32.1
Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3)|MUTYH, MYH|604933|1p34.1
Colorectal cancer with chromosomal instability (3)|BUB1|602452|2q13
Colorectal cancer, 114500 (3)|BAX|600040|19q13.33
Colorectal cancer, 114500 (3)|MCC|159350|5q22.2
Colorectal cancer, 114500 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3)|MSH2, COCA1, FCC1, HNPCC1|609309|2p21
Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3)|MLH1, COCA2, HNPCC2|120436|3p22.2
Colorectal cancer, hereditary nonpolyposis, type 4, 614337 (3)|PMS2, PMSL2, HNPCC4|600259|7p22.1
Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3)|MSH6, GTBP, HNPCC5|600678|2p16.3
Colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3)|TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p24.1
Colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3)|MLH3, HNPCC7|604395|14q24.3
Colorectal cancer, hereditary nonpolyposis, type 8, 613244 (3)|EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8|185535|2p21
Colorectal cancer, somatic (3)|BRAF, NS7|164757|7q34
Colorectal cancer, somatic (3)|DLC1|604258|8p22
Colorectal cancer, somatic, 114500 (3)|AKT1, CWS6|164730|14q32.33
Colorectal cancer, somatic, 114500 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Colorectal cancer, somatic, 114500 (3)|AXIN2, ODCRCS|604025|17q24.1
Colorectal cancer, somatic, 114500 (3)|BUB1B, BUBR1, MVA1|602860|15q15.1
Colorectal cancer, somatic, 114500 (3)|CTNNB1, MRD19|116806|3p22.1
Colorectal cancer, somatic, 114500 (3)|DCC, MRMV1|120470|18q21.2
Colorectal cancer, somatic, 114500 (3)|EP300, RSTS2|602700|22q13.2
Colorectal cancer, somatic, 114500 (3)|FGFR3, ACH|134934|4p16.3
Colorectal cancer, somatic, 114500 (3)|FLCN, BHD|607273|17p11.2
Colorectal cancer, somatic, 114500 (3)|MLH3, HNPCC7|604395|14q24.3
Colorectal cancer, somatic, 114500 (3)|NRAS, ALPS4, NS6|164790|1p13.2
Colorectal cancer, somatic, 114500 (3)|PDGFRL, PDGRL, PRLTS|604584|8p22
Colorectal cancer, somatic, 114500 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Combined C6/C7 deficiency (3)|C6|217050|5p13.1
Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 (3)|SLC25A1, SLC20A3, CTP, D2L2AD|190315|22q11.21
Combined SAP deficiency, 611721 (3)|PSAP, SAP1|176801|10q22.1
Combined cellular and humoral immune defects with granulomas, 233650 (3)|RAG1|179615|11p12
Combined cellular and humoral immune defects with granulomas, 233650 (3)|RAG2|179616|11p12
Combined factor V and VIII deficiency, 227300 (3)|LMAN1, ERGIC53, F5F8D, MCFD1|601567|18q21.32
Combined hyperlipidemia, familial, 144250 (3)|LPL, LIPD, HDLCQ11|609708|8p21.3
Combined immunodeficiency, X-linked, moderate, 312863 (3)|IL2RG, SCIDX1, SCIDX, IMD4|308380|Xq13.1
Combined malonic and methylmalonic aciduria, 614265 (3)|ACSF3|614245|16q24.3
Combined oxidative phosphorylation deficiency 1, 609060 (3)|GFM1, EFG1, GFM, COXPD1|606639|3q25.32
Combined oxidative phosphorylation deficiency 10, 614702 (3)|MTO1, COXPD10|614667|6q13
Combined oxidative phosphorylation deficiency 11, 614922 (3)|RMND1, COXPD11|614917|6q25.1
Combined oxidative phosphorylation deficiency 12, 614924 (3)|EARS2, KIAA1970, COXPD12|612799|16p12.2
Combined oxidative phosphorylation deficiency 13, 614932 (3)|PNPT1, OLD35, COXPD13, DFNB70|610316|2p16.1
Combined oxidative phosphorylation deficiency 14, 614946 (3)|FARS2, FARS1, COXPD14|611592|6p25.1
Combined oxidative phosphorylation deficiency 15, 614947 (3)|MTFMT, COXPD15|611766|15q22.31
Combined oxidative phosphorylation deficiency 17, 615440 (3)|ELAC2, HPC2, COXPD17|605367|17p12
Combined oxidative phosphorylation deficiency 18, 615578 (3)|SFXN4, COXPD18|615564|10q26.11
Combined oxidative phosphorylation deficiency 2, 610498 (3)|MRPS16, COXPD2|609204|10q22.2
Combined oxidative phosphorylation deficiency 3, 610505 (3)|TSFM, COXPD3|604723|12q14.1
Combined oxidative phosphorylation deficiency 4, 610678 (3)|TUFM, EFTU, COXPD4|602389|16p11.2
Combined oxidative phosphorylation deficiency 5, 611719 (3)|MRPS22, C3orf5, COXPD5|605810|3q23
Combined oxidative phosphorylation deficiency 6, 300816 (3)|AIFM1, PDCD8, AIF, COXPD6, COWCK, CMTX4|300169|Xq26.1
Combined oxidative phosphorylation deficiency 7, 613559 (3)|C12orf65, COXPD7, SPG55|613541|12q24.31
Combined oxidative phosphorylation deficiency 8, 614096 (3)|AARS2, KIAA1270, MTALARS, COXPD8|612035|6p21.1
Combined oxidative phosphorylation deficiency 9, 614582 (3)|MRPL3, MRL3, COXPD9|607118|3q22.1
Complement component 4, partial deficiency of, 120790 (3)|C1NH, HAE1, HAE2, SERPING1|606860|11q12.1
Complement factor D deficiency, 613912 (3)|CFD, ADN|134350|19p13.3
Complement factor H deficiency, 609814 (3)|HF1, CFH, HUS, ARMD4, AHUS1|134370|1q31.3
Complement factor I deficiency, 610984 (3)|CFI, FI, AHUS3, ARMD13|217030|4q25
Complex I, mitochondrial respiratory chain, deficiency of, 252010 (3)|NDUFS6|603848|5p15.33
Cone dystrophy 4, 613093 (3)|PDE6C, PDEA2, COD4|600827|10q23.33
Cone dystrophy, progressive X-linked, 2 (2)|COD2|300085|Xq27
Cone dystrophy-3, 602093 (3)|GUCA1A, GCAP, COD3, CORD14|600364|6p21.1
Cone-rod dystrophy 10, 610283 (3)|SEMA4A, SEMB, RP35, CORD10|607292|1q22
Cone-rod dystrophy 11, 610381 (3)|RAXL1, QRX, CORD11, ARMD6|610362|19p13.3
Cone-rod dystrophy 12, 612657 (3)|PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.32
Cone-rod dystrophy 13, 608194 (3)|RPGRIP1, LCA6, CORD13|605446|14q11.2
Cone-rod dystrophy 14, 602093 (3)|GUCA1A, GCAP, COD3, CORD14|600364|6p21.1
Cone-rod dystrophy 15, 613660 (3)|CDHR1, PCDH21, PRCAD, CORD15, RP65|609502|10q23.1
Cone-rod dystrophy 16, 614500 (3)|C8orf37, CORD16, RP64|614477|8q22.1
Cone-rod dystrophy 17 (2)|CORD17|615163|10q26
Cone-rod dystrophy 18, 615374 (3)|RAB28, CORD18|612994|4p15.33
Cone-rod dystrophy 3, 604116 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Cone-rod dystrophy 5, 600977 (3)|PITPNM3, NIR1, CORD5|608921|17p13.2
Cone-rod dystrophy 6, 601777(3)|GUCY2D, GUC2D, LCA1, CORD6, RCD2|600179|17p13.1
Cone-rod dystrophy 7, 603649 (3)|RIMS1, RIM1, RIM, KIAA0340, CORD7|606629|6q13
Cone-rod dystrophy 8 (2)|CORD8|605549|1q12-q24
Cone-rod dystrophy 9, 612775 (3)|ADAM9, MDC9, MCMP, CORD9|602713|8p11.22
Cone-rod dystrophy, 604393 (3)|AIPL1, LCA4|604392|17p13.2
Cone-rod dystrophy, X-linked, 1, 304020 (3)|RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Cone-rod dystropy, X-linked, 3, 300476 (3)|CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Cone-rod retinal dystrophy-1 (2)|CORD1, CRD1|600624|18q21.1-q21.3
Cone-rod retinal dystrophy-2, 120970 (3)|CRX, CORD2, CRD, LCA7|602225|19q13.33
Congenital bilateral absence of vas deferens, 277180 (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3)|CTDP1, FCP1, CCFDN|604927|18q23
Congenital cataracts, hearing loss, and neurodegeneration, 614482 (3)|SLC33A1, ACATN, AT1, SPG42, CCHLND|603690|3q25.31
Congenital disorder of glycosylation, type IIa, 212066 (3)|MGAT2, CDGS2, CDG2A|602616|14q21.3
Congenital disorder of glycosylation, type IIb, 606056 (3)|GCS1, CDG2B|601336|2p13.1
Congenital disorder of glycosylation, type IIc, 266265 (3)|SLC35C1, FUCT1, CDG2C|605881|11p11.2
Congenital disorder of glycosylation, type IId, 607091 (3)|B4GALT1, GGTB2, GT1, GTB, CDG2D|137060|9p21.1
Congenital disorder of glycosylation, type IIe, 608779 (3)|COG7, CDG2E|606978|16p12.2
Congenital disorder of glycosylation, type IIf, 603585 (3)|SLC35A1, CST, CDG2F|605634|6q15
Congenital disorder of glycosylation, type IIg, 611209 (3)|COG1, LDLB, KIAA1381, CDG2G|606973|17q25.1
Congenital disorder of glycosylation, type IIh, 611182 (3)|COG8, DOR1, CDG2H|606979|16q22.1
Congenital disorder of glycosylation, type IIi, 613612 (3)|COG5, GOLTC1, GTC90, CDG2I|606821|7q22.3
Congenital disorder of glycosylation, type IIj, 613489 (3)|COG4, COD1, CDG2J|606976|16q22.1
Congenital disorder of glycosylation, type IIk, 614727 (3)|TMEM165, FT27, CDG2K|614726|4q12
Congenital disorder of glycosylation, type IIl, 614576 (3)|COG6, COD2, KIAA1134, CDG2L, SHNS|606977|13q14.11
Congenital disorder of glycosylation, type IIm, 300896 (3)|SLC35A2, UGALT, UGTL, UGT2, CDGX, CDG2M|314375|Xp11.23
Congenital disorder of glycosylation, type Ia, 212065 (3)|PMM2, CDG1A|601785|16p13.2
Congenital disorder of glycosylation, type Ib, 602579 (3)|MPI, PMI1, CDG1B|154550|15q24.1
Congenital disorder of glycosylation, type Ic, 603147 (3)|ALG6, CDG1C|604566|1p31.3
Congenital disorder of glycosylation, type Id, 601110 (3)|ALG3, NOT56L, CDGS4, CDG1D|608750|3q27.1
Congenital disorder of glycosylation, type Ie, 608799 (3)|DPM1, MPDS, CDGIE|603503|20q13.13
Congenital disorder of glycosylation, type If, 609180 (3)|MPDU1, SL15, CDGIF|604041|17p13.1
Congenital disorder of glycosylation, type Ig, 607143 (3)|ALG12, CDG1G|607144|22q13.33
Congenital disorder of glycosylation, type Ih, 608104 (3)|ALG8, CDG1H|608103|11q14.1
Congenital disorder of glycosylation, type Ii, 607906 (3)|ALG2, CDGII|607905|9q22.33
Congenital disorder of glycosylation, type Ij, 608093 (3)|DPAGT1, DPAGT2, DGPT, CDG1J, CMSTA2|191350|11q23.3
Congenital disorder of glycosylation, type Ik, 608540 (3)|ALG1, HMAT1, HMT1, CDG1K|605907|16p13.3
Congenital disorder of glycosylation, type Il, 608776 (3)|ALG9, DIBD1, CDG1L|606941|11q23.1
Congenital disorder of glycosylation, type Im, 610768 (3)|TMEM15, DK1, SEC59, KIAA1094, CDG1M|610746|9q34.11
Congenital disorder of glycosylation, type In, 612015 (3)|RFT1, CDG1N|611908|3p21.1
Congenital disorder of glycosylation, type Io, 612937 (3)|DPM3, CDG1O|605951|1q22
Congenital disorder of glycosylation, type Ip, 613661 (3)|ALG11, KIAA1266, CDG1P|613666|13q14.3
Congenital disorder of glycosylation, type Iq, 612379 (3)|SRD5A3, SRD5A2L, CDG1Q, KRIZI|611715|4q12
Congenital disorder of glycosylation, type Ir, 614507 (3)|DDOST, OST, OST48, CDG1R|602202|1p36.12
Congenital disorder of glycosylation, type Is, 300884 (3)|ALG13, GLT28D1, CDG1S|300776|Xq23
Congenital disorder of glycosylation, type It, 614921 (3)|PGM1, GSD14, GSD14, CDG1T|171900|1p31.3
Congenital disorder of glycosylation, type Iu, 615042 (3)|DPM2, CDG1U|603564|9q34.11
Congenital heart defects, multiple types, 3 (2)|CHDT3|614954|9q31.1
Congenital heart defects, nonsyndromic, 1, X-linked, 306955 (3)|ZIC3, HTX1, HTX, VACTERLX|300265|Xq26.3
Congenital heart defects, nonsyndromic, 2, 614980 (3)|TAB2, MAP3K7IP2, KIAA0733, CHTD2|605101|6q25.1
Congenital myopathy with excess of muscle spindles, 218040 (3)|HRAS|190020|11p15.5
Congenital short bowel syndrome, 300048 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Congenital short bowel syndrome, 615237 (3)|CLMP, ASAM, ACAM, CSBS|611693|11q24.1
Conjunctivitis, ligneous, 217090 (3)|PLG|173350|6q26
Conotruncal anomaly face syndrome, 217095 (3)|TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.21
Conotruncal heart malformations, variable, 217095 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Contractural arachnodactyly, congenital, 121050 (3)|FBN2, CCA|612570|5q23.3
Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3)|PRRT2, PKC, DYT10, EKD1, BFIS2, BFIC2, ICCA|614386|16p11.2
Coproporphyria, 121300 (3)|CPOX|612732|3q11.2-q12.1
Cornea plana congenita, recessive, 217300 (3)|KERA, CNA2|603288|12q21.33
Corneal clouding, autosomal recessive (3)|APOA1|107680|11q23.3
Corneal dystrophy polymorphous posterior, 2, 609140 (3)|COL8A2, FECD1, PPCD2|120252|1p34.3
Corneal dystrophy, Avellino type, 607541 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, Fuchs endothelial, 1, 136800 (3)|COL8A2, FECD1, PPCD2|120252|1p34.3
Corneal dystrophy, Fuchs endothelial, 2 (2)|FECD2, FCD1|610158|13pter-q12.13
Corneal dystrophy, Fuchs endothelial, 3 (2)|FECD3, FCD2|613267|18q21.2-q21.3
Corneal dystrophy, Fuchs endothelial, 4, 613268 (3)|SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13
Corneal dystrophy, Fuchs endothelial, 5 (2)|FECD5, FCD3|613269|5q33.1-q35.2
Corneal dystrophy, Fuchs endothelial, 6, 613270 (3)|ZEB1, TCF8, NIL2A, PPCD3, FECD6|189909|10p11.22
Corneal dystrophy, Fuchs endothelial, 7 (2)|FECD7, FCD4|613271|9p24.1-p22.1
Corneal dystrophy, Fuchs endothelial, 8, 615523 (3)|AGBL1, CCP4, FECD8|615496|15q25.3
Corneal dystrophy, Groenouw type I, 121900 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, Lisch epithelial (2)|LECD|300778|Xp22.3
Corneal dystrophy, Reis-Bucklers type, 608470 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, Schnyder type, 121800 (3)|UBIAD1, TERE1, SCCD|611632|1p36.22
Corneal dystrophy, Thiel-Behnke type (2)|CDB2, CDTB|602082|10q24
Corneal dystrophy, Thiel-Behnke type, 602082 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, congenital stromal, 610048 (3)|DCN, CSCD|125255|12q21.33
Corneal dystrophy, endothelial, X-linked (2)|XECD|300779|Xq25
Corneal dystrophy, epithelial basement membrane, 121820 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, gelatinous drop-like, 204870 (3)|TACSTD2, TROP2, M1S1|137290|1p32.1
Corneal dystrophy, hereditary polymorphous posterior, 122000 (3)|VSX1, RINX, PPCD, PPD, KTCN1, CAASDS|605020|20p11.21
Corneal dystrophy, lattice type I, 122200 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, lattice type IIIA, 608471 (3)|TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31.1
Corneal dystrophy, posterior polymorphous, 3, 609141 (3)|ZEB1, TCF8, NIL2A, PPCD3, FECD6|189909|10p11.22
Corneal endothelial dystrophy 1, autosomal dominant (2)|CHED1, CHED|121700|20p11.2-q11.2
Corneal endothelial dystrophy 2, autosomal recessive, 217700 (3)|SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13
Corneal endothelial dystrophy and perceptive deafness, 217400 (3)|SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13
Corneal fleck dystrophy, 121850 (3)|PIKFYVE, PIP5K3|609414|2q34
Cornelia de Lange syndrome 1, 122470 (3)|NIPBL, CDLS1|608667|5p13.2
Cornelia de Lange syndrome 2, 300590 (3)|DXS423E, SMC1, CDLS2|300040|Xp11.22
Cornelia de Lange syndrome 3, 610759 (3)|CSPG6, SMC3, HCAP, BAM, CDLS3|606062|10q25.2
Cornelia de Lange syndrome 4, 614701 (3)|RAD21, SCC1, NXP1, KIAA0078, CDLS4|606462|8q24.11
Cornelia de Lange syndrome 5, 300882 (3)|HDAC8, WTS, MRXS6, CDLS5|300269|Xq13.1
Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3)|IGBP1|300139|Xq13.1
Corpus callosum, partial agenesis of, 304100 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
Cortical dysplasia, complex, with other brain malformations 1, 614039 (3)|TUBB3, TUBB4, CFEOM3A, CDCBM1|602661|16q24.3
Cortical dysplasia, complex, with other brain malformations 3, 615411 (3)|KIF2A, CDCBM3|602591|5q12.1
Cortical dysplasia, complex, with other brain malformations 4, 615412 (3)|TUBG1, CDCBM4|191135|17q21.2
Cortical dysplasia-focal epilepsy syndrome, 610042 (3)|CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
Cortical malformations, occipital, 614115 (3)|LAMC3, OCCM|604349|9q34.12
Corticosteroid-binding globulin deficiency, 611489 (3)|CBG, SERPINA6|122500|14q32.13
Cortisol resistance (3)|NR3C1, GCR, GRL|138040|5q31.3
Cortisone reductase deficiency 1, 604931 (3)|H6PD, GDH, G6PDH, CORTRD1|138090|1p36.22
Cortisone reductase deficiency 2, 614662 (3)|HSD11B1, HSD11, HSD11L, CORTRD2|600713|1q32.2
Costello syndrome, 218040 (3)|HRAS|190020|11p15.5
Coumarin resistance, 122700 (3)|CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
Cousin syndrome, 260660 (3)|TBX15|604127|1p12
Cowchock syndrome (2)|NAMSD, NADMR|310490|Xq24-q26.1
Cowchock syndrome, 310490 (3)|AIFM1, PDCD8, AIF, COXPD6, COWCK, CMTX4|300169|Xq26.1
Cowden syndrome 1, 158350 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Cowden syndrome 2, 612359 (3)|SDHB, SDH2, SDHIP, PGL4, CWS2|185470|1p36.13
Cowden syndrome 3, 615106 (3)|SDHD, PGL1, CWS3|602690|11q23.1
Cowden syndrome 4, 615107 (3)|KLLN, CWS4|612105|10q23.31
Cowden syndrome 5, 615108 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Cowden syndrome 6, 615109 (3)|AKT1, CWS6|164730|14q32.33
Craniodiaphyseal dysplasia, autosomal dominant, 122860 (3)|SOST, VBCH, CDD|605740|17q21.31
Cranioectodermal dysplasia 1, 218330 (3)|IFT122, WDR10, CED1|606045|3q21.3-q22.1
Cranioectodermal dysplasia 2, 613610 (3)|WDR35, NAOFEN, KIAA1336, CED2, SRTD7|613602|2p24.1
Cranioectodermal dysplasia 3, 614099 (3)|IFT43, C14orf179, CED3|614068|14q24.3
Cranioectodermal dysplasia 4, 614378 (3)|WDR19, SRTD5, ATD5, NPHP13, CED4|608151|4p14
Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3)|VSX1, RINX, PPCD, PPD, KTCN1, CAASDS|605020|20p11.21
Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 614132 (3)|TMCO1, CFSMR|614123|1q24.1
Craniofacial-deafness-hand syndrome, 122880 (3)|PAX3, WS1, HUP2, CDHS, WS3|606597|2q36.1
Craniofacial-skeletal-dermatologic dysplasia, 101600 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Craniofrontonasal dysplasia, 304110 (3)|EFNB1, EPLG2, CFNS, CFND|300035|Xq13.1
Craniolenticulosutural dysplasia, 607812 (3)|SEC23A, CLSD|610511|14q21.1
Craniometaphyseal dysplasia, 123000 (3)|ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD|605145|5p15.2
Craniometaphyseal dysplasia, autosomal recessive (2)|CMDR|218400|6q21-q22
Craniometaphyseal dysplasia, autosomal recessive, 218400 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Cranioosteoarthropathy, 259100 (3)|HPGD, PGDH1, PHOAR1|601688|4q34.1
Craniosynostosis 3, 615314 (3)|TCF12, HTF4, CRS3|600480|15q21.3
Craniosynostosis 4, 600775 (3)|ERF, PE2, CRS4|611888|19q13.2
Craniosynostosis and dental anomalies, 614188 (3)|IL11RA, CRSDA|600939|9p13.3
Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3)|CYP26B1, CYP26A2, P450RAI2, RHFCA|605207|2p13.2
Craniosynostosis, Adelaide type (2)|CRSA, CRS3|600593|4p16
Craniosynostosis, Philadelphia type, 185900 (4)|CUP2q35, C2DUPq35, SDTY1, SD1|185900|2q34-q36
Craniosynostosis, nonspecific (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Craniosynostosis, type 1, 123100 (3)|TWIST1, ACS3, SCS, CRS1|601622|7p21.1
Craniosynostosis, type 2, 604757 (3)|MSX2, CRS2, HOX8|123101|5q35.2
Creatine phosphokinase, elevated serum, 123320 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Creatinine clearance QTL (2)|CRCL|607135|3p
Creutzfeldt-Jakob disease, 123400 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Crigler-Najjar syndrome, type I, 218800 (3)|UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37.1
Crigler-Najjar syndrome, type II, 606785 (3)|UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37.1
Crouzon syndrome with acanthosis nigricans, 612247 (3)|FGFR3, ACH|134934|4p16.3
Crouzon syndrome, 123500 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Cryptorchidism, 219050 (3)|INSL3|146738|19p13.11
Cryptorchidism, 219050 (3)|LGR8, GREAT|606655|13q13.1
Cubitus valgus with mental retardation and unusual facies (2)|CVMRF|300471|Chr.X
Currarino syndrome, 176450 (3)|MNX1, HLXB9, HOXHB9, SCRA1|142994|7q36.3
Cutaneous telangiectasia and cancer syndrome, familial, 614564 (3)|ATR, FRP1, SCKL1, FCTCS|601215|3q23
Cutis laxa, AD, 123700 (3)|ELN|130160|7q11.23
Cutis laxa, autosomal dominant 2, 614434 (3)|FBLN5, ARMD3, ADCL2, ARCL1A|604580|14q32.12
Cutis laxa, autosomal recessive, type IA, 219100 (3)|FBLN5, ARMD3, ADCL2, ARCL1A|604580|14q32.12
Cutis laxa, autosomal recessive, type IB, 614437 (3)|EFEMP2, FBLN4, UPH1, ARCL1B|604633|11q13.1
Cutis laxa, autosomal recessive, type IC, 613177 (3)|LTBP4, LTBP4S, LTBP4L, ARCL1C|604710|19q13.2
Cutis laxa, autosomal recessive, type IIA, 219200 (3)|ATP6V0A2, WSS, ARCL2A|611716|12q24.31
Cutis laxa, autosomal recessive, type IIB, 612940 (3)|PYCR1, PRO3, ARCL2B, ARCL3B|179035|17q25.3
Cutis laxa, autosomal recessive, type IIIA, 219150 (3)|ALDH18A1, PYCS, GSAS, ARCL3A|138250|10q24.1
Cutis laxa, autosomal recessive, type IIIB, 614438 (3)|PYCR1, PRO3, ARCL2B, ARCL3B|179035|17q25.3
Cyanosis, transient neonatal, 613977 (3)|HBG2, TNCY|142250|11p15.4
Cylindromatosis, familial, 132700 (3)|CYLD, CDMT, EAC, MFT1, KIAA0849, BRSS|605018|16q12.1
Cystathioninuria, 219500 (3)|CTH|607657|1p31.1
Cystic fibrosis, 219700 (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
Cystinosis, atypical nephropathic, 219800 (3)|CTNS|606272|17p13.2
Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3)|CTNS|606272|17p13.2
Cystinosis, nephropathic, 219800 (3)|CTNS|606272|17p13.2
Cystinosis, ocular nonnephropathic, 219750 (3)|CTNS|606272|17p13.2
Cystinuria, 220100 (3)|SLC3A1, ATR1, D2H, NBAT|104614|2p21
Cystinuria, 220100 (3)|SLC7A9, CSNU3|604144|19q13.11
Czech dysplasia, 609162 (3)|COL2A1|120140|12q13.11
D-2-hydroxyglutaric aciduria 2, 613657 (3)|IDH2, IDPM, D2HGA2|147650|15q26.1
D-2-hydroxyglutaric aciduria, 600721 (3)|D2HGDH, D2HGD|609186|2q37.3
D-bifunctional protein deficiency, 261515 (3)|HSD17B4, PRLTS1|601860|5q23.1
D-glyceric aciduria, 220120 (3)|GLYCTK, GLYCTK1|610516|3p21.1
DNA ligase I deficiency (3)|LIG1|126391|19q13.33
DNA topoisomerase I, camptothecin-resistant (3)|TOP1|126420|20q12
DNA topoisomerase II, resistance to inhibition of, by amsacrine (3)|TOP2A, TOP2|126430|17q21.2
DOOR syndrome, 220500 (3)|TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86|613577|16p13.3
Dandy-Walker syndrome (4)|DWS, C3DELq22q24, DEL3q22q24|220200|3q22-q24
Danon disease, 300257 (3)|LAMP2, LAMPB, LGP110|309060|Xq24
Darier disease, 124200 (3)|ATP2A2, ATP2B, DAR|108740|12q24.11
De Sanctis-Cacchione syndrome, 278800 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
De la Chapelle dysplasia, 256050 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Deafness , autosomal recessive 86, 614617 (3)|TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86|613577|16p13.3
Deafness and male infertility (4)|DEL15q15.3, C15DELq15.3|611102|15q15.3
Deafness and myopia, 221200 (3)|SLITRK6, DFNMYP|609681|13q31.1
Deafness, X-linked 1, 304500 (3)|PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22.3
Deafness, X-linked 1, progressive (3)|TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22.1
Deafness, X-linked 2, 304400 (3)|POU3F4, DFN3, DFNX2|300039|Xq21.1
Deafness, X-linked 3 (2)|DFNX3, DFN4|300030|Xp21.2
Deafness, X-linked 4, 300066 (3)|SMPX, DFNX4|300226|Xp22.12
Deafness, X-linked 5 (2)|DFNX5, AUNX1|300614|Xq23-q27.3
Deafness, Y-linked 1 (1)|DFNY1|400043|Chr.Y
Deafness, autosomal dominant 1, 124900 (3)|DIAPH1, DFNA1, LFHL1|602121|5q31.3
Deafness, autosomal dominant 10, 601316 (3)|EYA4, DFNA10, CMD1J|603550|6q23.2
Deafness, autosomal dominant 11, 601317 (3)|MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Deafness, autosomal dominant 13, 601868 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Deafness, autosomal dominant 15, 602459 (3)|POU4F3, BRN3C|602460|5q32
Deafness, autosomal dominant 16 (2)|DFNA16|603964|2q23-q24.3
Deafness, autosomal dominant 17, 603622 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
Deafness, autosomal dominant 18 (2)|DFNA18|606012|3q22
Deafness, autosomal dominant 20/26, 604717 (3)|ACTG1, DFNA20, DFNA26, BRWS2|102560|17q25.3
Deafness, autosomal dominant 21 (2)|DFNA21|607017|6p24.1-p22.3
Deafness, autosomal dominant 22, 606346 (3)|MYO6, DFNA22, DFNB37|600970|6q14.1
Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3)|MYO6, DFNA22, DFNB37|600970|6q14.1
Deafness, autosomal dominant 23, 605192 (3)|SIX1, BOS3, DFNA23|601205|14q23.1
Deafness, autosomal dominant 24 (2)|DFNA24|606282|4q35-qter
Deafness, autosomal dominant 25, 605583 (3)|SLC17A8, VGLUT3, DFNA25|607557|12q23.1
Deafness, autosomal dominant 27 (2)|DFNA27|612431|4q12-q13.1
Deafness, autosomal dominant 28, 608641 (3)|GRHL2, TFCP2L3, DFNA28|608576|8q22.3
Deafness, autosomal dominant 2A, 600101 (3)|KCNQ4, DFNA2A|603537|1p34.2
Deafness, autosomal dominant 2B, 612644 (3)|GJB3, CX31, DFNA2B|603324|1p34.3
Deafness, autosomal dominant 30 (2)|DFNA30|606451|15q25-q26
Deafness, autosomal dominant 31 (2)|DFNA31|608645|6p21.3
Deafness, autosomal dominant 33 (2)|DFNA33|614211|13q34
Deafness, autosomal dominant 36, 606705 (3)|TMC1, DFNB7, DFNB11, DFNA36|606706|9q21.13
Deafness, autosomal dominant 36, with dentinogenesis, 605594 (3)|DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q22.1
Deafness, autosomal dominant 3A, 601544 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
Deafness, autosomal dominant 3B, 612643 (3)|GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2|604418|13q12.11
Deafness, autosomal dominant 40 (3)|CRYM, DFNA40|123740|16p12.2
Deafness, autosomal dominant 41, 608224 (3)|P2RX2, P2X2, DFNA41|600844|12q24.33
Deafness, autosomal dominant 43 (2)|DFNA43|608394|2p12
Deafness, autosomal dominant 44, 607453 (3)|CCDC50, C3orf6, DFNA44|611051|3q28
Deafness, autosomal dominant 47 (2)|DFNA47, DFNB83|608652|9p22-p21
Deafness, autosomal dominant 48, 607841 (3)|MYO1A, DFNA48|601478|12q13.3
Deafness, autosomal dominant 49 (2)|DFNA49|608372|1q21-q23
Deafness, autosomal dominant 4A, 600652 (3)|MYH14, KIAA2034, DFNA4A, PNMHH|608568|19q13.33
Deafness, autosomal dominant 4B, 614614 (3)|CEACAM16, CEAL2, DFNA4B|614591|19q13.32
Deafness, autosomal dominant 5, 600994 (3)|DFNA5|608798|7p15.3
Deafness, autosomal dominant 50, 613074 (3)|MIR96, MIRN96, DFNA50|611606|7q32.2
Deafness, autosomal dominant 51 (4)|DFNA51, C9DUPq21.11, DUP9q21.11|613558|9q21.11
Deafness, autosomal dominant 52 (2)|DFNA52, DFNA42|607683|5q31.1-q32
Deafness, autosomal dominant 53 (2)|DFNA53|609965|14q11.2-q12
Deafness, autosomal dominant 54 (2)|DFNA54|615649|5q31
Deafness, autosomal dominant 56, 615629 (3)|TNC, HXB, DFNA56|187380|9q33.1
Deafness, autosomal dominant 58 (2)|DFNA58|615654|2p21-p12
Deafness, autosomal dominant 59 (2)|DFNA59|612642|11p14.2-q12.3
Deafness, autosomal dominant 6/14/38, 600965 (3)|WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41|606201|4p16.1
Deafness, autosomal dominant 64, 614152 (3)|SMAC, DIABLO, DFNA64|605219|12q24.31
Deafness, autosomal dominant 7 (2)|DFNA7|601412|1q21-q23
Deafness, autosomal dominant 8/12, 601543 (3)|TECTA, DFNA8, DFNA12, DFNB21|602574|11q23.3
Deafness, autosomal dominant 9, 601369 (3)|COCH, DFNA9|603196|14q12
Deafness, autosomal dominant, with peripheral neuropathy (3)|GJB3, CX31, DFNA2B|603324|1p34.3
Deafness, autosomal recessive (3)|GJB3, CX31, DFNA2B|603324|1p34.3
Deafness, autosomal recessive 12, 601386 (3)|CDH23, USH1D|605516|10q22.1
Deafness, autosomal recessive 13 (2)|DFNB13|603098|7q34-q36
Deafness, autosomal recessive 14 (2)|DFNB14|603678|7q31
Deafness, autosomal recessive 15, 601869 (3)|GIPC3, DFNB15, DFNB72, DFNB95|608792|19p13.3
Deafness, autosomal recessive 16, 603720 (3)|STRC, DFNB16|606440|15q15.3
Deafness, autosomal recessive 17 (2)|DFNB17|603010|7q31
Deafness, autosomal recessive 18A, 602092 (3)|USH1C, DFNB18A|605242|11p15.1
Deafness, autosomal recessive 18B, 614945 (3)|OTOG, OTGN, DFNB18B|604487|11p15.1
Deafness, autosomal recessive 1A, 220290 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
Deafness, autosomal recessive 1B, 612645 (3)|GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2|604418|13q12.11
Deafness, autosomal recessive 2, 600060 (3)|MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Deafness, autosomal recessive 20 (2)|DFNB20|604060|11q25-qter
Deafness, autosomal recessive 21, 603629 (3)|TECTA, DFNA8, DFNA12, DFNB21|602574|11q23.3
Deafness, autosomal recessive 22, 607039 (3)|OTOA, DFNB22|607038|16p12.2
Deafness, autosomal recessive 23, 609533 (3)|PCDH15, DFNB23, USH1F|605514|10q21.1
Deafness, autosomal recessive 24, 611022 (3)|RDX, DFNB24|179410|11q22.3
Deafness, autosomal recessive 25, 613285 (3)|GRXCR1|613283|4p13
Deafness, autosomal recessive 26 (2)|DFNB26|605428|4q31
Deafness, autosomal recessive 27 (2)|DFNB27|605818|2q23-q31
Deafness, autosomal recessive 28, 609823 (3)|TRIOBP, KIAA1662|609761|22q13.1
Deafness, autosomal recessive 29, 614035 (3)|CLDN14, DFNB29|605608|21q22.13
Deafness, autosomal recessive 3, 600316 (3)|MYO15A, DFNB3|602666|17p11.2
Deafness, autosomal recessive 30, 607101 (3)|MYO3A, DFNB30|606808|10p12.1
Deafness, autosomal recessive 31, 607084 (3)|WHRN, CIP98, KIAA1526, DFNB31, USH2D|607928|9q32
Deafness, autosomal recessive 32 (2)|DFNB32|608653|1p22.1-p13.3
Deafness, autosomal recessive 33 (2)|DFNB33|607239|10p11.23-q21.1
Deafness, autosomal recessive 35, 608565 (3)|ESRRB, ESRL2, DFNB35|602167|14q24.3
Deafness, autosomal recessive 36, 609006 (3)|ESPN|606351|1p36.31
Deafness, autosomal recessive 37, 607821 (3)|MYO6, DFNA22, DFNB37|600970|6q14.1
Deafness, autosomal recessive 38 (2)|DFNB38|608219|6q26-q27
Deafness, autosomal recessive 39, 608265 (3)|HGF, DFNB39|142409|7q21.11
Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3)|SLC26A4, PDS, DFNB4, EVA, TDH2B|605646|7q22.3
Deafness, autosomal recessive 40 (2)|DFNB40|608264|22q11.21-q12.1
Deafness, autosomal recessive 42, 609646 (3)|ILDR1, DFNB42|609739|3q13.33
Deafness, autosomal recessive 44 (2)|DFNB44|610154|7p14.1-q11.22
Deafness, autosomal recessive 45 (2)|DFNB45|612433|1q43-q44
Deafness, autosomal recessive 46 (2)|DFNB46|609647|18p11.32-p11.31
Deafness, autosomal recessive 48, 609439 (3)|CIB2, KIP2|605564|15q25.1
Deafness, autosomal recessive 49, 610153 (3)|MARVELD2, MARVD2, TRIC, DFNB49|610572|5q13.2
Deafness, autosomal recessive 5 (2)|DFNB5|600792|14q12
Deafness, autosomal recessive 51 (2)|DFNB51|609941|11p13-p12
Deafness, autosomal recessive 53, 609706 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Deafness, autosomal recessive 55 (2)|DFNB55|609952|4q12-q13.2
Deafness, autosomal recessive 59, 610220 (3)|PJVK, DFNB59|610219|2q31.2
Deafness, autosomal recessive 6, 600971 (3)|TMIE, DFNB6|607237|3p21.31
Deafness, autosomal recessive 61, 613865 (3)|SLC26A5, PRES|604943|7q22.1
Deafness, autosomal recessive 62 (2)|DFNB62|610143|12p13.2-p11.23
Deafness, autosomal recessive 63, 611451 (3)|LRTOMT, LRTOMT1, LRTOMT2, DFNB63|612414|11q13.4
Deafness, autosomal recessive 65 (2)|DFNB65|610248|20q13.2-q13.3
Deafness, autosomal recessive 66 (2)|DFNB66|610212|6p22.3-p21.2
Deafness, autosomal recessive 67, 610265 (3)|LHFPL5, TMHS, DFNB67|609427|6p21.31
Deafness, autosomal recessive 68 (2)|DFNB68|610419|19p13.2
Deafness, autosomal recessive 7, 600974 (3)|TMC1, DFNB7, DFNB11, DFNA36|606706|9q21.13
Deafness, autosomal recessive 70, 614934 (3)|PNPT1, OLD35, COXPD13, DFNB70|610316|2p16.1
Deafness, autosomal recessive 71 (2)|DFNB71|612789|8p22-p21.3
Deafness, autosomal recessive 74, 613718 (3)|MSRB3, DFNB74|613719|12q14.3
Deafness, autosomal recessive 76, 615540 (3)|SYNE4, NESP4, C19orf46, DFNB76|615535|19q13.12
Deafness, autosomal recessive 77, 613079 (3)|LOXHD1, DFNB77|613072|18q21.1
Deafness, autosomal recessive 79, 613307 (3)|TPRN, C9orf75, DFNB79|613354|9q34.3
Deafness, autosomal recessive 8/10, 601072 (3)|TMPRSS3, ECHOS1, DFNB8, DFNB10|605511|21q22.3
Deafness, autosomal recessive 81 (2)|DFNB81|614129|19p13
Deafness, autosomal recessive 83 (2)|DFNB83|613685|9p23-p21.2
Deafness, autosomal recessive 84A, 613391 (3)|PTPRQ, PTPGMC1, DFNB84A|603317|12q21.31
Deafness, autosomal recessive 84B, 614944 (3)|OTOGL, C12orf64, DFNB84B|614925|12q21.31
Deafness, autosomal recessive 85 (2)|DFNB85|613392|17p12-q11.2
Deafness, autosomal recessive 89, 613916 (3)|KARS, CMTRIB, DFNB89|601421|16q23.1
Deafness, autosomal recessive 9, 601071 (3)|OTOF, DFNB9, NSRD9, AUNB1|603681|2p23.3
Deafness, autosomal recessive 91, 613453 (3)|SERPINB6, PI6, PTI, SPI3, DFNB91|173321|6p25.2
Deafness, autosomal recessive 93, 614899 (3)|CABP2, DFNB93|607314|11q13.2
Deafness, autosomal recessive 96 (2)|DFNB96|614414|1p36.31-p36.13
Deafness, autosomal recessive 98, 614861 (3)|TSPEAR, C21orf29, DFNB98|612920|21q22.3
Deafness, cataract, retinitis pigmentosa, and sperm abnormalities (2)|DFCTRPS|300719|Chr.X
Deafness, congenital heart defects, and posterior embryotoxon (3)|JAG1, AGS, AHD|601920|20p12.2
Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3)|FGF3, INT2|164950|11q13.3
Deafness, digenic GJB2/GJB6, 220290 (3)|GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2|604418|13q12.11
Deafness, digenic, GJB2/GJB3, 220290 (3)|GJB3, CX31, DFNA2B|603324|1p34.3
Deafness, dystonia, and cerebral hypomyelination, 300475 (3)|BCAP31, BAP31, DXS1357E, DDCH|300398|Xq28
Deafness, neurosensory, autosomal recessive 47 (2)|DFNB47|609946|2p25.1-p24.3
Deafness, neurosensory, without vestibular involvement, autosomal dominant (3)|ESPN|606351|1p36.31
Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3)|PIEZO1, FAM38A, MIB, DHS|611184|16q24.3
Dejerine-Sottas disease, 145900 (3)|EGR2, KROX20|129010|10q21.3
Dejerine-Sottas disease, 145900 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Dejerine-Sottas disease, 145900 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Dejerine-Sottas disease, autosomal recessive, 145900 (3)|PRX, CMT4F|605725|19q13.2
Delta-beta thalassemia, 141749 (3)|HBB|141900|11p15.4
Dementia, Lewy body, 127750 (3)|SNCA, NACP, PARK1, PARK4|163890|4q22.1
Dementia, Lewy body, 127750 (3)|SNCB|602569|5q35.2
Dementia, familial British, 176500 (3)|ITM2B, BRI, ABRI, FBD|603904|13q14.2
Dementia, familial Danish, 117300 (3)|ITM2B, BRI, ABRI, FBD|603904|13q14.2
Dementia, familial, nonspecific, 600795 (3)|CHMP2B, DMT1, VPS2B, ALS17|609512|3p11.2
Dementia, frontotemporal, 600274 (3)|PSEN1, AD3|104311|14q24.2
Dementia, frontotemporal, with or without parkinsonism, 600274 (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency, 614172 (3)|GATA2, DCML, MONOMAC|137295|3q21.3
Dent disease 2, 300555 (3)|OCRL, LOCR, OCRL1, NPHL2|300535|Xq25-q26
Dent disease, 300009 (3)|CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.23-p11.22
Dentatorubro-pallidoluysian atrophy, 125370 (3)|ATN1, DRPLA, HRS, NOD|607462|12p13.31
Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3)|SMOC2, SMAP2, DTDP1|607223|6q27
Dentin dysplasia, type II, 125420 (3)|DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q22.1
Dentinogenesis imperfecta, Shields type II, 125490 (3)|DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q22.1
Dentinogenesis imperfecta, Shields type III, 125500 (3)|DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q22.1
Denys-Drash syndrome, 194080 (3)|WT1, NPHS4|607102|11p13
Dermatofibrosarcoma protuberans, 607907 (3)|PDGFB, SIS, IBGC5|190040|22q13.1
Dermatopathia pigmentosa reticularis, 125595 (3)|KRT14|148066|17q21.2
Dermoids of cornea (2)|CND|304730|Xq24-qter
Desbuquois dysplasia, 251450 (3)|CANT1, SCAN1, DBQD|613165|17q25.3
Desmoid disease, hereditary, 135290 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Desmosterolosis, 602398 (3)|DHCR24, KIAA0018|606418|1p32.3
Developmental dysplasia of the hip 1 (2)|DDH1|142700|13q22
Developmental dysplasia of the hip 2 (2)|DDH2|615612|3p22.2
DiGeorge syndrome, 188400 (3)|TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.21
DiGeorge syndrome/velocardiofacial syndrome complex-2 (2)|DGCR2, DGS2|601362|10p14-p13
Diabetes insipidus, nephrogenic, 125800 (3)|AQP2|107777|12q13.12
Diabetes insipidus, nephrogenic, 304800 (3)|AVPR2, DIR, DI1, ADHR|300538|Xq28
Diabetes insipidus, neurohypophyseal, 125700 (3)|AVP, AVRP, VP|192340|20p13
Diabetes mellitus, gestational, 125851 (3)|GCK, HHF3|138079|7p13
Diabetes mellitus, insulin-dependent, 2, 125852 (3)|INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, insulin-dependent, 20, 612520 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3)|INSR, HHF5|147670|19p13.2
Diabetes mellitus, ketosis-prone, 612227 (3)|PAX4, MODY9, KPD|167413|7q32.1
Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3)|GLIS3, ZNF515|610192|9p24.2
Diabetes mellitus, noninsulin-dependent, 125853 (3)|ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, noninsulin-dependent, 125853 (3)|HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
Diabetes mellitus, noninsulin-dependent, 2 (2)|NIDDM2|601407|12q24.2
Diabetes mellitus, noninsulin-dependent, late onset, 125853 (3)|GCK, HHF3|138079|7p13
Diabetes mellitus, permanent neonatal, 606176 (3)|ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, permanent neonatal, 606176 (3)|GCK, HHF3|138079|7p13
Diabetes mellitus, permanent neonatal, 606176 (3)|INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, permanent neonatal, with cerebellar agenesis, 609069 (3)|PTF1A|607194|10p12.2
Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3)|KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diabetes mellitus, transient neonatal 2, 610374 (3)|ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, transient neonatal, 1, 601410 (3)|ZFP57, TNDM1|612192|6p22.1
Diabetes mellitus, transient neonatal, 3, 610582 (3)|KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diabetes mellitus, type 1, 125852 (3)|INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, type 2, 125853 (3)|PAX4, MODY9, KPD|167413|7q32.1
Diabetes mellitus, type II, 125853 (3)|AKT2, HIHGHH|164731|19q13.2
Diabetes, permanent neonatal, 606176 (3)|KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diamond-Blackfan anemia 1, 105650 (3)|RPS19, DBA, DBA1|603474|19q13.2
Diamond-Blackfan anemia 10, 613309 (3)|RPS26, DBA10|603701|12q13.2
Diamond-Blackfan anemia 2 (2)|DBA2|606129|8p23.3-p22
Diamond-Blackfan anemia 4, 612527 (3)|RPS17, RPS17L1, RPS17L2, DBA4|180472|15q25.2
Diamond-Blackfan anemia 5, 612528 (3)|RPL35A, DBA5|180468|3q29
Diamond-Blackfan anemia 6, 612561 (3)|RPL5, DBA6|603634|1p22.1
Diamond-Blackfan anemia 7, 612562 (3)|RPL11, DBA7|604175|1p36.11
Diamond-Blackfan anemia 8, 612563 (3)|RPS7, DBA8|603658|2p25.3
Diamond-Blackfan anemia 9, 613308 (3)|RPS10, DBA9|603632|6p21.31
Diamond-blackfan anemia 3, 610629 (3)|RPS24, DBA3|602412|10q22.3
Diaphanospondylodysostosis, 608022 (3)|BMPER, CV2|608699|7p14.3
Diaphragmatic hernia 3, 610187 (3)|ZFPM2, FOG2, DIH3|603693|8q23.1
Diaphyseal medullary stenosis with malignant fibrous histiocytoma (2)|DMSMFH, BDMF|112250|9p22-p21
Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3)|MTAP, DMSMFH|156540|9p21.3
Diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3)|SPINT2, HAI2, DIAR3|605124|19q13.2
Diarrhea 4, malabsorptive, congenital, 610370 (3)|NEUROG3, NGN3, ATOH5|604882|10q22.1
Diarrhea 5, with tufting enteropathy, congenital, 613217 (3)|EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8|185535|2p21
Diarrhea 6, 614616 (3)|GUCY2C, GUC2C, DIAR6, MECIL|601330|12p13.1-p12.3
Diastrophic dysplasia, 222600 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Digital arthropathy-brachydactyly, familial, 606835 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Digital clubbing, isolated congenital, 119900 (3)|HPGD, PGDH1, PHOAR1|601688|4q34.1
Dihydrolipoamide dehydrogenase deficiency, 246900 (3)|DLD, LAD, PHE3, DLDD|238331|7q31.1
Dihydropyrimidine dehydrogenase deficiency, 274270 (3)|DPYD, DPD|612779|1p21.3
Dihydropyrimidinuria, 222748 (3)|DPYS, DHP|613326|8q22.3
Dilated cardiomyopathy with woolly hair and keratoderma, 605676 (3)|DSP, KPPS2, PPKS2|125647|6p24.3
Dimethylglycine dehydrogenase deficiency, 605850 (3)|DMGDH, DMGDHD|605849|5q14.1
Diphenylhydantoin toxicity (1)|EPHX1|132810|1q42.12
Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 (3)|POR|124015|7q11.23
Donnai-Barrow syndrome, 222448 (3)|LRP2, DBS|600073|2q31.1
Dopamine beta-hydroxylase deficiency, 223360 (3)|DBH|609312|9q34.2
Dopamine receptor D2, reduced brain density of (3)|ANKK1|608774|11q23.2
Double-outlet right ventricle, 217095 (3)|CFC1, CRYPTIC, HTX2, DTGA2|605194|2q21.1
Double-outlet right ventricle, 217095 (3)|GDF1, DTGA3, DORV, RAI|602880|19p13.11
Dowling-Degos disease 1, 179850 (3)|KRT5, DDD1|148040|12q13.13
Dowling-Degos disease 2, 615327 (3)|POFUT1, OFUCT1, KIAA0180, DDD2|607491|20q11.21
Dowling-Degos disease 3 (2)|DDD3|615674|17q21.3-q22
Down syndrome (4)|DCR, DSCR|190685|21q22.3
Doyne honeycomb degeneration of retina, 126600 (3)|EFEMP1, FBNL, DHRD|601548|2p16.1
Dravet syndrome, 607208 (3)|SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24.3
Du Pan syndrome, 228900 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Duane retraction syndrome 1 (2)|DURS1, DUS|126800|8q13
Duane retraction syndrome 2, 604356 (3)|CHN1, CHN, ARHGAP2, RHOGAP2, DURS2|118423|2q31.1
Duane-radial ray syndrome, 607323 (3)|SALL4, HSAL4|607343|20q13.2
Dubin-Johnson syndrome, 237500 (3)|ABCC2, CMOAT|601107|10q24.2
Duchenne muscular dystrophy, 310200 (3)|DMD, BMD, CMD3B|300377|Xp21.2-p21.1
Dupuytren contracture 1 (2)|DUPC1|126900|16q11.1-q22
Dursun syndrome, 612541 (3)|G6PC3, UGRP, SCN4|611045|17q21.31
Dyggve-Melchior-Clausen disease, 223800 (3)|DYM, FLJ90130, DMC, SMC|607461|18q21.1
Dysautonomia, familial, 223900 (3)|IKBKAP, IKAP|603722|9q31.3
Dyschromatosis symmetrica hereditaria, 127400 (3)|ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6|146920|1q21.3
Dyschromatosis universalis hereditaria 1 (2)|DUH1, DUH|127500|6q24.2-q25.2
Dyschromatosis universalis hereditaria 2 (2)|DUH2|612715|12q21-q23
Dyschromatosis universalis hereditaria 3, 615402 (3)|ABCB6, MTABC3, MCOPCB7, LAN, DUH3|605452|2q35
Dyserythropoietic anemia, congenital, type II, 224100 (3)|SEC23B, CDAN2, HEMPAS|610512|20p11.23
Dyserythropoietic anemia, congenital, type III (2)|CDAN3, CDA3|105600|15q21
Dyserythropoietic anemia, congenital, type IV, 613673 (3)|KLF1, EKLF, INLU, HBFQTL6, CDAN4|600599|19p13.2
Dyserythropoietic anemia, congenital, type Ia, 224120 (3)|CDAN1, CDA1, CDAN1A|607465|15q15.2
Dyserythropoietic anemia, congenital, type Ib, 615631 (3)|C15orf41|615626|15q14
Dysfibrinogenemia, alpha type, causing bleeding diathesis (3)|FGA|134820|4q31.3
Dysfibrinogenemia, alpha type, causing recurrent thrombosis (3)|FGA|134820|4q31.3
Dysfibrinogenemia, beta type (3)|FGB|134830|4q31.3
Dysfibrinogenemia, gamma type (3)|FGG|134850|4q31.3
Dyskeratosis congenita, X-linked, 305000 (3)|DKC1, DKCX|300126|Xq28
Dyskeratosis congenita, autosomal dominant 1, 127550 (3)|TERC, TRC3, TR, DKCA1, PFBMFT2|602322|3q26.2
Dyskeratosis congenita, autosomal dominant 3, 613990 (3)|TINF2, TIN2, DKCA3|604319|14q12
Dyskeratosis congenita, autosomal dominant 4, 615190 (3)|RTEL1, C20orf41, NHL, KIAA1088, DKCB5, DKCA4|608833|20q13.33
Dyskeratosis congenita, autosomal recessive 1, 224230 (3)|NOLA3, NOP10, DKCB1|606471|15q14
Dyskeratosis congenita, autosomal recessive 2, 613987 (3)|NOLA2, NHP2, DKCB2|606470|5q35.3
Dyskeratosis congenita, autosomal recessive 3, 613988 (3)|WRAP53, TCAB1, WDR79, DKCB3|612661|17p13.1
Dyskeratosis congenita, autosomal recessive 5, 615190 (3)|RTEL1, C20orf41, NHL, KIAA1088, DKCB5, DKCA4|608833|20q13.33
Dyskeratosis, hereditary benign intraepithelial (2)|DKBI|127600|4q35
Dyskinesia, familial, with facial myokymia, 606703 (3)|ADCY5, FDFM|600293|3q21.1
Dysprothrombinemia, 613679 (3)|F2, THPH1, RPRGL2|176930|11p11.2
Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3)|HSPG2, PLC, SJS, SJA, SJS1|142461|1p36.12
Dystonia 13, torsion (2)|DYT13|607671|1p36.32-p36.13
Dystonia 16, 612067 (3)|PRKRA, PACT, RAX, DYT16|603424|2q31.2
Dystonia 21 (2)|DYT21|614588|2q14.3-q21.3
Dystonia 24, 615034 (3)|ANO3, TMEM16C, C11orf25, DYT24|610110|11p14.2
Dystonia 25, 615073 (3)|GNAL, DYT25|139312|18p11.21
Dystonia 4, torsion, autosomal dominant, 128101 (3)|TUBB4A, TUBB4, TUBB5, DYT4, HLD6|602662|19p13.3
Dystonia 6, torsion, 602629 (3)|THAP1, DYT6|609520|8p11.21
Dystonia 9, 601042 (3)|SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9|138140|1p34.2
Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 (3)|GCH1, DYT5, HPABH4B|600225|14q22.2
Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3)|SPR|182125|2p13.2
Dystonia, early-onset atypical, with myoclonic features (3)|DYT1, TOR1A|605204|9q34.11
Dystonia, juvenile-onset, 607371 (3)|ACTB, BRWS1|102630|7p22.1
Dystonia, myoclonic, 159900 (3)|DRD2|126450|11q23.2
Dystonia, primary cervical (3)|DRD5, DRD1B, DRD1L2|126453|4p16.1
Dystonia-1, torsion, 128100 (3)|DYT1, TOR1A|605204|9q34.11
Dystonia-11, myoclonic, 159900 (3)|SGCE, DYT11|604149|7q21.3
Dystonia-12, 128235 (3)|ATP1A3, DYT12, RDP, AHC2|182350|19q13.2
Dystonia-15, myoclonic (2)|DYT15|607488|18p11
Dystonia-17, primary torsion (2)|DYT17|612406|20p11.2-q13.12
Dystonia-7, torsion (2)|DYT7|602124|18p
Dystonia-Parkinsonism, X-linked, 314250 (3)|TAF1, TAF2A, CCG1, BA2R, DYT3|313650|Xq13.1
EBD inversa, 226600 (3)|COL7A1|120120|3p21.31
EBD, Bart type, 132000 (3)|COL7A1|120120|3p21.31
EBD, localisata variant (3)|COL7A1|120120|3p21.31
EDICT syndrome, 614303 (3)|MIR184, MIRN184, KTCNCT, EDICT|613146|15q25.1
Eagle-Barrett syndrome, 100100 (3)|CHRM3, EGBRS|118494|1q43
Ectodermal dysplasia 1, hypohidrotic, X-linked, 305100 (3)|ED1, EDA, ECTD1, EDA, HED1, STHAGX1|300451|Xq13.1
Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 (3)|EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B|604095|2q12.3
Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 (3)|EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B|604095|2q12.3
Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, 614940 (3)|EDARADD, ED3, EDA3, ECTD11B, ECTD11A|606603|1q42-q43
Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 (3)|EDARADD, ED3, EDA3, ECTD11B, ECTD11A|606603|1q42-q43
Ectodermal dysplasia 2, Clouston type, 129500 (3)|GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2|604418|13q12.11
Ectodermal dysplasia 3, Witkop type, 189500 (3)|MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3|142983|4p16.2
Ectodermal dysplasia 4, hair/nail type, 602032 (3)|KRT85, KRTHB5, HB5, ECTD4|602767|12q13.13
Ectodermal dysplasia 5, hair/nail type (2)|ECTD5|614927|10q24.32-q25.1
Ectodermal dysplasia 6, hair/nail type (2)|ECTD6|614928|17p12-q21.2
Ectodermal dysplasia 7, hair/nail type (2)|ECTD7|614929|12p11.1-q21.1
Ectodermal dysplasia 8, hair/tooth/nail type (2)|ECTD8|602401|18q22.1-q22.3
Ectodermal dysplasia 9, hair/nail type, 614931 (3)|HOXC13, HOX3G, ECTD9|142976|12q13.13
Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 (3)|NFKBIA, IKBA|164008|14q13.2
Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3)|CDH3, CDHP, PCAD, HJMD|114021|16q22.1
Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3)|PVRL4, PRR4, EDSS1|609607|1q23.3
Ectodermal dysplasia-syndactyly syndrome 2 (2)|EDSS2|613576|7p21.2-p14.3
Ectodermal dysplasia/skin fragility syndrome, 604536 (3)|PKP1|601975|1q32.1
Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Ectopia lentis et pupillae, 225200 (3)|ADAMTSL4, TSRC1, ECTOL2|610113|1q21.3
Ectopia lentis, familial, 129600 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Ectopia lentis, isolated, autosomal recessive, 225100 (3)|ADAMTSL4, TSRC1, ECTOL2|610113|1q21.3
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Efavirenz, poor metabolism of, 614546 (3)|CYP2B6, CYP2B, EFVM|123930|19q13.2
Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 (3)|FKBP14, EDSKMH|614505|7p14.3
Ehlers-Danlos syndrome, autosomal dominant, hypermobility type, 130020 (3)|TNXB, TNX, TNXB1, TNXBS, TNXB2, EDS3|600985|6p21.33
Ehlers-Danlos syndrome, autosomal recessive, due to tenascin X deficiency, 606408 (3)|TNXB, TNX, TNXB1, TNXBS, TNXB2, EDS3|600985|6p21.33
Ehlers-Danlos syndrome, cardiac valvular form, 225320 (3)|COL1A2|120160|7q21.3
Ehlers-Danlos syndrome, musculocontractural type 1, 601776 (3)|CHST14, D4ST1, ATCS, EDSMC1|608429|15q15.1
Ehlers-Danlos syndrome, progeroid type, 1, 130070 (3)|B4GALT7, XGALT1, XGPT1, EDSP1|604327|5q35.3
Ehlers-Danlos syndrome, progeroid type, 2, 615349 (3)|B3GALT6, SEMDJL1, EDSP2|615291|1p36.33
Ehlers-Danlos syndrome, type I, 130000 (3)|COL1A1|120150|17q21.33
Ehlers-Danlos syndrome, type I, 130000 (3)|COL5A1|120215|9q34.3
Ehlers-Danlos syndrome, type I, 130000 (3)|COL5A2|120190|2q32.2
Ehlers-Danlos syndrome, type II, 130010 (3)|COL5A1|120215|9q34.3
Ehlers-Danlos syndrome, type III, 130020 (3)|COL3A1|120180|2q32.2
Ehlers-Danlos syndrome, type IV, 130050 (3)|COL3A1|120180|2q32.2
Ehlers-Danlos syndrome, type VI, 225400 (3)|PLOD1, LH1, LLH, EDS6|153454|1p36.22
Ehlers-Danlos syndrome, type VIIA, 130060 (3)|COL1A1|120150|17q21.33
Ehlers-Danlos syndrome, type VIIB, 130060 (3)|COL1A2|120160|7q21.3
Ehlers-Danlos syndrome, type VIIC, 225410 (3)|ADAMTS2, NPI|604539|5q35.3
Ehlers-Danlos syndrome, type VIII (2)|EDS8|130080|12p13
Eiken syndrome, 600002 (3)|PTHR1, PTHR, PFE|168468|3p21.31
Elliptocytosis-1, 611804 (3)|EPB41, EL1|130500|1p35.3
Elliptocytosis-2, 130600 (3)|SPTA1, EL2, SPH3, HS3, HPP|182860|1q23.1
Elliptocytosis-3 (3)|SPTB, SPH2, EL3, HS2|182870|14q23.3
Ellis-van Creveld syndrome, 225500 (3)|EVC|604831|4p16.2
Ellis-van Creveld syndrome, 225500 (3)|LBN, EVC2|607261|4p16.2
Emanuel syndrome (4)|DER22t11-22|609029|22q11.2
Emberger syndrome, 614038 (3)|GATA2, DCML, MONOMAC|137295|3q21.3
Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 (3)|EMD, EDMD, STA|300384|Xq28
Emery-Dreifuss muscular dystrophy 2, AD, 181350 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Emery-Dreifuss muscular dystrophy 3, AR, 181350 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 (3)|SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4|608441|6q25.1-q25.2
Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 (3)|SYNE2, NUANCE, KIAA1011, EDMD5|608442|14q23.2
Emery-Dreifuss muscular dystrophy 6, X-linked, 300696 (3)|FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq26.3
Emery-Dreifuss muscular dystrophy 7, AD, 614302 (3)|TMEM43, ARVD5, ARVC5, EDMD7|612048|3p25.1
Emphysema due to AAT deficiency, 613490 (3)|SERPINA1, PI, AAT|107400|14q32.13
Emphysema-cirrhosis, due to AAT deficiency, 613490 (3)|SERPINA1, PI, AAT|107400|14q32.13
Encephalopahty, lethal, due to defective mitochondrial peroxisomal fission, 614388 (3)|DNM1L, DRP1, DVLP, DYMPLE, EMPF|603850|12p11.21
Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3)|SERPINI1, PI12|602445|3q26.1
Encephalopathy, neonatal severe, 300673 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Endocrine-cerebroosteodysplasia, 612651 (3)|ICK, MRK, KIAA0936, ECO|612325|6p12.2-p12.1
Endometrial cancer, 608089 (3)|MLH3, HNPCC7|604395|14q24.3
Endometrial cancer, familial, 608089 (3)|MSH6, GTBP, HNPCC5|600678|2p16.3
Endometrial carcinoma (3)|MSH3|600887|5q14.1
Endometrial carcinoma, somatic, 608089 (3)|CDH1, UVO, LCAM, ECAD|192090|16q22.1
Endometrial carcinoma, somatic, 608089 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Endometrial stromal tumors (2)|JAZF1, TIP27|606246|7p15.2-p15.1
Endometrial stromal tumors (2)|JJAZ1, KIAA0160|606245|17q11.2
Endotoxin hyporesponsiveness (3)|TLR4, ARMD10|603030|9q33.1
Endplate acetylcholinesterase deficiency, 603034 (3)|COLQ, EAD|603033|3p25.1
Enhanced S-cone syndrome, 268100 (3)|NR2E3, PNR, ESCS, RP37|604485|15q23
Enlarged vestibular aqueduct, 600791 (3)|FOXI1, FKHL10, FREAC6|601093|5q35.1
Enlarged vestibular aqueduct, digenic, 600791 (3)|KCNJ10, SESAME|602208|1q23.2
Enolase deficiency (1)|ENO1, PPH, MPB1|172430|1p36.23
Enterokinase deficiency, 226200 (3)|PRSS7, ENTK|606635|21q21.1
Enuresis, nocturnal, 1 (2)|ENUR1|600631|13q13-q14.3
Enuresis, nocturnal, 2 (2)|ENUR2|600808|12q13-q21
Eosinophil peroxidase deficiency, 261500 (3)|EPX|131399|17q22
Eosinophilia, familial (2)|EOS|131400|5q31-q33
Epidermal nevus, somatic, 162900 (3)|NRAS, ALPS4, NS6|164790|1p13.2
Epidermodysplasia verruciformis, 226400 (3)|TMC6, EVER1, EV1|605828|17q25.3
Epidermodysplasia verruciformis, 226400 (3)|TMC8, EVER2, EV2|605829|17q25.3
Epidermolysis bullosa dystrophica, AD, 131750 (3)|COL7A1|120120|3p21.31
Epidermolysis bullosa dystrophica, AR, 226600 (3)|COL7A1|120120|3p21.31
Epidermolysis bullosa of hands and feet, 131800 (3)|ITGB4|147557|17q25.1
Epidermolysis bullosa pruriginosa, 604129 (3)|COL7A1|120120|3p21.31
Epidermolysis bullosa simplex with pyloric atresia, 612138 (3)|PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24.3
Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3)|KRT14|148066|17q21.2
Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3)|KRT5, DDD1|148040|12q13.13
Epidermolysis bullosa simplex, Koebner type, 131900 (3)|KRT14|148066|17q21.2
Epidermolysis bullosa simplex, Koebner type, 131900 (3)|KRT5, DDD1|148040|12q13.13
Epidermolysis bullosa simplex, Ogna type, 131950 (3)|PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24.3
Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3)|KRT14|148066|17q21.2
Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3)|KRT5, DDD1|148040|12q13.13
Epidermolysis bullosa simplex, recessive 1, 601001 (3)|KRT14|148066|17q21.2
Epidermolysis bullosa simplex, recessive 1, 601001 (3)|KRT5, DDD1|148040|12q13.13
Epidermolysis bullosa simplex, sutosomal recessive 2, 615425 (3)|DST, BPAG1, DMH, D6S1101, HSAN6, EBSB2|113810|6p12.1
Epidermolysis bullosa simplex-MP, 131960 (3)|KRT5, DDD1|148040|12q13.13
Epidermolysis bullosa, generalized atrophic benign, 226650 (3)|LAMA3, LOCS|600805|18q11.2
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)|LAMA3, LOCS|600805|18q11.2
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)|LAMB3|150310|1q32.2
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)|LAMC2, LAMNB2, LAMB2T|150292|1q25.3
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)|COL17A1, BPAG2|113811|10q24.3-q25.1
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)|ITGB4|147557|17q25.1
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)|LAMB3|150310|1q32.2
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)|LAMC2, LAMNB2, LAMB2T|150292|1q25.3
Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3)|ITGB4|147557|17q25.1
Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3)|ITGA6|147556|2q31.1
Epidermolysis bullosa, lethal acantholytic, 609638 (3)|DSP, KPPS2, PPKS2|125647|6p24.3
Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 (3)|EXPH5, SLAC2B, KIAA0624|612878|11q22.3
Epidermolysis bullosa, pretibial, 131850 (3)|COL7A1|120120|3p21.31
Epidermolytic hyperkeratosis, 113800 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Epidermolytic hyperkeratosis, 113800 (3)|KRT10, EHK, BCIE, BIE|148080|17q21.2
Epidermylysis bullosa simplex-MCR, 609352 (3)|KRT5, DDD1|148040|12q13.13
Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3)|SYN1|313440|Xp11.23
Epilepsy, childhood absence, 1 (2)|ECA1|600131|8q24
Epilepsy, familial adult myoclonic, 4 (2)|FAME4, FCMTE4|615127|3q26.32-q28
Epilepsy, familial focal, with variable foci, 604364 (3)|DEPDC5, KIAA0645, FFEVF|614191|22q12.2-q12.3
Epilepsy, familial mesial temporal lobe (2)|FMTLE, ETL3|611630|4q13.2-q21.3
Epilepsy, familial temporal lobe, 1, 600512 (3)|LGI1, EPT, ETL1, ADLTE, ADPEAF|604619|10q23.33
Epilepsy, familial temporal lobe, 2 (2)|ETL2, FTLE|608096|12q22-q23.3
Epilepsy, familial temporal lobe, 4 (2)|ETL4, ETOLM|611631|9q21-q22
Epilepsy, familial temporal lobe, 5, 614417 (3)|CPA6, CPAH, ETL5, FEB11|609562|8q13.2
Epilepsy, focal, with speech disorder and with or without mental retardation, 245570 (3)|GRIN2A, NMDAR2A, FESD, LKS|138253|16p13.2
Epilepsy, generalized, with febrile seizures plus, type 1, 604233 (3)|SCN1B, GEFSP1, BRGDA5, ATFB13|600235|19q13.12
Epilepsy, generalized, with febrile seizures plus, type 2, 604403 (3)|SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24.3
Epilepsy, generalized, with febrile seizures plus, type 3, 611277 (3)|GABRG2, GEFSP3, CAE2, ECA2|137164|5q34
Epilepsy, generalized, with febrile seizures plus, type 4 (2)|GEFSP4|609800|2p24
Epilepsy, generalized, with febrile seizures plus, type 6 (2)|GEFSP6|612279|8p23-p21
Epilepsy, generalized, with febrile seizures plus, type 7, 613863 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Epilepsy, hot water, 1 (2)|HWE1|613339|10q21.3-q22.3
Epilepsy, hot water, 2 (2)|HWE2|613340|4q24-q28
Epilepsy, idiopathic generalized, susceptibility to 4 (2)|EIG4|609750|10q25-q26
Epilepsy, idiopathic generalized, susceptibility to, 5 (2)|EIG5|611934|10p11.22
Epilepsy, juvenile myoclonic (2)|EIG7, EJM2|604827|15q14
Epilepsy, juvenile myoclonic 3 (2)|EJM3|608816|6p21
Epilepsy, myoclonic, adult familial, 1 (2)|FAME1, BAFME1, MEBA|601068|8q24
Epilepsy, myoclonic, adult familial, 2 (2)|FAME2, BAFME2, ADCME|607876|2p11.1-q12.2
Epilepsy, myoclonic, familial adult, 3 (2)|FAME3, FCMTE3|613608|5p15.31-p15.1
Epilepsy, nocturnal frontal lobe, 1, 600513 (3)|CHRNA4, ENFL1|118504|20q13.33
Epilepsy, nocturnal frontal lobe, 3, 605375 (3)|CHRNB2, EFNL3|118507|1q21.3
Epilepsy, nocturnal frontal lobe, 5, 615005 (3)|KCNT1, KIAA1422, EIEE14, ENFL5|608167|9q34.3
Epilepsy, nocturnal frontal lobe, type 2 (2)|ENFL2|603204|15q24
Epilepsy, nocturnal frontal lobe, type 4, 610353 (3)|CHRNA2|118502|8p21.2
Epilepsy, partial, with pericentral spikes (2)|EPPS|607221|4p15
Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 (3)|CSTB, STFB, EPM1, PME, EPM1A, ULD|601145|21q22.3
Epilepsy, progressive myoclonic 1B, 612437 (3)|PRICKLE1, RILP, EPM1B|608500|12q12
Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3)|EPM2A, MELF, EPM2|607566|6q24.3
Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3)|NHLRC1, EPM2A, EPM2B|608072|6p22.3
Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3)|KCTD7, EPM3, CLN14|611725|7q11.21
Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3)|SCARB2, CD36L2, LIMPII, AMRF, EPM4|602257|4q21.1
Epilepsy, progressive myoclonic 5, 613832 (3)|PRICKLE2, EPM5|608501|3p14.1
Epilepsy, progressive myoclonic 6, 614018 (3)|GOSR2, GS27, EPM6|604027|17q21.32
Epilepsy, pyridoxine-dependent, 266100 (3)|ALDH7A1, ATQ1, EPD, PDE|107323|5q23.2
Epilepsy, rolandic, with paroxysmal exercise-induced dystonia and writer's cramp (2)|EPRPDC|608105|16p12-p11.2
Epileptic encephalopathy, childhood-onset, 615369 (3)|CHD2, EEOC|602119|15q26.1
Epileptic encephalopathy, early infantile, 1, 308350 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Epileptic encephalopathy, early infantile, 10, 613402 (3)|PNKP, PNK, MCSZ, EIEE10|605610|19q13.33
Epileptic encephalopathy, early infantile, 11, 613721 (3)|SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS|182390|2q24.3
Epileptic encephalopathy, early infantile, 12, 613722 (3)|PLCB1, KIAA0581, PLCB1A, PLCB1B, EIEE12|607120|20p12.3
Epileptic encephalopathy, early infantile, 13, 614558 (3)|SCN8A, CIAT, EIEE13|600702|12q13.13
Epileptic encephalopathy, early infantile, 14, 614959 (3)|KCNT1, KIAA1422, EIEE14, ENFL5|608167|9q34.3
Epileptic encephalopathy, early infantile, 15, 615006 (3)|ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15|606494|1p34.1
Epileptic encephalopathy, early infantile, 16, 615338 (3)|TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86|613577|16p13.3
Epileptic encephalopathy, early infantile, 17, 615473 (3)|GNAO1, EIEE17|139311|16q12.2
Epileptic encephalopathy, early infantile, 18, 615476 (3)|SZT2, KIAA0467, EIEE18|615463|1p34.2
Epileptic encephalopathy, early infantile, 2, 300672 (3)|CDKL5, STK9, ISSX, EIEE2|300203|Xp22.13
Epileptic encephalopathy, early infantile, 3, 609304 (3)|SLC25A22, GC1, EIEE3|609302|11p15.5
Epileptic encephalopathy, early infantile, 4, 612164 (2)|STXBP1, UNC18, EIEE4|602926|9q34.11
Epileptic encephalopathy, early infantile, 5, 613477 (3)|SPTAN1, NEAS, EIEE5|182810|9q34.11
Epileptic encephalopathy, early infantile, 7, 613720 (3)|KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.33
Epileptic encephalopathy, early infantile, 8, 300607 (3)|ARHGEF9, PEM2, KIAA0424, EIEE8|300429|Xq11.1-q11.2
Epileptic encephalopathy, early infantile, 9, 300088 (3)|PCDH19, KIAA1313, EFMR, EIEE9|300460|Xq22.1
Epilespy, generalized, with febrile seizures plus, type 8 (2)|GEFSP8|613828|6q16.3-q22.31
Epiphyseal dysplasia, multiple 1, 132400 (3)|COMP, EDM1, MED, PSACH|600310|19p13.11
Epiphyseal dysplasia, multiple, 2, 600204 (3)|COL9A2, EDM2, STL5|120260|1p34.2
Epiphyseal dysplasia, multiple, 3, 600969 (3)|COL9A3, EDM3, IDD|120270|20q13.33
Epiphyseal dysplasia, multiple, 4, 226900 (3)|SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32
Epiphyseal dysplasia, multiple, 5, 607078 (3)|MATN3, EDM5, HOA, OS2|602109|2p24.1
Epiphyseal dysplasia, multiple, 6, 614135 (3)|COL9A1, EDM6, STL4|120210|6q13
Epiphyseal dysplasia, multiple, with myopathy (3)|COL9A3, EDM3, IDD|120270|20q13.33
Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3)|COL2A1|120140|12q13.11
Episodic ataxia, type 2, 108500 (3)|CACNA1A, CACNL1A4, SCA6|601011|19p13.2
Episodic ataxia, type 3 (2)|EA3|606554|1q42
Episodic ataxia, type 5, 613855 (3)|CACNB4, EJM6, EA5, EIG9|601949|2q23.3
Episodic ataxia, type 6, 612656 (3)|SLC1A3, EAAT1, EA6|600111|5p13.2
Episodic ataxia, type 7 (2)|EA7|611907|19q13
Episodic ataxia/myokymia syndrome, 160120 (3)|KCNA1, AEMK, EA1|176260|12p13.32
Episodic kinesigenic dyskinesia 1, 128200 (3)|PRRT2, PKC, DYT10, EKD1, BFIS2, BFIC2, ICCA|614386|16p11.2
Episodic kinesigenic dyskinesia 2 (2)|EKD2|611031|16q13-q22.1
Episodic muscle weakness, X-linked (2)|EMWX|300211|Xp22.3
Episodic pain syndrome, familial, 2, 615551 (3)|SCN10A, FEPS2|604427|3p22.2
Episodic pain syndrome, familial, 3, 615552 (3)|SCN11A, HSAN7, FEPS3|604385|3p22.2
Episodic pain syndrome, familial, 615040 (3)|TRPA1, ANKTM1, FEPS|604775|8q13.3
Epsilon-trimethyllysine hydroxylase deficiency, 300872 (3)|TMLHE, BBOX2, TMLH, TMLHED, AUTSX6|300777|Xq28
Epstein syndrome, 153650 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
Erythermalgia, primary, 133020 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Erythremias, alpha- (3)|HBA1, HBH|141800|16p13.3
Erythremias, beta- (3)|HBB|141900|11p15.4
Erythrocyte lactate transporter defect, 245340 (3)|SLC16A1, MCT1, HHF7|600682|1p13.2
Erythrocytosis (3)|HBA2, HBH|141850|16p13.3
Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 (3)|BPGM|613896|7q33
Erythrocytosis, familial, 2, 263400 (3)|VHL|608537|3p25.3
Erythrocytosis, familial, 3, 609820 (3)|EGLN1, PHD2, HIFPH2, C1orf12, ZMYND6, SM20, ECYT3|606425|1q42.2
Erythrocytosis, familial, 4, 611783 (3)|EPAS1, MOP2, HIF2A, ECYT4|603349|2p21
Erythrocytosis, somatic, 133100 (3)|JAK2, THCYT3|147796|9p24.1
Erythrocytosis, somatic, 133100 (3)|SH2B3, LNK|605093|12q24.12
Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, 615508 (3)|DSG1, PPKS1, SPPK1, EPKHE|125670|18q12.1
Erythrokeratodermia variabilis et progressiva, 133200 (3)|GJB3, CX31, DFNA2B|603324|1p34.3
Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3)|GJB4, CX30.3|605425|1p34.3
Escobar syndrome, 265000 (3)|CHRNG, ACHRG|100730|2q37.1
Esophageal cancer, 133239 (1)|DLEC1, DLC1|604050|3p22.2
Esophageal cancer, somatic, 133239 (3)|TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p24.1
Esophageal carcinoma, somatic 133239 (3)|DCC, MRMV1|120470|18q21.2
Esophageal carcinoma, somatic, 133239 (3)|RNF6|604242|13q12.13
Esophageal squamous cell carcinoma, 133239 (1)|DEC1|604767|9q33.1
Esophageal squamous cell carcinoma, 133239 (3)|LZTS1, F37, FEZ1|606551|8p21.3
Esophageal squamous cell carcinoma, somatic, 133239 (3)|WWOX, FOR, SCAR12|605131|16q23.1-q23.2
Estrogen resistance, 615363 (3)|ESR1, ESR, ESTRR|133430|6q25.1
Ethylmalonic encephalopathy, 602473 (3)|ETHE1, HSCO, D83198|608451|19q13.31
Ewing sarcoma, 612219 (3)|EWSR1, EWS|133450|22q12.2
Exfoliative ichthyosis, autosomal recessive, ichthyosis bullosa of Siemens-like, 607936 (3)|CSTA, STFA, STF1, AREI|184600|3q21.1
Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3)|COX4I2|607976|20q11.21
Exostoses, multiple, type 1, 133700 (3)|EXT1|608177|8q24.11
Exostoses, multiple, type 2, 133701 (3)|EXT2|608210|11p11.2
Exostoses, multiple, type 3 (2)|EXT3|600209|19p
Exudative vitreoretinopathy 4, 601813 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
Exudative vitreoretinopathy 5, 613310 (3)|TSPAN12, NET2, EVR5|613138|7q31.31
Exudative vitreoretinopathy, 133780 (3)|FZD4, EVR1|604579|11q14.2
Exudative vitreoretinopathy, X-linked, 305390 (3)|NDP, ND|300658|Xp11.3
Exudative vitreoretinopathy-3 (2)|EVR3|605750|11p13-p12
FG syndrome 2, 300321 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
FG syndrome 3 (2)|FGS3|300406|Xp22.3
FG syndrome 4, 300422 (3)|CASK, MICPCH, FGS4, CMG, MRXSNA|300172|Xp11.4
FG syndrome 5 (2)|FGS5|300581|Xq22.3
FILS syndrome, 615139 (3)|POLE1, CRCS12, FILS|174762|12q24.33
Fabry disease, 301500 (3)|GLA|300644|Xq22.1
Fabry disease, cardiac variant, 301500 (3)|GLA|300644|Xq22.1
Facial clefting, oblique, 1, 600251 (3)|SPECC1L, KIAA0376, OBLFC1|614140|22q11.23
Facial paresis, hereditary congenital, 1 (2)|HCFP1, MBS2|601471|3q21-q22
Facial paresis, hereditary congenital, 3, 614744 (3)|HOXB1, HOX2I, HCFP3|142968|17q21.32
Facioscapulohumeral muscular dystrophy 1 (4)|FSHD1, FSHD1A|158900|4q35
Factor V and factor VIII, combined deficiency of, 613625 (3)|MCFD2, F5F8D2|607788|2p21
Factor V deficiency, 227400 (3)|F5, THPH2, RPRGL1|612309|1q24.2
Factor VII deficiency, 227500 (3)|F7|613878|13q34
Factor X deficiency, 227600 (3)|F10|613872|13q34
Factor XI deficiency, autosomal dominant, 612416 (3)|F11|264900|4q35.2
Factor XI deficiency, autosomal recessive, 612416 (3)|F11|264900|4q35.2
Factor XII deficiency, 234000 (3)|F12, HAF, HAE3|610619|5q35.3
Factor XIIIA deficiency, 613225 (3)|F13A1, F13A|134570|6p25.1
Factor XIIIB deficiency, 613235 (3)|F13B|134580|1q31.3
Failure of tooth eruption, primary, 125350 (3)|PTHR1, PTHR, PFE|168468|3p21.31
Familial Mediterranean fever, AD, 134610 (3)|MEFV, MEF, FMF|608107|16p13.3
Familial Mediterranean fever, AR, 249100 (3)|MEFV, MEF, FMF|608107|16p13.3
Familial cold autoinflammatory syndrome 2, 611762 (3)|NLRP12, NALP12, PYPAF7, RNO, FCAS2|609648|19q13.42
Familial cold autoinflammatory syndrome 3, 614468 (3)|PLCG2, FCAS3, APLAID|600220|16q23.3
Fanconi anemia, complementation group A, 227650 (3)|FANCA, FACA, FA1, FA, FAA|607139|16q24.3
Fanconi anemia, complementation group B, 300514 (3)|FAAP95, FAAP90, FLJ34064, FANCB|300515|Xp22.2
Fanconi anemia, complementation group C, 227645 (3)|FANCC, FACC|613899|9q22.32
Fanconi anemia, complementation group D1, 605724 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
Fanconi anemia, complementation group D2, 227646 (3)|FANCD2, FANCD, FACD, FAD|613984|3p25.3
Fanconi anemia, complementation group E, 600901 (3)|FANCE, FACE|613976|6p21.31
Fanconi anemia, complementation group F, 603467 (3)|FANCF|613897|11p14.3
Fanconi anemia, complementation group G, 614082 (3)|XRCC9, FANCG|602956|9p13.3
Fanconi anemia, complementation group I, 609053 (3)|FANCI, KIAA1794|611360|15q26.1
Fanconi anemia, complementation group J, 609054 (3)|BRIP1, BACH1, FANCJ|605882|17q23.2
Fanconi anemia, complementation group L, 614083 (3)|PHF9, FANCL|608111|2p16.1
Fanconi anemia, complementation group M, 614087 (3)|FANCM, KIAA1596|609644|14q21.2
Fanconi anemia, complementation group N, 610832 (3)|PALB2, FANCN, PNCA3|610355|16p12.2
Fanconi anemia, complementation group O, 613390 (3)|RAD51C, FANCO, BROVCA3|602774|17q22
Fanconi anemia, complementation group P, 613951 (3)|SLX4, BTBD12, MUS312, KIAA1784, KIAA1987, FANCP|613278|16p13.3
Fanconi anemia, complementation group Q, 615272 (3)|ERCC4, XPF, FANCQ|133520|16p13.12
Fanconi renotubular syndrome 1 (2)|FRTS1, FRTS, RFS|134600|15q15.3
Fanconi renotubular syndrome 2, 613388 (3)|SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2|182309|5q35.3
Fanconi-Bickel syndrome, 227810 (3)|SLC2A2, GLUT2|138160|3q26.2
Farber lipogranulomatosis, 228000 (3)|ASAH1, AC, SMAPME|613468|8p22
Fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3)|SMCHD1, KIAA0650|614982|18p11.32
Fatty liver, acute, of pregnancy, 609016 (3)|HADHA, MTPA|600890|2p23.3
Favism, 134700 (3)|G6PD, G6PD1|305900|Xq28
Fazio-Londe disease, 211500 (3)|SLC52A3, C20orf54, RFT2, BVVLS1|613350|20p13
Febrile seizures, familial, 1 (2)|FEB1|121210|8q13-q21
Febrile seizures, familial, 10 (2)|FEB10|612637|3q26.2-q26.33
Febrile seizures, familial, 11, 614418 (3)|CPA6, CPAH, ETL5, FEB11|609562|8q13.2
Febrile seizures, familial, 2 (2)|FEB2|602477|19p13.3
Febrile seizures, familial, 3A, 604403 (3)|SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24.3
Febrile seizures, familial, 3B, 613863 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Febrile seizures, familial, 4, 604352 (3)|GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C|602851|5q14.3
Febrile seizures, familial, 5 (2)|FEB5|609255|6q22-q24
Febrile seizures, familial, 6 (2)|FEB6|609253|18p11.2
Febrile seizures, familial, 7 (2)|FEB7|611515|21q22
Febrile seizures, familial, 8, 611277 (3)|GABRG2, GEFSP3, CAE2, ECA2|137164|5q34
Febrile seizures, familial, 9 (2)|FEB9|611634|3p24.2-p23
Fechtner syndrome, 153640 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
Feingold syndrome 2, 614326 (3)|MIR17HG, MIRH1, MIHG1, MIRHG1, C13orf25, FGLDS2|609415|13q31.3
Feingold syndrome, 164280 (3)|MYCN, NMYC, ODED, MODED|164840|2p24.3
Fertile eunuch syndrome, 228300 (3)|GNRHR, LHRHR, HH7|138850|4q13.2
Fetal akinesia deformation sequence, 208150 (3)|DOK7, C4orf25, CMS1B|610285|4p16.3
Fetal akinesia deformation sequence, 208150 (3)|RAPSN, CMS1D, CMS1E|601592|11p11.2
Fetal hemoglobin quantitative trait locus 1, 141749 (3)|HBG1|142200|11p15.4
Fetal hemoglobin quantitative trait locus 1, 141749 (3)|HBG2, TNCY|142250|11p15.4
Fetal hemoglobin quantitative trait locus 2 (2)|HBFQTL2, FCP|142470|6q22.3-q23.1
Fetal hemoglobin quantitative trait locus 3 (2)|HBFQTL3, FCP1, FCPX, FCP|305435|Xp22.2
Fetal hemoglobin quantitative trait locus 4 (2)|HBFQTL4|606789|8q
Fibrochondrogenesis 2, 614524 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Fibrochondrogenesis, 228520 (3)|COL11A1, STL2|120280|1p21.1
Fibrodysplasia ossificans progressiva, 135100 (3)|ACVR1, ACVRLK2, ALK2, FOP|102576|2q24.1
Fibromatosis, gingival, 135300 (3)|SOS1, GINGF, GF1, HGF, NS4|182530|2p22.1
Fibromatosis, gingival, 2 (2)|GINGF2, GGF2, HGF2|605544|5q13-q22
Fibromatosis, gingival, 3 (2)|GINGF3, HGF3, GGF3|609955|2p23.3-p22.3
Fibromatosis, gingival, 4 (2)|GINGF4, HGF4, GGF4|611010|11p15
Fibrosis of extraocular muscles, congenital, 1, 135700 (3)|KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B|608283|12q12
Fibrosis of extraocular muscles, congenital, 2, 602078 (3)|PHOX2A, ARIX, CFEOM2|602753|11q13.4
Fibrosis of extraocular muscles, congenital, 3A, 600638 (3)|TUBB3, TUBB4, CFEOM3A, CDCBM1|602661|16q24.3
Fibrosis of extraocular muscles, congenital, 3B, 135700 (3)|KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B|608283|12q12
Fibrosis of extraocular muscles, congenital, 3C (2)|CFEOM3C, FEOM4|609384|13q12.11
Fish-eye disease, 136120 (3)|LCAT|606967|16q22.1
Fleck retina, familial benign, 228980 (3)|PLA2G5, FRFB|601192|1p36.13-p36.12
Fletcher factor deficiency, 612423 (3)|KLKB1, KLK3|229000|4q35.2
Floating-Harbor syndrome, 136140 (3)|SRCAP, SWR1, KIAA0309, FLHS|611421|16p11.2
Focal cortical dysplasia, Taylor balloon cell type, 607341 (3)|TSC1, LAM|605284|9q34.13
Focal dermal hypoplasia, 305600 (3)|PORCN, PORC, DHOF, FODH|300651|Xp11.23
Focal facial dermal dysplasia 3, Setleis type, 227260 (3)|TWIST2, DERMO1, SETLSS, FFDD3|607556|2q37.3
Focal facial dermal dysplasia 4, 614974 (3)|CYP26C1, FFDD4|608428|10q23.33
Folate malabsorption, hereditary, 229050 (3)|SLC46A1, HCP1, PCFT|611672|17q11.2
Follicle-stimulating hormone deficiency, isolated, 229070 (3)|FSHB|136530|11p14.1
Forebrain defects (3)|TDGF1|187395|3p21.31
Forsythe-Wakeling syndrome (2)|FWS|613606|1p33-p31.1
Foveal hyperplasia, 136520 (3)|PAX6, AN2, MGDA|607108|11p13
Foveal hypoplasia and anterior segment dysgenesis (2)|FHASD|609218|16q23.2-q24.2
Foveomacular dystrophy, adult-onset, with choroidal neovascularization, 608161 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Fragile X syndrome, 300624 (3)|FMR1, FRAXA, POF1|309550|Xq27.3
Fragile X tremor/ataxia syndrome, 300623 (3)|FMR1, FRAXA, POF1|309550|Xq27.3
Frank-ter Haar syndrome, 249420 (3)|SH3PXD2B, TKS4, KIAA1295, FTHS|613293|5q35.1
Fraser syndrome, 219000 (3)|FRAS1|607830|4q21.21
Fraser syndrome, 219000 (3)|FREM2|608945|13q13.3
Fraser syndrome, 219000 (3)|GRIP1|604597|12q14.3
Frasier syndrome, 136680 (3)|WT1, NPHS4|607102|11p13
Friedreich ataxia 2 (2)|FRDA2|601992|9p23-p11
Friedreich ataxia with retained reflexes, 229300 (3)|FXN, FRDA, FARR, X25|606829|9q21.11
Friedreich ataxia, 229300 (3)|FXN, FRDA, FARR, X25|606829|9q21.11
Frontometaphyseal dysplasia, 305620 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Frontonasal dysplasia 1, 136760 (3)|ALX3, FND1|606014|1p13.3
Frontonasal dysplasia 2, 613451 (3)|ALX4, PFM2, FPP, FND2, CRS5|605420|11p11.2
Frontonasal dysplasia 3, 613456 (3)|ALX1, CART1, FND3|601527|12q21.31
Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3)|GRN, CLN11|138945|17q21.31
Frontotemporal lobar degeneration, TARDBP-related, 612069 (3)|TARDBP, TDP43, ALS10|605078|1p36.22
Fructose intolerance, 229600 (3)|ALDOB|612724|9q31.1
Fructose-1,6-bidphosphatase deficiency, 229700 (3)|FBP1|611570|9q22.32
Fucosidosis, 230000 (3)|FUCA1|612280|1p36.11
Fucosyltransferase 6 deficiency, 613852 (3)|FUT6|136836|19p13.3
Fuhrmann syndrome, 228930 (3)|WNT7A|601570|3p25.1
Fumarase deficiency, 606812 (3)|FH, HLRCC, MCUL1|136850|1q43
Fundus albipunctatus, 136880 (3)|RDH5|601617|12q13.2
Fundus albipunctatus, 136880 (3)|RLBP1|180090|15q26.1
Fundus flavimaculatus, 248200 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
GABA-transaminase deficiency, 613163 (3)|ABAT, GABAT|137150|16p13.2
GAPO syndrome, 230740 (3)|ANTXR1, TEM8, ATR, GAPO|606410|2p13.3
GLUT1 deficiency syndrome 1, 606777 (3)|SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9|138140|1p34.2
GLUT1 deficiency syndrome 2, 612126 (3)|SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9|138140|1p34.2
GM1-gangliosidosis, type I, 230500 (3)|GLB1, MPS4B|611458|3p22.3
GM1-gangliosidosis, type II, 230600 (3)|GLB1, MPS4B|611458|3p22.3
GM1-gangliosidosis, type III, 230650 (3)|GLB1, MPS4B|611458|3p22.3
GM2-gangliosidosis, AB variant, 272750 (3)|GM2A|613109|5q33.1
GM2-gangliosidosis, several forms, 272800 (3)|HEXA, TSD|606869|15q23
GRACILE syndrome, 603358 (3)|BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1|603647|2q35
Galactokinase deficiency with cataracts, 230200 (3)|GALK1|604313|17q25.1
Galactose epimerase deficiency, 230350 (3)|GALE|606953|1p36.11
Galactosemia, 230400 (3)|GALT|606999|9p13.3
Galactosialidosis, 256540 (3)|CTSA, PPGB, GSL, NGBE, GLB2|613111|20q13.12
Gallbladder disease 1, 600803 (3)|ABCB4, PGY3, MDR3, ICP3|171060|7q21.12
Gallbladder disease 2 (2)|GBD2|609918|1p36.21
Gallbladder disease 3 (2)|GBD3|609919|1p34.3
Gallbladder disease 4, 611465 (3)|ABCG8, GBD4|605460|2p21
Gardner syndrome, 175100 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 (3)|CDH1, UVO, LCAM, ECAD|192090|16q22.1
Gastric cancer, somatic, 137215 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Gastric cancer, somatic, 613659 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Gastric cancer, somatic, 613659 (3)|CASP10, MCH4, ALPS2|601762|2q33.1
Gastric cancer, somatic, 613659 (3)|ERBB2, NGL, NEU, HER2|164870|17q12
Gastric cancer, somatic, 613659 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Gastric cancer, somatic, 613659 (3)|IRF1, MAR|147575|5q31.1
Gastric cancer, somatic, 613659 (3)|KLF6, COPEB, BCD1, ZF9|602053|10p15.1
Gastric cancer, somatic, 613659 (3)|MUTYH, MYH|604933|1p34.1
Gastric cancer, somatic, 613659 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Gastroesophageal reflux (2)|GER|109350|13q14
Gastrointestinal stromal tumor, 606764 (3)|SDHB, SDH2, SDHIP, PGL4, CWS2|185470|1p36.13
Gastrointestinal stromal tumor, 606764 (3)|SDHC, PGL3|602413|1q23.3
Gastrointestinal stromal tumor, familial, 606764 (3)|KIT, PBT|164920|4q12
Gastrointestinal stromal tumor, somatic, 606764 (3)|PDGFRA|173490|4q12
Gaucher disease, atypical, 610539 (3)|PSAP, SAP1|176801|10q22.1
Gaucher disease, perinatal lethal, 608013 (3)|GBA|606463|1q22
Gaucher disease, type I, 230800(3)|GBA|606463|1q22
Gaucher disease, type II, 230900 (3)|GBA|606463|1q22
Gaucher disease, type III, 231000 (3)|GBA|606463|1q22
Gaucher disease, type IIIC, 231005 (3)|GBA|606463|1q22
Gaze palsy, horizontal, with progressive scoliosis, 607313 (3)|ROBO3, RBIG1, RIG1, HGPPS|608630|11q24.2
Geleophysic dysplasia 1, 231050 (3)|ADAMTSL2, KIAA0605, GPHYSD1|612277|9q34.2
Geleophysic dysplasia 2, 614185 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Generalized epilepsy and paroxysmal dyskinesia, 609446 (3)|KCNMA1, SLO|600150|10q22.3
Geniospasm (2)|GSM1, GSP|190100|9q13-q21
Genitopatellar syndrome, 606170 (3)|KAT6B, MYST4, MORF, GTPTS|605880|10q22.2
Germ cell tumors, 273300 (3)|KIT, PBT|164920|4q12
Geroderma osteodysplasticum, 231070 (3)|GORAB, SCYL1BP1, NTKLBP1, GO|607983|1q24.2
Gerstmann-Straussler disease, 137440 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Ghosal hematodiaphyseal syndrome, 231095 (3)|TBXAS1, GHOSAL, CYP5, BDPLT14|274180|7q34
Giant axonal neuropathy-1, 256850 (3)|GAN, GAN1|605379|16q23.2
Giant platelet disorder, isolated, 231200 (3)|GP1BB, BS, BDPLT1|138720|22q11.21
Gigantism due to GHRF hypersecretion (1)|GHRH, GHRF|139190|20q11.23
Gillespie syndrome, 206700 (3)|PAX6, AN2, MGDA|607108|11p13
Gitelman syndrome, 263800 (3)|SLC12A3, NCCT, TSC|600968|16q13
Glanzmann thrombasthenia, 273800 (3)|ITGA2B, GP2B, CD41B, GT, BDPLT2, BDPLT16|607759|17q21.31
Glanzmann thrombasthenia, 273800 (3)|ITGB3, GP3A, GT, BDPLT2, BDPLT16|173470|17q21.32
Glass syndrome, 119540 (3)|SATB2, KIAA1034|608148|2q33.1
Glaucoma 1, open angle, 1O, 613100 (3)|NTF4 , NTF5, NT5, NT4, GLC1O|162662|19q13.33
Glaucoma 1, open angle, E, 137760 (3)|OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p13
Glaucoma 1, open angle, F, 603383 (3)|ASB10, GLC1F|615054|7q36.1
Glaucoma 1, open angle, G, 609887 (3)|WDR36, TAWDRP, GLC1G|609669|5q22.1
Glaucoma 1, open angle, H (2)|GLC1H|611276|2p16-p15
Glaucoma 1, open angle, I (2)|GLC1I|609745|15q11-q13
Glaucoma 1, open angle, M (2)|GLC1M|610535|5q22.1-q32
Glaucoma 1, open angle, P (4)|GLC1P|177700|12q14
Glaucoma 1A, primary open angle, 137750 (3)|MYOC, TIGR, GLC1A, JOAG, GPOA|601652|1q24.3
Glaucoma 1B, primary open angle, adult onset, (2)|GLC1B|606689|2cen-q13
Glaucoma 1C, primary open angle (2)|GLC1C|601682|3q21-q24
Glaucoma 1D, primary open angle (2)|GLC1D|602429|8q23
Glaucoma 1K, primary open angle, juvenile-onset (2)|GLC1K, JOAG3|608696|20p12
Glaucoma 3, primary congenital, C (2)|GLC3C|613085|14q24.3
Glaucoma 3, primary congenital, D, 613086 (3)|LTBP2, LTBP3, GLC3D, MSPKA, WMS3|602091|14q24.3
Glaucoma 3, primary infantile, B (2)|GLC3B|600975|1p36.2-p36.1
Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 (3)|CYP1B1, GLC3A|601771|2p22.2
Glaucoma, primary open angle, juvenile-onset, 2 (2)|JOAG2|608695|9q22
Glioblastoma, somatic, 137800 (3)|ERBB2, NGL, NEU, HER2|164870|17q12
Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 (3)|UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Glomerulopathy with fibronectin deposits 1 (2)|GFND1|137950|1q32
Glomerulopathy with fibronectin deposits 2, 601894 (3)|FN1, FN, LETS, FNZ, GFND2|135600|2q35
Glomerulosclerosis, focal segmental, 1, 603278 (3)|ACTN4, FSGS1, FSGS|604638|19q13.2
Glomerulosclerosis, focal segmental, 2, 603965 (3)|TRPC6, TRP6, FSGS2|603652|11q22.1
Glomerulosclerosis, focal segmental, 3, 607832 (3)|CD2AP, CMS|604241|6p12.3
Glomerulosclerosis, focal segmental, 5, 613237 (3)|INF2, FSGS5, C14orf173, CMTDIE|610982|14q32.33
Glomerulosclerosis, focal segmental, 6, 614131 (3)|MYO1E, MYO1C, FSGS6|601479|15q22.2
Glomuvenous malformations, 138000 (3)|GLML, GVM, VMGLOM|601749|1p22.1
Glucocorticoid deficiency 2, 607398 (3)|MRAP, FALP, C21orf61, GCCD2, FGD2|609196|21q22.11
Glucocorticoid deficiency 3 (2)|GCCD3, FGD3, GCCD2|609197|8q11.2-q13.2
Glucocorticoid deficiency 4, 614736 (3)|NNT, GCCD4|607878|5p12
Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3)|MC2R|607397|18p11.21
Glucose/galactose malabsorption, 606824 (3)|SLC5A1, SGLT1|182380|22q12.3
Glutamate formiminotransferase deficiency, 229100 (3)|FTCD|606806|21q22.3
Glutamine deficiency, congenital, 610015 (3)|GLUL, GLNS|138290|1q25.3
Glutaric acidemia IIA, 231680 (3)|ETFA, GA2, MADD|608053|15q24.2-q24.3
Glutaric acidemia IIB, 231680 (3)|ETFB, MADD|130410|19q13.41
Glutaric acidemia IIC, 231680 (3)|ETFDH, MADD|231675|4q32.1
Glutaricaciduria, type I, 231670 (3)|GCDH|608801|19p13.2
Glutathione synthetase deficiency, 266130 (3)|GSS, GSHS|601002|20q11.22
Glutathioninuria (1)|GGT1, GTG|231950|22q11.1-q11.2
Glycerol kinase deficiency, 307030 (3)|GK|300474|Xp21.2
Glycine N-methyltransferase deficiency, 606664 (3)|GNMT|606628|6p21.1
Glycine encephalopathy, 605899 (3)|AMT, NKH, GCE|238310|3p21.31
Glycine encephalopathy, 605899 (3)|GCSH, NKH|238330|16q23.2
Glycine encephalopathy, 605899 (3)|GLDC, HYGN1, GCSP, GCE, NKH|238300|9p24.1
Glycogen storage disease 0, muscle, 611556 (3)|GYS1, GYS|138570|19q13.33
Glycogen storage disease II, 232300 (3)|GAA|606800|17q25.3
Glycogen storage disease IIIa, 232400 (3)|AGL, GDE|610860|1p21.2
Glycogen storage disease IIIb, 232400 (3)|AGL, GDE|610860|1p21.2
Glycogen storage disease IV, 232500 (3)|GBE1, GSD4, APBD|607839|3p12.2
Glycogen storage disease IXc, 613027 (3)|PHKG2, GSD9C|172471|16p11.2
Glycogen storage disease Ia, 232200 (3)|G6PC, G6PT|613742|17q21.31
Glycogen storage disease Ib, 232220 (3)|SLC37A4, G6PT1|602671|11q23.3
Glycogen storage disease Ic, 232240 (3)|SLC37A4, G6PT1|602671|11q23.3
Glycogen storage disease VI, 232700 (3)|PYGL|613741|14q22.1
Glycogen storage disease VII, 232800 (3)|PFKM, GSD7|610681|12q13.11
Glycogen storage disease X, 261670 (3)|PGAM2, PGAMM, GSD10|612931|7p13
Glycogen storage disease XI, 612933 (3)|LDHA, LDH1, GSD11|150000|11p15.1
Glycogen storage disease XII, 611881 (3)|ALDOA, GSD12|103850|16p11.2
Glycogen storage disease XIII, 612932 (3)|ENO3, GSD13|131370|17p13.2
Glycogen storage disease XIV, 612934 (3)|PGM1, GSD14, GSD14, CDG1T|171900|1p31.3
Glycogen storage disease XV, 613507 (3)|GYG1, GSD15|603942|3q24
Glycogen storage disease of heart, lethal congenital, 261740 (3)|PRKAG2, WPWS, CMH6|602743|7q36.1
Glycogen storage disease, type 0, 240600 (3)|GYS2|138571|12p12.1
Glycogen storage disease, type IXa1, 306000 (3)|PHKA2, PHK, XLG, PHK, PYKL, GSD9A|300798|Xp22.13
Glycogen storage disease, type IXa2, 306000 (3)|PHKA2, PHK, XLG, PHK, PYKL, GSD9A|300798|Xp22.13
Glycosylphosphatidylinositol deficiency, 610293 (3)|PIGM|610273|1q23.2
Gnathodiaphyseal dysplasia, 166260 (3)|ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Goeminne TKCR syndrome (2)|TKCR, TKC|314300|Xq28
Goiter, familial, due to TTF-1 defect (1)|NKX2-1, TITF1, NKX2A, TTF1|600635|14q13.3
Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 (3)|DICER1, HERNA, KIAA0928, MNG1, RMSE2|606241|14q32.13
Goiter, multinodular, 2 (2)|MNG2|300273|Xp22
Goiter, multinodular, 3 (2)|MNG3|606082|3q26.1-q26.3
Goldberg-Shprintzen megacolon syndrome, 609460 (3)|KIAA1279|609367|10q22.1
Gonadal dysgenesis, XY female type (2)|GDXY, TDFX, SRVX|306100|Xp22.11-p21.2
Gout, PRPS-related, 300661 (3)|PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22.3
Gracile bone dysplasia, 602361 (3)|FAM111A, KIAA1895, KCS2, GCLEB|615292|11q12.1
Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 (3)|NCF4, P40PHOX|601488|22q12.3
Gray platelet syndrome, 139090 (3)|NBEAL2, KIAA0540, GPS, BDPLT4|614169|3p21.31
Greenberg skeletal dysplasia, 215140 (3)|LBR, PHA|600024|1q42.12
Greig cephalopolysyndactyly syndrome, 175700 (3)|GLI3, PAPA, PAPB|165240|7p14.1
Griscelli syndrome, type 1, 214450 (3)|MYO5A, MYH12, GS1|160777|15q21.2
Griscelli syndrome, type 2, 607624 (3)|RAB27A, RAM, GS2|603868|15q21.3
Griscelli syndrome, type 3, 609227 (3)|MLPH|606526|2q37.3
Growth hormone deficiency with pituitary anomalies, 182230 (3)|HESX1, RPX, CPHD5|601802|3p14.3
Growth hormone deficiency, isolated, type IA, 262400 (3)|GH1, GHN, IGHD1B|139250|17q23.3
Growth hormone deficiency, isolated, type IB, 612781 (3)|GH1, GHN, IGHD1B|139250|17q23.3
Growth hormone deficiency, isolated, type IB, 612781 (3)|GHRHR, GHRFR, IGHD1B|139191|7p14.3
Growth hormone deficiency, isolated, type II, 173100 (3)|GH1, GHN, IGHD1B|139250|17q23.3
Growth hormone insensitivity with immunodeficiency, 245590 (3)|STAT5B|604260|17q21.2
Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3)|IGF1|147440|12q23.2
Growth retardation, developmental delay, coarse facies, and early death, 612938 (3)|FTO|610966|16q12.2
Gustavson syndrome (2)|GUST|309555|Xq26
Guttmacher syndrome, 176305 (3)|HOXA13, HOX1J|142959|7p15.2
Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3)|OAT, GACR|613349|10q26.13
HARP syndrome, 607236 (3)|PANK2, NBIA1, PKAN, HARP|606157|20p13
HDL deficiency, type 2, 604091 (3)|ABCA1, ABC1, HDLDT1, TGD|600046|9q31.1
HELLP syndrome, maternal, of pregnancy, 609016 (3)|HADHA, MTPA|600890|2p23.3
HMG-CoA lyase deficiency, 246450 (3)|HMGCL|613898|1p36.11
HMG-CoA synthase-2 deficiency, 605911 (3)|HMGCS2|600234|1p12
HPRT-related gout, 300323 (3)|HPRT1, HPRT|308000|Xq26.2-q26.3
Haddad syndrome, 209880 (3)|ASCL1, ASH1|100790|12q23.2
Hailey-Hailey disease, 169600 (3)|ATP2C1, BCPM, HHD|604384|3q22.1
Haim-Munk syndrome, 245010 (3)|CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD|602365|11q14.2
Hair, curly (2)|HRM2|139450|1q21.3
Hajdu-Cheney syndrome, 102500 (3)|NOTCH2, AGS2, HJCYS|600275|1p12-p11
Hamamy syndrome, 611174 (3)|IRX5, HMMS|606195|16q12.2
Hand-foot-uterus syndrome, 140000 (3)|HOXA13, HOX1J|142959|7p15.2
Harderoporphyria, 121300 (3)|CPOX|612732|3q11.2-q12.1
Hartnup disorder, 234500 (3)|SLC6A19, HND|608893|5p15.33
Hartsfield syndrome, 615465 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Hashimoto thyroiditis (2)|HT|140300|8q23-q24
Hawkinsinuria, 140350 (3)|HPD|609695|12q24.31
Hay-Wells syndrome, 106260 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Heart block, nonprogressive, 113900 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Heart block, progressive, type IA, 113900 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Heart-hand syndrome, Slovenian type, 610140 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Heinz body anemia, 140700 (3)|HBA2, HBH|141850|16p13.3
Heinz body anemias, alpha-, 140700 (3)|HBA1, HBH|141800|16p13.3
Heinz body anemias, beta-, 140700 (3)|HBB|141900|11p15.4
Hemangioblastoma, cerebellar, somatic (3)|VHL|608537|3p25.3
Hemangioma, capillary infantile, somatic, 602089 (3)|FLT4, VEGFR3, PCL, LMPH1A|136352|5q35.3
Hemangioma, capillary infantile, somatic, 602089 (3)|KDR|191306|4q12
Hematuria, benign familial, 141200 (3)|COL4A3|120070|2q36.3
Hematuria, familial benign (3)|COL4A4|120131|2q36.3
Heme oxygenase-1 deficiency, 614034 (3)|HMOX1, HMOX1D|141250|22q12.3
Hemifacial microsomia (2)|HFM|164210|14q32
Hemihypertrophy (2)|IH, HHP|235000|11p15
Hemochromatosis, 235200 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
Hemochromatosis, type 2A, 602390 (3)|HJV, HFE2A|608374|1q21.1
Hemochromatosis, type 2B, 613313 (3)|HAMP, LEAP1, HEPC, HFE2B|606464|19q13.12
Hemochromatosis, type 3, 604250 (3)|TFR2, HFE3|604720|7q22.1
Hemochromatosis, type 4, 606069 (3)|SLC40A1, SLC11A3, FPN1, IREG1, HFE4|604653|2q32.2
Hemoglobin H disease, nondeletional, 613978 (3)|HBA1, HBH|141800|16p13.3
Hemoglobin H disease, nondeletional, 613978 (3)|HBA2, HBH|141850|16p13.3
Hemolytic anemia due to G6PD deficiency, 300908 (3)|G6PD, G6PD1|305900|Xq28
Hemolytic anemia due to adenylate kinase deficiency, 612631 (3)|AK1|103000|9q34.11
Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3)|GCLC, GLCLC|606857|6p12.1
Hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1)|GPX1, GPXD|138320|3p21.31
Hemolytic anemia due to glutathione reductase deficiency (1)|GSR|138300|8p12
Hemolytic anemia due to glutathione synthetase deficiency, 231900 (3)|GSS, GSHS|601002|20q11.22
Hemolytic anemia due to hexokinase deficiency, 235700 (3)|HK1, HKD, HMSNR|142600|10q22.1
Hemolytic anemia due to phosphofructokinase deficiency (1)|PFKL|171860|21q22.3
Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 (3)|TPI1, TPID|190450|12p13.31
Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 (3)|CD59, MIC11|107271|11p13
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3)|GPI|172400|19q13.11
Hemophagocytic lymphohistiocytosis, familial, 1 (2)|FHL1, HPLH1, HLH1|267700|9q21.3-q22
Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3)|PRF1, HPLH2, FLH2|170280|10q22.1
Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3)|UNC13D, MUNC13-4, HPLH3, HLH3, FHL3|608897|17q25.1
Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3)|STX11, FHL4, HPLH4, HLH4|605014|6q24.2
Hemophagocytic lymphohistiocytosis, familial, 5, 613101 (3)|STXBP2, UNC18B, FHL5|601717|19p13.2
Hemophilia A, 306700 (3)|F8, F8C, HEMA|300841|Xq28
Hemophilia B, 306900 (3)|F9, HEMB, THPH8|300746|Xq27.1
Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3)|JAM3|606871|11q25
Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh, 613490 (3)|SERPINA1, PI, AAT|107400|14q32.13
Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3)|CP|117700|3q24-q25
Hennekam lymphangiectasia-lymphedema syndrome, 235510 (3)|CCBE1, KIAA1983|612753|18q21.32
Hepatic adenoma, somatic, 142330 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
Hepatic failure, early onset, and neurologic disorder (3)|SCOD1, SCO1|603644|17p13.1
Hepatic lipase deficiency, 614025 (3)|LIPC, HL, LIPH, HDLCQ12|151670|15q21.3
Hepatic venoocclusive disease with immunodeficiency, 235550 (3)|SP110, IFI41, IFI75, VODI|604457|2q37.1
Hepatoblastoma, somatic, 114550 (3)|APC, GS, FPC, BTPS2|611731|5q22.2
Hepatocellular cancer, somatic, 114550 (3)|PDGFRL, PDGRL, PRLTS|604584|8p22
Hepatocellular carcinoma, 114550 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Hepatocellular carcinoma, childhood type, 114550 (3)|MET|164860|7q31.2
Hepatocellular carcinoma, somatic, 114550 (3)|AXIN1, AXIN|603816|16p13.3
Hepatocellular carcinoma, somatic, 114550 (3)|CASP8, MCH5, ALPS2B|601763|2q33.1
Hepatocellular carcinoma, somatic, 114550 (3)|CTNNB1, MRD19|116806|3p22.1
Hepatocellular carcinoma, somatic, 114550 (3)|IGF2R, MPRI|147280|6q25.3
Hepatocellular carcinoma, somatic, 114550 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Hereditary motor and sensory neuropathy V (2)|HMSN5|600361|4q34.3-q35.2
Hereditary motor and sensory neuropathy VI, 601152 (3)|MFN2, KIAA0214, CMT2A2|608507|1p36.22
Hereditary motor and sensory neuropathy, proximal type, 604484 (3)|TFG, HMSNP, SPG57|602498|3q12.2
Hereditary motor and sensory neuropathy, type IIc, 606071 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Hereditary persistence of fetal hemoglobin, 141749 (3)|HBB|141900|11p15.4
Hermansky-Pudlak syndrome 1, 203300 (3)|HPS1|604982|10q24.2
Hermansky-Pudlak syndrome 2, 608233 (3)|AP3B1, ADTB3A, HPS2|603401|5q14.1
Hermansky-Pudlak syndrome 3, 614072 (3)|HPS3|606118|3q24
Hermansky-Pudlak syndrome 4, 614073 (3)|HPS4|606682|22q12.1
Hermansky-Pudlak syndrome 5, 614074 (3)|HPS5, RU2, KIAA1017|607521|11p15.1
Hermansky-Pudlak syndrome 6, 614075 (3)|HPS6, RU|607522|10q24.32
Hermansky-Pudlak syndrome 7, 614076 (3)|DTNBP1, HPS7|607145|6p22.3
Hermansky-Pudlak syndrome 8, 614077 (3)|BLOC1S3, BLOS3, HPS8|609762|19q13.32
Hermansky-pudlak syndrome 9, 614171 (3)|BLOC1S6, BLOS6, PLDN, PA, HPS9|604310|15q21.1
Hernia, congenital diaphragmatic 1 (2)|DIH1, HCD|142340|15q26.1
Hernia, congenital diaphragmatic 2 (2)|DIH2|222400|8p23.1
Herpes simplex encephalitis, susceptibility to, 1, 610551 (3)|UNC93B1, IIAE1|608204|11q13.2
Heterotaxy, visceral, 1, X-linked 306955 (3)|ZIC3, HTX1, HTX, VACTERLX|300265|Xq26.3
Heterotaxy, visceral, 2, autosomal, 605376 (3)|CFC1, CRYPTIC, HTX2, DTGA2|605194|2q21.1
Heterotaxy, visceral, 4, autosomal, 613751 (3)|ACVR2B, ACTRIIB, HTX4|602730|3p22.2
Heterotaxy, visceral, 5, 270100 (3)|NODAL, HTX5|601265|10q22.1
Heterotaxy, visceral, 6, autosomal recessive, 614779 (3)|CCDC11, HTX6|614759|18q21.1
Heterotopia, periventricular, 300049 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Heterotopia, periventricular, ED variant, 300537 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
High density lipoprotein cholesterol level QTL14 (2)|HDLCQ14, HYLAP|605201|11q23.3
Hip dysplasia, Beukes type (2)|BHD, BFHD|142669|4q35
Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3)|ECE1|600423|1p36.12
Histiocytoma, angiomatoid fibrous, somatic, 612160 (3)|CREB1|123810|2q33.3
Histiocytosis-lymphadenopathy plus syndrome, 602782 (3)|HJCD, HCLAP|602782|11q25
Histiocytosis-lymphadenopathy plus syndrome, 602782 (3)|SLC29A3, ENT3, PHID, HCLAP|612373|10q22.1
Hodgkin lymphoma, 236000 (3)|KLHDC8B|613169|3p21.31
Holocarboxylase synthetase deficiency, 253270 (3)|HLCS, HCS|609018|21q22.13
Holoprosencephaly 11, 614226 (3)|CDON, CDO, HPE11|608707|11q24.2
Holoprosencephaly-1 (2)|HPE1|236100|21q22.3
Holoprosencephaly-2, 157170 (3)|SIX3, HPE2|603714|2p21
Holoprosencephaly-3, 142945 (3)|SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36.3
Holoprosencephaly-4, 142946 (3)|TGIF, HPE4|602630|18p11.31
Holoprosencephaly-5, 609637 (3)|ZIC2, HPE5|603073|13q32.3
Holoprosencephaly-6 (2)|HPE6|605934|2q37.1-q37.3
Holoprosencephaly-7, 610828 (3)|PTCH1, NBCCS, BCNS, HPE7|601309|9q22.32
Holoprosencephaly-8 (2)|HPE8|609408|14q13
Holoprosencephaly-9, 610829 (3)|GLI2, HPE9|165230|2q14.2
Holt-Oram syndrome, 142900 (3)|TBX5|601620|12q24.21
Homocysteine plasma level (2)|NNMT|600008|11q23.2
Homocysteine, total plasma, elevated (3)|CTH|607657|1p31.1
Homocystinuria due to MTHFR deficiency, 236250 (3)|MTHFR|607093|1p36.22
Homocystinuria, B6-responsive and nonresponsive types, 236200 (3)|CBS|613381|21q22.3
Homocystinuria, cblD type, variant 1, 277410 (3)|C2orf25, MMADHC|611935|2q23.2
Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3)|MTRR|602568|5p15.31
Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 (3)|MTR, HMAG|156570|1q43
Humoral hypercalcemia of malignancy (1)|PTHLH, BDE2|168470|12p11.22
Huntington disease, 143100 (3)|HTT, HD, IT15|613004|4p16.3
Huntington disease-like 1, 603218 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Huntington disease-like 2, 606438 (3)|JPH3, JP3, HDL2|605268|16q24.2
Huntington disease-like 3 (2)|HDL3, HLN2|604802|4p15.3
Huriez syndrome (2)|TYS, HRZ|181600|4q23
Hutchinson-Gilford progeria, 176670 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Hyaline fibromatosis syndrome, 228600 (3)|ANTXR2, CMG2, HFS|608041|4q21.21
Hydatidiform mole, 231090 (3)|NALP7, NOD12, PYPAF3, HYDM|609661|19q13.42
Hydatidiform mole, recurrent, 2, 614293 (3)|KHDC3L, C6orf221, ECAT1, HYDM2|611687|6q13
Hydranencephaly with abnormal genitalia, 300215 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Hydrocephalus due to aqueductal stenosis, 307000 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
Hydrocephalus with Hirschsprung disease, 307000 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 (3)|MPDZ, MUPP1, HYC2|603785|9p23
Hydrocephalus, nonsyndromic, autosomal recessive, 236600 (3)|CCDC88C, HKRP2, DAPLE, KIAA1509, HYC|611204|14q32.11
Hydrolethalus syndrome 2, 614120 (3)|KIF7, HLS2, ACLS, JBTS12|611254|15q26.1
Hydrolethalus syndrome, 236680 (3)|HYLS1, FLJ32915|610693|11q24.2
Hyper-IgD syndrome, 260920 (3)|MVK, MVLK, POROK3|251170|12q24.11
Hyper-IgE recurrent infection syndrome, 147060 (3)|STAT3, APRF, HIES|102582|17q21.2
Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3)|DOCK8, MRD2|611432|9p24.3
Hyperaldosteronism, familial, type II (2)|FHII|605635|7p22
Hyperaldosteronism, familial, type III, 613677 (3)|KCNJ5, GIRK4, KATP1, LQT13|600734|11q24.3
Hyperalphalipoproteinemia 2, 614028 (3)|APOC3, HALP2|107720|11q23.3
Hyperalphalipoproteinemia, 143470 (3)|CETP, HDLCQ10|118470|16q13
Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3)|CYP21A2, CYP21, CA21H|613815|6p21.33
Hyperbilirubinemia, Rotor type, digenic, 237450 (3)|SLCO1B1, LST1, OATP2, OATPC, OATP1B1, HBLRR|604843|12p12.2-p12.1
Hyperbilirubinemia, Rotor type, digenic, 237450 (3)|SLCO1B3, OATP8, OATP1B3, SLC21A8, HBLRR|605495|12p12.2
Hyperbilirubinemia, familial transcient neonatal, 237900 (3)|UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37.1
Hyperbiliverdinemia, 614156 (3)|BLVRA|109750|7p13
Hypercalcemia, infantile, 143880 (3)|CYP24A1, CYP24, HCAI|126065|20q13.2
Hypercalciuria, absorptive (2)|HCA1|607258|4q33-qter
Hypercalciuric hypercalcemia (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 (3)|BCMO1, BCDO, BCO1|605748|16q23.2
Hyperchlorhidrosis, isolated, 143860 (3)|CA12|603263|15q22.2
Hypercholanemia, familial, 607748 (3)|BAAT|602938|9q31.1
Hypercholanemia, familial, 607748 (3)|EPHX1|132810|1q42.12
Hypercholanemia, familial, 607748 (3)|TJP2, ZO2|607709|9q21.11
Hypercholesterolemia, due to ligand-defective apo B, 144010 (3)|APOB, FLDB, LDLCQ4|107730|2p24.1
Hypercholesterolemia, familial, 143890 (3)|LDLR, FHC, FH, LDLCQ2|606945|19p13.2
Hypercholesterolemia, familial, 3, 603776 (3)|PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1|607786|1p32.3
Hypercholesterolemia, familial, autosomal recessive, 603813 (3)|LDLRAP1, ARH, FHCB2, FHCB1|605747|1p36.11
Hyperchylomicronemia, late-onset, 144650 (3)|APOA5|606368|11q23.3
Hyperekplexia 2, autosomal recessive, 614619 (3)|GLRB, HKPX2|138492|4q32.1
Hyperekplexia 3, 614618 (3)|SLC6A5, GLYT2, HKPX3|604159|11p15.1
Hyperekplexia, hereditary 1, autosomal dominant or recessive, 149400 (3)|GLRA1, STHE, HKPX1|138491|5q33.1
Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3)|PDGFRA|173490|4q12
Hyperferritinemia-cataract syndrome, 600886 (3)|FTL, NBIA3, LFTD|134790|19q13.33
Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1)|PLAT, TPA|173370|8p11.21
Hyperglycinuria, 138500 (3)|SLC36A2, PAT2|608331|5q33.1
Hyperglycinuria, 138500 (3)|SLC6A19, HND|608893|5p15.33
Hyperglycinuria, 138500 (3)|SLC6A20, XT3|605616|3p21.31
Hyperhidrosis palmaris et plantaris (2)|HHPP|144110|14q11.2-q13
Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3)|ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3)|KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Hyperinsulinemic hypoglycemia, familial, 3, 602485 (3)|GCK, HHF3|138079|7p13
Hyperinsulinemic hypoglycemia, familial, 4, 609975 (3)|HADHSC, SCHAD, HHF4|601609|4q25
Hyperinsulinemic hypoglycemia, familial, 5, 609968 (3)|INSR, HHF5|147670|19p13.2
Hyperinsulinemic hypoglycemia, familial, 7, 610021 (3)|SLC16A1, MCT1, HHF7|600682|1p13.2
Hyperinsulinism-hyperammonemia syndrome, 606762 (3)|GLUD1|138130|10q23.2
Hyperkalemic periodic paralysis, type 2, 170500 (3)|SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.3
Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3)|CCM1, CAM, KRIT1|604214|7q21.2
Hyperlipidemia, combined, 2 (2)|HYPLIP2|604499|11p
Hyperlipoproteinemia, type III (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
Hyperlipoproteinemia, type Ib, 207750 (3)|APOC2|608083|19q13.32
Hyperlysinemia, 238700 (3)|AASS|605113|7q31.32
Hypermanganesemia with dystonia, polycythemia, and cirrhosis, 613280 (3)|SLC30A10, ZNT10, HMDPC|611146|1q41
Hypermethioninemia due to adenosine kinase deficiency, 614300 (3)|ADK|102750|10q22.2
Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 (3)|AHCY, SAHH|180960|20q11.22
Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3)|MAT1A, MATA1, SAMS1|610550|10q23.1
Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3)|SLC25A15, ORNT1, HHH|603861|13q14.11
Hyperostosis, endosteal, 144750 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
Hyperoxaluria, primary, type 1, 259900 (3)|AGXT, SPAT|604285|2q37.3
Hyperoxaluria, primary, type II, 260000 (3)|GRHPR, GLXR|604296|9p13.2
Hyperoxaluria, primary, type III, 613616 (3)|HOGA1, DHDPSL, HP3|613597|10q24.2
Hyperparathyroidism 3 (2)|HRPT3|610071|2p14-p13.3
Hyperparathyroidism, familial primary, 145000 (3)|HRPT2, C1orf28|607393|1q31.2
Hyperparathyroidism, neonatal, 239200 (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
Hyperparathyroidism-jaw tumor syndrome, 145001 (3)|HRPT2, C1orf28|607393|1q31.2
Hyperphenylalaninemia, BH4-deficient, A, 261640 (3)|PTS|612719|11q23.1
Hyperphenylalaninemia, BH4-deficient, B, 233910 (3)|GCH1, DYT5, HPABH4B|600225|14q22.2
Hyperphenylalaninemia, BH4-deficient, C, 261630 (3)|QDPR, DHPR|612676|4p15.32
Hyperphenylalaninemia, BH4-deficient, D, 264070 (3)|PCBD, DCOH|126090|10q22.1
Hyperphosphatasia with mental retardation syndrome 1, 239300 (3)|PIGV, HPMRS1|610274|1p36.11
Hyperphosphatasia with mental retardation syndrome 2, 614749 (3)|PIGO, HPMRS2|614730|9p13.3
Hyperphosphatasia with mental retardation syndrome 3, 614207 (3)|PGAP2, FRAG1, HPMRS3, MRT17, MRT21|615187|11p15.4
Hyperpigmentation, familial progressive, 1 (2)|FPH1, MUH, HPP|614233|19pter-p13.1
Hyperpigmentation, familial progressive, 2, 145250 (3)|KITLG, MGF, SF, SCF, SHEP7|184745|12q21.32
Hyperproinsulinemia, familial, with or without diabetes (3)|INS, MODY10, IDDM2|176730|11p15.5
Hyperprolinemia, type I, 239500 (3)|PRODH, PRODH2, SCZD4|606810|22q11.21
Hyperprolinemia, type II, 239510 (3)|ALDH4A1, ALDH4, P5CDH|606811|1p36.13
Hypertelorism, preauricular sinus, punctal pits, and deafness (2)|HPPD|614187|14q31
Hypertension with brachydactyly (2)|HTNB|112410|12p12.2-p11.2
Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3)|NR3C2, MLR, MCR|600983|4q31.23
Hypertension, essential, 145500 (3)|AGTR1, AGTR1A, AT2R1|106165|3q24
Hypertension, essential, 145500 (3)|PTGIS, CYP8A1, PGIS, CYP8|601699|20q13.13
Hypertensive nephropathy (2)|HNP1|608026|9q31-q32
Hyperthyroidism, familial gestational, 603373 (3)|TSHR, CHNG1|603372|14q31.1
Hyperthyroidism, nonautoimmune, 609152 (3)|TSHR, CHNG1|603372|14q31.1
Hypertrichosis terminalis, generalized, with or without gingival hyperplasia (4)|HTGH, DEL17q24|135400|17q24.2-q24.3
Hypertrichosis, congenital generalized (4)|HTC2, HCG, CGH, CXINSq27.1,|307150|Xq27.1
Hypertrichotic osteochondrodysplasia, 239850 (3)|ABCC9, SUR2, CMD1O, ATFB12, CANTU|601439|12p12.1
Hypertriglyceridemia, transient infantile, 614480 (3)|GPD1, HTGTI|138420|12q13.12
Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 (3)|HPGD, PGDH1, PHOAR1|601688|4q34.1
Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 (3)|SLCO2A1, OATP2A1, PGT, SLC21A2, PHOAR2|601460|3q22.1-q22.2
Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3)|SARS2|612804|19q13.2
Hyperuricemic nephropathy, familial juvenile 1, 162000 (3)|UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Hyperuricemic nephropathy, familial juvenile 2, 613092 (3)|REN, HNFJ2|179820|1q32.1
Hyperuricemic nephropathy, familial juvenile, 3 (2)|HNFJ3|614227|2p22.1-p21
Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3)|CYP11B2|124080|8q24.3
Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3)|CYP11B2|124080|8q24.3
Hypoalphalipoproteinemia, 604091 (3)|APOA1|107680|11q23.3
Hypobetalipoproteinemia, 615558 (3)|APOB, FLDB, LDLCQ4|107730|2p24.1
Hypobetalipoproteinemia, familial, 2, 605019 (3)|ANGPTL3, ANGPT5, FHBL2|604774|1p31.3
Hypocalcemia, autosomal dominant 2, 615361 (3)|GNA11, HHC2, HYPOC2|139313|19p13.3
Hypocalcemia, autosomal dominant, 601198 (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
Hypocalciuric hypercalcemia, familial, type III, 600740 (3)|AP2S1, CLAPS2, AP17, HHC3|602242|19q13.32
Hypocalciuric hypercalcemia, type I, 145980 (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
Hypocalciuric hypercalcemia, type II (2)|HHC2, FHH2|145981|19p13.3
Hypocalciuric hypercalcemia, type II, 145981 (3)|GNA11, HHC2, HYPOC2|139313|19p13.3
Hypochondroplasia, 146000 (3)|FGFR3, ACH|134934|4p16.3
Hypochromic microcytic anemia (3)|HBA2, HBH|141850|16p13.3
Hypofibrinogenemia, gamma type (3)|FGG|134850|4q31.3
Hypoglycemia of infancy, leucine-sensitive, 240800 (3)|ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Hypogonadism, hypergonadotropic (3)|LHB|152780|19q13.33
Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 (3)|KAL1, KMS, ADMLX, HH1|300836|Xp22.31
Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3)|TAC3, NKNB, HH10|162330|12q13.3
Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3)|TACR3, NK3R, HH11|162332|4q24
Hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3)|GNRH1, LNRH, HH12|152760|8p21.2
Hypogonadotropic hypogonadism 13 with or without anosmia, 614842 (3)|KISS1, HH13|603286|1q32.1
Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3)|WDR11, DR11, KIAA1351, BRWD2, HH14|606417|10q26.12
Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 (3)|SPRY4, HH17|607984|5q31.3
Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3)|IL17RD, SEF, HH18|606807|3p14.3
Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3)|DUSP6, MKP3, PYST1, HH19|602748|12q21.33
Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3)|FGF17, HH20|603725|8p21.3
Hypogonadotropic hypogonadism 21 with anosmia, 615271 (3)|FLRT3, HH21|604808|20p12.1
Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3)|PROKR2, PKR2, GPR73L1, HH3|607123|20p12.3
Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3)|PROK2, PK2, BV8, HH4|607002|3p13
Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3)|CHD7, IS3, HH5|608892|8q12.1-q12.2
Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3)|FGF8, HH6|600483|10q24.32
Hypogonadotropic hypogonadism 7 with or without anosmia, 146110 (3)|GNRHR, LHRHR, HH7|138850|4q13.2
Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3)|KISS1R, GPR54 , HH8, CPPB1|604161|19p13.3
Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3)|NSMF, NELF, HH9|608137|9q34.3
Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3)|AKT2, HIHGHH|164731|19q13.2
Hypokalemic periodic paralysis, type 1, 170400 (3)|CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32.1
Hypokalemic periodic paralysis, type 2, 613345 (3)|SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.3
Hypomagnesemia 1, intestinal, 602014 (3)|TRPM6, CHAK2, HOMG1|607009|9q21.13
Hypomagnesemia 3, renal, 248250 (3)|CLDN16, PCLN1, HOMG3|603959|3q28
Hypomagnesemia 4, renal, 611718 (3)|EGF, URG, HOMG4|131530|4q25
Hypomagnesemia 5, renal, with ocular involvement, 248190 (3)|CLDN19, HOMG5|610036|1p34.2
Hypomagnesemia 6, renal, 613882 (3)|CNNM2, ACDP2|607803|10q24.32
Hypomagnesemia-2, renal, 154020 (3)|FXYD2, ATP1G1, HOMG2|601814|11q23.3
Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3)|DARS, HBSL|603084|2q21.3
Hypomyelination, global cerebral, 612949 (3)|SLC25A12, ARALAR|603667|2q31.1
Hypoparathyroidism, X-linked (2)|HPT, HPTX, HYPX|307700|Xq26-q27
Hypoparathyroidism, autosomal dominant, 146200 (3)|PTH|168450|11p15.2
Hypoparathyroidism, autosomal recessive, 146200 (3)|PTH|168450|11p15.2
Hypoparathyroidism, familial isolated, 146200 (3)|GCMB|603716|6p24.2
Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3)|GATA3, HDR, HDRS|131320|10p14
Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3)|TBCE, KCS, KCS1, HRD|604934|1q42.3
Hypophosphatasia, adult, 146300 (3)|ALPL, HOPS, TNSALP|171760|1p36.12
Hypophosphatasia, childhood, 241510 (3)|ALPL, HOPS, TNSALP|171760|1p36.12
Hypophosphatasia, infantile, 241500 (3)|ALPL, HOPS, TNSALP|171760|1p36.12
Hypophosphatemic rickets and hyperparathyroidism (2)|HPRHP|612089|13q13.1
Hypophosphatemic rickets with hypercalciuria, 241530 (3)|SLC34A3, NPTIIC, HHRH|609826|9q34.3
Hypophosphatemic rickets, 300554 (3)|CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.23-p11.22
Hypophosphatemic rickets, AR, 241520 (3)|DMP1, ARHR, ARHP|600980|4q22.1
Hypophosphatemic rickets, X-linked dominant, 307800 (3)|PHEX, HYP, HPDR1, LXHR|300550|Xp22.11
Hypophosphatemic rickets, autosomal dominant, 193100 (3)|FGF23, ADHR, HPDR2, PHPTC|605380|12p13.32
Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
Hypoplastic left heart syndrome 1, 241550 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Hypoplastic left heart syndrome 2, 614435 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Hypoproteinemia, hypercatabolic, 241600 (3)|B2M|109700|15q21.1
Hypoprothrombinemia, 613679 (3)|F2, THPH1, RPRGL2|176930|11p11.2
Hypospadias 1, X-linked, 300633 (3)|AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq12
Hypospadias 2, X-linked, 300758 (3)|MAMLD1, CXorf6, F18, HYSP2|300120|Xq28
Hypospadias 3, autosomal (2)|HYSP3|146450|7q32.2-q36.1
Hypothryoidism, congenital, nongoitrous 4, 275100 (3)|TSHB, CHNG4|188540|1p13.2
Hypothyroidism, central, and testicular enlargement, 300888 (3)|IGSF1, IGDC1, CHTE|300137|Xq26.2
Hypothyroidism, congenital nongoitrous, 5, 225250 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3)|PAX8|167415|2q13
Hypothyroidism, congenital, nongoitrous, 1 275200 (3)|TSHR, CHNG1|603372|14q31.1
Hypothyroidism, congenital, nongoitrous, 3 (2)|CHNG3, RTSH|609893|15q25.3-q26.1
Hypothyroidism, congenital, nongoitrous, 6, 614450 (3)|THRA, ERBA1, THRA1, CHNG6|190120|17q21.1
Hypotonia-cystinuria syndrome (4)|DEL2p21, C2DELp21|606407|2p21
Hypotrichosis 10 (2)|HYP10|614238|7p22.3-p21.3
Hypotrichosis 11, 615059 (3)|SNRPE, HYPT11|128260|1q32.1
Hypotrichosis 8, 278150 (3)|LPAR6, P2RY5, P2Y5, LAH3, ARWH1|609239|13q14.2
Hypotrichosis 9 (2)|HYPT9|614237|10q11.23-q22.3
Hypotrichosis and recurrent skin vesicles, 613102 (3)|DSC3, DSC4|600271|18q12.1
Hypotrichosis simplex of scalp 1, 146520 (3)|CDSN, HTSS1, PSS|602593|6p21.33
Hypotrichosis simplex of the scalp 2, 613981 (3)|KRT74, K6IRS4, KRT6IRS4, HTSS2|608248|12q13.13
Hypotrichosis simplex, 605389 (3)|APCDD1, HHS, HTS|607479|18p11.22
Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3)|CDH3, CDHP, PCAD, HJMD|114021|16q22.1
Hypotrichosis, hereditary, Marie Unna type, 1, 146550 (3)|HR, AU, MUHH1|602302|8p21.3
Hypotrichosis, hereditary, Marie Unna type, 2 (2)|MUHH2|612841|1p21.1-q21.3
Hypotrichosis, localized, autosomal recessive 2, 604379 (3)|LIPH, LAH2, ARWH2|607365|3q27.2
Hypotrichosis, localized, autosomal recessive, 607903 (3)|DSG4, LAH|607892|18q12.1
Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3)|SOX18, HLTS|601618|20q13.33
Hypouricemia, renal, 2, 612076 (3)|SLC2A9, GLUT9, UAQTL2|606142|4p16.1
Hypouricemia, renal, 220150 (3)|SLC22A12, OAT4L, URAT1|607096|11q13.1
Hystrix-like ichthyosis with deafness, 602540 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
IFAP syndrome with or without BRESHECK syndrome, 308205 (3)|MBTPS2, S2P, IFAP, KFSDX|300294|Xp22.12-p22.11
IMAGE syndrome, 614732 (3)|CDKN1C, KIP2, BWS, IMAGE|600856|11p15.4
IRAK4 deficiency, 607676 (3)|IRAK4, REN64, IPD1|606883|12q12
IVIC syndrome, 147750 (3)|SALL4, HSAL4|607343|20q13.2
Ichthyosis bullosa of Siemens, 146800 (3)|KRT2, KRT2A, KRT2E|600194|12q13.13
Ichthyosis histrix, Curth-Macklin type, 146590 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Ichthyosis prematurity syndrome, 608649 (3)|SLC27A4, FATP4, IPS|604194|9q34.11
Ichthyosis vulgaris, 146700 (3)|FLG, ATOD2|135940|1q21.3
Ichthyosis with confetti, 609165 (3)|KRT10, EHK, BCIE, BIE|148080|17q21.2
Ichthyosis with hypotrichosis, 610765 (3)|ST14, MTSP1|606797|11q24.3
Ichthyosis, X-linked, 308100 (3)|STS, ARSC1, ARSC, SSDD, XLI|300747|Xp22.31
Ichthyosis, autosomal recessive 4B (harlequin), 242500 (3)|ABCA12, ARCI4A, ARCI4B, ICR2B, LI2|607800|2q35
Ichthyosis, congenital, autosomal recessive 1, 242300 (3)|TGM1, ICR2, ARCI1|190195|14q12
Ichthyosis, congenital, autosomal recessive 10, 615024 (3)|PNPLA1, ARCI10|612121|6p21.31
Ichthyosis, congenital, autosomal recessive 2, 242100 (3)|ALOX12B, ARCI2|603741|17p13.1
Ichthyosis, congenital, autosomal recessive 3, 606545 (3)|ALOXE3, ARCI3|607206|17p13.1
Ichthyosis, congenital, autosomal recessive 4A, 601277 (3)|ABCA12, ARCI4A, ARCI4B, ICR2B, LI2|607800|2q35
Ichthyosis, congenital, autosomal recessive 5, 604777 (3)|CYP4F22, ARCI5, LI3|611495|19p13.12
Ichthyosis, congenital, autosomal recessive 6, 612281 (3)|NIPAL4, ICHYN, ARCI6|609383|5q33.3
Ichthyosis, congenital, autosomal recessive 7, 615022 (3)|ARCI7|615022|12p11.2-q13.1
Ichthyosis, congenital, autosomal recessive 8, 613943 (3)|LIPN, LIPL4, ARCI8, LI4|613924|10q23.31
Ichthyosis, congenital, autosomal recessive 9, 615023 (3)|CERS3, LASS3, ARCI9|615276|15q26.3
Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3)|KRT10, EHK, BCIE, BIE|148080|17q21.2
Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3)|CLDN1, SEMP1, ILVASC|603718|3q28
Ichthyosis, spastic quadriplegia, and mental retardation, 614457 (3)|ELOVL4, ADMD, STGD2, STGD3, ISQMR|605512|6q14.1
IgA nephropathy, susceptibility to, 1 (2)|IGAN1|161950|6q22-q23
IgG2 deficiency, selective (3)|IGHG2|147110|14q32.33
Iminoglycinuria, digenic, 242600 (3)|SLC36A2, PAT2|608331|5q33.1
Iminoglycinuria, digenic, 242600 (3)|SLC6A19, HND|608893|5p15.33
Iminoglycinuria, digenic, 242600 (3)|SLC6A20, XT3|605616|3p21.31
Immunodeficiency 10, 612783 (3)|STIM1, TAM, IMD10|605921|11p15.4
Immunodeficiency 11, 615206 (3)|CARD11, CARMA1, BIMP3, PPBL, BENTA, IMD11|607210|7p22.2
Immunodeficiency 15, 615592 (3)|IKBKB, NFKBIKB, IMD15|603258|8p11.21
Immunodeficiency 17, CD3 gamma deficient, 615607 (3)|CD3G, IMD17|186740|11q23.3
Immunodeficiency 18, 615615 (3)|CD3E, IMD18|186830|11q23.3
Immunodeficiency 18, SCID variant, 615615 (3)|CD3E, IMD18|186830|11q23.3
Immunodeficiency 19, 615617 (3)|CD3D, T3D, IMD19|186790|11q23.3
Immunodeficiency 7, TCR-alpha/beta deficient, 615387 (3)|TRAC, TRCA, TRA, IMD7|186880|14q11.2
Immunodeficiency 8, 615401 (3)|CORO1A, TACO, CLIPINA, IMD8|605000|16p11.2
Immunodeficiency 9, 612782 (3)|ORAI1, TMEM142A, CRACM1, IMD9|610277|12q24.31
Immunodeficiency due to CASP8 deficiency, 607271 (3)|CASP8, MCH5, ALPS2B|601763|2q33.1
Immunodeficiency due to defect in CD3-zeta, 610163 (3)|CD247, CD3Z, TCRZ|186780|1q24.2
Immunodeficiency due to defect in MAPBP-interacting protein, 610798 (3)|LAMTOR2, MAPBPIP, p14|610389|1q22
Immunodeficiency due to ficolin 3 deficiency, 613860 (3)|FCN3, HAKA1|604973|1p36.11
Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3)|PNP, NP|164050|14q11.2
Immunodeficiency with hyper IgM, type 5, 608106 (3)|UNG, DGU, HIGM5|191525|12q24.11
Immunodeficiency with hyper-IgM, type 2, 605258 (3)|AICDA, AID, HIGM2|605257|12p13.31
Immunodeficiency with hyper-IgM, type 3, 606843 (3)|CD40, TNFRSF5|109535|20q13.12
Immunodeficiency, X-linked, with hyper-IgM, 308230 (3)|TNFSF5, CD40LG, HIGM1, IGM|300386|Xq26.3
Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 (3)|MAGT1, IAP, XMEN|300715|Xq21.1
Immunodeficiency, common variable, 1, 607594 (3)|ICOS, AILIM, CVID1|604558|2q33.2
Immunodeficiency, common variable, 10, 615577 (3)|NFKB2, LYT10, CVID10|164012|10q24.32
Immunodeficiency, common variable, 2, 240500 (3)|TNFRSF13B, TACI, CVID2|604907|17p11.2
Immunodeficiency, common variable, 3, 613493 (3)|CD19, CVID3|107265|16p11.2
Immunodeficiency, common variable, 4, 613494 (3)|TNFRSF13C, BAFFR, CVID4|606269|22q13.2
Immunodeficiency, common variable, 5, 613495 (3)|MS4A1, CD20, CVID5|112210|11q12.2
Immunodeficiency, common variable, 6, 613496 (3)|CD81, TAPA1, CVID6|186845|11p15.5
Immunodeficiency, common variable, 7, 614699 (3)|CR2, C3DR, SLEB9, CVID7|120650|1q32.2
Immunodeficiency, common variable, 8, with autoimmunity, 614700 (3)|LRBA, LBA, CDC4L, CVID8|606453|4q31.3
Immunodeficiency, isolated, 300584 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 (3)|IL21R|605383|16p12.1
Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 (3)|DNMT3B, ICF1|602900|20q11.21
Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 (3)|ZBTB24, PATZ2, ZNF450, KIAA0441, ICF2|614064|6q21
Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 (3)|FOXP3, IPEX, AIID, XPID, PIDX|300292|Xp11.23
Immunoglobulin A deficiency (2)|IGAD1|137100|6p21.3
Immunoglobulin A deficiency 2, 609529 (3)|TNFRSF13B, TACI, CVID2|604907|17p11.2
Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 (3)|VCP, IBMPFD1, ALS14|601023|9p13.3
Inclusion body myopathy, autosomal recessive, 600737 (3)|GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Inclusion body myopathy-3, 605637 (3)|MYH2|160740|17p13.1
Incontinentia pigmenti, type II, 308300 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Increased responsiveness to growth hormone (3)|GHR|600946|5p13-p12
Infantile cerebellar-retinal degeneration, 614559 (3)|ACO2, ICRD|100850|22q13.2
Infantile neuroaxonal dystrophy 1, 256600 (3)|PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations, 613759 (3)|FADD|602457|11q13.3
Inflammatory bowel disease 19, 612278 (3)|IRGM, LRG47, IFI1, IBD19|608212|5q33.1
Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 (3)|CRFB4, IBD25|123889|21q22.11
Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3)|IL10RA, IL10R, IBD28|146933|11q23.3
Inflammatory skin and bowel disease, neonatal, 614328 (3)|ADAM17, TACE, NISBD|603639|2p25.1
Insensitivity to pain, channelopathy-associated, 243000 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Insensitivity to pain, congenital, with anhidrosis, 256800 (3)|NTRK1, TRKA, MTC|191315|1q23.1
Insomnia (3)|GABRB3, ECA5|137192|15q12
Insomnia, fatal familial, 600072 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Insulin resistance, severe, digenic, 604367 (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
Insulin resistance, severe, digenic, 604367 (3)|PPP1R3A, PPP1R3|600917|7q31.1
Insulin-like growth factor I, resistance to, 270450 (3)|IGF1R|147370|15q26.3
Insulinoma (1)|ITS|606960|22q12.1-q12.2
Interferon, alpha, deficiency (1)|IFNA1, IFNA@|147660|9p21.3
Interleukin 1 receptor antagonist deficiency, 612852 (3)|IL1RN, MVCD4, DIRA|147679|2q13
Interleukin-2 receptor, alpha chain, deficiency of, 606367 (3)|IL2RA, IL2R, IDDM10|147730|10p15.1
Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, 614748 (3)|ITGA3, CD49C, GAPB3, ILNEB|605025|17q21.33
Interstitial nephritis, karyomegalic, 614817 (3)|FAN1, MTMR15, KIAA1018, KMIN|613534|15q13.2-q13.3
Intestinal atresia, multiple, 243150 (3)|TTC7A, TTC7, KIAA1140, MINAT|609332|2p21
Intestinal pseudoobstruction, neuronal, 300048 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Intrinsic factor deficiency, 261000 (3)|GIF, IF|609342|11q12.1
Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3)|IRAK4, REN64, IPD1|606883|12q12
Invasive pneumococcal disease, recurrent isolated, 2, 300640 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Iridogoniodysgenesis, type 1, 601631 (3)|FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25.3
Iridogoniodysgenesis, type 2, 137600 (3)|PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25
Iris hypoplasia and glaucoma, 601631 (3)|FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25.3
Iron-refractory iron deficiency anemia, 206200 (3)|TMPRSS6, IRIDA|609862|22q12.3
Isobutyryl-CoA dehydrogenase deficiency, 611283 (3)|ACAD8|604773|11q25
Isovaleric acidemia, 243500 (3)|IVD|607036|15q15.1
Jackson-Weiss syndrome, 123150 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Jackson-Weiss syndrome, 123150 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Jacobsen syndrome (4)|JBS|147791|11q23
Jalili syndrome, 217080 (3)|CNNM4, ACDP4|607805|2q11.2
Jawad syndrome, 251255 (3)|RBBP8, RIM, SCKL2, JWDS|604124|18q11.2
Jensen syndrome, 311150 (3)|TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22.1
Jervell and Lange-Nielsen syndrome 2, 612347 (3)|KCNE1, JLNS, LQT5, JLNS2|176261|21q22.11-q22.12
Jervell and Lange-Nielsen syndrome, 220400 (3)|KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5-p15.4
Johanson-Blizzard syndrome, 243800 (3)|UBR1, JBS|605981|15q15.2
Joubert syndrome 1, 213300 (3)|INPP5E, MORMS, JBTS1, CORS1|613037|9q34.3
Joubert syndrome 10, 300804 (3)|OFD1, CXorf5, SGBS2, JBTS10, RP23|300170|Xp22.2
Joubert syndrome 12, 200990 (3)|KIF7, HLS2, ACLS, JBTS12|611254|15q26.1
Joubert syndrome 13, 614173 (3)|TECT1, JBTS13|609863|12q24.11
Joubert syndrome 14, 614424 (3)|TMEM237, ALS2CR4, JBTS14|614423|2q33.1
Joubert syndrome 15, 614464 (3)|CEP41, TSGA14, JBTS15|610523|7q32.2
Joubert syndrome 16, 614465 (3)|TMEM138, JBTS16|614459|11q12.2
Joubert syndrome 17, 614615 (3)|C5orf42, JBTS17|614571|5p13.2
Joubert syndrome 18, 614815 (3)|TCTN3, TECT3, C10orf61, OFD4, JBTS18|613847|10q24.1
Joubert syndrome 19, 614844 (3)|ZNF423, ZFP423, OAZ, KIAA0760, NPHP14, JBTS19|604557|16q12.1
Joubert syndrome 2, 608091 (3)|TMEM216, JBTS2, CORS2, MKS2|613277|11q12.2
Joubert syndrome 20, 614970 (3)|TMEM231, JBTS20, MKS11|614949|16q23.1
Joubert syndrome 21, 615636 (3)|CSPP1, CSPP, JBTS21|611654|8q13.1-q13.2
Joubert syndrome 4, 609583 (3)|NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Joubert syndrome 5, 610188 (3)|CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.32
Joubert syndrome 6, 610688 (3)|TMEM67, MKS3, JBTS6, NPHP11|609884|8q22.1
Joubert syndrome 7, 611560 (3)|RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
Joubert syndrome 8, 612291 (3)|ARL13B, ARL2L1, JBTS8|608922|3q11.1
Joubert syndrome 9, 612285 (3)|CC2D2A, KIAA1345, MKS6|612013|4p15.32
Joubert syndrome-3, 608629 (3)|AHI1|608894|6q23.3
Juvenile polyposis syndrome, infantile form, 174900 (3)|BMPR1A, ACVRLK3, ALK3|601299|10q23.2
Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3)|MADH4, DPC4, SMAD4, JIP, MYHRS|600993|18q21.2
KBG syndrome, 148050 (3)|ANKRD11, ANCO1, KBGS|611192|16q24.3
Kabuki syndrome 1, 147920 (3)|MLL2, ALR, KABUK1|602113|12q13.12
Kabuki syndrome 2, 300867 (3)|KDM6A, UTX, KABUK2|300128|Xp11.3
Kahrizi syndrome, 612713 (3)|SRD5A3, SRD5A2L, CDG1Q, KRIZI|611715|4q12
Kanzaki disease, 609242 (3)|NAGA|104170|22q13.2
Kenny-Caffey syndrome, type 2, 127000 (3)|FAM111A, KIAA1895, KCS2, GCLEB|615292|11q12.1
Kenny-Caffey syndrome-1, 244460 (3)|TBCE, KCS, KCS1, HRD|604934|1q42.3
Keratitis, 148190 (3)|PAX6, AN2, MGDA|607108|11p13
Keratitis-ichthyosis-deafness syndrome, 148210 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
Keratoconus 1, 148300 (3)|VSX1, RINX, PPCD, PPD, KTCN1, CAASDS|605020|20p11.21
Keratoconus 2 (2)|KTCN2|608932|16q22.3-q23.1
Keratoconus 3 (2)|KTCN3|608586|3p14-q13
Keratoconus 4 (2)|KTCN4|609271|2p24
Keratoconus 5 (2)|KTCN5|614622|5q14.1-q21.3
Keratoconus 6 (2)|KTCN6|614623|9q34
Keratoconus 7 (2)|KTCN7|614629|13q32
Keratoconus 8 (2)|KTCN8|614628|14q24.3
Keratoderma, palmoplantar, punctate type IA, 148600 (3)|AAGAB, p34, PPKP1A, PPKP1, KPPP1|614888|15q22-q23
Keratoderma, palmoplantar, punctate type IB (2)|PPKP1B|614936|8q24.13-q24.21
Keratoderma, palmoplantar, with deafness, 148350 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
Keratolytic winter erythema (2)|KWE|148370|8p23-p22
Keratosis follicularis spinulosa decalvans, 308800 (3)|SAT1, SSAT, KFSD, KFSDX|313020|Xp22.11
Keratosis follicularis spinulosa decalvans, X-linked, 308800 (3)|MBTPS2, S2P, IFAP, KFSDX|300294|Xp22.12-p22.11
Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3)|POMP, UMP1|613386|13q12.3
Keratosis palmoplantaris striata I, AD, 148700 (3)|DSG1, PPKS1, SPPK1, EPKHE|125670|18q12.1
Keratosis palmoplantaris striata II, 612908 (3)|DSP, KPPS2, PPKS2|125647|6p24.3
Keratosis palmoplantaris striata III, 607654 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Keratosis, seborrheic, somatic, 182000 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Keutel syndrome, 245150 (3)|MGP, NTI|154870|12p12.3
Kindler syndrome, 173650 (3)|KIND1, URP1, C20orf42|607900|20p12.3
King-Denborough syndrome, 145600 (3)|RYR1, MHS, CCO|180901|19q13.2
Kleefstra syndrome, 610253 (3)|EHMT1, EUHMTASE1, DEL9q34|607001|9q34.3
Klippel-Feil syndrome 1, autosomal dominant, 118100 (3)|GDF6, MCOP4, KFS1, MCOPCB6, LCA17|601147|8q22.1
Klippel-Feil syndrome 2, 214300 (3)|MEOX1, MOX1, KFS2|600147|17q21.31
Klippel-Feil syndrome 3, autosomal dominant, 613702 (3)|GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.31
Klippel-Trenaunay-Weber syndrome (2)|KTWS, KTS|149000|8q22.3
Kniest dysplasia, 156550 (3)|COL2A1|120140|12q13.11
Knobloch syndrome, type 1, 267750 (3)|COL18A1, KNO1|120328|21q22.3
Kohlschutter-Tonz syndrome, 226750 (3)|ROGDI, KTZS|614574|16p13.3
Kondoh syndrome (2)|KONDS|606242|1p36.32-p35.3
Koolen-De Vries syndrome, 610443 (3)|KANSL1, KIAA1267, MSL1V1, KDVS|612452|17q21.31
Kowarski syndrome, 262650 (3)|GH1, GHN, IGHD1B|139250|17q23.3
Krabbe disease, 245200 (3)|GALC|606890|14q31.3
Krabbe disease, atypical, 611722 (3)|PSAP, SAP1|176801|10q22.1
Kufor-Rakeb syndrome, 606693 (3)|ATP13A2, PARK9, KRPPD, CLN12|610513|1p36.13
Kyphoscoliosis 1 (2)|KYPSC1|610170|5p13
L-2-hydroxyglutaric aciduria, 236792 (3)|L2HGDH, C14orf160|609584|14q21.3
L-ferritin deficiency, dominant and recessive, 615604 (3)|FTL, NBIA3, LFTD|134790|19q13.33
LADD syndrome, 149730 (3)|FGF10|602115|5p12
LADD syndrome, 149730 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
LADD syndrome, 149730 (3)|FGFR3, ACH|134934|4p16.3
LCHAD deficiency, 609016 (3)|HADHA, MTPA|600890|2p23.3
LDL cholesterol level QTL2, 143890 (3)|LDLR, FHC, FH, LDLCQ2|606945|19p13.2
LEOPARD syndrome 1, 151100 (3)|PTPN11, PTP2C, SHP2, NS1|176876|12q24.13
LEOPARD syndrome 2, 611554 (3)|RAF1, CRAF, NS5|164760|3p25.2
LEOPARD syndrome 3, 613707 (3)|BRAF, NS7|164757|7q34
LIG4 syndrome, 606593 (3)|LIG4|601837|13q33.3
Lactase deficiency, congenital, 223000 (3)|LCT, LAC, LPH|603202|2q21.3
Lactase persistance/nonpersistance, 223100 (3)|MCM6|601806|2q21.3
Lactate dehydrogenase-B deficiency, 614128 (3)|LDHB, LDHBD|150100|12p12.1
Lacticacidemia due to PDX1 deficiency, 245349 (3)|PDX1|608769|11p13
Laing distal myopathy, 160500 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Langer mesomelic dysplasia, 249700 (3)|SHOX, GCFX, SS, PHOG|312865|Xp22.33
Langer mesomelic dysplasia, 249700 (3)|SHOXY|400020|Yp11.32
Laron dwarfism, 262500 (3)|GHR|600946|5p13-p12
Larsen syndrome, 150250 (3)|FLNB, SCT, AOI, LRS1|603381|3p14.3
Larsen-like syndrome (2)|LRSL|608545|6p25
Laryngoonychocutaneous syndrome, 245660 (3)|LAMA3, LOCS|600805|18q11.2
Lathosterolosis, 607330 (3)|SC5DL, ERG3|602286|11q23.3
Leber congenital amaurosis 1, 204000 (3)|GUCY2D, GUC2D, LCA1, CORD6, RCD2|600179|17p13.1
Leber congenital amaurosis 10, 611755 (3)|CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.32
Leber congenital amaurosis 11, 613837 (3)|IMPDH1, RP10, LCA11|146690|7q32.1
Leber congenital amaurosis 12, 610612 (3)|RD3, LCA12, C1orf36|180040|1q32.3
Leber congenital amaurosis 13, 612712 (3)|RDH12, LCA13|608830|14q24.1
Leber congenital amaurosis 14, 613341 (3)|LRAT, LCA14|604863|4q32.1
Leber congenital amaurosis 15, 613843 (3)|TULP1, RP14, LCA15|602280|6p21.31
Leber congenital amaurosis 16, 614186 (3)|KCNJ13, SVD, LCA16|603208|2q37.1
Leber congenital amaurosis 17, 615360 (3)|GDF6, MCOP4, KFS1, MCOPCB6, LCA17|601147|8q22.1
Leber congenital amaurosis 2, 204100 (3)|RPE65, RP20, LCA2|180069|1p31.3-p31.2
Leber congenital amaurosis 3, 604232 (3)|SPATA7, HSD3, LCA3|609868|14q31.3
Leber congenital amaurosis 4, 604393 (3)|AIPL1, LCA4|604392|17p13.2
Leber congenital amaurosis 5, 604537 (3)|LCA5, C6orf152|611408|6q14.1
Leber congenital amaurosis 6, 613826 (3)|RPGRIP1, LCA6, CORD13|605446|14q11.2
Leber congenital amaurosis 7, 613829 (3)|CRX, CORD2, CRD, LCA7|602225|19q13.33
Leber congenital amaurosis 8, 613835 (3)|CRB1, RP12, LCA8|604210|1q31.3
Leber congenital amaurosis 9, 608553 (3)|NMNAT1, NMNAT, PNAT1, LCA9|608700|1p36.22
Left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3)|DTNA, D18S892E, DRP3, LVNC1|601239|18q12.1
Left ventricular noncompaction 10, 615396 (3)|MYBPC3, CMH4, CMD1MM, LVNC10|600958|11p11.2
Left ventricular noncompaction 2 (2)|LVNC2|609470|11p15
Left ventricular noncompaction 3, with or without dilated cardiomyopathy, 601493 (3)|LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3, MFM4|605906|10q23.2
Left ventricular noncompaction 4, 613424 (3)|ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Left ventricular noncompaction 5, 613426 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Left ventricular noncompaction 6, 601494 (3)|TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32.1
Left ventricular noncompaction 7, 615092 (3)|MIB1, MIB, DIP1, KIAA1323, LVNC7|608677|18q11.2
Left ventricular noncompaction 8, 615373 (3)|PRDM16, MEL1, LVNC8, CMD1LL|605557|1p36.32
Left ventricular noncompaction 9, 611878 (3)|TPM1, CMH3, CMD1Y , LVNC9|191010|15q22.2
Left-right axis malformations (3)|EBAF, TGFB4, LEFTY2, LEFTA, LEFTYA|601877|1q42.12
Legg-Calve-Perthes disease, 150600 (3)|COL2A1|120140|12q13.11
Legius syndrome, 611431 (3)|SPRED1, NFLS|609291|15q14
Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3)|COX15, CEMCOX2|603646|10q24.2
Leigh syndrome due to mitochondrial COX4 deficiency, 256000 (3)|COX10|602125|17p12
Leigh syndrome due to mitochondrial complex 1 deficiency, 256000 (3)|NDUFA12|614530|12q22
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|FOXRED1|613622|11q24.2
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|NDUFA2|602137|5q31.3
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|NDUFA9|603834|12p13.32
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|NDUFAF6, C8orf38|612392|8q22.1
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|NDUFS3|603846|11p11.2
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)|NDUFS8|602141|11q13.2
Leigh syndrome, 256000 (3)|BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1|603647|2q35
Leigh syndrome, 256000 (3)|NDUFA10|603835|2q37.3
Leigh syndrome, 256000 (3)|NDUFAF2, NDUFA12L, MMTN, B17.2L|609653|5q12.1
Leigh syndrome, 256000 (3)|NDUFS4, AQDQ|602694|5q11.2
Leigh syndrome, 256000 (3)|NDUFS7, PSST|601825|19p13.3
Leigh syndrome, 256000 (3)|SDHA, SDH1, SDHF, CMD1GG, PGL5|600857|5p15.33
Leigh syndrome, French-Canadian type, 220111 (3)|LRPPRC, LRP130, LSFC|607544|2p21
Leigh syndrome, X-linked, 308930 (3)|PDHA1, PHE1A|300502|Xp22.12
Leigh syndrome, due to COX deficiency, 256000 (3)|SURF1|185620|9q34.2
Leiomyoma, uterine, somatic, 150699 (2)|HMGA2, HMGIC, BABL|600698|12q14.3
Leiomyomatosis and renal cell cancer, 150800 (3)|FH, HLRCC, MCUL1|136850|1q43
Lenz-Majewski hyperostotic dwarfism, 151050 (3)|PTDSS1, PSS1, KIAA0024, LMHD|612792|8q22.1
Leprechaunism, 246200 (3)|INSR, HHF5|147670|19p13.2
Leri-Weill dyschondrosteosis, 127300 (3)|SHOX, GCFX, SS, PHOG|312865|Xp22.33
Leri-Weill dyschondrosteosis, 127300 (3)|SHOXY|400020|Yp11.32
Lesch-Nyhan syndrome, 300322 (3)|HPRT1, HPRT|308000|Xq26.2-q26.3
Lethal congenital contractural syndrome 2, 607598 (3)|ERBB3, LCCS2|190151|12q13.2
Lethal congenital contractural syndrome 3, 611369 (3)|PIP5K1C, LCCS3|606102|19p13.3
Lethal congenital contracture syndrome 1, 253310 (3)|GLE1, GLE1L, LCCS, LCCS1|603371|9q34.11
Lethal congenital contracture syndrome 4, 614915 (3)|MYBPC1, LCCS4|160794|12q23.2
Lethal congenital contracture syndrome 5, 615368 (3)|DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5|602378|19p13.2
Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3)|ABL1|189980|9q34.12
Leukemia, T-cell acute lymphoblastic (2)|LMO1, RBTN1, RHOM1|186921|11p15.4
Leukemia, T-cell acute lymphoblastic (2)|NOTCH1, TAN1|190198|9q34.3
Leukemia, T-cell acute lymphoblastic (3)|NUP214, D9S46E, CAN, CAIN|114350|9q34.13
Leukemia, T-cell acute lymphoblastoid (2)|LYL1|151440|19p13.2
Leukemia, acute T-cell (2)|LMO2, RBTNL1, RHOM2, TTG2|180385|11p13
Leukemia, acute T-cell lymphoblastic (3)|AF10|602409|10p12.31
Leukemia, acute T-cell lymphoblastic (3)|PICALM, CALM, CLTH, LAP|603025|11q14.2
Leukemia, acute lymphoblastic (1)|TCF3, E2A|147141|19p13.3
Leukemia, acute lymphoblastic (2)|LALL|247640|9p22-p21
Leukemia, acute lymphoblastic (3)|IKZF1, ZNFN1A1, IK1, LYF1|603023|7p12.2
Leukemia, acute lymphoblastic, 613065 (3)|NBS1, NBS|602667|8q21.3
Leukemia, acute lymphoblastic, somatic, 613065 (3)|FLT3|136351|13q12.2
Leukemia, acute lymphocytic, 613065 (3)|BCR, CML, PHL, ALL|151410|22q11.23
Leukemia, acute myeloblastic (3)|ARNT|126110|1q21.3
Leukemia, acute myelogenous (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Leukemia, acute myelogenous, 601626 (3)|GMPS|600358|3q25.31
Leukemia, acute myelogenous, 601626 (3)|JAK2, THCYT3|147796|9p24.1
Leukemia, acute myeloid, 601626 (1)|MLF1|601402|3q25.32
Leukemia, acute myeloid, 601626 (1)|NSD1, ARA267, STO, SOTOS1|606681|5q35.2-q35.3
Leukemia, acute myeloid, 601626 (1)|SH3GL1, EEN|601768|19p13.3
Leukemia, acute myeloid, 601626 (3)|AF10|602409|10p12.31
Leukemia, acute myeloid, 601626 (3)|ARHGEF12, LARG, KIAA0382|604763|11q23.3
Leukemia, acute myeloid, 601626 (3)|CEBPA, CEBP|116897|19q13.11
Leukemia, acute myeloid, 601626 (3)|FLT3|136351|13q12.2
Leukemia, acute myeloid, 601626 (3)|KIT, PBT|164920|4q12
Leukemia, acute myeloid, 601626 (3)|LPP|600700|3q27-q28
Leukemia, acute myeloid, 601626 (3)|NPM1|164040|5q35.1
Leukemia, acute myeloid, 601626 (3)|NUP214, D9S46E, CAN, CAIN|114350|9q34.13
Leukemia, acute myeloid, 601626 (3)|PICALM, CALM, CLTH, LAP|603025|11q14.2
Leukemia, acute myeloid, 601626 (3)|RUNX1, CBFA2, AML1|151385|21q22.12
Leukemia, acute myeloid, 601626 (3)|WHSC1L1, NSD3|607083|8p11.23
Leukemia, acute myeloid, reduced survival in, 601626 (3)|FLT3|136351|13q12.2
Leukemia, acute myeloid, somatic, 601626 (3)|ETV6, TEL|600618|12p13.2
Leukemia, acute myeloid, therapy-related (1)|SEPT9, MSF, MSF1, NAPB|604061|17q25.2-q25.3
Leukemia, acute myeloid, with eosinophilia (1)|ABL2, ABLL, ARG|164690|1q25.2
Leukemia, acute myelomonocytic (3)|MLLT11, AF1Q|604684|1q21.3
Leukemia, acute nonlymphocytic (2)|DEK, D6S231E|125264|6p22.3
Leukemia, acute pre-B-cell (2)|PBX1|176310|1q23.3
Leukemia, acute promyelocytic, 612376 (1)|RARA|180240|17q21.2
Leukemia, acute promyelocytic, NPM/RARA type (3)|NPM1|164040|5q35.1
Leukemia, acute promyelocytic, NUMA/RARA type (3)|NUMA1|164009|11q13.4
Leukemia, acute promyelocytic, PL2F/RARA type (3)|ZBTB16, ZNF145, PLZF|176797|11q23.2
Leukemia, acute promyelocytic, PML/RARA type (3)|PML, MYL|102578|15q24.1
Leukemia, acute promyelocytic, STAT5B/RARA type (3)|STAT5B|604260|17q21.2
Leukemia, chronic myeloid, 608232 (3)|BCR, CML, PHL, ALL|151410|22q11.23
Leukemia, juvenile myelomonocytic, 607785 (3)|ARHGAP26, GRAF|605370|5q31.3
Leukemia, juvenile myelomonocytic, 607785 (3)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Leukemia, juvenile myelomonocytic, 607785 (3)|PTPN11, PTP2C, SHP2, NS1|176876|12q24.13
Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 190685 (3)|GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP|305371|Xp11.23
Leukemia, myeloid/lymphoid or mixed-lineage (2)|MLL, HRX, HTRX1, WDSTS|159555|11q23.3
Leukemia, transient, of Down syndrome (2)|TAM, MST|159595|21q11.2
Leukemia-1, T-cell acute lymphocytic (3)|TAL1, TCL5, SCL|187040|1p33
Leukemia-2, T-cell acute lymphoblastic (3)|TAL2|186855|9q31.2
Leukemia/lymphoma, B-cell, 2 (3)|BCL2|151430|18q21.33
Leukemia/lymphoma, B-cell, 3 (2)|BCL3|109560|19q13.32
Leukemia/lymphoma, T-cell (2)|TCL1A, TCL1|186960|14q32.13
Leukemia/lymphoma, T-cell (2)|TCL1B, TML1|603769|14q32.13
Leukemia/lymphoma, T-cell (2)|TCL4|186860|2q34
Leukocyte adhesion deficiency, 116920 (3)|ITGB2, CD18, LCAMB, LAD|600065|21q22.3
Leukocyte adhesion deficiency, type III, 612840 (3)|KIND3, URP2, MIG2B, FERMT3|607901|11q13.1
Leukodystrophy, adult-onset, autosomal dominant, 169500 (3)|LMNB1, ADLD|150340|5q23.2
Leukodystrophy, hypomyelinating, 2, 608804 (3)|GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q42.13
Leukodystrophy, hypomyelinating, 3, 260600 (3)|AIMP1, SCYE1, EMAP2, EMAPII, HLD3|603605|4q24
Leukodystrophy, hypomyelinating, 4, 612233 (3)|HSPD1, SPG13, HSP60, HLD4|118190|2q33.1
Leukodystrophy, hypomyelinating, 5, 610532 (3)|FAM126A, DRCTNNB1A, HLD5|610531|7p15.3
Leukodystrophy, hypomyelinating, 6, 612438 (3)|TUBB4A, TUBB4, TUBB5, DYT4, HLD6|602662|19p13.3
Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3)|POLR3A, RPC1, RPC155, ADDH, HLD7|614258|10q22.3
Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3)|POLR3B, RPC2, C128, HLD8|614366|12q23.3
Leukoencephalopathy with ataxia, 615651 (3)|CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT|600570|3q27.1
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3)|DARS2, ASPRS. LBSL|610956|1q25.1
Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3)|SCP2|184755|1p32.3
Leukoencephalopathy with metaphyseal chondrodysplasia (2)|LKMCD|300660|Xq25-q27
Leukoencephalopathy with vanishing white matter, 603896 (3)|EIF2B1, EIF2BA|606686|12q24.31
Leukoencephalopathy with vanishing white matter, 603896 (3)|EIF2B2|606454|14q24.3
Leukoencephalopathy with vanishing white matter, 603896 (3)|EIF2B3|606273|1p34.1
Leukoencephalopathy with vanishing white matter, 603896 (3)|EIF2B5, LVWM, CACH, CLE|603945|3q27.1
Leukoencephalopathy, cystic, without megalencephaly, 612951 (3)|RNASET2, RNASE6PL|612944|6q27
Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 (3)|CSF1R, FMS, HDLS|164770|5q32
Leukoencephaly with vanishing white matter, 603896 (3)|EIF2B4|606687|2p23.3
Leukotriene C4 synthase deficiency, 614037 (1)|LTC4S|246530|5q35.3
Levy-Shanske syndrome (4)|LVSKS|614846|15q26-qter
Leydig cell adenoma, somatic, with precocious puberty, 176410 (3)|LHCGR, LHR, LCGR|152790|2p16.3
Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3)|LHCGR, LHR, LCGR|152790|2p16.3
Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3)|LHCGR, LHR, LCGR|152790|2p16.3
Lhermitte-Duclos syndrome, 158350 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Li-Fraumeni syndrome 3 (2)|LFS3|609266|1q23
Li-Fraumeni syndrome, 151623 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Li-Fraumeni syndrome, 609265 (3)|CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
Liddle syndrome, 177200 (3)|SCNN1B, BESC1|600760|16p12.2
Liddle syndrome, 177200 (3)|SCNN1G, PHA1, BESC3|600761|16p12.2
Liebenberg syndrome, 186550 (4)|PITX1, PTX1, BFT, POTX, CCF, LBNBG|602149|5q31.1
Limb-girdle muscular dystrophy, type 1G (2)|LGMD1G|609115|4q21
Limb-mammary syndrome, 603543 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Lipase deficiency, combined, 246650 (3)|LMF1, TMEM112|611761|16p13.3
Lipodystrophy, congenital generalized, type 1, 608594 (3)|AGPAT2, LPAAB, BSCL, BSCL1|603100|9q34.3
Lipodystrophy, congenital generalized, type 2, 269700 (3)|BSCL2, SPG17, HMN5|606158|11q12.3
Lipodystrophy, congenital generalized, type 3, 612526 (3)|CAV1, BSCL3, CGL3, PPH3|601047|7q31.2
Lipodystrophy, congenital generalized, type 4, 613327 (3)|PTRF, CAVIN, CGL4|603198|17q21.2
Lipodystrophy, familial partial, 2, 151660 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Lipodystrophy, familial partial, type 3, 604367 (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
Lipodystrophy, familial partial, type 4, 613877 (3)|PLIN1, PLIN, FPLD4|170290|15q26.1
Lipoid adrenal hyperplasia, 201710 (3)|STAR|600617|8p11.23
Lipoma (3)|LPP|600700|3q27-q28
Lipoma, somatic (3)|MEN1|613733|11q13.1
Lipoprotein glomerulopathy, 611771 (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
Lipoprotein lipase deficiency, 238600 (3)|LPL, LIPD, HDLCQ11|609708|8p21.3
Liposarcoma (1)|LPSA, D19S381E|164953|19p13.2-q13.3
Lissencephaly 1, 607432 (3)|PAFAH1B1, LIS1|601545|17p13.3
Lissencephaly 2 (Norman-Roberts type), 257320 (3)|RELN, RL, LIS2|600514|7q22.1
Lissencephaly 3, 611603 (3)|TUBA1A, TUBA3, LIS3|602529|12q13.12
Lissencephaly 4 (with microcephaly), 614019 (3)|NDE1, NUDE, LIS4|609449|16p13.11
Lissencephaly 5, 615191 (3)|LAMB1, LIS5|150240|7q31.1
Lissencephaly, X-linked 2, 300215 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Lissencephaly, X-linked, 300067 (3)|DCX, DBCN, LISX|300121|Xq23
Liver failure, transient infantile, 613070 (3)|TRMU, MTO2, TRNT1|610230|22q13.31
Loeys-Dietz syndrome, type 1A, 609192 (3)|TGFBR1, ALK5, AAT5, LDS2A, LDS1A, MSSE|190181|9q22.33
Loeys-Dietz syndrome, type 1B, 610168 (3)|TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p24.1
Loeys-Dietz syndrome, type 2A, 608967 (3)|TGFBR1, ALK5, AAT5, LDS2A, LDS1A, MSSE|190181|9q22.33
Loeys-Dietz syndrome, type 2B, 610380 (3)|TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p24.1
Loeys-Dietz syndrome, type 3, 613795 (3)|SMAD3, MADH3, LDS3|603109|15q22.33
Loeys-Dietz syndrome, type 4, 614816 (3)|TGFB2, LDS4|190220|1q41
Long QT syndrome 1, 192500 (3)|KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5-p15.4
Long QT syndrome 12, 612955 (3)|SNT1, LQT12|601017|20q11.21
Long QT syndrome 13, 613485 (3)|KCNJ5, GIRK4, KATP1, LQT13|600734|11q24.3
Long QT syndrome 2, 613688 (3)|KCNH2, LQT2, HERG, SQT1|152427|7q36.1
Long QT syndrome 4, 600919 (3)|ANK2, LQT4|106410|4q25-q26
Long QT syndrome 5, 613695 (3)|KCNE1, JLNS, LQT5, JLNS2|176261|21q22.11-q22.12
Long QT syndrome 6, 613693 (3)|KCNE2, MIRP1, LQT6, ATFB4|603796|21q22.11
Long QT syndrome 9, 611818 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Long QT syndrome-10, 611819 (3)|SCN4B|608256|11q23.3
Long QT syndrome-11, 611820 (3)|AKAP9, YOTIAO, AKAP450|604001|7q21.2
Long QT syndrome-3, 603830 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Lowe syndrome, 309000 (3)|OCRL, LOCR, OCRL1, NPHL2|300535|Xq25-q26
Lujan-Fryns syndrome, 309520 (3)|MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX|300188|Xq13.1
Lung cancer, 211980 (1)|DLEC1, DLC1|604050|3p22.2
Lung cancer, 211980 (2)|RASSF1|605082|3p21.31
Lung cancer, 211980 (3)|PPP2R1B|603113|11q23.1
Lung cancer, somatic, 211980 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Lung cancer, somatic, 211980 (3)|MAP3K8, COT, EST, TPL2|191195|10p11.23
Lung cancer, somatic, 211980 (3)|SLC22A1L, BWSCR1A, IMPT1|602631|11p15.4
Luteinizing hormone resistance, female, 238320 (3)|LHCGR, LHR, LCGR|152790|2p16.3
Lymphangioleiomyomatosis, 606690 (3)|TSC1, LAM|605284|9q34.13
Lymphangioleiomyomatosis, somatic, 606690 (3)|TSC2, LAM|191092|16p13.3
Lymphedema, hereditary I, 153100 (3)|FLT4, VEGFR3, PCL, LMPH1A|136352|5q35.3
Lymphedema, hereditary, IB (2)|LMPH1B|611944|6q16.2-q22.1
Lymphedema, hereditary, IC, 613480 (3)|GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q42.13
Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3)|FOXC2, FKHL14, MFH1|602402|16q24.1
Lymphedema-distichiasis syndrome, 153400 (3)|FOXC2, FKHL14, MFH1|602402|16q24.1
Lymphocytic leukemia, acute T-cell (3)|RAP1GDS1|179502|4q23
Lymphoma, B-cell (2)|BCL6|109565|3q27.3
Lymphoma, B-cell non-Hodgkin, somatic (3)|ATM, ATA, AT1|607585|11q22.3
Lymphoma, MALT, somatic, 137245 (3)|BCL10|603517|1p22.3
Lymphoma, diffuse large cell (3)|NBEAP1, BCL8|601889|15q11.2
Lymphoma, mantle cell (3)|ATM, ATA, AT1|607585|11q22.3
Lymphoma, non-Hodgkin, 605027 (3)|PRF1, HPLH2, FLH2|170280|10q22.1
Lymphoma, non-Hodgkin, somatic, 605027 (3)|RAD54B|604289|8q22.1
Lymphoma, non-Hodgkin, somatic, 605027 (3)|RAD54L, HR54, HRAD54|603615|1p34.1
Lymphoma, somatic (3)|MAD1L1, TXBP181|602686|7p22.3
Lymphoma/leukemia, B-cell, variant (1)|FVT1|136440|18q21.33
Lymphoproliferative syndrome 1, 613011 (3)|ITK, EMT, LPFS1|186973|5q33.3
Lymphoproliferative syndrome 2, 615122 (3)|TNFRSF7, CD27, S152. LPFS2|186711|12p13.31
Lymphoproliferative syndrome, X-linked, 1, 308240 (3)|SH2D1A, LYP, IMD5, XLP, XLPD1|300490|Xq25
Lymphoproliferative syndrome, X-linked, 2, 300635 (3)|XIAP, BIRC4, API3, XLP2|300079|Xq25
Lysinuric protein intolerance, 222700 (3)|SLC7A7, LPI|603593|14q11.2
Lysyl hydroxylase 3 deficiency, 612394 (3)|PLOD3, LH3|603066|7q22.1
MASA syndrome, 303350 (3)|L1CAM, CAML1, HSAS1, MASA, SPG1|308840|Xq28
MASP2 deficiency, 613791 (3)|MASP2|605102|1p36.22
MASS syndrome, 604308 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
MEDNIK syndrome, 609313 (3)|AP1S1, CLAPS1, AP19, MEDNIK|603531|7q22.1
MEHMO syndrome (2)|MEHMO|300148|Xp22.13-p21.1
MHC class II deficiency, complementation group B, 209920 (3)|RFXANK|603200|19p13.11
MODY, type I, 125850 (3)|HNF4A, TCF14, MODY1|600281|20q13.12
MODY, type II, 125851 (3)|GCK, HHF3|138079|7p13
MODY, type III, 600496 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
MODY, type IV, 606392 (3)|IPF1, MODY4|600733|13q12.2
Machado-Joseph disease, 109150 (3)|ATXN3, MJD, SCA3|607047|14q32.12
Macrocephaly with multiple epiphyseal dysplasia and distinctive facies (2)|MMEDF|607131|15q26.1
Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3)|RIN2, MACS|610222|20p11.23
Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 (3)|RNF135, MMFD|611358|17q11.2
Macrocephaly/autism syndrome, 605309 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)|RPS14, EMTB|130620|5q33.1
Macroglobulinemia, Waldenstrom, somatic, 153600 (3)|MYD88, MYD88D|602170|3p22.2
Macrostomia (2)|MACST|613545|1p34-p32
Macrothrombocytopenia and progressive sensorineural deafness, 600208 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3)|TUBB1|612901|20q13.32
Macular corneal dystrophy, 217800 (3)|CHST6, MCDC1|605294|16q23.1
Macular degeneration, X-linked atrophic, 300834 (3)|RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Macular degeneration, age-related, 11, 611953 (3)|CST3, ARMD11|604312|20p11.21
Macular degeneration, age-related, 15, suscepbitility to, 615591 (3)|C9, C9D, ARMD15|120940|5p13.1
Macular degeneration, age-related, 2, 153800 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Macular degeneration, age-related, 3, 608895 (3)|FBLN5, ARMD3, ADCL2, ARCL1A|604580|14q32.12
Macular degeneration, age-related, 6, 613757 (3)|RAXL1, QRX, CORD11, ARMD6|610362|19p13.3
Macular degeneration, juvenile, 248200 (3)|CNGB3, ACHM3, ACHM1|605080|8q21.3
Macular dystrophy (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Macular dystrophy, North Carolina type (2)|MCDR1|136550|6q14-q16.2
Macular dystrophy, autosomal dominant, chromosome 6-linked, 600110 (3)|ELOVL4, ADMD, STGD2, STGD3, ISQMR|605512|6q14.1
Macular dystrophy, dominant cystoid (2)|MDDC|153880|7p21-p15
Macular dystrophy, patterned, 169150 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Macular dystrophy, retinal, 2, 608051 (3)|PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.32
Macular dystrophy, retinal, 3 (2)|MCDR3|608850|5p15.33-p13.1
Macular dystrophy, vitelliform, 608161 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Maculopathy, IMPG2-related, 613581 (3)|IMPG2, IPM200, RP56|607056|3q12.3
Maculopathy, bull's-eye (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Majeed syndrome, 609628 (3)|LPIN2|605519|18p11.31
Major affective disorder 4 (2)|MAFD4, BPAD|611247|16p12
Major depressive disorder 1, 608516 (2)|MDD1|608520|12q22-q23.2
Major depressive disorder 2, 608516 (2)|MDD2|608691|15q25.3-q26.2
Male germ cell tumor (2)|MGCT|273300|12q22
Malignant fibrous histiocytoma (2)|MFHAS1, MASL1|605352|8p23.1
Malignant melanoma, somatic, 155600 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Malonyl-CoA decarboxylase deficiency, 248360 (3)|MLYCD, MCD|606761|16q23.3
Malouf syndrome, 212112 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Mammary-digital-nail syndrome (2)|MDNS|613689|22q12.3-q13.1
Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3)|POLD1, CRCS10, MDPL|174761|19q13.33
Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3)|ZMPSTE24, FACE1, STE24, MADB|606480|1p34.2
Mandibuloacral dysplasia, 248370 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Mandibulofacial dysostosis, Guion-Almeida type, 610536 (3)|EFTUD2, KIAA0031, MFDGA|603892|17q21.31
Manitoba oculotrichoanal syndrome, 248450 (3)|FREM1, C9orf154, BNAR, MOTA, TRIGNO2|608944|9p22.3
Mannosidosis, alpha-, types I and II, 248500 (3)|MAN2B1, MANB|609458|19p13.2
Mannosidosis, beta, 248510 (3)|MANBA, MANB1|609489|4q24
Maple syrup urine disease, mild variant, 615135 (3)|PPM1K, PP2CM, PTMP, MSUDMV|611065|4q22.1
Maple syrup urine disease, type II, 248600 (3)|DBT, BCATE2|248610|1p21.2
Maple syrup urine disease, type Ia, 248600 (3)|BCKDHA, MSUD1|608348|19q13.2
Maple syrup urine disease, type Ib, 248600 (3)|BCKDHB, E1B|248611|6q14.1
Marfan syndrome, 154700 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Marinesco-Sjogren syndrome, 248800 (3)|SIL1, BAP, MSS|608005|5q31.2
Marshall syndrome, 154780 (3)|COL11A1, STL2|120280|1p21.1
Marshall-Smith syndrome, 602535 (3)|NFIX, NF1A, SOTOS2, MRSHSS|164005|19p13.2
Martinez-Frias syndrome, 601346 (3)|RFX6, RFXDC1, MTFS|612659|6q22.1
Martsolf syndrome, 212720 (3)|RAB3GAP2, RAB3GAP150, p150, KIAA0839, WARBM2|609275|1q41
Mast cell disease, 154800 (3)|KIT, PBT|164920|4q12
Mast syndrome, 248900 (3)|ACP33, MAST, SPG21|608181|15q22.31
Maturity-onset diabetes of the young 6, 606394 (3)|NEUROD1, NIDDM|601724|2q31.3
Maturity-onset diabetes of the young, type 10, 613370 (3)|INS, MODY10, IDDM2|176730|11p15.5
Maturity-onset diabetes of the young, type 11, 613375 (3)|BLK, MODY11|191305|8p23.1
Maturity-onset diabetes of the young, type IX, 612225 (3)|PAX4, MODY9, KPD|167413|7q32.1
Maturity-onset diabetes of the young, type VII, 610508 (3)|KLF11, TIEG2, FKLF1, FKLF, MODY7|603301|2p25.1
Maturity-onset diabetes of the young, type VIII, 609812 (3)|CEL, BSSL, CELL, MODY8|114840|9q34.2
May-Hegglin anomaly, 155100 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
McArdle disease, 232600 (3)|PYGM|608455|11q13.1
McCune-Albright syndrome, 174800 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
McKusick-Kaufman syndrome, 236700 (3)|MKKS, HMCS, KMS, MKS, BBS6|604896|20p12.2
McLeod syndrome with or without chronic granulomatous disease, 300842 (3)|XK, MCLDS|314850|Xp21.1
Meacham syndrome, 608978 (3)|WT1, NPHS4|607102|11p13
Mean platelet volume QTL4 (2)|MPVQTL4|614644|6p21.3-p21.2
Mean platelet volume QTL5 (2)|MPVQTL5|614645|6q23.3
Mean platelet volume QTL6 (2)|MPVQTL6|614646|7q22.3
Meckel syndrome 1, 249000 (3)|MKS1, MKS, BBS13|609883|17q22
Meckel syndrome 10, 614175 (3)|B9D2, MKS10|611951|19q13.2
Meckel syndrome 2, 603194 (3)|TMEM216, JBTS2, CORS2, MKS2|613277|11q12.2
Meckel syndrome 3, 607361 (3)|TMEM67, MKS3, JBTS6, NPHP11|609884|8q22.1
Meckel syndrome 4, 611134 (3)|CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.32
Meckel syndrome 5, 611561 (3)|RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
Meckel syndrome 6, 612284 (3)|CC2D2A, KIAA1345, MKS6|612013|4p15.32
Meckel syndrome 7, 267010 (3)|NPHP3, NPH3, RHPD1, MKS7|608002|3q22.1
Meckel syndrome 8, 613885 (3)|TCTN2, TECT2, MKS8|613846|12q24.31
Meckel syndrome 9, 614209 (3)|B9D1, MKSR1, MKS9|614144|17p11.2
Meckel syndrome, type 11, 615397 (3)|TMEM231, JBTS20, MKS11|614949|16q23.1
Meconium ileus, 614665 (3)|GUCY2C, GUC2C, DIAR6, MECIL|601330|12p13.1-p12.3
Medullary cystic kidney disease 1, 174000 (3)|MUC1, PUM, MCKD1|158340|1q22
Medullary cystic kidney disease 2, 603860 (3)|UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Medullary thyroid carcinoma, 155240 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Medullary thyroid carcinoma, familial, 155240 (3)|NTRK1, TRKA, MTC|191315|1q23.1
Medulloblastoma, 155255 (3)|PTCH2|603673|1p34.1
Medulloblastoma, desmoplastic, 155255 (3)|SUFU, SUFUXL, SUFUH|607035|10q24.32
Meesmann corneal dystrophy, 122100 (3)|KRT12|601687|17q21.2
Meesmann corneal dystrophy, 122100 (3)|KRT3|148043|12q13.13
Megakaryoblastic leukemia, acute (2)|RBM15, SPEN, OTT|606077|1p13.3
Megakaryoblastic leukemia, acute (3)|MKL1, AMKL, MAL|606078|22q13.1-q13.2
Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 (3)|HEPACAM, MLC2A, MLC2B|611642|11q24.2
Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 (3)|HEPACAM, MLC2A, MLC2B|611642|11q24.2
Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3)|MLC1, LVM, VL|605908|22q13.33
Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome, 603387 (3)|AKT3, PKBG, MPPH|611223|1q43-q44
Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome, 603387 (3)|PIK3R2, MPPH|603157|19p13.11
Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome, somatic, 603387 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3)|DHFR|126060|5q14.1
Megaloblastic anemia-1, Finnish type, 261100 (3)|CUBN, IFCR, MGA1|602997|10p13
Megaloblastic anemia-1, Norwegian type, 261100 (3)|AMN|605799|14q32.32
Megalocornea 1, X-linked 309300 (3)|CHRDL1, VOPT, MGC1|300350|Xq23
Meier-Gorlin syndrome 1, 224690 (3)|ORC1, ORC1L|601902|1p32.3
Meier-Gorlin syndrome 2, 613800 (3)|ORC4, ORC4L|603056|2q22.3-q23.1
Meier-Gorlin syndrome 3, 613803 (3)|ORC6, ORC6L|607213|16q11.2
Meier-Gorlin syndrome 4, 613804 (3)|CDT1|605525|16q24.3
Meier-Gorlin syndrome 5, 613805 (3)|CDC6, CDC18L|602627|17q21.2
Melanoma and neural system tumor syndrome, 155755 (3)|CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21.3
Melanoma, desmoplastic neurotrophic (2)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Melanoma, malignant, somatic (3)|BRAF, NS7|164757|7q34
Melanoma, malignant, somatic (3)|STK11, PJS, LKB1|602216|19p13.3
Meleda disease, 248300 (3)|SLURP1, MDM|606119|8q24.3
Melnick-Needles syndrome, 309350 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Melorheostosis with osteopoikilosis, 155950 (3)|LEMD3, MAN1|607844|12q14.3
Membranous glomerulonephritis, antenatal (1)|MME, CD10, CALLA, NEP|120520|3q25.2
Meningioma, 607174 (3)|MN1, MGCR|156100|22q12.1
Meningioma, NF2-related, somatic, 607174 (3)|NF2|607379|22q12.2
Meningioma, SIS-related, 607174 (3)|PDGFB, SIS, IBGC5|190040|22q13.1
Meningioma, radiation-induced (2)|MNRI|606190|1p11
Menkes disease, 309400 (3)|ATP7A, MNK, MK, OHS, SMAX3|300011|Xq21.1
Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 (3)|CASK, MICPCH, FGS4, CMG, MRXSNA|300172|Xp11.4
Mental retardation syndrome, X-linked, Armfield type (2)|MRXSA|300261|Xq28
Mental retardation syndrome, X-linked, Siderius type, 300263 (3)|PHF8, ZNF422, KIAA1111, MRXSSD|300560|Xp11.22
Mental retardation with language impairment and autistic features, 613670 (3)|FOXP1, QRF1|605515|3p13
Mental retardation, FRA12A type, 136630 (3)|DIP2B, KIAA1463|611379|12q13.12
Mental retardation, X-linked 1, 309530 (3)|IQSEC2, KIAA0522, MRX1|300522|Xp11.22
Mental retardation, X-linked 14 (2)|MRX14|300062|Xp11.3-q13.3
Mental retardation, X-linked 17/31, microduplication, 300705 (3)|HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.22
Mental retardation, X-linked 19, 300844 (3)|RPS6KA3, RSK2, MRX19|300075|Xp22.12
Mental retardation, X-linked 2 (2)|MRX2|300428|Xp22.3
Mental retardation, X-linked 20 (2)|MRX20|300047|Xp11-q21
Mental retardation, X-linked 21/34, 300143 (3)|IL1RAPL1, IL1R8, MRX21, MRX34|300206|Xp21.3-p21.2
Mental retardation, X-linked 23 (2)|MRX23|300046|Xq23-q24
Mental retardation, X-linked 29 (2)|MRX29|300077|Xp22.3-p21.3
Mental retardation, X-linked 29 and others, 300419 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type ), 309541 (3)|HCFC1, HCF1, MRX3|300019|Xq28
Mental retardation, X-linked 30/47, 300558 (3)|PAK3, MRX30, MRX47|300142|Xq23
Mental retardation, X-linked 41, 300849 (3)|GDI1, RABGD1A, MRX41, MRX48|300104|Xq28
Mental retardation, X-linked 42 (2)|MRX42|300372|Xq26
Mental retardation, X-linked 45, 300498 (3)|ZNF81, MRX45|314998|Xp11.23
Mental retardation, X-linked 46, 300436 (3)|ARHGEF6, MRX46, COOL2|300267|Xq26.3
Mental retardation, X-linked 49 (2)|MRX49|300114|Xp22.3
Mental retardation, X-linked 50 (2)|MRX50|300115|Xp11.3-p11.21
Mental retardation, X-linked 52 (2)|MRX52|300504|Xp11.21-q22.3
Mental retardation, X-linked 53 (2)|MRX53|300324|Xq22.2-q26
Mental retardation, X-linked 58, 300210 (3)|TSPAN7, TM4SF2, MXS1, A15, MRX58|300096|Xp11.4
Mental retardation, X-linked 63, 300387 (3)|ACSL4, FACL4, ACS4, MRX63|300157|Xq23
Mental retardation, X-linked 72, 300271 (3)|RAB39B, MRX72|300774|Xq28
Mental retardation, X-linked 77 (2)|MRX77|300454|Xq12-q21.3
Mental retardation, X-linked 78 (2)|MRX78|300551|Xp11.4-q21.1
Mental retardation, X-linked 81 (2)|MRX81|300433|Xp11.2-q12
Mental retardation, X-linked 82 (2)|MRX82|300518|Xq24-q25
Mental retardation, X-linked 84 (2)|MRX84|300505|Xp11.3-q22.3
Mental retardation, X-linked 89 (2)|MRX89|300848|Xp11.3
Mental retardation, X-linked 9, 309549 (3)|FTSJ1, JM23, SPB1, MRX44, MRX9|300499|Xp11.23
Mental retardation, X-linked 90, 300850 (3)|DLG3, NEDLG, SAP102, MRX90|300189|Xq13.1
Mental retardation, X-linked 92 (2)|MRX92|300851|Xp11.3
Mental retardation, X-linked 93, 300659 (3)|BRWD3, MRX93|300553|Xq21.1
Mental retardation, X-linked 94, 300699 (3)|GRIA3, GLUR3, MRX94|305915|Xq25
Mental retardation, X-linked 95 (2)|MRX95|300716|Chr.X
Mental retardation, X-linked 96, 300802 (3)|SYP, MRXSYP|313475|Xp11.23
Mental retardation, X-linked 97, 300803 (3)|ZNF711, ZNF6, CMPX1, MRX97|314990|Xq21.1
Mental retardation, X-linked 98, 300912 (3)|KIAA2022, MRX98|300524|Xq13.3
Mental retardation, X-linked syndromic 10, 300220 (3)|HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.22
Mental retardation, X-linked syndromic 16, 305400 (3)|FGD1, FGDY, AAS, MRXS16|300546|Xp11.22
Mental retardation, X-linked syndromic 7 (2)|MRXS7|300218|Xp11.3-q22
Mental retardation, X-linked syndromic, Abidi type (2)|MRXSAB|300262|Xq13.2
Mental retardation, X-linked syndromic, Christianson type, 300243 (3)|SLC9A6, NHE6|300231|Xq26.3
Mental retardation, X-linked syndromic, Fried type, 300630 (3)|AP1S2, MRX59, MRXSF, MRXS21|300629|Xp22.2
Mental retardation, X-linked syndromic, Lubs type, 300260 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Mental retardation, X-linked syndromic, Nascimento-type, 300860 (3)|UBE2A, RAD6A, MRXSN, MRXS30|312180|Xq24
Mental retardation, X-linked syndromic, Raymond type, 300799 (3)|ZDHHC9, DHHC9, MRXSZ|300646|Xq26.1
Mental retardation, X-linked syndromic, Shashi type (2)|MRXS11, SMRXS|300238|Xq26-q27
Mental retardation, X-linked syndromic, Turner type, 300706 (3)|HUWE1, UREB1, KIAA0312, LASU1|300697|Xp11.22
Mental retardation, X-linked, 300495 (3)|NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.32-p22.31
Mental retardation, X-linked, FRAXE type, 309548 (3)|AFF2, FMR2, FRAXE, MRX2|300806|Xq28
Mental retardation, X-linked, Snyder-Robinson type, 309583 (3)|SMS, SRS, MRSR|300105|Xp22.11
Mental retardation, X-linked, syndromic 13, 300055 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Mental retardation, X-linked, syndromic 14, 300676 (3)|UPF3B, RENT3B, MRXS14|300298|Xq24
Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 (3)|CUL4B, MRXSC, MRXHF2, SFM2, MRXS15|300304|Xq24
Mental retardation, X-linked, syndromic 17 (2)|MRXS17|300858|Xp21.1-p11.23
Mental retardation, X-linked, syndromic 32, 300886 (3)|CLIC2, XAP121, MRXS32|300138|Xq28
Mental retardation, X-linked, syndromic 9 (2)|MRXS9|300709|Xq12-q21.31
Mental retardation, X-linked, syndromic, Chudley-Schwartz type, (2)|MRXSCS|300861|Xq21.33-q23
Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534 (3)|KDM5C, JARID1C, SMCX, DXS1272E, XE169, MRXSCJ|314690|Xp11.22
Mental retardation, X-linked, syndromic, Martin-Probst type, 300519 (3)|RAB40AL, RLGP, MRXSMP|300405|Xq22.1
Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 (3)|OPHN1, MRX60|300127|Xq12
Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 (3)|SOX3, MRGH|313430|Xq27.1
Mental retardation, X-linked, with short stature (2)|MRSS|300360|Xq24
Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3)|SOBP, JXC1, MRAMS|613667|6q21
Mental retardation, autosomal dominant 1, 156200 (3)|MBD5, KIAA1461, MRD1|611472|2q23.1
Mental retardation, autosomal dominant 10, 614256 (3)|CACNG2, MRD10|602911|22q12.3
Mental retardation, autosomal dominant 12, 614562 (3)|ARID1B, BAF250B, KIAA1235, MRD12|614556|6q25.3
Mental retardation, autosomal dominant 13, 614563 (3)|DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1|600112|14q32.31
Mental retardation, autosomal dominant 14, 614607 (3)|ARID1A, C1orf4, B120, SMARCF1, MRD14|603024|1p36.11
Mental retardation, autosomal dominant 15, 614608 (3)|SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1|601607|22q11.23
Mental retardation, autosomal dominant 16, 614609 (3)|SMARCA4, BRG1, RTPS2, MRD16|603254|19p13.2
Mental retardation, autosomal dominant 17, 615009 (3)|PACS1, MRD17|607492|11q13.1-q13.2
Mental retardation, autosomal dominant 18, 615074 (3)|GATAD2B, KIAA1150, p68, MRD18|614998|1q21.3
Mental retardation, autosomal dominant 19, 615075 (3)|CTNNB1, MRD19|116806|3p22.1
Mental retardation, autosomal dominant 2, 614113 (3)|DOCK8, MRD2|611432|9p24.3
Mental retardation, autosomal dominant 21, 615502 (3)|CTCF, MRD21|604167|16q22.1
Mental retardation, autosomal dominant 3, 612580 (3)|CDH15, CDH14, CDH3, MRD3|114019|16q24.3
Mental retardation, autosomal dominant 4, 612581 (3)|KIRREL3, NEPH2, KIAA1867, KIRRE, MRD4|607761|11q24.2
Mental retardation, autosomal dominant 5, 612621 (3)|SYNGAP1, MRD5|603384|6p21.32
Mental retardation, autosomal dominant 6, 613970 (3)|GRIN2B, NMDAR2B, MRD6|138252|12p13.1
Mental retardation, autosomal dominant 7, 614104 (3)|DYRK1A, MNBH, MNB, MRD7|600855|21q22.13
Mental retardation, autosomal dominant 8, 614254 (3)|GRIN1, NMDAR1, MRD8|138249|9q34.3
Mental retardation, autosomal dominant 9, 614255 (3)|KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9|601255|2q37.3
Mental retardation, autosomal recessive 1, 249500 (3)|PRSS12, BSSP3, MRT1|606709|4q26
Mental retardation, autosomal recessive 10/20 (2)|MRT10, MRT20|611096|16p12.2-q12.1
Mental retardation, autosomal recessive 12, 611090 (3)|ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15|606494|1p34.1
Mental retardation, autosomal recessive 13, 613192 (3)|TRAPPC9, NIBP, KIAA1882, MRT13|611966|8q24.3
Mental retardation, autosomal recessive 14, 614020 (3)|TECR, GPSN2, TER, SC2, MRT14|610057|19p13.12
Mental retardation, autosomal recessive 15, 614202 (3)|MAN1B1, MRT15|604346|9q34.3
Mental retardation, autosomal recessive 16 (2)|MRT16|614208|9p23-p13.3
Mental retardation, autosomal recessive 18, 614249 (3)|MED23, MRT18|605042|6q23.2
Mental retardation, autosomal recessive 19 (2)|MRT19|614343|18p11.3
Mental retardation, autosomal recessive 2, 607417 (3)|CRBN, MRT2|609262|3p26.2
Mental retardation, autosomal recessive 23 (2)|MRT23|614344|11p13-q14.1
Mental retardation, autosomal recessive 24 (2)|MRT24|614345|6p12.2-q12
Mental retardation, autosomal recessive 25 (2)|MRT25|614346|12q13.11-q15
Mental retardation, autosomal recessive 27 (2)|MRT27|614340|15q24.1-q26.1
Mental retardation, autosomal recessive 28 (2)|MRT28|614347|6q26-q27
Mental retardation, autosomal recessive 29 (2)|MRT29|614333|4q27-q28.2
Mental retardation, autosomal recessive 3, 608443 (3)|CC2D1A, MRT3|610055|19p13.12
Mental retardation, autosomal recessive 30 (2)|MRT30|614342|6q12-q15
Mental retardation, autosomal recessive 31 (2)|MRT31|614329|4q12-q13.1
Mental retardation, autosomal recessive 32 (2)|MRT32|614339|14q32.13-q32.2
Mental retardation, autosomal recessive 33 (2)|MRT33|614341|17p13.2-p13.1
Mental retardation, autosomal recessive 34, 614499 (3)|CRADD, RAIDD, MRT34|603454|12q22
Mental retardation, autosomal recessive 35, 615162 (3)|MRT35|615162|17q21.31-q22
Mental retardation, autosomal recessive 36, 615286 (3)|ADAT3, TAD3, MRT36|615302|19p13.3
Mental retardation, autosomal recessive 38, 615516 (3)|HERC2, SHEP1, MRT38|605837|15q13.1
Mental retardation, autosomal recessive 39, 615541 (3)|TTI2, C8orf41, MRT39|614426|8p12
Mental retardation, autosomal recessive 40, 615599 (3)|TAF2, TAF2B, TAFII150, CIF150, MRT40|604912|8q24.12
Mental retardation, autosomal recessive 41, 615637 (3)|KPTN, 2E4, MRT41|615620|19q13.32
Mental retardation, autosomal recessive 5, 611091 (3)|NSUN2, TRM4, SAKI, MISU, MRT5|610916|5p15.31
Mental retardation, autosomal recessive 7, 611093 (3)|TUSC3, M33, D8S1992, MRT7, MRT22|601385|8p22
Mental retardation, autosomal recessive, 11 (2)|MRT11|611097|19q13.2-q13.3
Mental retardation, autosomal recessive, 4 (2)|MRT4|611107|1p21.1-p13.3
Mental retardation, autosomal recessive, 6, 611092 (3)|GRIK2, GLUR6, MRT6|138244|6q16.3
Mental retardation, autosomal recessive, 8 (2)|MRT8|611094|10q22
Mental retardation, autosomal recessive, 9/26 (3)|MRT9, MRT26|611095|14q11.2-q12
Mental retardation, severe, with spasticity and tapetoretinal degeneration (2)|MRST|602685|15q24
Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 (3)|MEF2C, C5DELq14.3, DEL5q14.3|600662|5q14.3
Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3)|INPP5E, MORMS, JBTS1, CORS1|613037|9q34.3
Mental retardation, with or without nystagmus, 300422 (3)|CASK, MICPCH, FGS4, CMG, MRXSNA|300172|Xp11.4
Mental retardation-hypotonic facies syndrome, X-linked, 309580 (3)|ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq21.1
Mental retardation-skeletal dysplasia (2)|MRSD, CHRS|309620|Xq28
Mephenytoin poor metabolizer, 609535 (3)|CYP2C, CYP2C19|124020|10q23.33
Merkel cell carcinoma, somatic (3)|SDHD, PGL1, CWS3|602690|11q23.1
Mesomelia-synostoses syndrome (4)|DEL8q13, C8DELq13|600383|8q13
Mesomelic dysplasia, Kantaputra type (2)|MMDK, MDK|156232|2q24-q32
Mesothelioma, somatic, 156240 (3)|WT1, NPHS4|607102|11p13
Metacarpal 4-5 fusion, 309630 (3)|FGF16, MF4|300827|Xq21.1
Metachondromatosis, 156250 (3)|PTPN11, PTP2C, SHP2, NS1|176876|12q24.13
Metachromatic leukodystrophy due to SAP-b deficiency, 249900 (3)|PSAP, SAP1|176801|10q22.1
Metachromatic leukodystrophy, 250100 (3)|ARSA|607574|22q13.33
Metaphyseal anadysplasia 1, 602111 (3)|MMP13, CLG3, MANDP1|600108|11q22.2
Metaphyseal anadysplasia 2, 613073 (3)|MMP9, CLG4B, MANDP2|120361|20q13.12
Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3)|PTHR1, PTHR, PFE|168468|3p21.31
Metaphyseal chondrodysplasia, Schmid type, 156500 (3)|COL10A1|120110|6q22.1
Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3)|RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD|600211|6p21.1
Metaphyseal dysplasia without hypotrichosis, 250460 (3)|RMRP, RMRPR, CHH|157660|9p13.3
Metastasis efficiency, modification of (1)|SIPA1, SPA1|602180|11q13.1
Metatropic dysplasia, 156530 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Methemoglobinemia, type I, 250800 (3)|CYB5R3, DIA1, B5R|613213|22q13.2
Methemoglobinemia, type II, 250800 (3)|CYB5R3, DIA1, B5R|613213|22q13.2
Methemoglobinemia, type IV, 250790 (3)|CYB5A, MCB5|613218|18q22.3
Methemoglobinemias, alpha- (3)|HBA1, HBH|141800|16p13.3
Methemoglobinemias, beta- (3)|HBB|141900|11p15.4
Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3)|MAT1A, MATA1, SAMS1|610550|10q23.1
Methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3)|ALDH6A1, MMSDH|603178|14q24.3
Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3)|MMACHC|609831|1p34.1
Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3)|C2orf25, MMADHC|611935|2q23.2
Methylmalonic aciduria and homocystinuria, cblF type, 277380 (3)|LMBRD1, LMBD1, NESI, MAHCF|612625|6q13
Methylmalonic aciduria and homocystinuria, cblJ type, 614857 (3)|ABCD4, PXMP1L, P79R, PMP69, MAHCJ|603214|14q24.3
Methylmalonic aciduria due to transcobalamin receptor defect, 613646 (3)|CD320, 8D6, 8D6A, TCBLR|606475|19p13.2
Methylmalonic aciduria, cblD type, variant 2, 277410 (3)|C2orf25, MMADHC|611935|2q23.2
Methylmalonic aciduria, mut(0) type, 251000 (3)|MUT, MCM|609058|6p12.3
Methylmalonic aciduria, vitamin B12-responsive, 251100 (3)|MMAA|607481|4q31.21
Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3)|MMAB|607568|12q24.11
Methylmalonyl-CoA epimerase deficiency, 251120 (3)|MCEE|608419|2p13.3
Mevalonic aciduria, 610377 (3)|MVK, MVLK, POROK3|251170|12q24.11
Microcephalic osteodysplastic primordial dwarfism, type I, 210710 (3)|RNU4ATAC, U4ATAC, MOPD1, TALS|601428|2q14.2
Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3)|PCNT, PCNT2, KEN, SCKL4, MOPD2|605925|21q22.3
Microcephaly 1, primary, autosomal recessive, 251200 (3)|MCPH1|607117|8p23.1
Microcephaly 10, primary, autosomal recessive, 615095 (3)|ZNF335, NIF1, NIF2, MCPH10|610827|20q13.12
Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 (3)|WDR62, C19orf14, MCPH2|613583|19q13.12
Microcephaly 3, primary, autosomal recessive, 604804 (3)|CDK5RAP2, KIAA1633, MCPH3|608201|9q33.2
Microcephaly 4, primary, autosomal recessive, 604321 (3)|CASC5, AF15Q14, KIAA1570, D40, MCPH4|609173|15q15.1
Microcephaly 5, primary, autosomal recessive, 608716 (3)|ASPM, MCPH5|605481|1q31.3
Microcephaly 6, primary, autosomal recessive, 608393 (3)|CENPJ, CPAP, MCPH6, SCKL4|609279|13q12.12
Microcephaly 7, primary, autosomal recessive, 612703 (3)|STIL, SIL, MCPH7|181590|1p33
Microcephaly 8, primary, autosomal recessive, 614673 (3)|CEP135, KIAA0635, MCPH8|611423|4q12
Microcephaly 9, primary, autosomal recessive, 614852 (3)|CEP152, KIAA0912, MCPH9, SCKL5|613529|15q21.1
Microcephaly and chorioretinopathy with or without mental retardation, 251270 (3)|TUBGCP6, GCP6, KIAA1669, MCPHCR|610053|22q13.33
Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3)|KIF11, KNSL1, MCLMR|148760|10q23.33
Microcephaly, Amish type, 607196 (3)|SLC25A19, DNC, MUP1, MCPHA, THMD3, THMD4|606521|17q25.1
Microcephaly, epilepsy, and diabetes syndrome, 614231 (3)|IER3IP1, MEDS|609382|18q21.1
Microcephaly, mental retardation, and distinctive facies, with cardiac and genitourinary malformations (2)|MMRFCGU|613680|16p13.3
Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3)|MED17, CRSP6, CRSP77, TRAP80, DRIP80|603810|11q21
Microcephaly-capillary malformation syndrome, 614261 (3)|STAMBP, AMSH, MICCAP|606247|2p13.1
Microcoria, congenital (2)|MCOR|156600|13q31-q32
Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3)|ADAMTS18, MMCAT|607512|16q23.1
Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Microhydranencephaly (2)|MHAC|605013|16p13.3-p12.1
Microphthalmia with cataract 1 (2)|MCOPCT1|156850|16p13.3
Microphthalmia with cataract 2, 212550 (3)|SIX6, MCOPCT2|606326|14q23.1
Microphthalmia with coloboma 1 (2)|MCOPCB1|300345|Chr.X
Microphthalmia with coloboma 2 (2)|MCOPCB2|605738|15q12-q15
Microphthalmia with coloboma 3, 610092 (3)|CHX10, HOX10, MCOP2, MCOPCB3|142993|14q24.3
Microphthalmia with coloboma 5, 611638 (3)|SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36.3
Microphthalmia with coloboma 6, 613703 (3)|GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.31
Microphthalmia with coloboma 6, digenic, 613703 (3)|GDF6, MCOP4, KFS1, MCOPCB6, LCA17|601147|8q22.1
Microphthalmia with limb anomalies, 206920 (3)|SMOC1, OAS|608488|14q24.2
Microphthalmia, isolated 1 (2)|MCOP1|251600|14q32
Microphthalmia, isolated 2, 610093 (3)|CHX10, HOX10, MCOP2, MCOPCB3|142993|14q24.3
Microphthalmia, isolated 3, 611038 (3)|RAX, RX, MCOP3|601881|18q21.32
Microphthalmia, isolated 4, 613094 (3)|GDF6, MCOP4, KFS1, MCOPCB6, LCA17|601147|8q22.1
Microphthalmia, isolated 5, 611040 (3)|MFRP, MCOP5, NNO2|606227|11q23.3
Microphthalmia, isolated 6, 613517 (3)|PRSS56, MCOP6|613858|2q37.1
Microphthalmia, isolated 7, 613704 (3)|GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.31
Microphthalmia, isolated 8, 615113 (3)|ALDH1A3, ALDH6, MCOP8|600463|15q26.3
Microphthalmia, isolated, with coloboma 7, 614497 (3)|ABCB6, MTABC3, MCOPCB7, LAN, DUH3|605452|2q35
Microphthalmia, isolated, with coloboma 8, 601186 (3)|STRA6, MCOPS9, MCOPCB8|610745|15q24.1
Microphthalmia, isolated, with coloboma 9, 615145 (3)|ODZ3, TNM3, KIAA1455, MCOPCB9|610083|4q34.3-q35.1
Microphthalmia, syndromic 1 (2)|MCOPS1, MAA, LZMS|309800|Xq27-q28
Microphthalmia, syndromic 11, 614402 (3)|VAX1, MCOPS11|604294|10q25.3
Microphthalmia, syndromic 12, 615524 (3)|RARB, HAP, MCOPS12|180220|3p24.2
Microphthalmia, syndromic 13 (2)|MCOPS13|300915|Chr.X
Microphthalmia, syndromic 2, 300166 (3)|BCOR, KIAA1575, MCOPS2, MAA2, ANOP2|300485|Xp11.4
Microphthalmia, syndromic 3, 206900 (3)|SOX2, MCOPS3|184429|3q26.33
Microphthalmia, syndromic 5, 610125 (3)|OTX2, MCOPS5, CPHD6|600037|14q22.3
Microphthalmia, syndromic 6, 607932 (3)|BMP4, BMP2B1, BMP2B, MCOPS6, OFC11|112262|14q22.2
Microphthalmia, syndromic 7, 309801 (3)|HCCS, MCOPS7|300056|Xp22.2
Microphthalmia, syndromic 8 (2)|MCOPS8, MMEP|601349|6q21
Microphthalmia, syndromic 9, 601186 (3)|STRA6, MCOPS9, MCOPCB8|610745|15q24.1
Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3)|LTBP2, LTBP3, GLC3D, MSPKA, WMS3|602091|14q24.3
Microtia with nasolacrimal duct imperforation and eye coloboma (1)|MNDEC|611863|4p16-p15
Microvillus inclusion disease, 251850 (3)|MYO5B, KIAA1119|606540|18q21.1
Migraine with or without aura, susceptibility to (2)|MGR6, FHM3|607516|1q31
Migraine, familial basilar, 602481 (3)|ATP1A2, FHM2, MHP2|182340|1q23.2
Migraine, familial hemiplegic (2)|MGR6, FHM3|607516|1q31
Migraine, familial hemiplegic, 1, 141500 (3)|CACNA1A, CACNL1A4, SCA6|601011|19p13.2
Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3)|CACNA1A, CACNL1A4, SCA6|601011|19p13.2
Migraine, familial hemiplegic, 2, 602481 (3)|ATP1A2, FHM2, MHP2|182340|1q23.2
Migraine, familial hemiplegic, 3, 609634 (3)|SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24.3
Migraine, resistance to, 157300 (3)|EDNRA|131243|4q31.22
Miles-Carpenter syndrome (2)|MCS, MRXS4|309605|Xq13-q22
Miller syndrome, 263750 (3)|DHODH, URA1, POADS|126064|16q22.2
Miller-Dieker lissencephaly syndrome (4)|MDLS, MDS, MDCR, DEL17p13.3, C17DELp13.3|247200|17p13.3
Minicore myopathy with external ophthalmoplegia, 255320 (3)|RYR1, MHS, CCO|180901|19q13.2
Mirror movements 1, 157600 (3)|DCC, MRMV1|120470|18q21.2
Mirror movements 2, 614508 (3)|RAD51A, RECA, MRMV2|179617|15q15.1
Mirror-image polydactyly, 135750 (1)|MIPOL1|606850|14q13.3-q21.1
Mismatch repair cancer syndrome, 276300 (3)|MLH1, COCA2, HNPCC2|120436|3p22.2
Mismatch repair cancer syndrome, 276300 (3)|MSH2, COCA1, FCC1, HNPCC1|609309|2p21
Mismatch repair cancer syndrome, 276300 (3)|MSH6, GTBP, HNPCC5|600678|2p16.3
Mismatch repair cancer syndrome, 276300 (3)|PMS2, PMSL2, HNPCC4|600259|7p22.1
Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 (3)|TYMP, ECGF1, MNGIE, PDECGF, MEDPS1, MTDPS1|131222|22q13.33
Mitochondrial DNA depletion syndrome 11, 615084 (3)|MGME1, C20orf72, MTDPS11|615076|20p11.23
Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 (3)|SLC25A4, ANT1, T1, PEO3, PEO2, MTDPS12|103220|4q35.1
Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 (3)|FBXL4, FBL4, MTDPS13|605654|6q16.1
Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 (3)|TK2, MTDPS2|188250|16q21
Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3)|DGUOK, DGK, MTDPS3|601465|2p13.1
Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 (3)|POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q26.1
Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 (3)|POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q26.1
Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3)|SUCLA2, MTDPS5|603921|13q14.2
Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3)|MPV17, MTDPS6|137960|2p23.3
Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 (3)|C10orf2, TWINKLE, PEO1, PEOA3, IOSCA, MTDPS7|606075|10q24.31
Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3)|RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q22.3
Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3)|RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q22.3
Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3)|SUCLG1, SUCLA1, MTDPS9|611224|2p11.2
Mitochondrial complex 1 deficiency, 252010 (3)|NDUFAF5, C20orf7|612360|20p12.1
Mitochondrial complex I deficiency, 252010 (3)|FOXRED1|613622|11q24.2
Mitochondrial complex I deficiency, 252010 (3)|NDUFA1, MWFE|300078|Xq24
Mitochondrial complex I deficiency, 252010 (3)|NDUFA11|612638|19p13.3
Mitochondrial complex I deficiency, 252010 (3)|NDUFAF1, CIA30, CGI65|606934|15q15.1
Mitochondrial complex I deficiency, 252010 (3)|NDUFAF2, NDUFA12L, MMTN, B17.2L|609653|5q12.1
Mitochondrial complex I deficiency, 252010 (3)|NDUFAF3|612911|3p21.31
Mitochondrial complex I deficiency, 252010 (3)|NDUFAF4, HRPAP20, C6orf66|611776|6q16.1
Mitochondrial complex I deficiency, 252010 (3)|NDUFB3|603839|2q33.1
Mitochondrial complex I deficiency, 252010 (3)|NDUFS1|157655|2q33.3
Mitochondrial complex I deficiency, 252010 (3)|NDUFS2|602985|1q23.3
Mitochondrial complex I deficiency, 252010 (3)|NDUFS3|603846|11p11.2
Mitochondrial complex I deficiency, 252010 (3)|NDUFS4, AQDQ|602694|5q11.2
Mitochondrial complex I deficiency, 252010 (3)|NDUFV1, UQOR1|161015|11q13.2
Mitochondrial complex I deficiency, 252010 (3)|NDUFV2|600532|18p11.22
Mitochondrial complex I deficiency, 252010 (3)|NUBPL, IND1|613621|14q12
Mitochondrial complex II deficiency, 252011 (3)|SDHAF1|612848|19q13.12
Mitochondrial complex III deficiency, nuclear type 1, 124000 (3)|BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1|603647|2q35
Mitochondrial complex III deficiency, nuclear type 2, 615157 (3)|TTC19, MC3DN2|613814|17p12
Mitochondrial complex III deficiency, nuclear type 3, 615158 (3)|UQCRB, UQBP, QPC, MC3DN3|191330|8q22.1
Mitochondrial complex III deficiency, nuclear type 4, 615159 (3)|UQCRQ, QPC, MC3DN4|612080|5q31.1
Mitochondrial complex III deficiency, nuclear type 5, 615160 (3)|UQCRC2, MC3DN5|191329|16p12.2
Mitochondrial complex III deficiency, nuclear type 6, 615453 (3)|CYC1, MC3DN6|123980|8q24.3
Mitochondrial complex IV deficiency, 220110 (3)|COA5, C2orf64, PET191|613920|2q11.2
Mitochondrial complex IV deficiency, 220110 (3)|COX10|602125|17p12
Mitochondrial complex IV deficiency, 220110 (3)|COX14, C12orf62|614478|12q13.12
Mitochondrial complex IV deficiency, 220110 (3)|COX20, FAM36A|614698|1q44
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 (3)|ATPAF2, ATP12, MC5DN1|608918|17p11.2
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 (3)|TMEM70, MC5DN2|612418|8q21.11
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3, 614053 (3)|ATP5E, MC5DN3|606153|20q13.32
Mitochondrial myopathy and sideroblastic anemia 1, 600462 (3)|PUS1, MLASA1|608109|12q24.33
Mitochondrial phosphate carrier deficiency, 610773 (3)|SLC25A3, PHC|600370|12q23.1
Mitochondrial pyruvate carrier deficiency, 614741 (3)|BRP44L, MPC1, MPYCD|614738|6q27
Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 (3)|POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q26.1
Mitochondrial respiratory chain complex II deficiency, 252011 (3)|SDHA, SDH1, SDHF, CMD1GG, PGL5|600857|5p15.33
Mitral valve prolapse, myxomatous 1 (2)|MMVP1, MVP, PMV|157700|16p12.1-p11.2
Mitral valve prolapse, myxomatous 2 (2)|MMVP2|607829|11p15.4
Mitral valve prolapse, myxomatous 3 (2)|MMVP3|610840|13q31.3-q32.1
Miyoshi muscular dystrophy 1, 254130 (3)|DYSF, LGMD2B, MMD1|603009|2p13.2
Miyoshi muscular dystrophy 2 (2)|MMD2|613318|8q22.3
Miyoshi muscular dystrophy 3, 613319 (3)|ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Moebius syndrome-3 (2)|MBS3|604185|10q21.3-q22.1
Mohr-Tranebjaerg syndrome, 304700 (3)|TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22.1
Molybdenum cofactor deficiency A, 252150 (3)|MOCS1, MOCODA|603707|6p21.2
Molybdenum cofactor deficiency B, 252160 (3)|MOCS2, MPTS, MOCODB|603708|5q11.2
Molybdenum cofactor deficiency C, 615501 (3)|GPHN, GPH, KIAA1385, GEPH, MOCODC|603930|14q23.3
Monilethrix, 158000 (3)|KRT81, KRTHB1, HB1|602153|12q13.13
Monilethrix, 158000 (3)|KRT83, KRTHB3, HB3|602765|12q13.13
Monilethrix, 158000 (3)|KRT86, KRTHB6, HB6|601928|12q13.13
Monocyte and dendritic cell deficiency, recessive, 614894 (3)|IRF8, ICSBP1|601565|16q24.1
Mononeuropathy of the median nerve, mild, 613353 (3)|SH3TC2, KIAA1985, MNMN|608206|5q32
Morning glory disc anomaly, 120430 (3)|PAX6, AN2, MGDA|607108|11p13
Mosaic variegated aneuploidy syndrome 1, 257300 (3)|BUB1B, BUBR1, MVA1|602860|15q15.1
Mosaic variegated aneuploidy syndrome 2, 614114 (3)|CEP57, PIG8, TSP57, KIAA0092, MVA2|607951|11q21
Mowat-Wilson syndrome, 235730 (3)|ZEB2, ZFHX1B, SMADIP1, SIP1|605802|2q22.3
Moyamoya disease (2)|MYMY1, MYMY|252350|3p26-p24.2
Moyamoya disease 3 (2)|MYMY3|608796|8q23
Moyamoya disease 4 (4)|MYMY4, CXDELq38|300845|Xq28
Moyamoya disease 5, 614042 (3)|ACTA2, ACTSA, AAT6, MYMY5|102620|10q23.31
Muckle-Wells syndrome, 191900 (3)|NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
Mucoepidermoid salivary gland carcinoma (3)|CRTC1, MECT1, KIAA0616, FLJ14027|607536|19p13.11
Mucoepidermoid salivary gland carcinoma (3)|MAML2, MAM3|607537|11q21
Mucolipidosis II alpha/beta, 252500 (3)|GNPTAB, GNPTA|607840|12q23.2
Mucolipidosis III alpha/beta, 252600 (3)|GNPTAB, GNPTA|607840|12q23.2
Mucolipidosis III gamma, 252605 (3)|GNPTAG|607838|16p13.3
Mucolipidosis IV, 252650 (3)|MCOLN1, ML4|605248|19p13.2
Mucopolysaccharidisis type IIIA (Sanfilippo A), 252900 (3)|SGSH, MPS3A, SFMD|605270|17q25.3
Mucopolysaccharidosis II, 309900 (3)|IDS, MPS2, SIDS|300823|Xq28
Mucopolysaccharidosis IVA, 253000 (3)|GALNS, MPS4A|612222|16q24.3
Mucopolysaccharidosis Ih, 607014 (3)|IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis Ih/s, 607015 (3)|IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis Is, 607016 (3)|IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis VII, 253220 (3)|GUSB, MPS7|611499|7q11.21
Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 (3)|NAGLU, MPS3B|609701|17q21.2
Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3)|HGSNAT, TMEM76, MPS3C|610453|8p11.21
Mucopolysaccharidosis type IIID, 252940 (3)|GNS, G6S|607664|12q14.3
Mucopolysaccharidosis type IVB (Morquio), 253010 (3)|GLB1, MPS4B|611458|3p22.3
Mucopolysaccharidosis type IX, 601492 (3)|HYAL1|607071|3p21.31
Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3)|ARSB, MPS6|611542|5q14.1
Muenke syndrome, 602849 (3)|FGFR3, ACH|134934|4p16.3
Muir-Torre syndrome, 158320 (3)|MLH1, COCA2, HNPCC2|120436|3p22.2
Muir-Torre syndrome, 158320 (3)|MSH2, COCA1, FCC1, HNPCC1|609309|2p21
Mulibrey nanism, 253250 (3)|TRIM37, MUL, KIAA0898|605073|17q22
Mullerian aplasia and hyperandrogenism, 158330 (3)|WNT4, SERKAL|603490|1p36.12
Multicentric carpotarsal osteolysis syndrome, 166300 (3)|MAFB, KRML, MCTO|608968|20q12
Multicentric osteolysis, nodulosis, and arthropathy, 259600 (3)|MMP2, CLG4A, MONA|120360|16q12.2
Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3)|PIGN, MCAHS1|606097|18q21.33
Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3)|PIGA, MCAHS2|311770|Xp22.2
Multiple endocrine neoplasia 1, 131100 (3)|MEN1|613733|11q13.1
Multiple endocrine neoplasia IIA, 171400 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Multiple endocrine neoplasia IIB, 162300 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Multiple endocrine neoplasia, type IV, 610755 (3)|CDKN1B, KIP1, CDKN4, MEN4|600778|12p13.1
Multiple fibroadenomas of the breast, 615554 (3)|PRLR, MFAB, HPRL|176761|5p13.2
Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects, 245600 (3)|B3GAT3, GLCATI|606374|11q12.3
Multiple mitochondrial dysfunctions syndrome 1, 605711 (3)|NFU1, HIRIP, MMDS1|608100|2p13.3
Multiple mitochondrial dysfunctions syndrome 2, 614299 (3)|BOLA3, MMDS2|613183|2p13.1
Multiple myeloma, 254500 (3)|IRF4, LSIRF|601900|6p25.3
Multiple pterygium syndrome, lethal type, 253290 (3)|CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q31.1
Multiple pterygium syndrome, lethal type, 253290 (3)|CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q37.1
Multiple pterygium syndrome, lethal type, 253290 (3)|CHRNG, ACHRG|100730|2q37.1
Multiple sulfatase deficiency, 272200 (3)|SUMF1, FGE|607939|3p26.1
Multiple synostoses syndrome 2, 610017 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Multiple synostoses syndrome 3, 612961 (3)|FGF9, SYNS3|600921|13q12.11
Multiple synostosis syndrome 1, 186500 (3)|NOG, SYM1, SYNS1|602991|17q22
Multisystemic smooth muscle dysfunction syndrome, 613834 (3)|ACTA2, ACTSA, AAT6, MYMY5|102620|10q23.31
Mungan syndrome (2)|MGS|611376|8q23-q24
Muscle glycogenosis, 300559 (3)|PHKA1|311870|Xq13.1-q13.2
Muscle hypertrophy, 614160 (3)|GDF8, MSTN, MSLHP|601788|2q32.2
Muscle strength quantitative trait locus 1 (2)|MUSTQTL1|612083|14q24.3
Muscular dystrophy with epidermolysis bullosa simplex, 226670 (3)|PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24.3
Muscular dystrophy with rimmed vacuoles (2)|MDRV|601846|19p13.3
Muscular dystrophy, congenital merosin-deficient, 607855 (3)|LAMA2, LAMM|156225|6q22.33
Muscular dystrophy, congenital, 1B (2)|MDC1B|604801|1q42
Muscular dystrophy, congenital, 613205 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3)|ITGA7|600536|12q13.2
Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 (3)|LAMA2, LAMM|156225|6q22.33
Muscular dystrophy, congenital, megaconial type, 602541 (3)|CHKB, CHKL, CKEKB, EKB, MDCMC|612395|22q13.33
Muscular dystrophy, congenital, merosin-positive (2)|MDCMP|609456|4p16.3
Muscular dystrophy, limb-girdle, type 1A, 159000 (3)|MYOT, TTOD, MFM3|604103|5q31.2
Muscular dystrophy, limb-girdle, type 1B, 159001 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Muscular dystrophy, limb-girdle, type 1E, 603511 (3)|DNAJB6, MRJ, DJ4, LGMD1E|611332|7q36.3
Muscular dystrophy, limb-girdle, type 1F (2)|LGMD1F|608423|7q32.1-q32.2
Muscular dystrophy, limb-girdle, type 1H (2)|LGMD1H|613530|3p25.1-p23
Muscular dystrophy, limb-girdle, type 2A, 253600 (3)|CAPN3, CANP3|114240|15q15.1
Muscular dystrophy, limb-girdle, type 2B, 253601 (3)|DYSF, LGMD2B, MMD1|603009|2p13.2
Muscular dystrophy, limb-girdle, type 2C, 253700 (3)|SGCG, LGMD2C, DMDA1, SCG3|608896|13q12.12
Muscular dystrophy, limb-girdle, type 2D, 608099 (3)|SGCA, ADL, DAG2, LGMD2D, DMDA2|600119|17q21.33
Muscular dystrophy, limb-girdle, type 2E, 604286 (3)|SGCB, LGMD2E|600900|4q12
Muscular dystrophy, limb-girdle, type 2F, 601287 (3)|SGCD, SGD, LGMD2F, CMD1L|601411|5q33.2-q33.3
Muscular dystrophy, limb-girdle, type 2G, 601954 (3)|TCAP, LGMD2G, CMD1N|604488|17q12
Muscular dystrophy, limb-girdle, type 2H, 254110 (3)|TRIM32, HT2A, LGMD2H, BBS11|602290|9q33.1
Muscular dystrophy, limb-girdle, type 2J, 608807 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Muscular dystrophy, limb-girdle, type 2L, 611307 (3)|ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Muscular dystrophy, limb-girdle, type 2Q, 613723 (3)|PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24.3
Muscular dystrophy, limb-girdle, type 2S, 615356 (3)|TRAPPC11, C4orf41, LGMD2S|614138|4q35.1
Muscular dystrophy, limb-girdle, type IC, 607801 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Muscular dystrophy, rigid spine, 1, 602771 (3)|SEPN1, SELN, RSMD1, CFTD|606210|1p36.11
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 (3)|POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.13
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 (3)|TMEM5, MDDGA10|605862|12q14.2
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 (3)|B3GNT1, IGNT, IGAT, MDDGA13|605517|11q13.2
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 (3)|GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14|615320|3p21.31
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 (3)|POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 (3)|POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34.1
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 (3)|FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31.2
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 (3)|FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.32
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 (3)|LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6|603590|22q12.3
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 (3)|ISPD, MDDGA7|614631|7p21.2
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 (3)|G3GALNT2, MGC39558, MDDGA11|610194|1q42.3
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830 (3)|GTDC2, C3orf39, AGO61, MDDGA8|614828|3p22.1
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 (3)|POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.13
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 (3)|GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14|615320|3p21.31
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 (3)|POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 (3)|POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34.1
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 (3)|LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6|603590|22q12.3
Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 (3)|FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.32
Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 (3)|FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31.2
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 (3)|POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.13
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 (3)|GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14|615320|3p21.31
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 (3)|POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 (3)|POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34.1
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 (3)|FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31.2
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 (3)|FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.32
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 (3)|DAG1, DAG, MDDGC9|128239|3p21.31
Myasthenia gravis with thymus hyperplasia (2)|MYAS1|607085|6p21.3
Myasthenia gravis, neonatal transient (2)|CHRNG, ACHRG|100730|2q37.1
Myasthenia, congenital, with tubular aggregates 1, 610542 (3)|GFPT1, GFAT1, GFPT1L, MSLG, CMSTA1|138292|2p13.3
Myasthenia, familial infantile, 1 (2)|CMS1A1, FIM1|605809|17p13
Myasthenia, limb-girdle, familial, 254300 (3)|AGRN|103320|1p36.33
Myasthenia, limb-girdle, familial, 254300 (3)|DOK7, C4orf25, CMS1B|610285|4p16.3
Myasthenic syndrome, acetazolamide-responsive, 614198 (3)|SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.3
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)|CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D|100710|17p13.1
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)|CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13.2
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)|MUSK|601296|9q31.3
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)|RAPSN, CMS1D, CMS1E|601592|11p11.2
Myasthenic syndrome, congenital, associated with episodic apnea, 254210 (3)|CHAT, CMS1A2|118490|10q11.23
Myasthenic syndrome, congenital, associated with facial dysmorphism and acetylcholine receptor deficiency, 608931 (3)|RAPSN, CMS1D, CMS1E|601592|11p11.2
Myasthenic syndrome, congenital, with tubular aggregates 2, 614750 (3)|DPAGT1, DPAGT2, DGPT, CDG1J, CMSTA2|191350|11q23.3
Myasthenic syndrome, fast-channel congenital, 608930 (3)|CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q31.1
Myasthenic syndrome, fast-channel congenital, 608930 (3)|CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q37.1
Myasthenic syndrome, fast-channel congenital, 608930 (3)|CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13.2
Myasthenic syndrome, slow-channel congenital, 601462 (3)|CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q31.1
Myasthenic syndrome, slow-channel congenital, 601462 (3)|CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D|100710|17p13.1
Myasthenic syndrome, slow-channel congenital, 601462 (3)|CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q37.1
Myasthenic syndrome, slow-channel congenital, 601462 (3)|CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13.2
Mycobacterial and viral infections, susceptibility to, autosomal recessive, 613796 (3)|STAT1, CANDF7|600555|2q32.2
Mycobacterial infection, atypical, familial disseminated, 209950 (3)|IFNGR1|107470|6q23.3
Mycobacterial infection, atypical, familial disseminated, 209950 (3)|STAT1, CANDF7|600555|2q32.2
Myelodysplasia and leukemia syndrome with monosomy 7 (4)|MLSM7, DEL7q, C7DELq|252270|7q
Myelodysplasia syndrome-1 (3)|MDS1|600049|3q26
Myelodysplastic syndrome (3)|ACSL6, FACL6, ACS2|604443|5q31.1
Myelodysplastic syndrome, preleukemic (3)|IRF1, MAR|147575|5q31.1
Myelodysplastic syndrome, somatic, 614286 (3)|ASXL1, KIAA0978, BOPS, MDS|612990|20q11.21
Myelodysplastic syndrome, somatic, 614286 (3)|SF3B1, SF3B155, SAP155, MDS|605590|2q33.1
Myelodysplastic syndrome, somatic, 614286 (3)|TET2, KIAA1546, MDS|612839|4q24
Myelofibrosis with myeloid metaplasia, somatic, 254450 (3)|MPL, TPOR, MPLV, THCYT2|159530|1p34.2
Myelofibrosis, somatic, 254450 (3)|CALR, SSA|109091|19p13.2
Myelofibrosis, somatic, 254450 (3)|JAK2, THCYT3|147796|9p24.1
Myelofibrosis, somatic, 254450 (3)|SH2B3, LNK|605093|12q24.12
Myelogenous leukemia, acute (3)|ACSL6, FACL6, ACS2|604443|5q31.1
Myelogenous leukemia, acute (3)|IRF1, MAR|147575|5q31.1
Myeloid leukemia, acute, M4/M4Eo subtype, somatic, 601626 (1)|CBFB, PEBP2B|121360|16q22.1
Myelokathexis, isolated (3)|CXCR4, D2S201E, NPY3R, WHIM|162643|2q22.1
Myeloperoxidase deficiency, 254600 (3)|MPO|606989|17q22
Myeloproliferative disorder (2)|FGFR1OP, FOP|605392|6q27
Myeloproliferative disorder with eosinophilia, 131440 (4)|PDGFRB, PDGFR, IBGC4, IMF1|173410|5q32
Myhre syndrome, 139210 (3)|MADH4, DPC4, SMAD4, JIP, MYHRS|600993|18q21.2
Myoclonic epilepsy, infantile, familial, 605021 (3)|TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86|613577|16p13.3
Myoclonic epilepsy, juvenile, 4 (2)|EJM4|611364|5q12-q14
Myoclonus, familial cortical, 614937 (3)|NOL3, NOP, MYC, ARC, FCM|605235|16q22.1
Myofibromatosis, infantile, 1, 228550 (3)|PDGFRB, PDGFR, IBGC4, IMF1|173410|5q32
Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3)|LPIN1|605518|2p25.1
Myokymia, 121200 (3)|KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.33
Myopathy congenital, with fiber-type disproportion, 255310 (3)|TPM3, NEM1, CFTD, CAPM1|191030|1q21.3
Myopathy due to CPT II deficiency, 255110 (3)|CPT2, IIAE4|600650|1p32.3
Myopathy due to myoadenylate deaminase deficiency, 615511 (3)|AMPD1, MMDD|102770|1p13.2
Myopathy with extrapyramidal signs, 615673 (3)|MICU1, CBARA1, MPXPS|605084|10q22.1
Myopathy with lactic acidosis, hereditary, 255125 (3)|ISCU, HML|611911|12q23.3
Myopathy, X-linked, with excessive autophagy (2)|MEAX, XMEA|310440|Xq28
Myopathy, X-linked, with postural muscle atrophy, 300696 (3)|FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq26.3
Myopathy, actin, congenital, with cores, 161800 (3)|ACTA1, ASMA, NEM3, CFTD1|102610|1q42.13
Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3)|ACTA1, ASMA, NEM3, CFTD1|102610|1q42.13
Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 (3)|MEGF10, KIAA1780, EMARDD|612453|5q23.2
Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 (3)|MEGF10, KIAA1780, EMARDD|612453|5q23.2
Myopathy, centronuclear, 160150 (3)|DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5|602378|19p13.2
Myopathy, centronuclear, 3, 614408 (3)|MYF6, CNM3|159991|12q21.31
Myopathy, centronuclear, 4, 614807 (3)|CCDC78, C16orf25, CNM4|614666|16p13.3
Myopathy, centronuclear, autosomal recessive, 255200 (3)|BIN1, AMPHL|601248|2q14.3
Myopathy, congenital, Compton-North, 612540 (3)|CNTN1|600016|12q12
Myopathy, congenital, with fiber-type disproportion 1, 255310 (3)|ACTA1, ASMA, NEM3, CFTD1|102610|1q42.13
Myopathy, congenital, with fiber-type disproportion, 255310 (3)|SEPN1, SELN, RSMD1, CFTD|606210|1p36.11
Myopathy, congenital, with fiber-type disproportion, X-linked (2)|CFTDX|300580|Xq13.1-q22.1
Myopathy, distal 2, 606070 (3)|MATR3, MPD2|164015|5q31.2
Myopathy, distal 3 (2)|MPD3|610099|8p22-q11
Myopathy, distal, 4, 614065 (3)|FLNC, FLN2, ABPA, ABPL, MFM5, MPD4|102565|7q32.1
Myopathy, distal, Tateyama type, 614321 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Myopathy, distal, with anterior tibial onset, 606768 (3)|DYSF, LGMD2B, MMD1|603009|2p13.2
Myopathy, early-onset, with fatal cardiomyopathy, 611705 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Myopathy, hyaline body (2)|MHB|255160|3p22.2-p21.32
Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3)|YARS2, TYRRS, MLASA2|610957|12p11.21
Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 (3)|GFER, ERV1, ALR|600924|16p13.3
Myopathy, myofibrillar, 1, 601419 (3)|DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R|125660|2q35
Myopathy, myofibrillar, 2, 608810 (3)|CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2|123590|11q23.1
Myopathy, myofibrillar, 3, 609200 (3)|MYOT, TTOD, MFM3|604103|5q31.2
Myopathy, myofibrillar, 4, 609452 (3)|LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3, MFM4|605906|10q23.2
Myopathy, myofibrillar, 5, 609524 (3)|FLNC, FLN2, ABPA, ABPL, MFM5, MPD4|102565|7q32.1
Myopathy, myofibrillar, 6, 612954 (3)|BAG3, MFM6|603883|10q26.11
Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 (3)|CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2|123590|11q23.1
Myopathy, myosin storage, 608358 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Myopathy, proximal, with early respiratory muscle involvement, 603689 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Myopathy, reducing body, X-linked, childhood-onset, 300718 (3)|FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq26.3
Myopathy, reducing body, X-linked, severe early-onset, 300717 (3)|FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq26.3
Myopathy, spheroid body, 182920 (3)|MYOT, TTOD, MFM3|604103|5q31.2
Myopathy, tubular aggregate, 160565 (3)|STIM1, TAM, IMD10|605921|11p15.4
Myopia 10 (2)|MYP10|609259|8p23
Myopia 11 (2)|MYP11|609994|4q22-q27
Myopia 12 (2)|MYP12|609995|2q37.1
Myopia 13 (2)|MYP13|300613|Xq23-q27.2
Myopia 14 (2)|MYP14|610320|1p36
Myopia 15 (2)|MYP15|612717|10q21.1
Myopia 16 (2)|MYP16|612554|5p15.33-p15.2
Myopia 17 (2)|MYP17, MYP4|608367|7p15
Myopia 18 (2)|MYP18|255500|14q22.1-q24.2
Myopia 19 (2)|MYP19|613969|5p15.1-p13.3
Myopia 20, autosomal dominant (2)|MYP20|614166|13q12.12
Myopia 21, autosomal dominant, 614167 (3)|ZNF644, MYP21|614159|1p22.2
Myopia 22, autosomal dominant, 615420 (3)|CCDC111, MYP22|615421|4q35.1
Myopia 23, autosomal recessive, 615431 (3)|LRPAP1, A2MRAP, MYP23|104225|4p16.3
Myopia 5 (2)|MYP5|608474|17q21-q22
Myopia 6, 608908 (3)|SCO2, CEMCOX1, MYP6|604272|22q13.33
Myopia 7 (2)|MYP7|609256|11p13
Myopia 8 (2)|MYP8|609257|3q26
Myopia 9 (2)|MYP9|609258|4q12
Myopia, high, with cataract and vitreoretinal degeneration, 614292 (3)|LEPREL1, P3H2, MCVD|610341|3q28
Myopia-1 (2)|MYP1|310460|Xq28
Myopia-2 (2)|MYP2|160700|18p11.31
Myopia-3 (2)|MYP3|603221|12q21-q23
Myopia-6 (2)|MYP6|608908|22q12
Myosclerosis, congenital, 255600 (3)|COL6A2|120240|21q22.3
Myotonia congenita, atypical, acetazolamide-responsive, 608390 (3)|SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.3
Myotonia congenita, dominant, 160800 (3)|CLCN1|118425|7q34
Myotonia congenita, recessive, 255700 (3)|CLCN1|118425|7q34
Myotonia levior, recessive (3)|CLCN1|118425|7q34
Myotonic dystrophy 1, 160900 (3)|DMPK, DM, DMK|605377|19q13.32
Myotonic dystrophy 2, 602668 (3)|ZNF9, CNBP1, DM2, PROMM|116955|3q21.3
Myotubular myopathy, X-linked, 310400 (3)|MTM1, MTMX|300415|Xq28
Myxoid liposarcoma, 613488 (1)|DDIT3, GADD153, CHOP10|126337|12q13.3
Myxoma, intracardiac, 255960 (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
N-acetylglutamate synthase deficiency, 237310 (3)|NAGS|608300|17q21.31
N-terminal acetyltransferase deficiency, 300855 (3)|NAA10, ARD1A, ARD1, TE2, NATD, MCOPS1|300013|Xq28
NOR polyagglutination syndrome, 111400 (3)|A4GALT, P1PK|607922|22q13.2
Nablus mask-like facial syndrome (4)|NMLFS, DEL8q22.1, C8DELq22.1|608156|8q22.1
Naegeli-Franceschetti-Jadassohn syndrome, 161000 (3)|KRT14|148066|17q21.2
Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 (3)|FZD6, NDNC10|603409|8q22.3
Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3)|PLCD1, NDNC3|602142|3p22.2
Nail disorder, nonsyndromic congenital, 9 (2)|NDNC9|614149|17q25.1-q25.3
Nail dysplasia, isolated congenital (2)|NDIC|605779|17p13
Nail-patella syndrome, 161200 (3)|LMX1B, NPS1|602575|9q33.3
Nance-Horan syndrome, 302350 (3)|NHS, CXN, CTRCT40|300457|Xp22.13
Nanophthalmos 2, 609549 (3)|MFRP, MCOP5, NNO2|606227|11q23.3
Nanophthalmos 3 (2)|NNO3|611897|2q11-q14
Nanophthalmos-1 (2)|NNO1|600165|11p
Narcolepsy 1, 161400 (3)|HCRT, OX, NRCLP1|602358|17q21.2
Narcolepsy 2 (2)|NRCLP2|605841|4p13-q21
Narcolepsy 3 (2)|NRCLP3|609039|21q11.2
Narcolepsy 6 (2)|NRCLP6|614223|19p13.2
Narcolepsy 7, 614250 (3)|MOG, NRCLP7|159465|6p22.1
Nasopharyngeal carcinoma, 607107 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Nasu-Hakola disease, 221770 (3)|TREM2|605086|6p21.1
Nasu-Hakola disease, 221770 (3)|TYROBP, PLOSL, DAP12|604142|19q13.12
Native American myopathy, 255995 (3)|STAC3, NAM|615521|12q13.3
Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 (3)|MCM4, NKGCD, NKCD|602638|8q11.21
Naxos disease, 601214 (3)|JUP, DP3, PDGB, ARVD12|173325|17q21.2
Nemaline myopathy 1, autosomal dominant or recessive, 609284 (3)|TPM3, NEM1, CFTD, CAPM1|191030|1q21.3
Nemaline myopathy 2, autosomal recessive, 256030 (3)|NEB, NEM2|161650|2q23.3
Nemaline myopathy 3, autosomal dominant or recessive, 161800 (3)|ACTA1, ASMA, NEM3, CFTD1|102610|1q42.13
Nemaline myopathy 4, autosomal dominant, 609285 (3)|TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.3
Nemaline myopathy 5, Amish type, 605355 (3)|TNNT1, ANM, NEM5|191041|19q13.42
Nemaline myopathy 6, autosomal dominant, 609273 (3)|KBTBD13, NEM6|613727|15q22.31
Nemaline myopathy 7, autosomal recessive, 610687 (3)|CFL2, NEM7|601443|14q13.1
Nemaline myopathy 8, autosomal recessive, 615348 (3)|KLHL40, SYRP, KBTBD5, NEM8|615340|3p22.1
Nephrogenic syndrome of inappropriate antidiuresis, 300539 (3)|AVPR2, DIR, DI1, ADHR|300538|Xq28
Nephrolithiasis, type I, 310468 (3)|CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.23-p11.22
Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3)|SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2|182309|5q35.3
Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3)|SLC9A3R1, EBP50, NHERF1, NPHLOP2|604990|17q25.1
Nephronophthisis 1, juvenile, 256100 (3)|NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Nephronophthisis 11, 613550 (3)|TMEM67, MKS3, JBTS6, NPHP11|609884|8q22.1
Nephronophthisis 12, 613820 (3)|TTC21B, THM1, NPHP12, SRTD4, ATD4|612014|2q24.3
Nephronophthisis 13, 614377 (3)|WDR19, SRTD5, ATD5, NPHP13, CED4|608151|4p14
Nephronophthisis 14, 614844 (3)|ZNF423, ZFP423, OAZ, KIAA0760, NPHP14, JBTS19|604557|16q12.1
Nephronophthisis 15, 614845 (3)|CEP164, KIAA1052|614848|11q23.3
Nephronophthisis 16, 615382 (3)|ANKS6, PKDR1, NPHP16|615370|9q22.33
Nephronophthisis 2, infantile, 602088 (3)|INVS, INV, NPHP2, NPH2|243305|9q31.1
Nephronophthisis 3, 604387 (3)|NPHP3, NPH3, RHPD1, MKS7|608002|3q22.1
Nephronophthisis 4, 606966 (3)|NPHP4, SLSN4|607215|1p36.31
Nephronophthisis 7, 611498 (3)|GLIS2, NPHP7|608539|16p13.3
Nephronophthisis-like nephropathy 1, 613159 (3)|XPNPEP3, APP3, NPHPL1|613553|22q13.2
Nephropathy due to CFHR5 deficiency, 614809 (3)|CFHR5, CFHL5, FHR5, CFHR5D|608593|1q31.3
Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3)|CD151, PETA3, SFA1, MER2|602243|11p15.5
Nephropathy, progressive, with deafness (2)|NEDE|609469|11q24
Nephropathy-hypertension (2)|RFH1, AORF|161900|1q21
Nephrotic syndrome, type 1, 256300 (3)|NPHS1, NPHN|602716|19q13.12
Nephrotic syndrome, type 2, 600995 (3)|PDCN, NPHS2, SRN1|604766|1q25.2
Nephrotic syndrome, type 3, 610725 (3)|PLCE1, KIAA1516, NPHS3|608414|10q23.33
Nephrotic syndrome, type 4, 256370 (3)|WT1, NPHS4|607102|11p13
Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3)|LAMB2, LAMS, NPHS5|150325|3p21.31
Nephrotic syndrome, type 6, 614196 (3)|PTPRO, GLEPP1, NPHS6|600579|12p12.3
Nephrotic syndrome, type 7, 615008 (3)|DGKE, NPHS7|601440|17q22
Nephrotic syndrome, type 9, 615573 (3)|ADCK4, NPHS9|615567|19q13.2
Nestor-Guillermo progeria syndrome, 614008 (3)|BANF1, BAF, NGPS|603811|11q13.1
Netherton syndrome, 256500 (3)|SPINK5, LEKTI|605010|5q32
Neural tube defects, 182940 (3)|FUZ, NTD|610622|19q13.33
Neural tube defects, 182940 (3)|VANGL1, STBM2|610132|1p13.1
Neural tube defects, 182940 (3)|VANGL2, LTAP|600533|1q23.2
Neuroaxonal neurodegeneration, infantile, with facial dysmophism, 615419 (3)|NALCN, INNFD|611549|13q33.1
Neuroblastoma with Hirschsprung disease, 613013 (3)|PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p13
Neuroblastoma, 256700 (3)|NME1, NM23|156490|17q21.33
Neurodegeneration due to cerebral folate transport deficiency, 613068 (3)|FOLR1|136430|11q13.4
Neurodegeneration with brain iron accululation 5, 300894 (3)|WDR45, WIPI4, NBIA5|300526|Xp11.23
Neurodegeneration with brain iron accumulation 1, 234200 (3)|PANK2, NBIA1, PKAN, HARP|606157|20p13
Neurodegeneration with brain iron accumulation 2B, 610217 (3)|PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Neurodegeneration with brain iron accumulation 3, 606159 (3)|FTL, NBIA3, LFTD|134790|19q13.33
Neurodegeneration with brain iron accumulation 4, 614298 (3)|C19orf12, NBIA4, SPG43|614297|19q12
Neurodegeneration with brain iron accumulation 6, 615643 (3)|COASY, NBIA6|609855|17q21.2
Neuroepithelioma, 612219 (3)|EWSR1, EWS|133450|22q12.2
Neurofibromatosis, familial spinal, 162210 (3)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibromatosis, type 1, 162200 (3)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibromatosis, type 2, 101000 (3)|NF2|607379|22q12.2
Neurofibromatosis-Noonan syndrome, 601321 (3)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibrosarcoma (3)|MXI1|600020|10q25.2
Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 (3)|RYR1, MHS, CCO|180901|19q13.2
Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 (3)|HINT1, PRKCNH1, NMAN|601314|5q23.3
Neuronopathy, distal hereditary motor, type I (2)|DHMN1|182960|7q34-q36
Neuronopathy, distal hereditary motor, type IIC, 613376 (3)|HSPB3, HSPL27, HMN2C, DHMN2C|604624|5q11.2
Neuronopathy, distal hereditary motor, type IID, 615575 (3)|FBXO38, FBX38, MOKA, HMN2D|608533|5q32
Neuronopathy, distal hereditary motor, type VB, 614751 (3)|REEP1, C2ORF23, SPG31, HMN5B|609139|2p11.2
Neuronopathy, distal hereditary motor, type VI, 604320 (3)|IGHMBP2, SMUBP2, CATF1, SMARD1, HMN6|600502|11q13.3
Neuronopathy, distal hereditary motor, type VIIA, 158580 (3)|SLC5A7, CHT1, HMN7A|608761|2q12.3
Neuropathy, congenital hypomyelinating, 1, 605253 (3)|EGR2, KROX20|129010|10q21.3
Neuropathy, congenital hypomyelinating, 605253 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Neuropathy, distal hereditary motor, Jerash type (2)|HMNJ, MNDJ|605726|9p21.1-p12
Neuropathy, distal hereditary motor, type IIA, 158590 (3)|HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A|608014|12q24.23
Neuropathy, distal hereditary motor, type IIB, 608634 (3)|HSPB1, HSP27, CMT2F, HMN2B|602195|7q11.23
Neuropathy, distal hereditary motor, type VA, 600794 (3)|BSCL2, SPG17, HMN5|606158|11q12.3
Neuropathy, distal hereditary motor, type VA, 600794 (3)|GARS, SMAD1, CMT2D, HMN5|600287|7p14.3
Neuropathy, distal hereditary motor, type VIIB, 607641 (3)|DCTN1, HMN7B|601143|2p13.1
Neuropathy, hereditary motor and sensory, Russe type, 605285 (3)|HK1, HKD, HMSNR|142600|10q22.1
Neuropathy, hereditary sensory and autonomic, type IA, 162400 (3)|SPTLC1, LBC1, SPT1, HSN1, HSAN|605712|9q22.31
Neuropathy, hereditary sensory and autonomic, type IC, 613640 (3)|SPTLC2, KIAA0526, SPT2, LCB2, HSN1C, NSAN1C|605713|14q24.3
Neuropathy, hereditary sensory and autonomic, type II, 201300 (3)|WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2|605232|12p13.33
Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3)|FAM134B, HSAN2B|613114|5p15.1
Neuropathy, hereditary sensory and autonomic, type V, 608654 (3)|NGFB, HSAN5|162030|1p13.2
Neuropathy, hereditary sensory and autonomic, type VI, 614653 (3)|DST, BPAG1, DMH, D6S1101, HSAN6, EBSB2|113810|6p12.1
Neuropathy, hereditary sensory and autonomic, type VII, 615548 (3)|SCN11A, HSAN7, FEPS3|604385|3p22.2
Neuropathy, hereditary sensory, type IB (2)|HSN1B|608088|3p24-p22
Neuropathy, hereditary sensory, type ID, 613708 (3)|ATL1, SPG3A, HSN1D|606439|14q22.1
Neuropathy, hereditary sensory, type IE, 614116 (3)|DNMT1, MCMT, HSN1E, ADCADN|126375|19p13.2
Neuropathy, hereditary sensory, type IF, 615632 (3)|ATL3, HSN1F|609369|11q12.3-q13.1
Neuropathy, hereditary sensory, type IIC, 614213 (3)|KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9|601255|2q37.3
Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3)|CCT5, KIAA0098, CCTE|610150|5p15.2
Neuropathy, inflammatory demyelinating, 139393 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Neuropathy, motor and sensory, Russe type (2)|NMSR, HMSNR|605285|10q23.2
Neuropathy, paraneoplastic sensory (1)|ELAVL4, HUD, PNEM|168360|1p33
Neuropathy, recurrent, with pressure palsies, 162500 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Neutral lipid storage disease with myopathy, 610717 (3)|PNPLA2, TTS2, ATGL|609059|11p15.5
Neutropenia, alloimmune neonatal (3)|FCGR3B|610665|1q23.3
Neutropenia, cyclic, 162800 (3)|ELANE, ELA2, SCN1|130130|19p13.3
Neutropenia, neonatal alloimmune (1)|LAG5|151450|Chr.4
Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3)|GFI1, ZNF163, SCN2|600871|1p22.1
Neutropenia, severe congenital 1, autosomal dominant, 202700 (3)|ELANE, ELA2, SCN1|130130|19p13.3
Neutropenia, severe congenital 2, autosomal dominant, 613107 (3)|GFI1, ZNF163, SCN2|600871|1p22.1
Neutropenia, severe congenital 3, autosomal recessive, 610738 (3)|HAX1, SCN3|605998|1q21.3
Neutropenia, severe congenital 4, autosomal recessive, 612541 (3)|G6PC3, UGRP, SCN4|611045|17q21.31
Neutropenia, severe congenital, 5, autosomal recessive, 615285 (3)|VPS45A, VPS45, SCN5|610035|1q21.2
Neutropenia, severe congenital, X-linked, 300299 (3)|WAS, IMD2, THC1, SCNX|300392|Xp11.23
Neutrophil immunodeficiency syndrome, 608203 (3)|RAC2|602049|22q13.1
Neutrophilia, hereditary, 162830 (3)|CSF3R, GCSFR|138971|1p34.3
Nevus, epidermal, somatic, 162900 (3)|FGFR3, ACH|134934|4p16.3
Nevus, epidermal, somatic, 162900 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Newfoundland rod-cone dystrophy, 607476 (3)|RLBP1|180090|15q26.1
Nicolaides-Baraitser syndrome, 601358 (3)|SMARCA2, SNF2L2, NCBRS|600014|9p24.3
Niemann-Pick disease, type A, 257200 (3)|SMPD1, NPD|607608|11p15.4
Niemann-Pick disease, type B, 607616 (3)|SMPD1, NPD|607608|11p15.4
Niemann-Pick disease, type C1, 257220 (3)|NPC1, NPC|607623|18q11.2
Niemann-Pick disease, type D, 257220 (3)|NPC1, NPC|607623|18q11.2
Niemann-pick disease, type C2, 607625 (3)|NPC2, HE1|601015|14q24.3
Night blindness, congenital stationary (complete), 1A, X-linked, 310500 (3)|NYX, CSNB1A, NBM1|300278|Xp11.4
Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 (3)|GRM6, MGLUR6, CSNB1B|604096|5q35.3
Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 (3)|TRPM1, MLSN1, CSNB1C|603576|15q13.3
Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 (3)|SLC24A1, NCKX1, CSNB1D|603617|15q22.31
Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 (3)|GPR179, GPR158L, GPR158L1, CSNB1E|614515|17q12
Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 (3)|LRIT3, FIGLER4, CSNB1F|615004|4q25
Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 (3)|CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Night blindness, congenital stationary (incomplete), 2B, autosomal recessive, 610427 (3)|CABP4, CSNB2B|608965|11q13.2
Night blindness, congenital stationary, autosomal dominant 1, 610445 (3)|RHO, RP4, OPN2, CSNBAD1|180380|3q22.1
Night blindness, congenital stationary, autosomal dominant 2, 163500 (3)|PDE6B, PDEB, RP40, CSNBAD2|180072|4p16.3
Night blindness, congenital stationary, autosomal dominant 3, 610444 (3)|GNAT1, CSNBAD3|139330|3p21.31
Nijmegen breakage syndrome, 251260 (3)|NBS1, NBS|602667|8q21.3
Nijmegen breakage syndrome-like disorder, 613078 (3)|RAD50, NBSLD|604040|5q31.1
Non-Hodgkin lymphoma, somatic, 605027 (3)|CASP10, MCH4, ALPS2|601762|2q33.1
Nonaka myopathy, 605820 (3)|GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3)|EGFR|131550|7p11.2
Nonsmall cell lung cancer, somatic (3)|BRAF, NS7|164757|7q34
Nonsmall cell lung cancer, somatic, 211980 (3)|IRF1, MAR|147575|5q31.1
Nonsmall cell lung cancer, somatic, 211980 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Noonan syndrome 1, 163950 (3)|PTPN11, PTP2C, SHP2, NS1|176876|12q24.13
Noonan syndrome 3, 609942 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Noonan syndrome 4, 610733 (3)|SOS1, GINGF, GF1, HGF, NS4|182530|2p22.1
Noonan syndrome 5, 611553 (3)|RAF1, CRAF, NS5|164760|3p25.2
Noonan syndrome 6, 613224 (3)|NRAS, ALPS4, NS6|164790|1p13.2
Noonan syndrome 7, 613706 (3)|BRAF, NS7|164757|7q34
Noonan syndrome 8, 615355 (3)|RIT1, RIT, ROC1, NS8|609591|1q22
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3)|CBL, CBL2, NSLL|165360|11q23.3
Noonan-like syndrome with loose anagen hair, 607721 (3)|SHOC2, SIAA0862, SOC2, SUR8|602775|10q25.2
Norrie disease, 310600 (3)|NDP, ND|300658|Xp11.3
Norum disease, 245900 (3)|LCAT|606967|16q22.1
Nystagmus 1, congenital, X-linked, 310700 (3)|FRMD7, NYS1, XIPAN|300628|Xq26.2
Nystagmus 3, congenital (2)|NYS3|608345|7p11.2
Nystagmus 4, congenital (2)|NYS4|193003|13q31-q33
Nystagmus 5, congenital, X-linked (2)|NYS5|300589|Xp11.4
Nystagmus 6, congenital, X-linked, 300814 (3)|GPR143, OA1, NYS6|300808|Xp22.2
Nystagmus 7, congenital (2)|NYS7|614826|1q31.3-q32.1
Nystagmus, infantile periodic alternating, X-linked, 310700 (3)|FRMD7, NYS1, XIPAN|300628|Xq26.2
Nystagmus-2, autosomal dominant (2)|NYS2, NYSA|164100|6p12
OI type II, 166210 (3)|COL1A1|120150|17q21.33
OI type III, 259420 (3)|COL1A1|120150|17q21.33
OI type IV, 166220 (3)|COL1A1|120150|17q21.33
OKT4 epitope deficiency, 613949 (3)|CD4|186940|12p13.31
Obesity with impaired prohormone processing, 600955 (3)|PCSK1, NEC1, PC1, PC3, BMIQ12|162150|5q15
Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 (3)|POMC|176830|2p23.3
Obesity, autosomal dominant, 601665 (3)|MC4R|155541|18q21.32
Obesity, hyperphagia, and developmental delay (3)|AKR1C2, DDH2, DD2, HAKRD, SRXY8|600450|10p15.1
Obesity, hyperphagia, and developmental delay, 613886 (3)|NTRK2, TRKB|600456|9q21.33
Obesity, mild, early-onset, 601665 (3)|NR0B2, SHP|604630|1p36.11
Obesity, morbid, due to leptin deficiency, 614962 (3)|LEP, OB, LEPD|164160|7q32.1
Obesity, morbid, due to leptin receptor deficiency, 614963 (3)|LEPR, OBR, LEPRD|601007|1p31.3
Obesity, severe, 601665 (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
Obesity, severe, 601665 (3)|SIM1|603128|6q16.3
Occipital horn syndrome, 304150 (3)|ATP7A, MNK, MK, OHS, SMAX3|300011|Xq21.1
Occult macular dystrophy, 613587 (3)|RP1L1|608581|8p23.1
Ocular albinism with sensorineural deafness (2)|OASD|300650|Xp22.3
Ocular albinism, type I, Nettleship-Falls type, 300500 (3)|GPR143, OA1, NYS6|300808|Xp22.2
Oculoauricular syndrome, 612109 (3)|HMX1, H6|142992|4p16.1
Oculodentodigital dysplasia, 164200 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Oculodentodigital dysplasia, autosomal recessive, 257850 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Oculomotor apraxia, congenital, Cogan-type (2)|COMA|257550|2q13
Oculopharyngeal muscular dystrophy, 164300 (3)|PABPN1, PABP2, PAB2|602279|14q11.2
Odontohypophosphatasia, 146300 (3)|ALPL, HOPS, TNSALP|171760|1p36.12
Odontoonychodermal dysplasia, 257980 (3)|WNT10A, SSPS, STHAG4, OODD|606268|2q35
Oguchi disease-1, 258100 (3)|SAG, RP47|181031|2q37.1
Oguchi disease-2, 613411 (3)|GRK1, RHOK, RK|180381|13q34
Ohdo syndrome, X-linked, 300895 (3)|MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX|300188|Xq13.1
Oligodontia-colorectal cancer syndrome, 608615 (3)|AXIN2, ODCRCS|604025|17q24.1
Olmsted syndrome, 614594 (3)|TRPV3, OLMS|607066|17p13.2
Omenn syndrome, 603554 (3)|DCLRE1C, ARTEMIS, SCIDA|605988|10p13
Omenn syndrome, 603554 (3)|RAG1|179615|11p12
Omenn syndrome, 603554 (3)|RAG2|179616|11p12
Omodysplasia 1, 258315 (3)|GPC6, OMIMD1|604404|13q31.3-q32.1
Omphalocele due to duplication of 1p31.3 (4)|OPHLC, C1DUPp31.3, DUP1p31.3|164750|1p31.3
Opitz GBBB syndrome, type I, 300000 (3)|MID1, OGS1, BBBG1, FXY, OSX|300552|Xp22.2
Opitz GBBB syndrome, type II (4)|OGS2, BBBG2, GBBB2|145410|22q11.2
Opitz-Kaveggia syndrome, 305450 (3)|MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX|300188|Xq13.1
Opremazole poor metabolizer, 609535 (3)|CYP2C, CYP2C19|124020|10q23.33
Opsismodysplasia, 258480 (3)|INPPL1, OPSMD|600829|11q13.4
Optic atrophy 1, 165500 (3)|OPA1, NTG, NPG|605290|3q29
Optic atrophy 2, X-linked (2)|OPA2|311050|Xp11.4-p11.21
Optic atrophy 3 with cataract, 165300 (3)|OPA3, MGA3|606580|19q13.32
Optic atrophy 5 (2)|OPA5|610708|22q12.1-q13.1
Optic atrophy 6 (2)|OPA6|258500|8q21-q22
Optic atrophy plus syndrome, 125250 (3)|OPA1, NTG, NPG|605290|3q29
Optic atrophy-4 (2)|OPA4|605293|18q12.2-q12.3
Optic atrophy-7, 612989 (3)|TMEM126A, OPA7|612988|11q14.1
Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3)|SOX2, MCOPS3|184429|3q26.33
Optic nerve hypoplasia, 165550 (3)|PAX6, AN2, MGDA|607108|11p13
Oral-facial-digital syndrome 1, 311200 (3)|OFD1, CXorf5, SGBS2, JBTS10, RP23|300170|Xp22.2
Ornithine transcarbamylase deficiency, 311250 (3)|OTC|300461|Xp11.4
Orofacial cleft 10, 613705 (3)|SUMO1, UBL1, SMT3, OFC10|601912|2q33.1
Orofacial cleft 11, 600625 (3)|BMP4, BMP2B1, BMP2B, MCOPS6, OFC11|112262|14q22.2
Orofacial cleft 12 (2)|OFC12|612858|8q24.3
Orofacial cleft 13 (2)|OFC13|613857|1p33
Orofacial cleft 4 (2)|OFC4|608371|4q21-q31
Orofacial cleft 5, 608874 (3)|MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3|142983|4p16.2
Orofacial cleft 6, 608864 (3)|IRF6, VWS, LPS, PIT, PPS1, OFC6|607199|1q32.2
Orofacial cleft 7, 225060 (3)|HVEC, PVRL1, PVRR1, PRR1, ED4, OFC7, CLPED1|600644|11q23.3
Orofacial cleft 8, 129400 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Orofacial cleft 9 (2)|OFC9|610361|13q33.1-q34
Orofacial cleft-1 (2)|OFC1, CL|119530|6p24.3
Orofacial cleft-2 (2)|OFC2|602966|2p13
Orofacial cleft-3 (2)|OFC3|600757|19q13
Orofaciodigital syndrome IV, 258860 (3)|TCTN3, TECT3, C10orf61, OFD4, JBTS18|613847|10q24.1
Orofaciodigital syndrome V, 174300 (3)|DDX59, OFD5|615464|1q32.1
Orolaryngeal cancer, multiple, (3)|CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21.3
Orotic aciduria, 258900 (3)|UMPS, OPRT|613891|3q21.2
Orthostatic hypotensive disorder of Streeten (2)|OHDS|143850|18q
Orthostatic intolerance, 604715 (3)|SLC6A2, NAT1, NET1|163970|16q12.2
Osseous heteroplasia, progressive, 166350 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Ossification of posterior longitudinal ligament of spine, 602475 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
Osteoarthritis with mild chondrodysplasia, 604864 (3)|COL2A1|120140|12q13.11
Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 (3)|ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Osteogenesis imperfecta, type I, 166200 (3)|COL1A1|120150|17q21.33
Osteogenesis imperfecta, type II, 166210 (3)|COL1A2|120160|7q21.3
Osteogenesis imperfecta, type III, 259420 (3)|COL1A2|120160|7q21.3
Osteogenesis imperfecta, type IV, 166220 (3)|COL1A2|120160|7q21.3
Osteogenesis imperfecta, type IX, 259440 (3)|PPIB, CYPB, OI9|123841|15q22.31
Osteogenesis imperfecta, type V, 610967 (3)|IFITM5, OI5|614757|11p15.5
Osteogenesis imperfecta, type VI, 613982 (3)|SERPINF1, PEDF, OI6|172860|17p13.3
Osteogenesis imperfecta, type VII, 610682 (3)|CRTAP, CASP, OI7|605497|3p22.3
Osteogenesis imperfecta, type VIII, 610915 (3)|LEPRE1, P3H1, GROS1, OI8|610339|1p34.2
Osteogenesis imperfecta, type X, 613848 (3)|SERPINH1, SERPINH2, PPROM, CBP2, CBP1, OI10|600943|11q13.5
Osteogenesis imperfecta, type XI, 610968 (3)|FKBP10, FKBP65, OI11|607063|17q21.2
Osteogenesis imperfecta, type XII, 613849 (3)|SP7, OSX, OI12|606633|12q13.13
Osteogenesis imperfecta, type XIII, 614856 (3)|BMP1, OI13|112264|8p21.3
Osteogenesis imperfecta, type XIV, 615066 (3)|TMEM38B, TRICB, OI14|611236|9q31.2
Osteogenesis imperfecta, type XV, 615220 (3)|WNT1, INT1, OI15, BMND16|164820|12q13.12
Osteoglophonic dysplasia, 166250 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Osteolysis, familial expansile, 174810 (3)|TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q21.33
Osteomalacia, tumor-induced (1)|FGF23, ADHR, HPDR2, PHPTC|605380|12p13.32
Osteopathia striata with cranial sclerosis, 300373 (3)|AMER1, FAM123B, WTX, OSCS|300647|Xq11.2
Osteopetrosis, autosomal dominant 1, 607634 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
Osteopetrosis, autosomal dominant 2, 166600 (3)|CLCN7, CLC7, OPTA2, OPTB4|602727|16p13.3
Osteopetrosis, autosomal recessive 1, 259700 (3)|TCIRG1, TIRC7, OC116, OPTB1|604592|11q13.2
Osteopetrosis, autosomal recessive 2, 259710 (3)|TNFSF11, OPGL, TRANCE, OPTB2|602642|13q14.11
Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3)|CA2|611492|8q21.2
Osteopetrosis, autosomal recessive 4, 611490 (3)|CLCN7, CLC7, OPTA2, OPTB4|602727|16p13.3
Osteopetrosis, autosomal recessive 5, 259720 (3)|OSTM1, GL, OPTB5|607649|6q21
Osteopetrosis, autosomal recessive 6, 611497 (3)|PLEKHM1, AP162, KIAA0356, OPTB6|611466|17q21.31
Osteopetrosis, autosomal recessive 7, 612301 (3)|TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q21.33
Osteopetrosis, autosomal recessive 8, 615085 (3)|SNX10, OPTB8|614780|7p15.2
Osteopoikilosis, 166700 (3)|LEMD3, MAN1|607844|12q14.3
Osteoporosis-pseudoglioma syndrome, 259770 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
Osteosarcoma, 259500 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Osteosarcoma, somatic, 259500 (3)|CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
Osteosarcoma, somatic, 259500 (3)|RB1|614041|13q14.2
Osteosclerosis, 144750 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
Otodental dysplasia chromsome deletion syndrome (4)|OTDD, DEL11q13, C11DELq13|166750|11q13
Otopalatodigital syndrome, type I, 311300 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Otopalatodigital syndrome, type II, 304120 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Otosclerosis 1 (2)|OTSC1, OTS|166800|15q26.1-qter
Otosclerosis 10 (2)|OTSC10|615589|1q41-q44
Otosclerosis 2 (2)|OTSC2|605727|7q34-q36
Otosclerosis 3 (2)|OTSC3|608244|6p22.3-p21.3
Otosclerosis 5 (2)|OTSC5|608787|3q22-q24
Otosclerosis 7 (2)|OTSC7|611572|6q13-q16.1
Otosclerosis 8 (2)|OTSC8|612096|9p13.1-q21.11
Otospondylomegaepiphyseal dysplasia, 215150 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Otospondylomegaepiphyseal dysplasia, 215150 (3)|COL2A1|120140|12q13.11
Ovalocytosis (3)|SLC4A1, AE1, EPB3|109270|17q21.31
Ovarian cancer, somatic, (3)|ERBB2, NGL, NEU, HER2|164870|17q12
Ovarian cancer, somatic, 167000 (3)|AKT1, CWS6|164730|14q32.33
Ovarian cancer, somatic, 167000 (3)|CTNNB1, MRD19|116806|3p22.1
Ovarian cancer, somatic, 167000 (3)|PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5|171834|3q26.32
Ovarian carcinoma (1)|SEPT9, MSF, MSF1, NAPB|604061|17q25.2-q25.3
Ovarian carcinoma (3)|RRAS2, TC21|600098|11p15.2
Ovarian carcinoma, somatic, 167000 (3)|CDH1, UVO, LCAM, ECAD|192090|16q22.1
Ovarian dysgenesis 1, 233300 (3)|FSHR, ODG1|136435|2p16.3
Ovarian dysgenesis 2, 300510 (3)|BMP15, GDF9B, ODG2, POF4|300247|Xp11.22
Ovarian dysgenesis 3, 614324 (3)|PSMC3IP, TBPIP, GT198, HOP2, ODG3|608665|17q21.2
Ovarian hyperstimulation syndrome, 608115 (3)|FSHR, ODG1|136435|2p16.3
Ovarian response to FSH stimulation, 276400 (3)|FSHR, ODG1|136435|2p16.3
Ovarioleukodystrophy, 603896 (3)|EIF2B2|606454|14q24.3
Ovarioleukodystrophy, 603896 (3)|EIF2B4|606687|2p23.3
Ovarioleukodystrophy, 603896 (3)|EIF2B5, LVWM, CACH, CLE|603945|3q27.1
PCWH syndrome, 609136 (3)|SOX10, WS4, WS4C, PCWH|602229|22q13.1
PEPCK deficiency, mitochondrial, 261650 (1)|PCK2, PEPCK2|614095|14q11.2
PTEN hamartoma tumor syndrome (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Pachyonychia congenita, Jackson-Lawler type, 167210 (3)|KRT17, PC2, PCHC1|148069|17q21.2
Pachyonychia congenita, Jackson-Lawler type, 167210 (3)|KRT6B, PC2|148042|12q13.13
Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)|KRT16, FNEPPK|148067|17q21.2
Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)|KRT6A|148041|12q13.13
Paget disease of bone, 602080 (2)|PDB4|606263|5q31
Paget disease of bone, 602080 (3)|SQSTM1, P62, PDB3|601530|5q35.3
Paget disease of bone, 602080 (3)|TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q21.33
Paget disease, juvenile, 239000 (3)|TNFRSF11B, OPG, OCIF|602643|8q24.12
Pallister-Hall syndrome, 146510 (3)|GLI3, PAPA, PAPB|165240|7p14.1
Pallister-Killian syndrome (4)|PKS|601803|12p
Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3)|RSPO1, FLJ40906|609595|1p34.3
Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3)|RSPO1, FLJ40906|609595|1p34.3
Palmoplantar keratoderma, Bothnia type (2)|PPKB|600231|12q11-q13
Palmoplantar keratoderma, Bothnian type, 600231 (3)|AQP5, PPKB|600442|12q13.12
Palmoplantar keratoderma, Nagashima type, 615598 (3)|SERPINB7, MEGSIN, PPKN|603357|18q21.33
Palmoplantar keratoderma, epidermolytic, 144200 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Palmoplantar keratoderma, epidermolytic, 144200 (3)|KRT9, EPPK|607606|17q21.2
Palmoplantar keratoderma, nonepidermolytic, 600962 (3)|KRT1, EPPK, NEPPK, EHK|139350|12q13.13
Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3)|KRT16, FNEPPK|148067|17q21.2
Panbronchiolitis, diffuse (2)|PBLT|604809|6p21.3
Pancreatic agenesis and congenital heart defects, 600001 (3)|GATA6, AVSD5, ASD9, AVSD5, PACHD|601656|18q11.2
Pancreatic agenesis, 260370 (3)|IPF1, MODY4|600733|13q12.2
Pancreatic cancer, 260350 (3)|STK11, PJS, LKB1|602216|19p13.3
Pancreatic cancer, 260350 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
Pancreatic cancer, 613347 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
Pancreatic cancer, somatic (3)|ACVR1B, ACVRLK4, ALK4|601300|12q13.13
Pancreatic cancer, somatic, 260350 (3)|MADH4, DPC4, SMAD4, JIP, MYHRS|600993|18q21.2
Pancreatic cancer/melanoma syndrome, 606719 (3)|CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21.3
Pancreatic carcinoma, somatic (3)|RBBP8, RIM, SCKL2, JWDS|604124|18q11.2
Pancreatic carcinoma, somatic, 260350 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
Pancreatic lipase deficiency, 614338 (1)|PNLIP, PNLIPD|246600|10q25.3
Pancreatitis, hereditary, 167800 (3)|PRSS1, TRY1|276000|7q34
Pancreatitis, hereditary, 167800 (3)|SPINK1, PSTI, PCTT, TATI, TCP|167790|5q32
Panhypopituitarism, X-linked, 312000 (3)|SOX3, MRGH|313430|Xq27.1
Panic disorder 2 (2)|PAND2|607853|9q31
Panic disorder 3 (2)|PAND3|609985|4q31-q34
Panic disorder syndrome 1 (2)|PAND1|167870|13q22-q32
Papillon-Lefevre syndrome, 245000 (3)|CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD|602365|11q14.2
Papillorenal syndrome, 120330 (3)|PAX2, PAPRS|167409|10q24.31
Paraganglioma and gastric stromal sarcoma, 606864 (3)|SDHB, SDH2, SDHIP, PGL4, CWS2|185470|1p36.13
Paraganglioma and gastric stromal sarcoma, 606864 (3)|SDHC, PGL3|602413|1q23.3
Paraganglioma and gastric stromal sarcoma, 606864 (3)|SDHD, PGL1, CWS3|602690|11q23.1
Paragangliomas 1, with or without deafness, 168000 (3)|SDHD, PGL1, CWS3|602690|11q23.1
Paragangliomas 2, 601650 (3)|SDHAF2, SDH5, PGL2|613019|11q12.2
Paragangliomas 3, 605373 (3)|SDHC, PGL3|602413|1q23.3
Paragangliomas 4, 115310 (3)|SDHB, SDH2, SDHIP, PGL4, CWS2|185470|1p36.13
Paragangliomas 5, 614165 (3)|SDHA, SDH1, SDHF, CMD1GG, PGL5|600857|5p15.33
Paramyotonia congenita, 168300 (3)|SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.3
Parasomnia, sleepwalking type (2)|PSMNSW|613938|20q12-q13.12
Parastremmatic dwarfism, 168400 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Parathyroid adenoma with cystic changes, 145001 (3)|HRPT2, C1orf28|607393|1q31.2
Parathyroid adenoma, somatic (3)|MEN1|613733|11q13.1
Parathyroid carcinoma, 608266 (3)|HRPT2, C1orf28|607393|1q31.2
Parietal foramina 1, 168500 (3)|MSX2, CRS2, HOX8|123101|5q35.2
Parietal foramina 2, 609597 (3)|ALX4, PFM2, FPP, FND2, CRS5|605420|11p11.2
Parietal foramina with cleidocranial dysplasia, 168550 (3)|MSX2, CRS2, HOX8|123101|5q35.2
Parkes Weber syndrome, 608355 (3)|RASA1, GAP, CMAVM, PKWS|139150|5q14.3
Parkinson disease 1, 168601 (3)|SNCA, NACP, PARK1, PARK4|163890|4q22.1
Parkinson disease 10 (2)|PARK10, AAOPD|606852|1p32
Parkinson disease 11, 607688 (3)|GIGYF2, KIAA0642, PARK11|612003|2q37.1
Parkinson disease 12 (2)|PARK12|300557|Xq21-q25
Parkinson disease 13, 610297 (3)|HTRA2, OMI, PARK13, PRSS25|606441|2p13.1
Parkinson disease 14, 612953 (3)|PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Parkinson disease 15, autosomal recessive, 260300 (3)|FBXO7, FBX7, FBX, PKPS, PARK15|605648|22q12.3
Parkinson disease 17, 614203 (3)|VPS35, MEM3, PARK17|601501|16q11.2
Parkinson disease 18, 614251 (3)|EIF4G1, EIF4G, PARK18|600495|3q27.1
Parkinson disease 19, juvenile-onset, 615528 (3)|DNAJC6, DJC6, KIAA0473, PARK19|608375|1p31.3
Parkinson disease 20, early-onset, 615530 (3)|SYNJ1, PARK20|604297|21q22.11
Parkinson disease 3 (2)|PARK3|602404|2p13
Parkinson disease 4, 605543 (3)|SNCA, NACP, PARK1, PARK4|163890|4q22.1
Parkinson disease 6, early onset, 605909 (3)|PINK1, PARK6|608309|1p36.12
Parkinson disease 7, autosomal recessive early-onset, 606324 (3)|DJ1, PARK7|602533|1p36.23
Parkinson disease 8, 607060 (3)|LRRK2, PARK8|609007|12q12
Parkinson disease, juvenile, type 2, 600116 (3)|PRKN, PARK2, PDJ, LPRS2|602544|6q26
Parkinsonism-dystonia, infantile, 613135 (3)|SLC6A3, DAT1, PKDYS|126455|5p15.33
Paroxysmal extreme pain disorder, 167400 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3)|PIGA, MCAHS2|311770|Xp22.2
Paroxysmal nonkinesigenic dyskinesia 2 (2)|PNKD2|611147|2q31
Paroxysmal nonkinesigenic dyskinesia, 118800 (3)|MR1, TAHCCP2, KIPP1184, BRP17, PNKD, FPD1, PDC, DYT8|609023|2q35
Partington syndrome, 309510 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Patella aplasia or hypoplasia (2)|PTLAH, FPAH|168860|17q21-q22
Peeling skin syndrome, 270300 (3)|CDSN, HTSS1, PSS|602593|6p21.33
Peeling skin syndrome, acral type, 609796 (3)|TGM5, TGX|603805|15q15.2
Pelger-Huet anomaly, 169400 (3)|LBR, PHA|600024|1q42.12
Pelizaeus-Merzbacher disease, 312080 (3)|PLP1, PMD, HLD1, SPG2|300401|Xq22.2
Pelviureteric junction obstruction (2)|PUJO|143400|6p
Pendred syndrome, 274600 (3)|SLC26A4, PDS, DFNB4, EVA, TDH2B|605646|7q22.3
Pentosuria, 260800 (1)|DCXR, P34H, PNTSU|608347|17q25.3
Periodic fever, familial, 142680 (3)|TNFRSF1A, TNFR1, TNFAR, FPF, MS5|191190|12p13.31
Periodic fever, menstrual cycle dependent, 614674 (3)|HTR1A, ADRB2RL1, PFMCD|109760|5q12.3
Periodontitis 1, juvenile, 170650 (3)|CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD|602365|11q14.2
Periodontitis, aggressive, 2 (2)|PDON2|608526|1q25
Peripheral arterial occlusive disease 1 (2)|PAOD1|606787|1p31
Peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3)|MYH14, KIAA2034, DFNA4A, PNMHH|608568|19q13.33
Periventricular heterotopia with microcephaly, 608097 (3)|ARFGEF2, BIG2, PVNH2|605371|20q13.13
Periventricular nodular heterotopia 3 (2)|PVNH3|608098|5p15.1
Periventricular nodular heterotopia 5 (4)|PVNH5|612881|5q14.3-q15
Perlman syndrome, 267000 (3)|DIS3L2, PRLMNS|614184|2q37.1
Peroxisomal acyl-CoA oxidase deficiency, 264470 (3)|ACOX1, ACOX, SCOX|609751|17q25.1
Peroxisome biogenesis disorder 10A (Zellweger), 614882 (3)|PEX3, PBD10A|603164|6q24.2
Peroxisome biogenesis disorder 11A (Zellweger), 614883 (3)|PEX13, ZWS, NALD, PBD11A, PBD11B|601789|2p16.1
Peroxisome biogenesis disorder 11B, 614885 (3)|PEX13, ZWS, NALD, PBD11A, PBD11B|601789|2p16.1
Peroxisome biogenesis disorder 12A (Zellweger), 614886 (3)|PEX19, PXF, HK33, D1S2223E, PBD12A|600279|1q23.2
Peroxisome biogenesis disorder 13A (Zellweger), 614887 (3)|PEX14, PBD13A|601791|1p36.22
Peroxisome biogenesis disorder 14B, 614920 (3)|PEX11B, PEX14B|603867|1q21.1
Peroxisome biogenesis disorder 1A (Zellweger), 214100 (3)|PEX1, ZWS1, PBD1A, PBD1B|602136|7q21.2
Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 (3)|PEX1, ZWS1, PBD1A, PBD1B|602136|7q21.2
Peroxisome biogenesis disorder 2A (Zellweger), 214110 (3)|PEX5, PXR1, PTS1R, PBD2A, PBD2B|600414|12p13.31
Peroxisome biogenesis disorder 2B, 202370 (3)|PEX5, PXR1, PTS1R, PBD2A, PBD2B|600414|12p13.31
Peroxisome biogenesis disorder 3A (Zellweger), 614859 (3)|PEX12, PBD3A|601758|17q12
Peroxisome biogenesis disorder 3B, 266510 (3)|PEX12, PBD3A|601758|17q12
Peroxisome biogenesis disorder 4A (Zellweger), 614862 (3)|PEX6, PXAAA1, PAF2, PBD4A, PDB4B|601498|6p21.1
Peroxisome biogenesis disorder 4B, 614863 (3)|PEX6, PXAAA1, PAF2, PBD4A, PDB4B|601498|6p21.1
Peroxisome biogenesis disorder 5A (Zellweger), 614866 (3)|PXMP3, PAF1, PMP35, PEX2, PBD5A, PBD5B|170993|8q21.11
Peroxisome biogenesis disorder 5B, 614867 (3)|PXMP3, PAF1, PMP35, PEX2, PBD5A, PBD5B|170993|8q21.11
Peroxisome biogenesis disorder 6A (Zellweger), 614870 (3)|PEX10, NALD, PBD6A, PBD6B|602859|1p36.32
Peroxisome biogenesis disorder 6B, 614871 (3)|PEX10, NALD, PBD6A, PBD6B|602859|1p36.32
Peroxisome biogenesis disorder 7A (Zellweger), 614872 (3)|PEX26, PBD7A, PBD7B|608666|22q11.21
Peroxisome biogenesis disorder 7B, 614873 (3)|PEX26, PBD7A, PBD7B|608666|22q11.21
Peroxisome biogenesis disorder 8A, (Zellweger), 614876 (3)|PEX16, PBD8A, PBD8B|603360|11p11.2
Peroxisome biogenesis disorder 8B, 614877 (3)|PEX16, PBD8A, PBD8B|603360|11p11.2
Peroxisome biogenesis disorder 9B, 614879 (3)|PEX7, RCDP1, PBD9B|601757|6q23.3
Perrault syndrome 1, 233400 (3)|HSD17B4, PRLTS1|601860|5q23.1
Perrault syndrome 2, 614926 (3)|HARS2, HARSL, HARSR, HO3, PRLTS2|600783|5q31.3
Perrault syndrome 3, 614129 (3)|CLPP, PRLTS3|601119|19p13.3
Perrault syndrome 4, 615300 (3)|LARS2, PRLTS4|604544|3p21.31
Perry syndrome, 168605 (3)|DCTN1, HMN7B|601143|2p13.1
Persistent Mullerian duct syndrome, type I, 261550 (3)|AMH, MIF|600957|19p13.3
Persistent Mullerian duct syndrome, type II, 261550 (3)|AMHR2, AMHR|600956|12q13.13
Persistent polyclonal B-cell lymphocytosis, 606445 (3)|CARD11, CARMA1, BIMP3, PPBL, BENTA, IMD11|607210|7p22.2
Persistent truncus arteriosus, 217095 (3)|GATA6, AVSD5, ASD9, AVSD5, PACHD|601656|18q11.2
Persistent truncus arteriosus, 217095 (3)|NKX2-6, CSX2|611770|8p21.2
Peters anomaly, 604229 (3)|CYP1B1, GLC3A|601771|2p22.2
Peters anomaly, 604229 (3)|PAX6, AN2, MGDA|607108|11p13
Peters anomaly, 604229 (3)|PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25
Peters-plus syndrome, 261540 (3)|B3GALTL, B3GTL, B3GLCT|610308|13q12.3
Pettigrew syndrome (2)|PGS, MRXS5|304340|Xq25-q27
Peutz-Jeghers syndrome, 175200 (3)|STK11, PJS, LKB1|602216|19p13.3
Pfeiffer syndrome, 101600 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Pfeiffer syndrome, 101600 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Phelan-McDermid syndrome, 606232 (3)|SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3, SCZD15|606230|22q13.33
Phenylketonuria, 261600 (3)|PAH, PKU1|612349|12q23.2
Pheochromocytoma, 171300 (3)|KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.22
Pheochromocytoma, 171300 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Pheochromocytoma, 171300 (3)|SDHB, SDH2, SDHIP, PGL4, CWS2|185470|1p36.13
Pheochromocytoma, 171300 (3)|SDHD, PGL1, CWS3|602690|11q23.1
Pheochromocytoma, 171300 (3)|VHL|608537|3p25.3
Phobia, specific (2)|PHOBS|608251|Chr.14
Phosphoglycerate dehydrogenase deficiency, 601815 (3)|PHGDH|606879|1p12
Phosphoglycerate kinase 1 deficiency, 300653 (3)|PGK1, PGKA|311800|Xq21.1
Phospholipase A2, group IV A, deficiency of (3)|PLA2G4A, PLA2G4|600522|1q31.1
Phosphoribosylpyrophosphate synthetase superactivity, 300661 (3)|PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22.3
Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3)|PHKB|172490|16q12.1
Phosphoserine aminotransferase deficiency, 610992 (3)|PSAT1, PSAT, EPIP|610936|9q21.2
Phosphoserine phosphatase deficiency, 614023 (3)|PSP, PSPHD|172480|7p11.2
Photoparoxysmal response 1 (2)|PPR1|132100|6p21.1
Photoparoxysmal response 2 (2)|PPR2|609572|13q31.3
Photoparoxysmal response 3 (2)|PPR3|609573|7q32
Pick disease, 172700 (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
Pick disease, 172700 (3)|PSEN1, AD3|104311|14q24.2
Piebaldism, 172800 (3)|KIT, PBT|164920|4q12
Piebaldism, 172800 (3)|SNAI2, SLUG, WS2D|602150|8q11.21
Pierre Robin syndrome (2)|PRBNS|261800|17q24.3-q25.1
Pierson syndrome, 609049 (3)|LAMB2, LAMS, NPHS5|150325|3p21.31
Pigment disorder, reticulate (2)|PDR|301220|Xp22-p21
Pigment dispersion syndrome (2)|GPDS1, PDS1|600510|7q35-q36
Pigmented nodular adrenocortical disease, primary, 1, 610489 (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
Pigmented nodular adrenocortical disease, primary, 2, 610475 (3)|PDE11A, PDE11A1, PDE11A2, PDE11A3, PPNAD2|604961|2q31.2
Pigmented nodular adrenocortical disease, primary, 3, 614190 (3)|PDE8B, PPNAD3, ADSD|603390|5q13.3
Pigmented paravenous chorioretinal atrophy, 172870 (3)|CRB1, RP12, LCA8|604210|1q31.3
Pilomatricoma, somatic, 132600 (3)|CTNNB1, MRD19|116806|3p22.1
Pitt-Hopkins like syndrome 1, 610042 (3)|CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
Pitt-Hopkins syndrome, 610954 (3)|TCF4, SEF2, ITF2, PTHS|602272|18q21.2
Pitt-Hopkins-like syndrome 2, 614325 (3)|NRXN1, PTHSL2, SCZD17|600565|2p16.3
Pituitary ACTH-secreting adenoma (3)|GNAI2, GNAI2B, GIP|139360|3p21.31
Pituitary adenoma, ACTH-secreting, 219090 (3)|AIP, XAP2, ARA9|605555|11q13.2
Pituitary adenoma, growth hormone-secreting, 102200 (3)|AIP, XAP2, ARA9|605555|11q13.2
Pituitary adenoma, prolactin-secreting, 600634 (3)|AIP, XAP2, ARA9|605555|11q13.2
Pituitary hormone deficiency, combined, 1, 613038 (3)|POU1F1, PIT1, CPHD1|173110|3p11.2
Pituitary hormone deficiency, combined, 2, 262600 (3)|PROP1, CPHD2|601538|5q35.3
Pituitary hormone deficiency, combined, 3, 221750 (3)|LHX3, CPHD3|600577|9q34.3
Pituitary hormone deficiency, combined, 4, 262700 (3)|LHX4, CPHD4|602146|1q25.2
Pituitary hormone deficiency, combined, 5, 182230 (3)|HESX1, RPX, CPHD5|601802|3p14.3
Pituitary hormone deficiency, combined, 6, 613986 (3)|OTX2, MCOPS5, CPHD6|600037|14q22.3
Pituitary tumor, invasive (3)|PRKCA, PKCA|176960|17q24.2
Pityriasis rubra pilaris, 173200 (3)|CARD14, CARMA2, BIMP2, PSORS2, PSS1, PRP|607211|17q25.3
Plasma fibronectin deficiency, 614101 (1)|FN1, FN, LETS, FNZ, GFND2|135600|2q35
Plasminogen Tochigi disease (3)|PLG|173350|6q26
Plasminogen activator inhibitor-1 deficiency, 613329 (3)|PAI1, PLANH1, SERPINE1|173360|7q22.1
Plasminogen deficiency, types I and II (1)|PLG|173350|6q26
Platelet PLC beta-2 deficiency (1)|PLCB2|604114|15q15.1
Platelet disorder, familial, with associated myeloid malignancy, 601399 (3)|RUNX1, CBFA2, AML1|151385|21q22.12
Platelet glycoprotein IV deficiency, 608404 (3)|CD36, CHDS7, BDPLT10|173510|7q21.11
Platelet-activating factor acetylhydrolase deficiency, 614278 (3)|PLA2G7, PAFAH, PAFAD|601690|6p12.3
Platyspondylic skeletal dysplasia, Torrance type, 151210 (3)|COL2A1|120140|12q13.11
Pleuropulmonary blastoma, 601200 (3)|DICER1, HERNA, KIAA0928, MNG1, RMSE2|606241|14q32.13
Pneumothorax, primary spontaneous, 173600 (3)|FLCN, BHD|607273|17p11.2
Poikiloderma with neutropenia, 604173 (3)|C16orf57, PN|613276|16q21
Polycystic kidney and hepatic disease, 263200 (3)|FCYT, PKHD1, ARPKD|606702|6p12.3-p12.2
Polycystic kidney disease 2, 613095 (3)|PKD2|173910|4q22.1
Polycystic kidney disease, adult type I, 173900 (3)|PKD1|601313|16p13.3
Polycystic kidney disease, infantile severe, with tuberous sclerosis (4)|PKDTS|600273|16p13.3
Polycystic liver disease, 174050 (3)|PRKCSH, G19P1, PCLD|177060|19p13.2
Polycystic liver disease, 174050 (3)|SEC63|608648|6q21
Polycystic ovary syndrome 1 (2)|PCOS1, PCO1, PCO|184700|19p13.2
Polycythemia vera, 263300 (3)|JAK2, THCYT3|147796|9p24.1
Polydactyly, postaxial, type A3 (2)|PAPA3|607324|19p13.2-p13.1
Polydactyly, postaxial, type A4 (2)|PAPA4|608562|7q22
Polydactyly, postaxial, type A5 (2)|PAPA5|263450|13q13.3-q21
Polydactyly, postaxial, types A1 and B, 174200 (3)|GLI3, PAPA, PAPB|165240|7p14.1
Polydactyly, preaxial type II, 174500 (3)|LMBR1, ACHP, C7orf2, PPD2|605522|7q36.3
Polydactyly, preaxial, type IV, 174700 (3)|GLI3, PAPA, PAPB|165240|7p14.1
Polyglucosan body disease, adult form, 263570 (3)|GBE1, GSD4, APBD|607839|3p12.2
Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3)|STRADA, STRAD, LYK5|608626|17q23.3
Polymicrogyria with optic nerve hypoplasia, 613180 (3)|TUBA8, TUBAL2|605742|22q11.21
Polymicrogyria with seizures, 614833 (3)|RTTN, PMGYS|610436|18q22.2
Polymicrogyria, bilateral frontoparietal, 606854 (3)|GPR56, TM7XN1, BFPP|604110|16q21
Polymicrogyria, bilateral occipital (2)|BOP|612691|6q16.3-q22.1
Polymicrogyria, bilateral perisylvian (2)|BPP, PMGX, CBPS|300388|Xq27.2-q28
Polymicrogyria, symmetric or asymmetric, 610031 (3)|TUBB2B, PMGYSA|612850|6p25.2
Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3)|ABHD12, PHARC|613599|20p11.21
Polyposis syndrome, hereditary mixed, 2, 610069 (3)|BMPR1A, ACVRLK3, ALK3|601299|10q23.2
Polyposis syndrome, mixed hereditary 1 (4)|HMPS1, CRAC1, CRCS4, DUP15q, C15DUPq|601228|15q15.3-q22.1
Polyposis, juvenile intestinal, 174900 (3)|BMPR1A, ACVRLK3, ALK3|601299|10q23.2
Polyposis, juvenile intestinal, 174900 (3)|MADH4, DPC4, SMAD4, JIP, MYHRS|600993|18q21.2
Pontocerebellar hypoplasia type 1A, 607596 (3)|VRK1, PCH1A|602168|14q32.2
Pontocerebellar hypoplasia type 2A, 277470 (3)|TSEN54, SEN54, PCH2A, PCH4|608755|17q25.1
Pontocerebellar hypoplasia type 2B, 612389 (3)|TSEN2, SEN2, PCH2B|608753|3p25.2
Pontocerebellar hypoplasia type 2C, 612390 (3)|TSEN34, PCH2C, LENG5, SEN34|608754|19q13.42
Pontocerebellar hypoplasia type 2D, 613811 (3)|SEPSECS, SLA, LP, PCH2D|613009|4p15.2
Pontocerebellar hypoplasia type 4, 225753 (3)|TSEN54, SEN54, PCH2A, PCH4|608755|17q25.1
Pontocerebellar hypoplasia, type 1B, 614678 (3)|EXOSC3, RRP40, PCH1B|606489|9p13.2
Pontocerebellar hypoplasia, type 3 (2)|PCH3, CLAM|608027|7q11-q21
Pontocerebellar hypoplasia, type 6, 611523 (3)|RARS2, RARSL, PCH6|611524|6q15
Pontocerebellar hypoplasia, type 8, 614961 (3)|CHMP1A, PCOLN3, PRSM1, PCH8|164010|16q24.3
Popliteal pterygium syndrome 1, 119500 (3)|IRF6, VWS, LPS, PIT, PPS1, OFC6|607199|1q32.2
Popliteal pterygium syndrome 2, lethal type, 263650 (3)|RIPK4, NKRD3, DIK, PPS2|605706|21q22.3
Porencephaly 1, 175780 (3)|COL4A1, POREN1, HANAC, ICH|120130|13q34
Porencephaly 2, 614483 (3)|COL4A2, POREN2, ICH|120090|13q34
Porokeratosis 2, palmar, plantar, and disseminated (2)|POROK2, PPPD1|175850|12q24.1-q24.2
Porokeratosis 3, disseminated superficial actinic, 175900 (3)|MVK, MVLK, POROK3|251170|12q24.11
Porokeratosis 4, disseminated superficial actinic (2)|POROK4, DSAP2|607728|15q25.1-q26.1
Porokeratosis 5, disseminated superficial actinic (2)|POROK5, DSAP3|612293|1p31.3-p31.1
Porokeratosis 6 (2)|POROK6, DSAP4|612353|18p11.3
Porokeratosis 7 (2)|POROK7|614714|16q24.1-q24.3
Porokeratosis, disseminated superficial actinic, 1, 175900 (3)|SART3, P100, KIAA0156, TIP110, DSAP1|611684|12q23.3
Porphyria cutanea tarda, 176100 (3)|UROD|613521|1p34.1
Porphyria variegata, 176200 (3)|PPOX|600923|1q23.3
Porphyria, acute hepatic, 612740 (3)|ALAD, ALADH, PBGS|125270|9q32
Porphyria, acute intermittent, 176000 (3)|HMBS, PBGD, UPS|609806|11q23.3
Porphyria, acute intermittent, nonerythroid variant, 176000 (3)|HMBS, PBGD, UPS|609806|11q23.3
Porphyria, congenital erythropoietic, 263700 (3)|UROS|606938|10q26.1-q26.2
Porphyria, hepatoerythropoietic, 176100 (3)|UROD|613521|1p34.1
Postaxial polydactyly, type A2 (2)|PAPA2|602085|13q21-q32
Potocki-Lupski syndrome (4)|PTLS|610883|17p11.2
Potocki-Shaffer syndrome (4)|PSS|601224|11p11.2
Prader-Willi syndrome, 176270 (3)|NDN|602117|15q11.2
Prader-Willi syndrome, 176270 (3)|SNRPN|182279|15q11.2
Prader-Willi-like syndrome, 615547 (3)|MAGEL2, NDNL1, PWLS|605283|15q11.2
Preauricular tag, isolated, autosomal dominant, 1 (2)|PAURT1|610420|14q11.2-q12
Precocious puberty, central, 1, 176400 (3)|KISS1R, GPR54 , HH8, CPPB1|604161|19p13.3
Precocious puberty, central, 2, 615346 (3)|MKRN3, ZFP127, ZNF127, CPPB2|603856|15q11.2
Precocious puberty, male, 176410 (3)|LHCGR, LHR, LCGR|152790|2p16.3
Preeclampsia/eclampsia 1 (2)|PEE1, PREG1|189800|2p13
Preeclampsia/eclampsia 2 (2)|PEE2|609402|2p25
Preeclampsia/eclampsia 3 (2)|PEE3|609403|9p13
Preeclampsia/eclampsia 4, 609404 (3)|STOX1, PEE4|609397|10q21.3-q22.1
Preeclampsia/eclampsia 5, 614595 (3)|CORIN, CRN, TMPRSS10, ATC2, PEE5|605236|4p12
Premature ovarian failure 1, 311360 (3)|FMR1, FRAXA, POF1|309550|Xq27.3
Premature ovarian failure 2B, 300604 (3)|FLJ22792, POF1B, POF2B|300603|Xq21.1-q21.2
Premature ovarian failure 3, 608996 (3)|FOXL2, BPES, BPES1, PFRK, POF3|605597|3q22.3
Premature ovarian failure 4, 300510 (3)|BMP15, GDF9B, ODG2, POF4|300247|Xp11.22
Premature ovarian failure 5, 611548 (3)|NOBOX, POF5|610934|7q35
Premature ovarian failure 6, 612310 (3)|FIGLA, POF6|608697|2p13.3
Premature ovarian failure 7, 612964 (3)|NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8|184757|9q33.3
Premature ovarian failure, 300511 (3)|DIAPH2, DIA, POF2|300108|Xq21.33
Prieto syndrome (2)|PRS, MRXS2|309610|Xp11-q21
Primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3)|CACNA1D, CACNL1A2, CCHL1A2, SANDD, PASNA|114206|3p21.1
Primary lateral sclerosis, adult, 1 (2)|PLSA1, PLSA|611637|4p16
Primary lateral sclerosis, juvenile, 606353 (3)|ALS2, ALSJ, PLSJ, IAHSP|606352|2q33.1
Prion disease with protracted course, 606688 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
Progressive external ophthalmoplegia with mitochondrial DNA deletions 3, 609283 (3)|SLC25A4, ANT1, T1, PEO3, PEO2, MTDPS12|103220|4q35.1
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 (3)|POLG2, POLGB, PEOA4|604983|17q23.3
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5, 613077 (3)|RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q22.3
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6, 615156 (3)|DNA2, DNA2L, KIAA0083, PEOA6|601810|10q21.3
Progressive external ophthalmoplegia, autosomal dominant, 157640 (3)|POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q26.1
Progressive external ophthalmoplegia, autosomal dominant, 3, 609286 (3)|C10orf2, TWINKLE, PEO1, PEOA3, IOSCA, MTDPS7|606075|10q24.31
Progressive external ophthalmoplegia, autosomal recessive, 258450 (3)|POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q26.1
Progressive familial heart block, type IB, 604559 (3)|TRPM4, PFHB1B|606936|19q13.33
Proguanil poor metabolizer, 609535 (3)|CYP2C, CYP2C19|124020|10q23.33
Prolidase deficiency, 170100 (3)|PEPD|613230|19q13.11
Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 (3)|FLVCR2, C14orf58, CCT, PVHH, EPV|610865|14q24.3
Prolonged bleeding time, brachydactyly and mental retardation (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Prolonged bleeding time, brachydactyly, and mental retardation (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Properdin deficiency, X-linked, 312060 (3)|PFC, PFD|300383|Xp11.23
Propionicacidemia, 606054 (3)|PCCA|232000|13q32.3
Propionicacidemia, 606054 (3)|PCCB|232050|3q22.3
Prostate adenocarcinoma (2)|ST12, PAC1|601188|10pter-q11
Prostate cancer 1, 601518 (3)|RNASEL, RNS4, PRCA1, HPC1|180435|1q25.3
Prostate cancer, 176807 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
Prostate cancer, hereditary, 176807 (3)|MSR1, SCARA1, SRA|153622|8p22
Prostate cancer, progression and metastasis of, 603688 (3)|EPHB2, EPHT3, DRT, ERK, PCBC, CAPB|600997|1p36.12
Prostate cancer, somatic, 176807 (3)|KLF6, COPEB, BCD1, ZF9|602053|10p15.1
Prostate cancer, somatic, 176807 (3)|MAD1L1, TXBP181|602686|7p22.3
Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3)|CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.23-p11.22
Proteus syndrome, somatic, 176920 (3)|AKT1, CWS6|164730|14q32.33
Protoporphyria, erythropoietic, X-linked, 300752 (3)|ALAS2, ANH1, ASB, XLEPP, XLSA, ANH1|301300|Xp11.21
Protoporphyria, erythropoietic, autosomal recessive, 177000 (3)|FECH, FCE|612386|18q21.31
Proud syndrome, 300004 (3)|ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp21.3
Pseudoachondroplasia, 177170 (3)|COMP, EDM1, MED, PSACH|600310|19p13.11
Pseudohermaphroditism, male, with gynecomastia, 264300 (3)|HSD17B3, EDH17B3|605573|9q22.32
Pseudohyperkalemia, familial, 2, due to red cell leak (2)|PSHK2|609153|2q35-q36
Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3)|NR3C2, MLR, MCR|600983|4q31.23
Pseudohypoaldosteronism, type I, 264350 (3)|SCNN1A, BESC2|600228|12p13.31
Pseudohypoaldosteronism, type I, 264350 (3)|SCNN1B, BESC1|600760|16p12.2
Pseudohypoaldosteronism, type I, 264350 (3)|SCNN1G, PHA1, BESC3|600761|16p12.2
Pseudohypoaldosteronism, type IIA (2)|PHA2A, PHA2|145260|1q31-q42
Pseudohypoaldosteronism, type IIB, 614491 (3)|WNK4, PRKWNK4, PHA2B|601844|17q21.31
Pseudohypoaldosteronism, type IIC, 614492 (3)|WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2|605232|12p13.33
Pseudohypoaldosteronism, type IID, 614495 (3)|KLHL3, PHA2D|605775|5q31.2
Pseudohypoaldosteronism, type IIE, 614496 (3)|CUL3, PHA2E|603136|2q36.2
Pseudohypoparathyroidism Ia, 103580 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Pseudohypoparathyroidism Ib, 603233 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Pseudohypoparathyroidism Ic, 612462 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Pseudohypoparathyroidism, type IB, 603233 (3)|GNASAS1, GNASAS, SANG, NESPAS|610540|20q13.32
Pseudohypoparathyroidism, type IB, 603233 (3)|STX16, SYN16|603666|20q13.32
Pseudopseudohypoparathyroidism, 612463 (3)|GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.32
Pseudovaginal perineoscrotal hypospadias, 264600 (3)|SRD5A2|607306|2p23.1
Pseudoxanthoma elasticum, 264800 (3)|ABCC6, ARA, ABC34, MLP1, PXE, GACI2|603234|16p13.11
Pseudoxanthoma elasticum, forme fruste, 177850 (3)|ABCC6, ARA, ABC34, MLP1, PXE, GACI2|603234|16p13.11
Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3)|GGCX|137167|2p11.2
Psoriasis, generalized pustular, 614204 (3)|IL36RN, IL1F5, FIL1D, IL1HY1, IL1RP3, PSORP|605507|2q13
Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 (3)|SNIP1, PMRED|608241|1p34.3
Ptosis, hereditary congenital 2 (2)|PTOS2, PTOSX|300245|Xq24-q27.1
Ptosis, hereditary congenital, 1 (2)|PTOS1|178300|1p34.1-p32
Pulmonary alveolar microlithiasis, 265100 (3)|SLC34A2|604217|4p15.2
Pulmonary disease, chronic obstructive, severe early-onset (2)|COPD|606963|2q
Pulmonary fibrosis, idiopathic, 178500 (3)|SFTPA2, SPA2, COLEC5|178642|10q22.3
Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 (3)|BMPR2, PPH1, POVD1|600799|2q33.1-q33.2
Pulmonary hypertension, primary, 2, 615342 (3)|MADH9, SMAD9, MADH6, PPH2|603295|13q13.3
Pulmonary hypertension, primary, 3, 615343 (3)|CAV1, BSCL3, CGL3, PPH3|601047|7q31.2
Pulmonary hypertension, primary, 4, 615344 (3)|KCNK3, TASK, PPH4|603220|2p23.3
Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3)|BMPR2, PPH1, POVD1|600799|2q33.1-q33.2
Pulmonary venoocclusive disease 1, 265450 (3)|BMPR2, PPH1, POVD1|600799|2q33.1-q33.2
Pulmonary venoocclusive disease 2, 234810 (3)|EIF2AK4, GCN2, KIAA1338, PVOD2|609280|15q15.1
Purpura, posttransfusion (3)|ITGB3, GP3A, GT, BDPLT2, BDPLT16|173470|17q21.32
Pycnodysostosis, 265800 (3)|CTSK|601105|1q21.3
Pyloric stenosis, infantile hypertrophic 1 (2)|IHPS1, IHPS|179010|12q
Pyloric stenosis, infantile hypertrophic, 2 (2)|IHPS2|610260|16p13-p12
Pyloric stenosis, infantile hypertrophic, 3 (2)|IHPS3|612017|11q14-q22
Pyloric stenosis, infantile hypertrophic, 4 (2)|IHPS4|300711|Xq23
Pyloric stenosis, infantile hypertrophic, 5 (2)|IHPS5|612525|16q24.3
Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3)|MYD88, MYD88D|602170|3p22.2
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3)|PSTPIP1, PSTPIP, CD2BP1, PAPAS|606347|15q24.3
Pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3)|PNPO|603287|17q21.32
Pyropoikilocytosis, 266140 (3)|SPTA1, EL2, SPH3, HS3, HPP|182860|1q23.1
Pyruvate carboxylase deficiency, 266150 (3)|PC|608786|11q13.2
Pyruvate dehydrogenase E1-alpha deficiency, 312170 (3)|PDHA1, PHE1A|300502|Xp22.12
Pyruvate dehydrogenase E1-beta deficiency, 614111 (3)|PDHB, PDHBD|179060|3p14.3
Pyruvate dehydrogenase E2 deficiency, 245348 (3)|DLAT, PDCE2|608770|11q23.1
Pyruvate dehydrogenase lipoic acid synthetase deficiency, 614462 (3)|LIAS, PDHLD|607031|4p14
Pyruvate dehydrogenase phosphatase deficiency, 608782 (3)|PDP1, PPM2C, PDP1, PDPC|605993|8q22.1
Pyruvate kinase deficiency, 266200 (3)|PKLR, PK1|609712|1q22
Quebec platelet disorder, 601709 (3)|PLAU, URK, QPD, BDPLT5|191840|10q22.2
RAPADILINO syndrome, 266280 (3)|RECQL4, RTS, RECQ4|603780|8q24.3
REtinitis pigmentosa 62, 614181 (3)|MAK, RP62|154235|6p24.2
RIDDLE syndrome, 611943 (3)|RNF168|612688|3q29
Rabson-Mendenhall syndrome, 262190 (3)|INSR, HHF5|147670|19p13.2
Radial ray deficiency (2)|RRDX|300378|Xq24-q25
Radiation sensitivity/chromosome instability syndrome, autosomal dominant (1)|RSCIS|605463|14q11.2
Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432 (3)|HOXA11, HOX1I|142958|7p15.2
Raine syndrome, 259775 (3)|FAM20C, DMP4|611061|7p22.3
Rajab syndrome (2)|RJBS|613658|2q36.2
Rapp-Hodgkin syndrome, 129400 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Recombination rate QTL 1, 612042 (3)|RNF212, ZHP3|612041|4p16.3
Refsum disease, 266500 (3)|PHYH, PAHX|602026|10p13
Refsum disease, adult, with increased pipecolicacidemia (2)|RDPA|600964|10pter-p11.2
Renal adysplasia, 191830 (3)|UPK3A, UPK3, UPIII|611559|22q13.31
Renal agenesis, 191830 (3)|RET, MEN2A, HSCR1|164761|10q11.21
Renal carcinoma, chromophobe, somatic, 144700 (3)|FLCN, BHD|607273|17p11.2
Renal cell carcinoma, 144700 (2)|DIRC2, RCC4|602773|3q21.1
Renal cell carcinoma, 144700 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
Renal cell carcinoma, 144700 (3)|RNF139, TRC8, RCA1|603046|8q24.13
Renal cell carcinoma, clear cell, somatic, 144700 (3)|OGG1|601982|3p25.3
Renal cell carcinoma, papillary, 1, 300854 (3)|TFE3, RCCX1|314310|Xp11.23
Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3)|MET|164860|7q31.2
Renal cell carcinoma, papillary, 3 (2)|RCCP3|605075|17q21.32
Renal cell carcinoma, papillary, 605074 (3)|PRCC, RCCP1|179755|1q23.1
Renal cell carcinoma, somatic, 144700 (3)|VHL|608537|3p25.3
Renal cysts and diabetes syndrome, 137920 (3)|HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
Renal glucosuria, 233100 (3)|SLC5A2, SGLT2|182381|16p11.2
Renal hypodysplasia, nonsyndromic, 1 (2)|RHDNS1|610805|1p33-p32
Renal hypoplasia, isolated, 191830 (3)|PAX2, PAPRS|167409|10q24.31
Renal tubular acidosis with deafness, 267300 (3)|ATP6B1, VPP3|192132|2p13.3
Renal tubular acidosis, distal, AD, 179800 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
Renal tubular acidosis, distal, AR, 611590 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
Renal tubular acidosis, distal, autosomal recessive, 602722 (3)|ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR|605239|7q34
Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3)|SLC4A4, NBC1, KNBC, SLC4A5|603345|4q13.3
Renal tubular dysgenesis, 267430 (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
Renal tubular dysgenesis, 267430 (3)|AGT, SERPINA8|106150|1q42.2
Renal tubular dysgenesis, 267430 (3)|AGTR1, AGTR1A, AT2R1|106165|3q24
Renal tubular dysgenesis, 267430 (3)|REN, HNFJ2|179820|1q32.1
Renal-hepatic-pancreatic dysplasia 1, 208540 (3)|NPHP3, NPH3, RHPD1, MKS7|608002|3q22.1
Renpenning syndrome, 309500 (3)|PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8|300463|Xp11.23
Restless legs syndrome, susceptibility to, 8 (2)|RLS8|615197|5q31
Restrictive dermopathy, lethal, 275210 (3)|LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B|150330|1q22
Restrictive dermopathy, lethal, 275210 (3)|ZMPSTE24, FACE1, STE24, MADB|606480|1p34.2
Reticular dysgenesis, 267500 (3)|AK2|103020|1p35.1
Reticulate acropigmentation of Kitamura, 615537 (3)|ADAM10, MADM, RAK, AD18|602192|15q21.3
Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3)|IGFBP7, MAC25, RAMSVPS|602867|4q12
Retinal cone dystrophy 3, 610024 (3)|PDE6H, RCD3, ACHM6|601190|12p12.3
Retinal cone dystrophy 3B, 610356 (3)|KCNV2, KV11.1, RCD3B|607604|9p24.2
Retinal cone dystrophy 4, 610478 (3)|CACNA2D4, RCD4|608171|12p13.33
Retinal degeneration, autosomal recessive, clumped pigment type (3)|NRL, D14S46E, RP27|162080|14q11.2
Retinal degeneration, late-onset, autosomal dominant, 605670 (3)|C1QTNF5, CTRP5, LORD|608752|11q23.3
Retinal dystrophy, early-onset severe, 248200 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Retinal dystrophy, early-onset severe, 613341 (3)|LRAT, LCA14|604863|4q32.1
Retinal dystrophy, early-onset, and pituitary dysfunction, 610125 (3)|OTX2, MCOPS5, CPHD6|600037|14q22.3
Retinal nonattachment, nonsyndromic congenital (2)|RNANC, NCRNA|221900|10q21
Retinitis pigmentosa 1, 180100 (3)|RP1, ORP1|603937|8q12.1
Retinitis pigmentosa 10, 180105 (3)|IMPDH1, RP10, LCA11|146690|7q32.1
Retinitis pigmentosa 11, 600138 (3)|PRPF31, PRP31, RP11|606419|19q13.42
Retinitis pigmentosa 13, 600059 (3)|PRPF8, PRPC8, RP13|607300|17p13.3
Retinitis pigmentosa 14, 600132 (3)|TULP1, RP14, LCA15|602280|6p21.31
Retinitis pigmentosa 17, 600852 (3)|CA4, RP17|114760|17q23.1
Retinitis pigmentosa 18, 601414 (3)|HPRP3, RP18|607301|1q21.2-q21.3
Retinitis pigmentosa 19, 601718 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Retinitis pigmentosa 2, 312600 (3)|RP2|300757|Xp11.23
Retinitis pigmentosa 20, 613794 (3)|RPE65, RP20, LCA2|180069|1p31.3-p31.2
Retinitis pigmentosa 22 (2)|RP22|602594|16p12.3-p12.1
Retinitis pigmentosa 23 (2)|RP23|300424|Xp22
Retinitis pigmentosa 24 (2)|RP24|300155|Xq26-q27
Retinitis pigmentosa 25, 602772 (3)|EYS, RP25|612424|6q12
Retinitis pigmentosa 26, 608380 (3)|CERKL, RP26|608381|2q31.3
Retinitis pigmentosa 27, 613750 (3)|NRL, D14S46E, RP27|162080|14q11.2
Retinitis pigmentosa 28, 606068 (3)|FAM161A, RP28|613596|2p15
Retinitis pigmentosa 29 (2)|RP29|612165|4q32-q34
Retinitis pigmentosa 3, 300029 (3)|RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Retinitis pigmentosa 30, 607921 (3)|FSCN2, RFSN, RP30|607643|17q25.3
Retinitis pigmentosa 31, 609923 (3)|TOPORS, P53BP3, LUN, RP31|609507|9p21.1
Retinitis pigmentosa 32 (2)|RP32|609913|1p21.3-p13.3
Retinitis pigmentosa 33, 610359 (3)|SNRNP200, ASCC3L1, KIAA0788, RP33|601664|2q11.2
Retinitis pigmentosa 34 (2)|RP34|300605|Xq28
Retinitis pigmentosa 35, 610282 (3)|SEMA4A, SEMB, RP35, CORD10|607292|1q22
Retinitis pigmentosa 36, 610599 (3)|PRCD, RP36|610598|17q25.1
Retinitis pigmentosa 37, 611131 (3)|NR2E3, PNR, ESCS, RP37|604485|15q23
Retinitis pigmentosa 38, 613862 (3)|MERTK, RP38|604705|2q13
Retinitis pigmentosa 39, 613809 (3)|USH2A, RP39|608400|1q41
Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3)|RHO, RP4, OPN2, CSNBAD1|180380|3q22.1
Retinitis pigmentosa 41, 612095 (3)|PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.32
Retinitis pigmentosa 42, 612943 (3)|KLHL7, RP42|611119|7p15.3
Retinitis pigmentosa 43, 613810 (3)|PDE6A, PDEA, RP43|180071|5q32
Retinitis pigmentosa 44, 613769 (3)|RGR, RP44|600342|10q23.1
Retinitis pigmentosa 45, 613767 (3)|CNGB1, CNCG3L, CNCG2, RP45|600724|16q21
Retinitis pigmentosa 46, 612572 (3)|IDH3B, RP46|604526|20p13
Retinitis pigmentosa 47, 613758 (3)|SAG, RP47|181031|2q37.1
Retinitis pigmentosa 48, 613827 (3)|GUCA1B, GCAP2, GUCA2, RP48|602275|6p21.1
Retinitis pigmentosa 49, 613756 (3)|CNGA1, CNCG1, RP49|123825|4p12
Retinitis pigmentosa 51, 613464 (3)|TTC8, BBS8, RP51|608132|14q31.3
Retinitis pigmentosa 54, 613428 (3)|C2orf71|613425|2p23.2
Retinitis pigmentosa 55, 613575 (3)|ARL6, BBS3, RP55|608845|3q11.2
Retinitis pigmentosa 56, 613581 (3)|IMPG2, IPM200, RP56|607056|3q12.3
Retinitis pigmentosa 57, 613582 (3)|PDE6G, PDEG, RP57|180073|17q25.3
Retinitis pigmentosa 58, 613617 (3)|ZNF513, RP58|613598|2p23.3
Retinitis pigmentosa 59, 613861 (3)|DHDDS, HDS, RP59|608172|1p36.11
Retinitis pigmentosa 60, 613983 (3)|PRPF6, PRP6, ANT1, TOM, C20orf14|613979|20q13.33
Retinitis pigmentosa 61, 614180 (3)|CLRN1, USH3A, USH3, RP61|606397|3q25.1
Retinitis pigmentosa 63 (2)|RP63|614494|6q23
Retinitis pigmentosa 64, 614500 (3)|C8orf37, CORD16, RP64|614477|8q22.1
Retinitis pigmentosa 65, 613660 (3)|CDHR1, PCDH21, PRCAD, CORD15, RP65|609502|10q23.1
Retinitis pigmentosa 7, 608133 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Retinitis pigmentosa 7, digenic, 608133 (3)|ROM1, ROSP1, RP7|180721|11q12.3
Retinitis pigmentosa 9, 180104 (3)|RP9|607331|7p14.3
Retinitis pigmentosa with or without situs inversus, 615434 (3)|ARL2BP, BART|615407|16q13
Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 (3)|RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Retinitis pigmentosa, Y-linked (2)|RPY|400004|Chr.Y
Retinitis pigmentosa, concentric, 613194 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Retinitis pigmentosa, digenic, 608133 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Retinitis pigmentosa, juvenile, 604393 (3)|AIPL1, LCA4|604392|17p13.2
Retinitis pigmentosa, juvenile, 613341 (3)|LRAT, LCA14|604863|4q32.1
Retinitis pigmentosa, juvenile, autosomal recessive, 604232 (3)|SPATA7, HSD3, LCA3|609868|14q31.3
Retinitis pigmentosa-12, autosomal recessive, 600105 (3)|CRB1, RP12, LCA8|604210|1q31.3
Retinitis pigmentosa-40, 613801 (3)|PDE6B, PDEB, RP40, CSNBAD2|180072|4p16.3
Retinitis pigmentosa-50, 613194 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Retinitis punctata albescens, 136880 (3)|PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1
Retinitis punctata albescens, 136880 (3)|RHO, RP4, OPN2, CSNBAD1|180380|3q22.1
Retinitis punctata albescens, 136880 (3)|RLBP1|180090|15q26.1
Retinoblastoma, 180200 (3)|RB1|614041|13q14.2
Retinoblastoma, trilateral, 180200 (3)|RB1|614041|13q14.2
Retinol dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3)|RBP4, RDCCAS|180250|10q23.33
Retinopathy of prematurity, 133780 (3)|FZD4, EVR1|604579|11q14.2
Retinoschisis, 312700 (3)|RS1, XLRS1|300839|Xp22.13
Rett syndrome, 312750 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Rett syndrome, congenital variant, 613454 (3)|FOXG1, FOXG1B, FKHL1, FKH2, QIN, BF1|164874|14q12
Rett syndrome, preserved speech variant, 312750 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Revesz syndrome, 268130 (3)|TINF2, TIN2, DKCA3|604319|14q12
Rh-mod syndrome (3)|RHAG, RH50A|180297|6p12.3
Rh-null disease, amorph type (3)|RHCE|111700|1p36.11
Rhabdoid predisposition syndrome 1, 609322 (3)|SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1|601607|22q11.23
Rhabdoid tumor predisposition syndrome 2, 613325 (3)|SMARCA4, BRG1, RTPS2, MRD16|603254|19p13.2
Rhabdoid tumors, somatic, 609322 (3)|SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1|601607|22q11.23
Rhabdomyolysis, cerivastatin-induced (3)|CYP2C8|601129|10q23.33
Rhabdomyosarcoma 2, alveolar, 268220 (3)|PAX3, WS1, HUP2, CDHS, WS3|606597|2q36.1
Rhabdomyosarcoma 2, alveolar, 268220 (3)|PAX7, RMS2|167410|1p36.13
Rhabdomyosarcoma, alveolar, 268220 (3)|FOXO1A, FKHR|136533|13q14.11
Rhabdomyosarcoma, embryonal, 2, 180295 (3)|DICER1, HERNA, KIAA0928, MNG1, RMSE2|606241|14q32.13
Rhabdomyosarcoma, somatic, 268210 (3)|SLC22A1L, BWSCR1A, IMPT1|602631|11p15.4
Rhizomelic chondrodysplasia punctata, type 1, 215100 (3)|PEX7, RCDP1, PBD9B|601757|6q23.3
Rhizomelic chondrodysplasia punctata, type 3, 600121 (3)|AGPS, ADHAPS|603051|2q31.2
Riboflavin deficiency, 615026 (3)|SLC52A1, GPR172B, GPCR42, PAR2, FLJ10060, RBFVD|607883|17p13.2
Ribose 5-phosphate isomerase deficiency, 608611 (3)|RPIA, RPI|180430|2p11.2
Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3)|CYP2R1|608713|11p15.2
Rickets, vitamin D-resistant, type IIA, 277440 (3)|VDR|601769|12q13.11
Rieger or Axenfeld anomalies, 602482 (3)|FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25.3
Rieger syndrome, type 2 (2)|RIEG2, RGS2|601499|13q14
Right atrial isomerism, 208530 (3)|GDF1, DTGA3, DORV, RAI|602880|19p13.11
Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3)|BRAT1, BAAT1, C7orf27, RMFSL|614506|7p22.3
Ring dermoid of cornea, 180550 (3)|PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25
Rippling muscle disease, 606072 (3)|CAV3, LGMD1C, LQT9|601253|3p25.3
Rippling muscle disease-1 (2)|RMD1|600332|1q41
Ritscher-Schinzel syndrome, 220210 (3)|KIAA0196, SPG8, RTSC|610657|8q24.13
Roberts syndrome, 268300 (3)|ESCO2|609353|8p21.1
Robin sequence with cleft mandible and limb anomalies, 268305 (3)|DDX48, EIF4A3, MUK34, NMP265, KIAA0111, RCPS|608546|17q25.3
Robinow syndrome, autosomal dominant, 180700 (3)|WNT5A|164975|3p14.3
Robinow syndrome, autosomal recessive, 268310 (3)|ROR2, BDB1, BDB, NTRKR2|602337|9q22.31
Robinow-Sorauf syndrome, 180750 (3)|TWIST1, ACS3, SCS, CRS1|601622|7p21.1
Roifman syndrome (2)|RFMN|300258|Chr.X
Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643 (3)|SRPX2, SRPUL, RESDX|300642|Xq22.1
Rothmund-Thomson syndrome, 268400 (3)|RECQL4, RTS, RECQ4|603780|8q24.3
Roussy-Levy syndrome, 180800 (3)|MPZ, CMT1B, CMTDID, CHM, DSS|159440|1q23.3
Roussy-Levy syndrome, 180800 (3)|PMP22, CMT1A, CMT1E, DSS|601097|17p12
Rubinstein-Taybi syndrome 2, 613684 (3)|EP300, RSTS2|602700|22q13.2
Rubinstein-Taybi syndrome, 180849 (3)|CREBBP, CBP, RSTS|600140|16p13.3
SARS infection, protection against (2)|CLEC4M, CD209L, LSIGN, DCSIGNR|605872|19p13.2
SBBYSS syndrome, 603736 (3)|KAT6B, MYST4, MORF, GTPTS|605880|10q22.2
SC phocomelia syndrome, 269000 (3)|ESCO2|609353|8p21.1
SCID due to LCK deficiency (1)|LCK|153390|1p35.1
SCID, autosomal recessive, T-negative/B-positive type, 600802 (3)|JAK3, JAKL|600173|19p13.11
SED congenita, 183900 (3)|COL2A1|120140|12q13.11
SED, Maroteaux type, 184095 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
SED, Namaqualand type (3)|COL2A1|120140|12q13.11
SERKAL syndrome, 611812 (3)|WNT4, SERKAL|603490|1p36.12
SESAME syndrome, 612780 (3)|KCNJ10, SESAME|602208|1q23.2
SFM syndrome, somatic mosaic, 163200 (3)|KRAS, KRAS2, RASK2, NS, CFC2|190070|12p12.1
SHORT syndrome, 269880 (3)|PIK3R1, GRB1, AGM7, SHORT|171833|5q13.1
SMED Strudwick type, 184250 (3)|COL2A1|120140|12q13.11
STAR syndrome, 300707 (3)|FAM58A, STAR|300708|Xq28
Saccharopinuria, 268700 (1)|AASS|605113|7q31.32
Saethre-Chotzen syndrome with eyelid anomalies, 101400 (3)|TWIST1, ACS3, SCS, CRS1|601622|7p21.1
Saethre-Chotzen syndrome, 101400 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Saethre-Chotzen syndrome, 101400 (3)|TWIST1, ACS3, SCS, CRS1|601622|7p21.1
Salla disease, 604369 (3)|SLC17A5, SIASD, SLD|604322|6q13
Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3)|HEXB|606873|5q13.3
Sarcoidosis, early-onset, 609464 (3)|NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12.1
Sarcoma, synovial (1)|SS18, SSXT, SYT|600192|18q11.2
Scalp-ear-nipple syndrome, 181270 (3)|KCTD1, SENS|613420|18q11.2
Scaphocephaly and Axenfeld-Rieger anomaly (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Scaphocephaly, maxillary retrusion, and mental retardation, 609579 (3)|FGFR2, BEK, CFD1, JWS, TK14, BBDS|176943|10q26.13
Scapuloperoneal myopathy, X-linked dominant, 300695 (3)|FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq26.3
Scapuloperoneal spinal muscular atrophy, 181405 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Scapuloperoneal syndrome, myopathic type, 181430 (3)|MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q11.2
Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3)|DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R|125660|2q35
Schimke immunoosseous dysplasia, 242900 (3)|SMARCAL1, HARP, SIOD|606622|2q35
Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3)|HRAS|190020|11p15.5
Schindler disease, type I, 609241 (3)|NAGA|104170|22q13.2
Schindler disease, type III, 609241 (3)|NAGA|104170|22q13.2
Schinzel-Giedion midface retraction syndrome, 269150 (3)|SETBP1, KIAA0437, SEB|611060|18q12.3
Schizencephaly, 269160 (3)|EMX2|600035|10q26.11
Schizencephaly, 269160 (3)|SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36.3
Schizensephaly, 269160 (3)|SIX3, HPE2|603714|2p21
Schizophrenia 16 (4)|SCZD16, C16DUPq36.3, DUP7q36.3|613959|7q36.3
Schizophrenia, 181500 (2)|DISC2|606271|1q42.2
Schizophrenia, neurophysiologic defect in (2)|CHRNA7|118511|15q13.3
Schneckenbecken dysplasia, 269250 (3)|SLC35D1, UGTREL7, KIAA0260|610804|1p31.3
Schopf-Schulz-Passarge syndrome, 224750 (3)|WNT10A, SSPS, STHAG4, OODD|606268|2q35
Schwannomatosis, 162091 (3)|NF2|607379|22q12.2
Schwartz-Jampel syndrome, type 1, 255800 (3)|HSPG2, PLC, SJS, SJA, SJS1|142461|1p36.12
Sclerosteosis 2, 614305 (3)|LRP4, MEGF7, CLSS, SOST2|604270|11p11.2
Sclerosteosis, 269500 (3)|SOST, VBCH, CDD|605740|17q21.31
Scoliosis, idiopathic 1 (2)|IS1, AIS|181800|19p13.3
Scoliosis, idiopathic 2 (2)|IS2, AIS2|607354|17p11.2
Scott syndrome, 262890 (3)|ANO6, TMEM16F, SCTS, BDPLT7|608663|12q12
Scurvy (3)|GULOP, GULO|240400|8p21.1
Sea-blue histiocyte disease, 269600 (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
Sebaceous tumors, somatic (3)|LEF1|153245|4q25
Sebastian syndrome, 605249 (3)|MYH9, MHA, FTNS, DFNA17, BDPLT6|160775|22q12.3
Seborrhea-like dermatitis with psoriasiform elements, 610227 (3)|ZNF750, FLJ13841|610226|17q25.3
Seckel syndrome 1, 210600 (3)|ATR, FRP1, SCKL1, FCTCS|601215|3q23
Seckel syndrome 2, 606744 (3)|RBBP8, RIM, SCKL2, JWDS|604124|18q11.2
Seckel syndrome 3 (2)|SCKL3|608664|14q21-q22
Seckel syndrome 4, 613676 (3)|CENPJ, CPAP, MCPH6, SCKL4|609279|13q12.12
Seckel syndrome 5, 613823 (3)|CEP152, KIAA0912, MCPH9, SCKL5|613529|15q21.1
Seckel syndrome 7, 614851 (3)|NIN, KIAA1565, SCKL7|608684|14q22.1
Segawa syndrome, recessive, 605407 (3)|TH, TYH|191290|11p15.5
Seizures, benign familial infantile, 1 (2)|BFIS1, BFIC1|601764|19q
Seizures, benign familial infantile, 2, 605751 (3)|PRRT2, PKC, DYT10, EKD1, BFIS2, BFIC2, ICCA|614386|16p11.2
Seizures, benign familial infantile, 3, 607745 (3)|SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS|182390|2q24.3
Seizures, benign familial infantile, 4 (2)|BFIS4, BFIC4|612627|1p36.12-p35.1
Seizures, benign neonatal, 1, 121200 (3)|KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.33
Seizures, benign neonatal, type 2, 121201 (3)|KCNQ3, EBN2, BFNC2|602232|8q24.22
Selective T-cell defect, 269840 (3)|ZAP70, SRK, STD, STCD|176947|2q11.2
Sengers syndrome, 212350 (3)|AGK, MULK, MTDPS10, CATC5, CTRCT38|610345|7q34
Senior-Loken syndrome 3 (2)|SLSN3|606995|3q22
Senior-Loken syndrome 4, 606996 (3)|NPHP4, SLSN4|607215|1p36.31
Senior-Loken syndrome 5, 609254 (3)|IQCB1, NPHP5, KIAA0036|609237|3q13.33
Senior-Loken syndrome 6, 610189 (3)|CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.32
Senior-Loken syndrome 7, 613615 (3)|SDCCAG8, CCCAP SLSN7|613524|1q43
Senior-Loken syndrome-1, 266900 (3)|NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Sensorineural deafness with mild renal dysfunction, 602522 (3)|BSND|606412|1p32.3
Septooptic dysplasia, 182230 (3)|HESX1, RPX, CPHD5|601802|3p14.3
Severe combined immunodeficiency due to ADA deficiency, 102700 (3)|ADA|608958|20q13.12
Severe combined immunodeficiency due to IL2 deficiency (1)|IL2|147680|4q27
Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)|NHEJ1, XLF|611290|2q35
Severe combined immunodeficiency with sensitivity to ionizing radiation, 602450 (3)|LIG4|601837|13q33.3
Severe combined immunodeficiency, Athabascan type, 602450 (3)|DCLRE1C, ARTEMIS, SCIDA|605988|10p13
Severe combined immunodeficiency, B cell-negative, 601457 (3)|RAG1|179615|11p12
Severe combined immunodeficiency, B cell-negative, 601457 (3)|RAG2|179616|11p12
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3)|PTPRC, CD45, LCA|151460|1q31.3-q32.1
Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3)|IL7R, IL7RA, CD127|146661|5p13.2
Severe combined immunodeficiency, X-linked, 300400 (3)|IL2RG, SCIDX1, SCIDX, IMD4|308380|Xq13.1
Shaheen syndrome, 615328 (3)|COG6, COD2, KIAA1134, CDG2L, SHNS|606977|13q14.11
Short QT syndrome 1, 609620 (3)|KCNH2, LQT2, HERG, SQT1|152427|7q36.1
Short QT syndrome 2, 609621 (3)|KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5-p15.4
Short QT syndrome 3, 609622 (3)|KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9|600681|17q24.3
Short stature, 604271 (3)|GHR|600946|5p13-p12
Short stature, 604271 (3)|GHSR|601898|3q26.31
Short stature, idiopathic familial, 300582 (3)|SHOX, GCFX, SS, PHOG|312865|Xp22.33
Short stature, idiopathic familial, 300582 (3)|SHOXY|400020|Yp11.32
Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3)|POC1A, PIX2, SOFT|614783|3p21.2
Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 (3)|NBAS, NAG, SOPH|608025|2p24.3
Short-rib thoracic dysplasia 1 with or without polydactyly (2)|SRTD1, ATD1|208500|15q13
Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3)|IFT172, SLB, KIAA1179, SRTD10|607386|2p23.3
Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3)|WDR34, SRTD11|613363|9q34.11
Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3)|IFT80, KIAA1374, WDR56, SRTD2, ATD2|611177|3q25.33
Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3)|DYNC2H1, DNCH2, DHC2, ATD3, SRPS2B, SRTD3|603297|11q22.3
Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3)|TTC21B, THM1, NPHP12, SRTD4, ATD4|612014|2q24.3
Short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3)|WDR19, SRTD5, ATD5, NPHP13, CED4|608151|4p14
Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3)|NEK1, SRTD6, SRPS2A|604588|4q33
Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3)|WDR35, NAOFEN, KIAA1336, CED2, SRTD7|613602|2p24.1
Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3)|WDR60, SRTD8, SRPS6|615462|7q36.3
Short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3)|IFT140, KIAA0590, SRTD9, MZSDS|614620|16p13.3
Shprintzen-Goldberg syndrome, 182212 (3)|SKI, SGS|164780|1p36.33
Shwachman-Bodian-Diamond syndrome, 260400 (3)|SBDS, SDS|607444|7q11.21
Sialic acid storage disorder, infantile, 269920 (3)|SLC17A5, SIASD, SLD|604322|6q13
Sialidosis, type I, 256550 (3)|NEU1, NEU, SIAL1|608272|6p21.33
Sialidosis, type II, 256550 (3)|NEU1, NEU, SIAL1|608272|6p21.33
Sialuria, 269921 (3)|GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Sick sinus syndrome 1, 608567 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Sick sinus syndrome 2, 163800 (3)|HCN4, SSS2|605206|15q24.1
Sickle cell anemia, 603903 (3)|HBB|141900|11p15.4
Silver spastic paraplegia syndrome, 270685 (3)|BSCL2, SPG17, HMN5|606158|11q12.3
Silver-Russell syndrome (4)|SRS, RSS|180860|7p11.2
Silver-Russell syndrome, 180860 (3)|H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Simpson-Golabi-Behmel syndrome, type 1, 312870 (3)|GPC3, SDYS, SGBS1|300037|Xq26.2
Simpson-Golabi-Behmel syndrome, type 2, 300209 (3)|OFD1, CXorf5, SGBS2, JBTS10, RP23|300170|Xp22.2
Single median maxillary central incisor, 147250 (3)|SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36.3
Sinoatrial node dysfunction and deafness, 614896 (3)|CACNA1D, CACNL1A2, CCHL1A2, SANDD, PASNA|114206|3p21.1
Sitosterolemia, 210250 (3)|ABCG5|605459|2p21
Sitosterolemia, 210250 (3)|ABCG8, GBD4|605460|2p21
Sjogren-Larsson syndrome, 270200 (3)|ALDH3A2, ALDH10, SLS, FALDH|609523|17p11.2
Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3)|ZBTB16, ZNF145, PLZF|176797|11q23.2
Skin fragility-woolly hair syndrome, 607655 (3)|DSP, KPPS2, PPKS2|125647|6p24.3
Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair), 612271 (3)|TYRP1, CAS2, GP75, SHEP11|115501|9p23
Slowed nerve conduction velocity, AD, 608236 (3)|ARHGEF10, KIAA0294|608136|8p23.3
Small cell cancer of the lung, somatic, 182280 (3)|RB1|614041|13q14.2
Small fiber neuropathy, 133020 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
Small patella syndrome, 147891 (3)|TBX4|601719|17q23.2
Small-cell cancer of lung (2)|SCLC1|182280|3p23-p21
Smith-Lemli-Opitz syndrome, 270400 (3)|DHCR7, SLOS|602858|11q13.4
Smith-Magenis syndrome, 182290 (3)|RAI1, SMCR, SMS|607642|17p11.2
Smith-McCort dysplasia 2, 615222 (3)|RAB33B, SMC2|605950|4q31.1
Smith-McCort dysplasia, 607326 (3)|DYM, FLJ90130, DMC, SMC|607461|18q21.1
Snowflake vitreoretinal degeneration, 193230 (3)|KCNJ13, SVD, LCA16|603208|2q37.1
Somatostatin analog, resistance to, 102200 (3)|SSTR5|182455|16p13.3
Sorsby fundus dystrophy, 136900 (3)|TIMP3, SFD|188826|22q12.3
Sotos syndrome 1, 117550 (3)|NSD1, ARA267, STO, SOTOS1|606681|5q35.2-q35.3
Sotos syndrome 2, 614753 (3)|NFIX, NF1A, SOTOS2, MRSHSS|164005|19p13.2
Spastic ataxia 1, autosomal dominant (2)|SPAX1|108600|12p13
Spastic ataxia 2, autosomal recessive, 611302 (3)|KIF1C, LTXS1, KIAA0706, SPAX2|603060|17p13.2
Spastic ataxia 3, autosomal recessive, 611390 (3)|MARS2, SPAX3|609728|2q33.1
Spastic ataxia, Charlevoix-Saguenay type, 270550 (3)|SACS, ARSACS|604490|13q12.12
Spastic paralysis, infantile onset ascending, 607225 (3)|ALS2, ALSJ, PLSJ, IAHSP|606352|2q33.1
Spastic paraplegia 10, autosomal dominant, 604187 (3)|KIF5A, NKHC, SPG10|602821|12q13.3
Spastic paraplegia 11, autosomal recessive, 604360 (3)|SPG11, KIAA1840, FLJ21439|610844|15q21.1
Spastic paraplegia 12, autosomal dominant, 604805 (3)|RTN2, NSPL1, SPG12|603183|19q13.32
Spastic paraplegia 13, autosomal dominant, 605280 (3)|HSPD1, SPG13, HSP60, HLD4|118190|2q33.1
Spastic paraplegia 14, autosomal recessive (2)|SPG14|605229|3q27-q28
Spastic paraplegia 15, autosomal recessive, 270700 (3)|ZFYVE26, KIAA0321, SPG15|612012|14q24.1
Spastic paraplegia 16, X-linked, complicated (2)|SPG16|300266|Xq11.2
Spastic paraplegia 18, autosomal recessive, 611225 (3)|ERLIN2, SPFH2, C8orf2, SPG18|611605|8p11.23
Spastic paraplegia 19, autosomal dominant (2)|SPG19|607152|9q
Spastic paraplegia 2, X-linked, 312920 (3)|PLP1, PMD, HLD1, SPG2|300401|Xq22.2
Spastic paraplegia 24, autosomal recessive (2)|SPG24|607584|13q14
Spastic paraplegia 25, autosomal recessive (2)|SPG25|608220|6q23-q24.1
Spastic paraplegia 26, autosomal recessive (2)|SPG26|609195|12p11.1-q14
Spastic paraplegia 26, autosomal recessive, 609195 (3)|B4GALNT1, GALGT, GALNACT, SPG26|601873|12q13.3
Spastic paraplegia 27, autosomal recessive (2)|SPG27|609041|10q22.1-q24.1
Spastic paraplegia 28, autosomal recessive, 609340 (3)|DDHD1, PAPLA1, KIAA1705, SPG28|614603|14q22.1
Spastic paraplegia 29, autosomal dominant (2)|SPG29|609727|1p31.1-p21.1
Spastic paraplegia 30, autosomal recessive, 610357 (3)|KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9|601255|2q37.3
Spastic paraplegia 31, autosomal dominant, 610250 (3)|REEP1, C2ORF23, SPG31, HMN5B|609139|2p11.2
Spastic paraplegia 32, autosomal recessive (2)|SPG32|611252|14q12-q21
Spastic paraplegia 33, autosomal dominant, 610244 (3)|ZFYVE27, SPG33|610243|10q24.2
Spastic paraplegia 34, X-linked (2)|SPG34|300750|Xq24-q25
Spastic paraplegia 35, autosomal recessive, 612319 (3)|FA2H, FAAH, FAXDC1, FAH1, SCS7, SPG35|611026|16q23.1
Spastic paraplegia 36, autosomal dominant (2)|SPG36|613096|12q23-q24
Spastic paraplegia 37, autosomal dominant (2)|SPG37|611945|8p21.1-q13.3
Spastic paraplegia 38, autosomal dominant (2)|SPG38|612335|4p16-p15
Spastic paraplegia 39, autosomal recessive, 612020 (3)|PNPLA6, NTE, SPG39, NTEMND, BNHS|603197|19p13.2
Spastic paraplegia 3A, autosomal dominant, 182600 (3)|ATL1, SPG3A, HSN1D|606439|14q22.1
Spastic paraplegia 4, autosomal dominant, 182601 (3)|SPAST, SPG4|604277|2p22.3
Spastic paraplegia 42, autosomal dominant, 612539 (3)|SLC33A1, ACATN, AT1, SPG42, CCHLND|603690|3q25.31
Spastic paraplegia 44, autosomal recessive, 613206 (3)|GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q42.13
Spastic paraplegia 45, 613162 (3)|NT5C2, NT5B, PNT5, SPG45|600417|10q24.32-q24.33
Spastic paraplegia 45, autosomal recessive (2)|SPG45|613162|10q24.3-q25.1
Spastic paraplegia 46, autosomal recessive, 614409 (3)|GBA2, KIAA1605, SPG46|609471|9p13.3
Spastic paraplegia 47, autosomal recessive, 614066 (3)|AP4B1, SPG47, CPSQ5|607245|1p13.2
Spastic paraplegia 48, autosomal recessive, 613647 (3)|AP5Z1, KIAA0415, SPG48|613653|7p22.1
Spastic paraplegia 49, autosomal recessive, 615031 (3)|TECPR2, KIAA0329, SPG49|615000|14q32.31
Spastic paraplegia 50, autosomal recessive, 612936 (3)|AP4M1, SPG50, CPSQ3|602296|7q22.1
Spastic paraplegia 51, autosomal recessive, 613744 (3)|AP4E1, SPG51, CPSQ4|607244|15q21.2
Spastic paraplegia 52, autosomal recessive, 614067 (3)|AP4S1, CPSQ6, SPG52|607243|14q12
Spastic paraplegia 53, autosomal recessive, 614898 (3)|VPS37A, HCRP1, SPG53|609927|8p22
Spastic paraplegia 54, autosomal recessive, 615033 (3)|DDHD2, KIAA0725, SPG54|615003|8p11.23
Spastic paraplegia 55, autosomal recessive, 615035 (3)|C12orf65, COXPD7, SPG55|613541|12q24.31
Spastic paraplegia 56, autosomal recessive, 615030 (3)|CYP2U1, SPG56|610670|4q25
Spastic paraplegia 5A, autosomal recessive, 270800 (3)|CYP7B1, CBAS3, SPG5A|603711|8q12.3
Spastic paraplegia 6, autosomal dominant, 600363 (3)|NIPA1, SPG6|608145|15q11.2
Spastic paraplegia 64, 615683 (3)|ENTPD1, CD39, SPG64|601752|10q24.1
Spastic paraplegia 7, autosomal recessive, 607259 (3)|PGN, SPG7, CMAR, CAR|602783|16q24.3
Spastic paraplegia 8, autosomal dominant, 603563 (3)|KIAA0196, SPG8, RTSC|610657|8q24.13
Spastic paraplegia 9, autosomal dominant (2)|SPG9|601162|10q23.3-q24.1
Spastic paraplegia, optic atrophy, and neuropathy (2)|SPOAN|609541|11q13
Specific granule deficiency, 245480 (3)|CEBPE, CRP1|600749|14q11.2
Specific language impairment QTL, 1 (2)|SLI1|606711|16q
Specific language impairment QTL, 2 (2)|SLI2|606712|19q
Specific language impairment QTL, 3 (2)|SLI3|607134|13q21
Speech-language disorder-1, 602081 (3)|FOXP2, SPCH1, TNRC10, CAGH44|605317|7q31.1
Spermatocytic seminoma, somatic, 273300 (3)|FGFR3, ACH|134934|4p16.3
Spermatogenic failure 10, 614822 (3)|SEPT12, SPGF10|611562|16p13.3
Spermatogenic failure 11, 615081 (3)|KLHL10, SPGF11|608778|17q21.2
Spermatogenic failure 12, 615413 (3)|NANOS1, NOS1, SPGF12|608226|10q26.11
Spermatogenic failure 2 (2)|SPGF2, ASG|108420|Chr.1
Spermatogenic failure 3, 606766 (3)|SLC26A8, TAT1, SPGF3|608480|6p21.31
Spermatogenic failure 4, 270960 (3)|SYCP3, SCP3, COR1, SPGF4|604759|12q23.2
Spermatogenic failure 5, 243060 (3)|STK13, AIE2, SPGF5|603495|19q13.43
Spermatogenic failure 6, 102530 (3)|SPATA16, SPGF6|609856|3q26.31
Spermatogenic failure 7, 612997 (3)|CATSPER1, CATSPER, SPGF7|606389|11q13.1
Spermatogenic failure 8, 613957 (3)|NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8|184757|9q33.3
Spermatogenic failure 9, 613958 (3)|DPY19L2, SPGF9|613893|12q14.2
Spermatogenic failure, X-linked, 2 (2)|SPGFX2|309120|Chr.X
Spermatogenic failure, Y-linked, 1 (4)|DELYq11, CYDELq11, SPGFY1|400042|Yq11
Spermatogenic failure, Y-linked, 2, 415000 (3)|USP9Y, DFFRY, SPGFY2|400005|Yq11.21
Spherocytosis, hereditary, type 5, 612690 (3)|EPB42, SPH5|177070|15q15.2
Spherocytosis, type 1, 182900 (3)|ANK1, SPH2|612641|8p11.21
Spherocytosis, type 2 (3)|SPTB, SPH2, EL3, HS2|182870|14q23.3
Spherocytosis, type 3, 270970 (3)|SPTA1, EL2, SPH3, HS3, HPP|182860|1q23.1
Spherocytosis, type 4, 612653 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
Spiegler-Brooke syndrome (2)|SBS|605041|16q12-q13
Spinal and bulbar muscular atrophy of Kennedy, 313200 (3)|AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq12
Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3)|ASAH1, AC, SMAPME|613468|8p22
Spinal muscular atrophy, Jokela type (2)|SMAJ|615048|22q11.2-q13.2
Spinal muscular atrophy, X-linked 2, infantile, 301830 (3)|UBA1, UBE1, GXP1, A1ST, SMAX2, AMCX1|314370|Xp11.23
Spinal muscular atrophy, chronic distal, autosomal recessive (2)|SMAR|607088|11q13
Spinal muscular atrophy, distal, X-linked 3, 300489 (3)|ATP7A, MNK, MK, OHS, SMAX3|300011|Xq21.1
Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3)|PLEKHG5, KIAA0720, DSMA4, CMTRIC|611101|1p36.31
Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 (3)|DNAJB2, HSJ1, HSPF3, DSMA5|604139|2q35
Spinal muscular atrophy, distal, congenital nonprogressive, 600175 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Spinal muscular atrophy, late-onset, Finkel type, 182980 (3)|VAPB, VAPC, ALS8|605704|20q13.32
Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 (3)|BICD2, KIAA0699, SMALED2|609797|9q22.31
Spinal muscular atrophy, lower extremity-predominant, AD, 158600 (3)|DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1|600112|14q32.31
Spinal muscular atrophy-1, 253300 (3)|SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q13.2
Spinal muscular atrophy-2, 253550 (3)|SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q13.2
Spinal muscular atrophy-3, 253400 (3)|SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q13.2
Spinal muscular atrophy-4, 271150 (3)|SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q13.2
Spinocerebellar ataxia 1, 164400 (3)|ATXN1, ATX1, SCA1|601556|6p22.3
Spinocerebellar ataxia 10, 603516 (3)|ATXN10, SCA10|611150|22q13.31
Spinocerebellar ataxia 11, 604432 (3)|TTBK2, SCA11|611695|15q15.2
Spinocerebellar ataxia 12, 604326 (3)|PPP2R2B|604325|5q32
Spinocerebellar ataxia 13, 605259 (3)|KCNC3, SCA13|176264|19q13.33
Spinocerebellar ataxia 14, 605361 (3)|PRKCG, PKCC, PKCG, SCA14|176980|19q13.42
Spinocerebellar ataxia 15, 606658 (3)|ITPR1, SCA15, SCA16, SCA29|147265|3p26.1
Spinocerebellar ataxia 17, 607136 (3)|TBP, SCA17, HDL4|600075|6q27
Spinocerebellar ataxia 18 (2)|SCA18, SMNA|607458|7q22-q32
Spinocerebellar ataxia 19, 607346 (3)|KCND3, KCND3S, KCND3L, SCA19, SCA22|605411|1p13.2
Spinocerebellar ataxia 2, 183090 (3)|ATXN2, ATX2, SCA2, ASL13|601517|12q24.12
Spinocerebellar ataxia 20 (4)|SCA20, DUP11q12, C11DUPq12|608687|11q12
Spinocerebellar ataxia 21 (2)|SCA21|607454|7p21.3-p15.1
Spinocerebellar ataxia 23, 610245 (3)|PDYN, SCA23|131340|20p13
Spinocerebellar ataxia 25 (2)|SCA25|608703|2p21-p13
Spinocerebellar ataxia 27, 609307 (3)|FGF14, FHF4, SCA27|601515|13q33.1
Spinocerebellar ataxia 28, 610246 (3)|AFG3L2, SCA28, SPAX5|604581|18p11.21
Spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3)|ITPR1, SCA15, SCA16, SCA29|147265|3p26.1
Spinocerebellar ataxia 31, 117210 (3)|BEAN, SCA31|612051|16q21
Spinocerebellar ataxia 32 (2)|SCA32|613909|7q32-q33
Spinocerebellar ataxia 34 (2)|SCA34|133190|6p12.3-q16.2
Spinocerebellar ataxia 35, 613908 (3)|TGM6, TG6, TGY, SCA35|613900|20p13
Spinocerebellar ataxia 36, 614153 (3)|NOP56, SCA36|614154|20p13
Spinocerebellar ataxia 4 (2)|SCA4|600223|16q22.1
Spinocerebellar ataxia 5, 600224 (3)|SPTBN2, SCA5, SCAR14|604985|11q13.2
Spinocerebellar ataxia 6, 183086 (3)|CACNA1A, CACNL1A4, SCA6|601011|19p13.2
Spinocerebellar ataxia 7, 164500 (3)|ATXN7, SCA7, OPCA3|607640|3p14.1
Spinocerebellar ataxia 8, 608768 (3)|ATXN8OS, SCA8, KLHL1AS|603680|13q21.33
Spinocerebellar ataxia 8, 608768 (3)|ATXN8|613289|13q21
Spinocerebellar ataxia, X-linked 1 (2)|SCAX1, CLA2, OPCA|302500|Xp11.21-q21.3
Spinocerebellar ataxia, X-linked 5 (2)|SCAX5|300703|Xq25-q27.1
Spinocerebellar ataxia, autosomal recessive 10, 613728 (3)|ANO10, TMEM16K, SCAR10|613726|3p22.1
Spinocerebellar ataxia, autosomal recessive 11, 614229 (3)|SYT14, SCAR11|610949|1q32.2
Spinocerebellar ataxia, autosomal recessive 12 (2)|SCAR12|614322|16q21-q23
Spinocerebellar ataxia, autosomal recessive 13, 614831 (3)|GRM1, MGLUR1, GRM1A, SCAR13|604473|6q24.3
Spinocerebellar ataxia, autosomal recessive 14, 615386 (3)|SPTBN2, SCA5, SCAR14|604985|11q13.2
Spinocerebellar ataxia, autosomal recessive 2 (2)|SCAR2, CPD3|213200|9q34-qter
Spinocerebellar ataxia, autosomal recessive 3 (2)|SCAR3, SCABD|271250|6p23-p21
Spinocerebellar ataxia, autosomal recessive 4 (2)|SCAR4, SCASI|607317|1p36
Spinocerebellar ataxia, autosomal recessive 5, 606937 (3)|ZNF592, KIAA0211, SCAR5, CAMOS|613624|15q25.3
Spinocerebellar ataxia, autosomal recessive 6 (2)|SCAR6, CLA3|608029|20q11-q13
Spinocerebellar ataxia, autosomal recessive 7, 609270 (3)|TPP1, CLN2, SCAR7|607998|11p15.4
Spinocerebellar ataxia, autosomal recessive 8, 610743 (3)|SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4|608441|6q25.1-q25.2
Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3)|TDP1|607198|14q32.11
Spinocrebellar ataxia, autosomal recessive 12, 614322 (3)|WWOX, FOR, SCAR12|605131|16q23.1-q23.2
Split hand/foot malformation 1 (4)|SHFM1, SHFD1, SHSF1|183600|7q21.2-q21.3
Split hand/foot malformation 2 (2)|SHFM2, SHFD2|313350|Xq26
Split-hand/foot malformation 3, gene duplication syndrome (4)|SHFM3, SHSF3, DUP10q24, C10DUPq24|246560|10q24
Split-hand/foot malformation 4, 605289 (3)|TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q28
Split-hand/foot malformation 5 (2)|SHFM5|606708|2q31
Split-hand/foot malformation 6, 225300 (3)|WNT10B, SHFM6|601906|12q13.12
Split-hand/foot malformation with long bone deficiency 1 (2)|SHFL1, SHFLD|119100|1q42.2-q43
Split-hand/foot malformation with long bone deficiency 2 (2)|SHFLD2|610685|6q14.1
Split-hand/foot malformation with long bone deficiency 3 (2)|SHFLD3|612576|17p13.3-p13.1
Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3)|NKX3-2, BAPX1, SMMD|602183|4p15.33
Spondylocarpotarsal synostosis syndrome, 272460 (3)|FLNB, SCT, AOI, LRS1|603381|3p14.3
Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3)|SLC39A13|608735|11p11.2
Spondylocostal dysostosis 1, autosomal recessive, 277300 (3)|DLL3, SCDO1|602768|19q13.2
Spondylocostal dysostosis 2, autosomal recessive, 608681 (3)|MESP2, SCDO2|605195|15q26.1
Spondylocostal dysostosis 3, autosomal recessive, 609813 (3)|LFNG, SCDO3|602576|7p22.3
Spondylocostal dysostosis 4, autosomal recessive, 613686 (3)|HES7, SCDO4|608059|17p13.1
Spondyloenchondrodysplasia with immune dysregulation, 607944 (3)|ACP5, SPENCDI|171640|19p13.2
Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3)|B3GALT6, SEMDJL1, EDSP2|615291|1p36.33
Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3)|KIF22, KNSL4, KID, OBP, SEMDJL2|603213|16p11.2
Spondyloepimetaphyseal dysplasia, 608728 (3)|MATN3, EDM5, HOA, OS2|602109|2p24.1
Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3)|MMP13, CLG3, MANDP1|600108|11q22.2
Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3)|ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3)|WISP3, PPAC, PPD|603400|6q21
Spondyloepiphyseal dysplasia tarda, 313400 (3)|TRAPPC2, SEDL, SEDT|300202|Xp22.2
Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3)|CHST3, C6ST, C6ST1, HSD|603799|10q22.1
Spondyloepiphyseal dysplasia, Kimberley type, 608361 (3)|ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3)|DDR2, NTRKR3, TKT|191311|1q23.3
Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3)|PCYT1A, CTPCT, PCYT1, SMDCRD|123695|3q29
Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
Spondyloperipheral dysplasia, 271700 (3)|COL2A1|120140|12q13.11
Squamous cell carcinoma, burn scar-related, somatic (3)|TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q23.31
Squamous cell carcinoma, head and neck, 275355 (3)|TNFRSF10B, DR5, TRAILR2|603612|8p21.3
Squamous cell carcinoma, head and neck, somatic, 275355 (3)|ING1|601566|13q34
Squamous cell carcinoma, head and neck, somatic, 275355 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Stapes ankylosis with broad thumb and toes, 184460 (3)|NOG, SYM1, SYNS1|602991|17q22
Stargardt disease 1, 248200 (3)|ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Stargardt disease 3, 600110 (3)|ELOVL4, ADMD, STGD2, STGD3, ISQMR|605512|6q14.1
Stargardt disease 4 (2)|STGD4|603786|4p
Stargardt disease 4, 603786 (3)|PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.32
Steatocystoma multiplex, 184500 (3)|KRT17, PC2, PCHC1|148069|17q21.2
Stickler sydrome, type I, nonsyndromic ocular, 609508 (3)|COL2A1|120140|12q13.11
Stickler syndrome, type I, 108300 (3)|COL2A1|120140|12q13.11
Stickler syndrome, type II, 604841 (3)|COL11A1, STL2|120280|1p21.1
Stickler syndrome, type III, 184840 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Stickler syndrome, type IV, 614134 (3)|COL9A1, EDM6, STL4|120210|6q13
Stickler syndrome, type V, 614284 (3)|COL9A2, EDM2, STL5|120260|1p34.2
Stiff skin syndrome, 184900 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Stocco dos Santos X-linked mental retardation syndrome, 300434 (3)|SHROOM4, KIAA1202, SDSX|300579|Xp11.22
Striatal degeneration, autosomal dominant, 609161 (3)|PDE8B, PPNAD3, ADSD|603390|5q13.3
Striatonigral degeneration, infantile, 271930 (3)|NUP62, SNDI, IBSN|605815|19q13.33
Sturge-Weber syndrome, somatic, mosaic, 185300 (3)|GNAQ, SWS, CMC1|600998|9q21.2
Stuttering, familial persistent 1 (2)|STUT1|184450|18p11.3-p11.2
Stuttering, familial persistent 2 (2)|STUT2|609261|12q24.1
Stuttering, familial persistent, 3 (2)|STUT3|614655|3q13.2-q13.33
Stuttering, familial persistent, 4 (2)|STUT4|614668|16q12.1-q23.1
Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3)|LIFR, STWS, SWS, SJS2|151443|5p13.1
Subcortical laminal heteropia, X-linked, 300067 (3)|DCX, DBCN, LISX|300121|Xq23
Subcortical laminar heterotopia, 607432 (3)|PAFAH1B1, LIS1|601545|17p13.3
Succinic semialdehyde dehydrogenase deficiency, 271980 (3)|ALDH5A1, SSADH|610045|6p22.3
Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 (3)|OXCT1, OXCT, SCOT|601424|5p13.1
Sucrase-isomaltase deficiency, congenital, 222900 (3)|SI|609845|3q26.1
Sudden infant death with dysgenesis of the testes syndrome, 608800 (3)|TSPYL1, TSPYL, SIDDT|604714|6q22.1
Sulfite oxidase deficiency, 272300 (3)|SUOX|606887|12q13.2
Supernumerary der(22)t(8-22) syndrome (4)|DER22t8-22|613700|22q11.2
Supranuclear palsy, progressive atypical, 260540 (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
Supranuclear palsy, progressive, 2 (2)|PSNP2|609454|1q31.1
Supranuclear palsy, progressive, 3 (2)|PSNP3|610898|11p12-p11
Supranuclear palsy, progressive, 601104 (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
Supravalvar aortic stenosis, 185500 (3)|ELN|130160|7q11.23
Surfactant metabolism dysfunction, pulmonary, 1, 265120 (3)|SFTPB, SFTB3, SMDP1|178640|2p11.2
Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3)|SFTPC, SFTP2, SMDP2|178620|8p21.3
Surfactant metabolism dysfunction, pulmonary, 3, 610921 (3)|ABCA3, ABC3, SMDP3|601615|16p13.3
Surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)|CSF2RA, SMDP4|306250|Xp22.33
Surfactant metabolism dysfunction, pulmonary, 5, 614370 (3)|CSF2RB, SMDP5|138981|22q12.3
Sveinsson choreoretinal atrophy, 108985 (3)|TEAD1, TCF13, REF1|189967|11p15.3-p15.2
Sweat chloride elevation without CF (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
Symphalangism, proximal, 185800 (3)|NOG, SYM1, SYNS1|602991|17q22
Symphalangism, proximal, 1B, 615298 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
Syndactyly, type 1 (4)|CUP2q35, C2DUPq35, SDTY1, SD1|185900|2q34-q36
Syndactyly, type III, 186100 (3)|GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR|121014|6q22.31
Syndactyly, type IV, 186200 (3)|LMBR1, ACHP, C7orf2, PPD2|605522|7q36.3
Syndactyly, type V, 186300 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Synesthesia (2)|SYNSTH|612759|2q24.1
Synpolydactyly 3 (2)|SPD3|610234|14q11.2-q12
Synpolydactyly with foot anomalies, 186000 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (3)|FBLN1|135820|22q13.31
Synpolydactyly, type II, 186000 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
Systemic lupus erythematosus 16, 614420 (3)|DNASE1L3, SLEB16|602244|3p14.3
T-cell acute lymphoblastic leukemia, 613065 (3)|BAX|600040|19q13.33
T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3)|FOXN1, WHN|600838|17q11.2
T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3)|STK4, MST1, KRS2, TIIAC|604965|20q13.12
T-cell prolymphocytic leukemia, somatic (3)|ATM, ATA, AT1|607585|11q22.3
TARP syndrome, 311900 (3)|RBM10, DXS8237E, KIAA0122, TARPS|300080|Xp11.23
Tangier disease, 205400 (3)|ABCA1, ABC1, HDLDT1, TGD|600046|9q31.1
Tarsal-carpal coalition syndrome, 186570 (3)|NOG, SYM1, SYNS1|602991|17q22
Tauopathy and respiratory failure (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
Tay-Sachs disease, 272800 (3)|HEXA, TSD|606869|15q23
Telangiectasia, hereditary benign (2)|HBT|187260|5q14
Telangiectasia, hereditary hemorrhagic, type 1, 187300 (3)|ENG, END, HHT1, ORW|131195|9q34.11
Telangiectasia, hereditary hemorrhagic, type 2, 600376 (3)|ACVRL1, ACVRLK1, ALK1, HHT2|601284|12q13.13
Telangiectasia, hereditary hemorrhagic, type 3 (2)|HHT3, ORW3|601101|5q31.3-q32
Telangiectasia, hereditary hemorrhagic, type 4 (2)|HHT4|610655|7p14
Telangiectasia, hereditary hemorrhagic, type 5, 615506 (3)|GDF2, BMP9, HHT5|605120|10q11.22
Temtamy preaxial brachydactyly syndrome, 605282 (3)|CHSY1, KIAA0990, TPBS|608183|15q26.3
Temtamy syndrome, 218340 (3)|C12orf57, C10, TEMTYS|615140|12p13.31
Terminal osseous dysplasia, 300244 (3)|FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS|300017|Xq28
Testicular germ cell tumor (2)|TGCT1|300228|Xq27
Testicular tumor, somatic, 273300 (3)|STK11, PJS, LKB1|602216|19p13.3
Tetra-amelia, autosomal recessive, 273395 (3)|WNT3, INT4|165330|17q21.31
Tetralogy of Fallot, 187500 (3)|GATA6, AVSD5, ASD9, AVSD5, PACHD|601656|18q11.2
Tetralogy of Fallot, 187500 (3)|GDF1, DTGA3, DORV, RAI|602880|19p13.11
Tetralogy of Fallot, 187500 (3)|JAG1, AGS, AHD|601920|20p12.2
Tetralogy of Fallot, 187500 (3)|TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.21
Tetralogy of Fallot, 187500 (3)|ZFPM2, FOG2, DIH3|603693|8q23.1
Tetrasomy 18p (4)|TET18P|614290|18p
Tetrology of Fallot, 187500 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Thalassemia due to Hb Lepore (3)|HBD|142000|11p15.4
Thalassemia, Hispanic gamma-delta-beta, 613985 (3)|LCRB|152424|11p15.5
Thalassemia, alpha-, 604131 (3)|HBA2, HBH|141850|16p13.3
Thalassemia, delta- (3)|HBD|142000|11p15.4
Thalassemia-beta, dominant inclusion-body, 603902 (3)|HBB|141900|11p15.4
Thalassemias, alpha-, 604131 (3)|HBA1, HBH|141800|16p13.3
Thalassemias, beta-, 613985 (3)|HBB|141900|11p15.4
Thanatophoric dysplasia, type I, 187600 (3)|FGFR3, ACH|134934|4p16.3
Thanatophoric dysplasia, type II, 187601 (3)|FGFR3, ACH|134934|4p16.3
Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3)|SLC19A3, THMD2, BBGD|606152|2q36.3
Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3)|SLC25A19, DNC, MUP1, MCPHA, THMD3, THMD4|606521|17q25.1
Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3)|TPK1, THMD5|606370|7q35
Thiamine-responsive megaloblastic anemia syndrome, 249270 (3)|SLC19A2, THTR1, TRMA, THMD1|603941|1q24.2
Thoracoabdominal syndrome (2)|THAS, TAS|313850|Xq25-q26.1
Three M syndrome 3, 614205 (3)|CCDC8, 3M3|614145|19q13.32
Thrombocythemia 1, 187950 (3)|THPO, MGDF, MPLLG, TPO, THCYT1|600044|3q27.1
Thrombocythemia 2, 601977 (3)|MPL, TPOR, MPLV, THCYT2|159530|1p34.2
Thrombocythemia 3, 614521 (3)|JAK2, THCYT3|147796|9p24.1
Thrombocythemia, X-linked (2)|THCYTX|300331|Chr.X
Thrombocythemia, somatic, 187950 (3)|CALR, SSA|109091|19p13.2
Thrombocythemia, somatic, 187950 (3)|SH2B3, LNK|605093|12q24.12
Thrombocytopenia 2, 188000 (3)|ANKRD26, KIAA1074, THC2|610855|10p12.1
Thrombocytopenia 4, 612004 (3)|CYCS, CYC, THC4|123970|7p15.3
Thrombocytopenia with beta-thalassemia, X-linked, 314050 (3)|GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP|305371|Xp11.23
Thrombocytopenia, X-linked, 313900 (3)|WAS, IMD2, THC1, SCNX|300392|Xp11.23
Thrombocytopenia, X-linked, intermittent, 313900 (3)|WAS, IMD2, THC1, SCNX|300392|Xp11.23
Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, 300367 (3)|GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP|305371|Xp11.23
Thrombocytopenia, congenital amegakaryocytic, 604498 (3)|MPL, TPOR, MPLV, THCYT2|159530|1p34.2
Thrombocytopenia, neonatal alloimmune (3)|ITGB3, GP3A, GT, BDPLT2, BDPLT16|173470|17q21.32
Thrombocytopenia, neonatal alloimmune, BAK antigen related (3)|ITGA2B, GP2B, CD41B, GT, BDPLT2, BDPLT16|607759|17q21.31
Thrombocytopenia-2, 188000 (3)|MASTL, FLJ14813, GWL, THC2|608221|10p12.1
Thrombocytopenia-absent radius syndrome, 274000 (3)|RBM8A, RBM8B, TAR, C1DELq21.1, DEL1q21.1|605313|1q21.1
Thrombocytopenic purpura, autoimmune, 188030 (1)|FCGR2C, CD32C|612169|1q23.3
Thrombophilia due to HRG deficiency, 613116 (3)|HRG, THPH11|142640|3q27.3
Thrombophilia due to activated protein C resistance, 188055 (3)|F5, THPH2, RPRGL1|612309|1q24.2
Thrombophilia due to antithrombin III deficiency, 613118 (3)|SERPINC1, AT3, AT3D, THPH7|107300|1q25.1
Thrombophilia due to elevated HRG, 613116 (1)|HRG, THPH11|142640|3q27.3
Thrombophilia due to heparin cofactor II deficiency, 612356 (3)|HCF2, HC2, SERPIND1, THPH10|142360|22q11.21
Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3)|PROC, PC, THPH3, THPH4|612283|2q14.3
Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3)|PROC, PC, THPH3, THPH4|612283|2q14.3
Thrombophilia due to protein S deficiency, autosomal dominant, 612336 (3)|PROS1, THPH5, THPH6|176880|3q11.1
Thrombophilia due to protein S deficiency, autosomal recessive, 614514 (3)|PROS1, THPH5, THPH6|176880|3q11.1
Thrombophilia due to thrombin defect, 188050 (3)|F2, THPH1, RPRGL2|176930|11p11.2
Thrombophilia due to thrombomodulin defect, 614486 (3)|THBD, THRM, AHUS6, THPH12|188040|20p11.21
Thrombophilia, X-linked, due to factor IX defect, 300807 (3)|F9, HEMB, THPH8|300746|Xq27.1
Thrombophilia, dysfibrinogenemic (3)|FGB|134830|4q31.3
Thrombophilia, dysfibrinogenemic (3)|FGG|134850|4q31.3
Thrombophilia, dysplasminogenemic (1)|PLG|173350|6q26
Thrombophilia, familial, due to decreased release of PLAT, 612348 (1)|PLAT, TPA|173370|8p11.21
Thrombosis, hyperhomocysteinemic, 236200 (3)|CBS|613381|21q22.3
Thrombotic thrombocytopenic purpura, familial, 274150 (3)|ADAMTS13, VWFCP, TTP|604134|9q34.2
Thryoid dyshormonogenesis 6, 607200 (3)|DUOX2, THOX2, TDH6|606759|15q21.1
Thyroid adenoma, hyperfunctioning, somatic (3)|TSHR, CHNG1|603372|14q31.1
Thyroid carcinoma with thyrotoxicosis (3)|TSHR, CHNG1|603372|14q31.1
Thyroid carcinoma, follicular, 188470 (3)|MINPP1, HIPER1|605391|10q23.2
Thyroid carcinoma, follicular, somatic, 188470 (3)|NRAS, ALPS4, NS6|164790|1p13.2
Thyroid carcinoma, follicular, somatic, 188470 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
Thyroid carcinoma, nonmedullary, 1 (2)|NMTC1|606240|2q21
Thyroid carcinoma, nonmedullary, with cell oxyphilia (2)|TCO|603386|19p13.2
Thyroid carcinoma, papillary, 188550 (3)|GOLGA5, RFG5, PTC5|606918|14q32.12
Thyroid carcinoma, papillary, 188550 (3)|NCOA4, ELE1, PTC3|601984|10q11.23
Thyroid carcinoma, papillary, 188550 (3)|PCM1, PTC4|600299|8p22
Thyroid carcinoma, papillary, 188550 (3)|TRIM24, TIF1, TIF1A, PTC6|603406|7q33-q34
Thyroid carcinoma, papillary, 188550 (3)|TRIM33, TIF1G, RFG7, PTC7|605769|1p13.2
Thyroid carcinoma, papillary, somatic, 188550 (3)|PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1|188830|17q24.2
Thyroid carcinoma, papillary, with papillary renal neoplasia (2)|PTCPRN, PRN1|605642|1q21
Thyroid dyshormonogenesis 1, 274400 (3)|SLC5A5, NIS, TDH1|601843|19p13.11
Thyroid dyshormonogenesis 2A, 274500 (3)|TPO, TPX, TDH2A|606765|2p25.3
Thyroid dyshormonogenesis 3, 274700 (3)|TG, AITD3, TDH3|188450|8q24.22
Thyroid dyshormonogenesis 4, 274800 (3)|IYD, DEHAL1, TDH4|612025|6q25.1
Thyroid dyshormonogenesis 5, 274900 (3)|DUOXA2, TDH5|612772|15q21.1
Thyroid hormone metabolism, abnormal, 609698 (3)|SECISBP2, SBP2|607693|9q22.2
Thyroid hormone resistance, 188570 (3)|THRB, ERBA2, THR1, PRTH|190160|3p24.2
Thyroid hormone resistance, autosomal recessive, 274300 (3)|THRB, ERBA2, THR1, PRTH|190160|3p24.2
Thyroid hormone resistance, selective pituitary, 145650 (3)|THRB, ERBA2, THR1, PRTH|190160|3p24.2
Thyroid papillary carcinoma, 188550 (1)|CCDC6, D10S170, H4, TST1, PTC, TPC|601985|10q21.2
Thyrotropin-releasing hormone deficiency, 275120 (1)|TRH|613879|3q22.1
Thyrotropin-releasing hormone resistance, generalized (3)|TRHR|188545|8q23.1
Thyroxine-binding globulin deficiency (3)|TBG|314200|Xq22.3
Tibial muscular dystrophy, tardive, 600334 (3)|TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31.2
Tietz albinism-deafness syndrome, 103500 (3)|MITF, WS2A, CMM8|156845|3p14-p13
Timothy syndrome, 601005 (3)|CACNA1C, CACNL1A1, CCHL1A1, TS|114205|12p13.33
Tn polyagglutination syndrome, somatic, 300622 (3)|C1GALT1C1, COSMC, C1GALT2, TNPS|300611|Xq24
Toenail dystrophy, isolated, 607523 (3)|COL7A1|120120|3p21.31
Tolbutamide poor metabolizer (3)|CYP2C9|601130|10q23.33
Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3)|MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3|142983|4p16.2
Tooth agenesis, selective, 2 (2)|STHAG2, HYD2|602639|16q12.1
Tooth agenesis, selective, 3, 604625 (3)|PAX9, STHAG3|167416|14q13.3
Tooth agenesis, selective, 4, 150400 (3)|WNT10A, SSPS, STHAG4, OODD|606268|2q35
Tooth agenesis, selective, 5 (2)|STHAG5|610926|10q11.2-q21
Tooth agenesis, selective, 6, 613097 (3)|LTBP3, LTBP2, STHAG6|602090|11q13.1
Tooth agenesis, selective, X-linked 1, 313500 (3)|ED1, EDA, ECTD1, EDA, HED1, STHAGX1|300451|Xq13.1
Total anomalous pulmonary venous return (2)|TAPVR1|106700|4q12
Tourette syndrome (2)|GTS|137580|11q23
Tourette syndrome, 137580 (3)|SLITRK1, KIAA1910, TTM|609678|13q31.1
Townes-Brocks branchiootorenal-like syndrome, 107480 (3)|SALL1, HSAL1, TBS|602218|16q12.1
Townes-Brocks syndrome, 107480 (3)|SALL1, HSAL1, TBS|602218|16q12.1
Transaldolase deficiency, 606003 (3)|TALDO1|602063|11p15.5
Transcobalamin II deficiency, 275350 (3)|TCN2, TC2|613441|22q12.2
Transient bullous of the newborn, 131705 (3)|COL7A1|120120|3p21.31
Transient erythroblastopenia of childhood (2)|TEC|227050|19q13.2
Transposition of great arteries, dextro-looped 3, 613854 (3)|GDF1, DTGA3, DORV, RAI|602880|19p13.11
Transposition of the great arteries, dextro-looped 1, 608808 (3)|MED13L, THRAP2, PROSIT240, TRAP240L, KIAA1025|608771|12q24.21
Transposition of the great arteries, dextro-looped 2, 613853 (3)|CFC1, CRYPTIC, HTX2, DTGA2|605194|2q21.1
Treacher Collins syndrome 1, 154500 (3)|TCOF1, MFD1, TCS1|606847|5q32
Treacher Collins syndrome 2, 613717 (3)|POLR1D, RPA16, RPAC2, TCS2|613715|13q12.2
Treacher Collins syndrome 3, 248390 (3)|POLR1C, RPA39, RPA40, RPAC1, RPA5, TCS3|610060|6p21.1
Trehalase deficiency, 612119 (1)|TREH|275360|11q23.3
Tremor, hereditary essential, 2 (2)|ETM2, ETM|602134|2p25-p22
Tremor, hereditary essential, 3 (2)|ETM3|611456|6p23
Tremor, hereditary essential, 4, 614782 (3)|FUS, TLS, ALS6, ETM4|137070|16p11.2
Trichilemmal cyst 1 (2)|TRICY1|609649|3p24-p21.2
Trichodontoosseous syndrome, 190320 (3)|DLX3, TDO, AI4|600525|17q21.33
Trichoepithelioma, multiple familial, 1, 601606 (3)|CYLD, CDMT, EAC, MFT1, KIAA0849, BRSS|605018|16q12.1
Trichoepithelioma, multiple familial, 2 (2)|MFT2, TEM|612099|9p21
Trichohepatoenteric syndrome 1, 222470 (3)|TTC37, KIAA0372|614589|5q15
Trichohepatoenteric syndrome 2, 614602 (3)|SKIV2L, SKI2, SKI2W, THES2|600478|6p21.33
Trichorhinophalangeal syndrome, type I, 190350 (3)|TRPS1|604386|8q23.3
Trichorhinophalangeal syndrome, type II (4)|TRPS2, LGCR, LGS|150230|8q24.11-q24.13
Trichorhinophalangeal syndrome, type III, 190351 (3)|TRPS1|604386|8q23.3
Trichothiodystrophy, 601675 (3)|ERCC2, EM9, XPD, COFS2|126340|19q13.32
Trichothiodystrophy, 601675 (3)|ERCC3, XPB|133510|2q14.3
Trichothiodystrophy, complementation group A, 601675 (3)|GTF2H5, TTDA, TFB5, C6orf175|608780|6q25.3
Trichothiodystrophy, nonphotosensitive 1, 234050 (3)|MPLKIP, C7orf11, ABHS, TTDN1|609188|7p14.1
Trichotillomania, 613229 (3)|SLITRK1, KIAA1910, TTM|609678|13q31.1
Trifunctional protein deficiency, 609015 (3)|HADHA, MTPA|600890|2p23.3
Trifunctional protein deficiency, 609015 (3)|HADHB|143450|2p23.3
Trigonocephaly 1, 190440 (3)|FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS|136350|8p11.23-p11.22
Trigonocephaly 2, 614485 (3)|FREM1, C9orf154, BNAR, MOTA, TRIGNO2|608944|9p22.3
Trimethylaminuria, 602079 (3)|FMO3, TMAU|136132|1q24.3
Triphalangeal thumb, type I, 174500 (3)|LMBR1, ACHP, C7orf2, PPD2|605522|7q36.3
Triphalangeal thumb-polysyndactyly syndrome, 174500 (3)|LMBR1, ACHP, C7orf2, PPD2|605522|7q36.3
Trismus-pseudocamptodactyly syndrome, 158300 (3)|MYH8|160741|17p13.1
Tropical calcific pancreatitis, 608189 (3)|SPINK1, PSTI, PCTT, TATI, TCP|167790|5q32
Troyer syndrome, 275900 (3)|SPG20|607111|13q13.3
Trypsinogen deficiency, 614044 (1)|PRSS1, TRY1|276000|7q34
Tuberous sclerosis-1, 191100 (3)|TSC1, LAM|605284|9q34.13
Tuberous sclerosis-2, 613254 (3)|TSC2, LAM|191092|16p13.3
Tukel syndrome (2)|TUKLS|609428|21q22
Tumor predisposition syndrome, 614327 (3)|BAP1, TPDS|603089|3p21.1
Tumoral calcinosis, familial, normophosphatemic, 610455 (3)|SAMD9, NFTC|610456|7q21.2
Tumoral calcinosis, hyperphosphatemic, 211900 (3)|KL, KLOTHO|604824|13q13.1
Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)|FGF23, ADHR, HPDR2, PHPTC|605380|12p13.32
Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)|GALNT3, HHS, HFTC|601756|2q24.3
Turner syndrome-associated neurocognitive phenotype (2)|VSPA|313000|Xp22.33
Tylosis with esophageal cancer, 148500 (3)|RHBDF2, IRHOM2, TOC|614404|17q25.1
Tyrosine kinase 2 deficiency, 611521 (3)|TYK2|176941|19p13.2
Tyrosinemia, type I, 276700 (3)|FAH|613871|15q25.1
Tyrosinemia, type II, 276600 (3)|TAT|613018|16q22.2
Tyrosinemia, type III, 276710 (3)|HPD|609695|12q24.31
Tyrosinemia, type Ib (1)|GSTZ1, MAAI|603758|14q24.3
UV-sensitive syndrome 1, 600630 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
UV-sensitive syndrome 2, 614621 (3)|ERCC8, CKN1, CSA, UVSS2|609412|5q12.1
UV-sensitive syndrome 3, 614640 (3)|UVSSA, KIAA1530, UVSS3|614632|4p16.3
Ullrich congenital muscular dystrophy, 254090 (3)|COL6A1, OPLL|120220|21q22.3
Ullrich congenital muscular dystrophy, 254090 (3)|COL6A2|120240|21q22.3
Ullrich congenital muscular dystrophy, 254090 (3)|COL6A3|120250|2q37.3
Ulna and fibula, absence of, with severe limb deficiency, 276820 (3)|WNT7A|601570|3p25.1
Ulnar-mammary syndrome, 181450 (3)|TBX3|601621|12q24.21
Urbach-Wiethe disease, 247100 (3)|ECM1, URBWD|602201|1q21.3
Urocanase deficiency, 276880 (3)|UROC1|613012|3q21.3
Urofacial syndrome 1, 236730 (3)|HPSE2, HPA2, UFS1|613469|10q24.2
Urofacial syndrome 2, 615112 (3)|LRIG2, LIG2, KIAA0806, UFS2|608869|1p13.2
Urogenital adysplasia, 191830 (3)|UPK3A, UPK3, UPIII|611559|22q13.31
Usher syndrome type 3B, 614504 (3)|HARS, USH3B|142810|5q31.3
Usher syndrome, type 1B, 276900 (3)|MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Usher syndrome, type 1C, 276904 (3)|USH1C, DFNB18A|605242|11p15.1
Usher syndrome, type 1D, 601067 (3)|CDH23, USH1D|605516|10q22.1
Usher syndrome, type 1D/F digenic, 601067 (3)|CDH23, USH1D|605516|10q22.1
Usher syndrome, type 1D/F digenic, 601067 (3)|PCDH15, DFNB23, USH1F|605514|10q21.1
Usher syndrome, type 1E (2)|USH1E|602097|21q21
Usher syndrome, type 1F, 602083 (3)|PCDH15, DFNB23, USH1F|605514|10q21.1
Usher syndrome, type 1G, 606943 (3)|SANS, USH1G|607696|17q25.1
Usher syndrome, type 1H (2)|USH1H|612632|15q22-q23
Usher syndrome, type 2A, 276901 (3)|USH2A, RP39|608400|1q41
Usher syndrome, type 2C, 605472 (3)|GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C|602851|5q14.3
Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 (3)|GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C|602851|5q14.3
Usher syndrome, type 2D, 611383 (3)|WHRN, CIP98, KIAA1526, DFNB31, USH2D|607928|9q32
Usher syndrome, type 3A, 276902 (3)|CLRN1, USH3A, USH3, RP61|606397|3q25.1
Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 (3)|PDZD7|612971|10q24.31
Usher syndrome, type IJ, 614869 (3)|CIB2, KIP2|605564|15q25.1
Usher syndrome, type IK (2)|USH1K|614990|10p11.21-q21.1
VACTERL association, 192350 (3)|HOXD13, HOX4I, SPD, BDSD|142989|2q31.1
VACTERL association, X-linked, 314390 (3)|ZIC3, HTX1, HTX, VACTERLX|300265|Xq26.3
VATER association with macrocephaly and ventriculomegaly, 276950 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
VLCAD deficiency, 201475 (3)|ACADVL, VLCAD|609575|17p13.1
Van Buchem disease, 239100 (3)|SOST, VBCH, CDD|605740|17q21.31
Van Maldergem syndrome 1, 601390 (3)|DCHS1, PCDH16, FIB1, CDH19, VMLDS1|603057|11p15.4
Van Maldergem syndrome 2, 615546 (3)|FAT4, VMLDS2|612411|4q28.1
Van den Ende-Gupta syndrome, 600920 (3)|SCARF2, SREC2, VDEGS|613619|22q11.21
Van der woude syndrome 2, 606713 (3)|GRHL3, SOM, TFCP2L4, VWS2|608317|1p36.11
Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3)|TREX1, AGS1, CRV, HERNS|606609|3p21.31
Velocardiofacial syndrome, 192430 (3)|TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.21
Venous malformations, multiple cutaneous and mucosal, 600195 (3)|TEK, TIE2, VMCM|600221|9p21.2
Ventricular fibrillation, familial, 1, 603829 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
Ventricular fibrillation, paroxysmal familial, 2, 612956 (3)|DPP6, VF2|126141|7q36.2
Ventricular septal defect 1, 614429 (3)|GATA4, ASD2, VSD1, TACHD|600576|8p23.1
Ventricular septal defect 2, 614431 (3)|CITED2, MRG1, P35SRJ, VSD2, ASD8|602937|6q24.1
Ventricular septal defect 3, 614432 (3)|NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2|600584|5q35.1
Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3)|RYR2, VTSIP, ARVD2, ARVC2|180902|1q43
Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3)|CASQ2|114251|1p13.1
Ventricular tachycardia, catecholaminergic polymorphic, 3 (2)|CPVT3|614021|7p22-p14
Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3)|CALM1, PHKD, CPVT4|114180|14q32.11
Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 (3)|TRDN, TDN, CPVT5|603283|6q22.31
Ventricular tachycardia, idiopathic, 192605 (3)|GNAI2, GNAI2B, GIP|139360|3p21.31
Verheij syndrome, 615583 (3)|PUF60, FIR, SIAHBP1, VRJS|604819|8q24.3
Vertical talus, congenital, 192950 (3)|HOXD10, HOX4D|142984|2q31.1
Vertigo, benign recurrent, 2 (2)|BRV2|613106|22q12
Vesicoureteral reflux (2)|VUR|193000|1p13
Vesicoureteral reflux 2, 610878 (3)|ROBO2, SAX3, KIAA1568|602431|3p12.3
Vesicoureteral reflux 3, 613674 (3)|SOX17, VUR3|610928|8q11.23
Vesicoureteral reflux 4 (2)|VUR4|614317|5q14.2
Vesicoureteral reflux 5 (2)|VUR5|614318|13q33.2
Vesicoureteral reflux 6 (2)|VUR6|614319|18q12.3
Vesicoureteral reflux 7 (2)|VUR7|615390|12p11-q13
Vestibulopathy, familial (2)|BPPV|193007|6q
Vici syndrome, 242840 (3)|EPG5, KIAA1632, HEEW1, VICIS|615068|18q12.3-q21.1
Vitamin D-dependent rickets, type I, 264700 (3)|CYP27B1, VDD1, PDDR|609506|12q14.1
Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 (3)|VKORC1, VKOR, VKCFD2, FLJ00289|608547|16p11.2
Vitamin K-dependent coagulation defect, 277450 (3)|GGCX|137167|2p11.2
Vitelliform macular dystrophy, adult-onset, 608161 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Vitreoretinochoroidopathy, 193220 (3)|BEST1, VMD2, ARB, RP50|607854|11q12.3
Vitreoretinopathy with phalangeal epiphyseal dysplasia (3)|COL2A1|120140|12q13.11
Vitreoretinopathy, neovascular inflammatory, 193235 (3)|CAPN5, HTRA3, VRNI|602537|11q13.5
Vohwinkel syndrome with ichthyosis, 604117 (3)|LOR|152445|1q21.3
Vohwinkel syndrome, 124500 (3)|GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q12.11
WAGRO syndrome (4)|WAGRO, DEL11p14p12|612469|11p13-p12
WHIM syndrome, 193670 (3)|CXCR4, D2S201E, NPY3R, WHIM|162643|2q22.1
Waardenburg syndrome, type 1, 193500 (3)|PAX3, WS1, HUP2, CDHS, WS3|606597|2q36.1
Waardenburg syndrome, type 2A, 193510 (3)|MITF, WS2A, CMM8|156845|3p14-p13
Waardenburg syndrome, type 2B (2)|WS2B|600193|1p21-p13.3
Waardenburg syndrome, type 2C (2)|WS2C|606662|8p23
Waardenburg syndrome, type 2D, 608890 (3)|SNAI2, SLUG, WS2D|602150|8q11.21
Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 (3)|SOX10, WS4, WS4C, PCWH|602229|22q13.1
Waardenburg syndrome, type 3, 148820 (3)|PAX3, WS1, HUP2, CDHS, WS3|606597|2q36.1
Waardenburg syndrome, type 4A, 277580 (3)|EDNRB, HSCR2, ABCDS, WS4A|131244|13q22.3
Waardenburg syndrome, type 4B, 613265 (3)|EDN3, WS4B, HSCR4|131242|20q13.32
Waardenburg syndrome, type 4C, 613266 (3)|SOX10, WS4, WS4C, PCWH|602229|22q13.1
Waardenburg syndrome/albinism, digenic, 103470 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
Waardenburg syndrome/ocular albinism, digenic, 103470 (3)|MITF, WS2A, CMM8|156845|3p14-p13
Wagner syndrome 1, 143200 (3)|VCAN, CSPG2, WGN, WGN1, ERVR|118661|5q14.2-q14.3
Waisman parkinsonism-mental retardation syndrome (2)|WSN, BGMR|311510|Xq28
Warburg micro syndrome 1, 600118 (3)|RAB3GAP1, WARBM1, P130|602536|2q21.3
Warburg micro syndrome 2, 614225 (3)|RAB3GAP2, RAB3GAP150, p150, KIAA0839, WARBM2|609275|1q41
Warburg micro syndrome 3, 614222 (3)|RAB18, WARBM3|602207|10p12.1
Warburg micro syndrome 4, 615663 (3)|TBC1D20, C20orf140, WARBM4|611663|20p13
Warfarin resistance, 122700 (3)|VKORC1, VKOR, VKCFD2, FLJ00289|608547|16p11.2
Warfarin sensitivity, 122700 (3)|CYP2C9|601130|10q23.33
Warsaw breakage syndrome, 613398 (3)|DDX11, CHLR1, KRG2|601150|12p11.21
Watson syndrome, 193520 (3)|NF1, VRNF, WSS, NFNS|613113|17q11.2
Weaver syndrome, 277590 (3)|EZH2, EZH1, WVS|601573|7q36.1
Wegener granulomatosis (2)|WG|608710|6p21.3
Wegener-like granulomatosis (3)|TAP2, ABCB3, PSF2, RING11|170261|6p21.32
Weill-Marchesani syndrome 1, recessive, 277600 (3)|ADAMTS10, WMS1|608990|19p13.2
Weill-Marchesani syndrome 2, dominant, 608328 (3)|FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1|134797|15q21.1
Weill-Marchesani syndrome 3, recessive, 614819 (3)|LTBP2, LTBP3, GLC3D, MSPKA, WMS3|602091|14q24.3
Weill-Marchesani-like syndrome, 613195 (3)|ADAMTS17|607511|15q26.3
Weissenbacher-Zweymuller syndrome, 277610 (3)|COL11A2, STL3, DFNA13, DFNB53, FBCG2|120290|6p21.32
Welander distal myopathy (2)|WDM|604454|2p13
Welander distal myopathy, 604454 (3)|TIA1, WDM|603518|2p13.3
Werner syndrome, 277700 (3)|RECQL2, RECQ3, WRN|604611|8p12
Weyers acrodental dysostosis, 193530 (3)|EVC|604831|4p16.2
White sponge nevus, 193900 (3)|KRT13|148065|17q21.2
White sponge nevus, 193900 (3)|KRT4, CYK4|123940|12q13.13
Wieacker-Wolf syndrome, 314580 (3)|ZC4H2, KIAA1166, WRWF|300897|Xq11.2
Wiedemann-Steiner syndrome, 605130 (3)|MLL, HRX, HTRX1, WDSTS|159555|11q23.3
Williams-Beuren syndrome (4)|WBS, WMS, WS, DEL7q11, C7DELq11|194050|7q11.23
Wilms tumor 2, 194071 (3)|H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Wilms tumor, 194070 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
Wilms tumor, aniridia, genitourinary anomalies and mental retardation syndrome (4)|DEL11p13, C11DELp13, WAGR|194072|11p13
Wilms tumor, somatic, 194070 (3)|GPC3, SDYS, SGBS1|300037|Xq26.2
Wilms tumor, type 1, 194070 (3)|WT1, NPHS4|607102|11p13
Wilms tumor, type 3 (2)|WT3|194090|16q
Wilms tumor, type 4 (2)|WT4|601363|17q12-q21
Wilson disease, 277900 (3)|ATP7B, WND|606882|13q14.3
Wilson-Turner syndrome, 309585 (3)|HDAC8, WTS, MRXS6, CDLS5|300269|Xq13.1
Wiskott-Aldrich syndrome 2, 614493 (3)|WIPF1, WASPIP, WIP|602357|2q31.1
Wiskott-Aldrich syndrome, 301000 (3)|WAS, IMD2, THC1, SCNX|300392|Xp11.23
Wolcott-Rallison syndrome, 226980 (3)|EIF2AK3, PEK, PERK, WRS|604032|2p11.2
Wolf-Hirschhorn syndrome (4)|WHS|194190|4p16.3
Wolff-Parkinson-White syndrome, 194200 (3)|PRKAG2, WPWS, CMH6|602743|7q36.1
Wolfram syndrome 2, 604928 (3)|CISD2, WFS2, ZCD2, ERIS|611507|4q24
Wolfram syndrome, 222300 (3)|WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41|606201|4p16.1
Wolfram-like syndrome, autosomal dominant, 614296 (3)|WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41|606201|4p16.1
Wolman disease, 278000 (3)|LIPA, CESD|613497|10q23.31
Wood neuroimmunologic syndrome (2)|INDX|300076|Xq26-qter
Woodhouse-Sakati syndrome, 241080 (3)|DCAF17, C20orf37|612515|2q31.1
Woolly hair, autosomal dominant, 194300 (3)|KRT74, K6IRS4, KRT6IRS4, HTSS2|608248|12q13.13
Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 (3)|LPAR6, P2RY5, P2Y5, LAH3, ARWH1|609239|13q14.2
Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 (3)|LIPH, LAH2, ARWH2|607365|3q27.2
Wrinkly skin syndrome, 278250 (3)|ATP6V0A2, WSS, ARCL2A|611716|12q24.31
X inactivation, familial skewed, 2 (2)|SXI2|300179|Xq25-q26
X-inactivation, familial skewed, 300087 (3)|XIC, XCE, XIST, SXI1|314670|Xq13.2
XFE progeroid syndrome, 610965 (3)|ERCC4, XPF, FANCQ|133520|16p13.12
Xanthinuria, type I, 278300 (3)|XDH|607633|2p23.1
Xeroderma pigmentosum, group A, 278700 (3)|XPA, XPAC|611153|9q22.33
Xeroderma pigmentosum, group B, 610651 (3)|ERCC3, XPB|133510|2q14.3
Xeroderma pigmentosum, group C, 278720 (3)|XPC, XPCC|613208|3p25.1
Xeroderma pigmentosum, group D, 278730 (3)|ERCC2, EM9, XPD, COFS2|126340|19q13.32
Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3)|DDB2|600811|11p11.2
Xeroderma pigmentosum, group F, 278760 (3)|ERCC4, XPF, FANCQ|133520|16p13.12
Xeroderma pigmentosum, group G, 278780 (3)|ERCC5, XPG, COFS3|133530|13q33.1
Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 (3)|ERCC5, XPG, COFS3|133530|13q33.1
Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 (3)|ERCC4, XPF, FANCQ|133520|16p13.12
Xeroderma pigmentosum, variant type, 278750 (3)|POLH, XPV|603968|6p21.1
Yunis-Varon syndrome, 216340 (3)|FIG4, KIAA0274, SAC3, ALS11, YVS|609390|6q21
Zinc deficiency, transient neonatal, 608118 (3)|SLC30A2, ZNT2, TNZD|609617|1p36.11
Zygodactyly 1 (2)|ZD1|609815|3p21.31
[?Homosexuality, male] (2)|HMS1, GAY1|306995|Xq28
[?Hyperproglucagonemia] (1)|GCG|138030|2q24.2
[AFP deficiency, congenital] (1)|AFP, HPAFP|104150|4q13.3
[AMP deaminase deficiency, erythrocytic], 612874 (3)|AMPD3|102772|11p15.4
[Acetylation, slow], 243400 (3)|NAT2, AAC2|612182|8p22
[Alpha-actinin-3 deficiency] (3)|ACTN3|102574|11q13.2
[Analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
[Angiotensin I-converting enzyme, benign serum increase] (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
[Anhaptoglobinemia], 614081 (3)|HP|140100|16q22.2
[Aquaporin-1 deficiency] (3)|AQP1, CHIP28, CO|107776|7p14.3
[Axillary odor, variation in], 117800 (3)|ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Beta-glycopyranoside tasting] (3)|RCBTB1, CLLD7, GLP|607867|13q14.2
[Bilirubin, serum level of, QTL1], 601816 (3)|UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37.1
[Birth weight QTL 1] (2)|FGQTL2, BWQTL1|613219|7p15-p13
[Birth weight QTL 2] (2)|BWQTL2|613459|3q25.3
[Birth weight QTL 3] (2)|FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Birth weight QTL4] (2)|BWQTL4|615192|6p22.3
[Blood group Cromer], 613793 (3)|CD55, DAF, CROM|125240|1q32.2
[Blood group GIL], 607457 (3)|AQP3|600170|9p13.3
[Blood group, ABO system] (3)|ABO|110300|9q34.2
[Blood group, Auberger system], 111200 (3)|LU, AU, BCAM|612773|19q13.32
[Blood group, Colton], 110450 (3)|AQP1, CHIP28, CO|107776|7p14.3
[Blood group, Diego], 110500 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Blood group, Dombrock] (3)|ART4, DO, DOK1|110600|12p12.3
[Blood group, Duffy system], 110700 (3)|DARC, FY, GPD, WBCQ1|613665|1q23.2
[Blood group, Froese], 601551 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Blood group, Gerbich] (3)|GYPC, GE, GPC|110750|2q14.3
[Blood group, Ii], 110800 (3)|GCNT2, Ii, CTRCT13|600429|6p24.3-p24.2
[Blood group, Indian system], 609027 (3)|CD44, MDU2, MDU3, MIC4, IN|107269|11p13
[Blood group, John-Milton-Hagen system], 614745 (3)|SEMA7A, SEMAL, SEMAK1, CDW108, JMH|607961|15q24.1
[Blood group, Kell], 110900 (3)|KEL|613883|7q34
[Blood group, Kidd], 111000 (3)|SLC14A1, JK, UTE, UT1|613868|18q12.3
[Blood group, Knops system], 607486 (3)|CR1, C3BR|120620|1q32.2
[Blood group, Landsteiner-Wiener], 111250 (3)|ICAM4, CD242, LW|614088|19p13.2
[Blood group, Langereis system], 111600 (3)|ABCB6, MTABC3, MCOPCB7, LAN, DUH3|605452|2q35
[Blood group, Lewis] (3)|FUT3, LE|111100|19p13.3
[Blood group, Lutheran null], 247420 (3)|LU, AU, BCAM|612773|19q13.32
[Blood group, Lutheran system], 111200 (3)|LU, AU, BCAM|612773|19q13.32
[Blood group, MN] (3)|GYPA, MN, GPA|111300|4q31.21
[Blood group, OK], 111380 (3)|BSG|109480|19p13.3
[Blood group, P1PK system, P(k) phenotype], 111400 (3)|B3GALT3, GLCT3, GLOB|603094|3q26.1
[Blood group, P1Pk system, P(2) phenotype], 111400 (3)|A4GALT, P1PK|607922|22q13.2
[Blood group, P1Pk system, p phenotype], 111400 (3)|A4GALT, P1PK|607922|22q13.2
[Blood group, Radin], 111620 (3)|ERMAP, SC, RD|609017|1p34.2
[Blood group, Raph], 179620 (3)|CD151, PETA3, SFA1, MER2|602243|11p15.5
[Blood group, Rhesus], 111690 (3)|RHCE|111700|1p36.11
[Blood group, Rodgers], 614374 (3)|C4A, C4S, C4AD|120810|6p21.33
[Blood group, Scianna system], 111750 (3)|ERMAP, SC, RD|609017|1p34.2
[Blood group, Ss] (3)|GYPB, SS, MNS|111740|4q31.21
[Blood group, Stoltzfus system] (2)|SF|111800|4q28-q31
[Blood group, Swann], 601550 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Blood group, Vel system], 615264 (3)|SMIM1, VEL|615242|1p36.32
[Blood group, Waldner], 112010 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Blood group, Wright], 112050 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Blood group, XG system] (3)|XG|314700|Xpter-p22.32
[Blood group, Yt system], 112100 (3)|ACHE, YT|100740|7q22.1
[Blood group, globoside system], 615021 (3)|B3GALT3, GLCT3, GLOB|603094|3q26.1
[Blood pressure regulation QTL], 145500 (2)|ATP1B1|182330|1q24.2
[Blood pressure regulation QTL], 145500 (2)|RGS5|603276|1q23.3
[Blood pressure regulation QTL], 145500 (2)|SELE, ELAM1|131210|1q24.2
[Body mass index QTL 15] (2)|BMIQ15|612967|17q23.2-q25.1
[Body mass index QTL13] (2)|BMIQ13|612459|2q14.1
[Body mass index QTL14] (2)|BMIQ14|612460|16q12.2
[Body mass index QTL16] (4)|BMIQ16, DEL16p.11.2, C16DELp11.2|613444|16p11.2
[Body mass index QTL1] (2)|BMIQ1|606641|7q32.3
[Body mass index QTL2] (2)|BMIQ2|606643|13q14
[Body mass index QTL3] (2)|BMIQ3|607446|6q23-q25
[Body mass index QTL5] (2)|BMIQ5|608558|16p13
[Body mass index QTL6] (2)|BMIQ6|608559|20pter-p11.2
[Bombay phenotype] (3)|FUT1, H, HH|211100|19q13.33
[Bombay phenotype] (3)|FUT2, SE, B12QTL1|182100|19q13.33
[Bone mineral density QTL 10] (2)|BMND10|612113|8q24
[Bone mineral density QTL 11] (2)|BMND11|612114|6q25
[Bone mineral density QTL 13] (2)|BMND13|612727|16q23
[Bone mineral density QTL 14] (2)|BMND14|612728|1p33-p32
[Bone mineral density QTL 15], 613418 (3)|MIR2861, MIRN2861, BMND15|613405|9q34.11
[Bone mineral density QTL 2] (2)|BMND2|605833|1q21-q23
[Bone mineral density QTL 3] (2)|BMND3|606928|1p36
[Bone mineral density QTL 4] (2)|BMND4|300536|Xq27
[Bone mineral density QTL 5] (2)|BMND5|609354|11q23
[Bone mineral density QTL 6] (2)|BMND6|609876|21q22.13-qter
[Bone mineral density QTL 9] (2)|BMND9|612110|13q14
[Bone mineral density variability 1], 601884 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
[Bone mineral density variation QTL], 166710 (3)|COL1A1|120150|17q21.33
[Bone size quantitative trait locus 3] (2)|BSZQTL3|610649|8q24
[C-reactive protein QTL] (2)|CPROTQ|611920|10q23-q24
[C3HEX, ability to smell], 615082 (3)|OR2J3, C3HEXS|615016|6p22.1
[Chitotriosidase deficiency], 614122 (3)|CHIT, CHITD|600031|1q32.1
[Cholesterol level QTL 1] (2)|CLQTL1, CLF|604595|13q
[Cholesterol level QTL 2] (2)|CLQTL2|610760|2p24-p22
[Cinnamon odor, pleasantness of] (2)|CINN|611109|4q32.3
[Colostrum secretion, variation in], 117800 (3)|ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Creatine kinase, brain type, ectopic expression of] (2)|CKBE|123270|14q32
[Dopamine-beta-hydroxylase activity levels, plasma] (3)|DBH|609312|9q34.2
[Dysalbuminemic hyperthyroxinemia] (3)|ALB|103600|4q13.3
[Dysalbuminemic hyperzincemia], 194470 (1)|ALB|103600|4q13.3
[Dystransthyretinemic hyperthyroxinemia], 145680 (3)|TTR, PALB|176300|18q12.1
[Earwax, wet/dry], 117800 (3)|ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Erythrocytosis, familial, 1], 133100 (3)|EPOR|133171|19p13.2
[Ezetimibe, nonresponse to] (3)|NPC1L1|608010|7p13
[Fasting insulin level quantitative trait locus 1] (2)|FIQTL1|606035|6q22-q24
[Fasting plasma glucose level QTL 1] (2)|FGQTL1|612108|2q24-q32
[Fasting plasma glucose level QTL 2] (2)|FGQTL2, BWQTL1|613219|7p15-p13
[Fasting plasma glucose level QTL 3] (2)|FGQTL3|613233|11q21-q22
[Fasting plasma glucose level QTL 4] (2)|FGQTL4|613462|7p21.2
[Fasting plasma glucose level QTL 5], 613463 (3)|GCKR, GKRP, FGQTL5|600842|2p23.3
[Fasting plasma glucose level QTL 6] (2)|FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Fetal hemoglobin QTL5] (2)|HBFQTL5|142335|7q36
[Fructosuria], 229800 (3)|KHK|614058|2p23.3
[Gamma-glutamyltransferase, familial high serum] (2)|GGT2|137181|22q11.21
[Gilbert syndrome], 143500 (3)|UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37.1
[Glutaric aciduria III], 231690 (3)|C7orf10|609187|7p14.1
[Glycerol quantitative trait locus], 614411 (3)|AQP7, GLYCQTL|602974|9p13.3
[Glyoxalase II deficiency], 614033 (1)|HAGH, GLO2|138760|16p13.3
[Hair morphology 1, hair thickness], 612630 (3)|EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B|604095|2q12.3
[Handedness] (2)|HSR|139900|2p12-q22
[Hematocrit/hemoglobin quantitative trait locus 1] (2)|HCHGQ1|609319|6q23
[Hematocrit/hemoglobin quantitative trait locus 2] (2)|HCHGQ2|609320|9q
[Hematocrit/hemoglobin quantitative trait locus 3] (2)|HCHGQ3|613284|22q12-q13
[Hereditary persistence of alpha-fetoprotein] (3)|AFP, HPAFP|104150|4q13.3
[Hereditary persistence of fetal hemoglobin], 613566 (3)|KLF1, EKLF, INLU, HBFQTL6, CDAN4|600599|19p13.2
[Hex A pseudodeficiency], 272800 (3)|HEXA, TSD|606869|15q23
[High density lipoprotein cholesterol level QTL 10], 143470 (3)|CETP, HDLCQ10|118470|16q13
[High density lipoprotein cholesterol level QTL 11] (3)|LPL, LIPD, HDLCQ11|609708|8p21.3
[High density lipoprotein cholesterol level QTL 12], 612797 (3)|LIPC, HL, LIPH, HDLCQ12|151670|15q21.3
[High density lipoprotein cholesterol level QTL 1] (2)|HDLCQ1|606613|9p
[High density lipoprotein cholesterol level QTL 2] (2)|HDLCQ2|607053|8q23
[High density lipoprotein cholesterol level QTL 4] (2)|HDLCQ4|610239|4q32.3
[High density lipoprotein cholesterol level QTL 5] (2)|HDLCQ5|610761|3q24-q26
[High density lipoprotein cholesterol level QTL 8] (3)|VNN1, HDLCQ8|603570|6q23.2
[High density lipoprotein cholesterol level QTL 9] (3)|PLTP, HDLCQ9|172425|20q13.12
[High density lipoprotien cholesterol level QTL6], 610762 (3)|SCARB1, CD36L1, CLA1, HDLQTL6|601040|12q24.31
[High molecular weight kininogen deficiency], 228960 (3)|KNG1, KNG|612358|3q27.3
[Histidinemia], 235800 (3)|HAL, HSTD|609457|12q23.1
[Hyperphenylalaninemia, non-PKU mild], 261600 (3)|PAH, PKU1|612349|12q23.2
[Hyperproreninemia] (3)|REN, HNFJ2|179820|1q32.1
[Hypoceruloplasminemia, hereditary], 604290 (3)|CP|117700|3q24-q25
[Hypohaptoglobinemia], 614081 (3)|HP|140100|16q22.2
[IMPDH2 enzyme activity, variation in] (3)|IMPDH2, IMPD2|146691|3p21.31
[IgE levels QTL], 147050 (3)|PHF11, NYREN34|607796|13q14.2
[IgE, elevated level of], 147050 (3)|IL21R|605383|16p12.1
[IgG receptor I, phagocytic, familial deficiency of] (3)|FCGR1A, IGFR1, CD64|146760|1q21.2
[Inosine triphosphatase deficiency], 613850 (3)|ITPA|147520|20p13
[Interleukin 6, serum level of, QTL], 614752 (3)|IL6R, IL6RQ, IL6Q|147880|1q21.3
[Interleukin-6 receptor, soluble, serum level of, QTL], 614689 (3)|IL6R, IL6RQ, IL6Q|147880|1q21.3
[Junior blood group system], 614490 (3)|ABCG2, BCRP, ABCP, UAQTL1, GOUT1|603756|4q22.1
[Kallikrein, decreased urinary activity of] (3)|KLK1, KLKR|147910|19q13.33
[Kappa light chain deficiency], 614102 (3)|IGKC, IGKCD|147200|2p11.2
[Kininogen deficiency], 228960 (3)|KNG1, KNG|612358|3q27.3
[LPA deficiency, congenital] (3)|LPA|152200|6q25-q26
[Lean body mass QTL 1] (2)|LBMQTL1|612729|8q23
[Leptin serum levels QTL1] (2)|LEPQTL1, LSL|601694|2p21
[Longevity 1] (2)|LGV1|152430|4q25
[Longevity 2] (2)|LGV2|606460|6q21
[Low density lipoprotein cholesterol level QTL 3] (3)|HMGCR, LDLCQ3|142910|5q13.3
[Low density lipoprotein cholesterol level QTL6], 613589 (3)|SORT1, NT3, LDLCQ6|602458|1p13.3
[Macrothrombocytopenia] (1)|CD36, CHDS7, BDPLT10|173510|7q21.11
[Malaria, resistance to], 611162 (3)|SLC4A1, AE1, EPB3|109270|17q21.31
[Mean platelet volume QTL1] (2)|MPVQTL1|612573|12q24.31
[Mean platelet volume QTL2] (2)|MPVQTL2|612574|3p21-p13
[Mean platelet volume QTL3] (2)|MPVQTL3|612575|17q11.2
[Memory, enhanced, QTL], 615602 (3)|WWC1, KIBRA, KIAA0869, MEMRYQTL|610533|5q34
[Musical aptitude QTL 1] (2)|MUSQTL1|612343|4q22
[Neutral endopeptidase deficiency] (1)|MME, CD10, CALLA, NEP|120520|3q25.2
[Novelty seeking personality], 601696 (1)|DRD4|126452|11p15.5
[Obesity, resistance to] (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
[Phenylthiocarbamide tasting], 171200 (3)|TAS2R38, T2R61, PTC|607751|7q34
[Phosphohydroxylysinuria], 615011 (3)|AGXT2L2, PHLU|614683|5q35.3
[Placental lactogen deficiency] (1)|CSH1, CSA, PL|150200|17q23.3
[Plasma glucose, 2-hour, QTL 1] (2)|FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Plasma glucose, 2-hour, QTL 2] (2)|GIPR, PGQTL2|137241|19q13.32
[Polyunsaturated fatty acids plasma level QTL1] (2)|PURAQTL1|612795|11q12-q13.1
[Premature chromatid separation trait], 176430 (3)|BUB1B, BUBR1, MVA1|602860|15q15.1
[Protein Z deficiency], 614024 (3)|PROZ, PZ|176895|13q34
[QT interval, variation in] (2)|QTV|610141|1q23.3
[Respiratory rhythmicity in sleep] (2)|RRIS|609116|10q26
[Resting heart rate], 607276 (3)|ADRB1, ADRB1R, RHR|109630|10q25.3
[Rh-negative blood type] (3)|RHD|111680|1p36.11
[Sarcosinemia], 268900 (3)|SARDH, SARD, SAR|604455|9q34.2
[Sex hormone-binding blobulin circulating level QTL 1] (2)|SXGQTL1|613498|17p13
[Short sleeper], 612975 (3)|BHLHE41, BHLHB3, DEC2, SHARP1|606200|12p12.1
[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3)|HERC2, SHEP1, MRT38|605837|15q13.1
[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3)|OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q12-q13
[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3)|HERC2, SHEP1, MRT38|605837|15q13.1
[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3)|OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q12-q13
[Skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3)|TPCN2, TPC2, SHEP10|612163|11q13.3
[Skin/hair/eye pigmentation 11, blue/nonblue eyes] (2)|SHEP11|612271|9p23
[Skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
[Skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
[Skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
[Skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
[Skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3)|SLC24A5, NCKX5, SHEP4, OCA6|609802|15q21.1
[Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3)|SLC45A2, MATP, AIM1, SHEP5, OCA4|606202|5p13.2
[Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3)|SLC45A2, MATP, AIM1, SHEP5, OCA4|606202|5p13.2
[Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3)|SLC45A2, MATP, AIM1, SHEP5, OCA4|606202|5p13.2
[Skin/hair/eye pigmentation 6, blond/brown hair], 210750 (3)|SLC24A4, NCKX4, SHEP6|609840|14q32.12
[Skin/hair/eye pigmentation 6, blue/green eyes], 210750 (3)|SLC24A4, NCKX4, SHEP6|609840|14q32.12
[Skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)|KITLG, MGF, SF, SCF, SHEP7|184745|12q21.32
[Skin/hair/eye pigmentation 8, freckling] (2)|SHEP8|611724|6p25.3
[Skin/hair/eye pigmentation 9, brown/nonbrown eyes], 611742 (3)|ASIP, AGTIL, SHEP9|600201|20q11.22
[Skin/hair/eye pigmentation 9, dark/light hair], 611742 (3)|ASIP, AGTIL, SHEP9|600201|20q11.22
[Social cognition] (2)|CGF1|300082|Xq
[Sodium serum level QTL 1], 613508 (3)|TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL|605427|12q24.11
[Sprinting performance] (3)|ACTN3|102574|11q13.2
[Statins, attenuated cholesterol lowering by] (3)|HMGCR, LDLCQ3|142910|5q13.3
[Superoxide dismutase, elevated extracellular] (3)|SOD3|185490|4p15.2
[Telomere length, mean leukocyte] (2)|TELM|609113|14q23.2
[Thyroid-stimulating hormone level QTL 1] (2)|TSHQTL1|612306|5q13
[Transferrin serum level QTL2], 614193 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
[Tuberculin skin test reactivity QTL] (2)|TST2|613637|5p15
[Tuberculin skin test reactivity, absence of] (2)|TST1|613636|11p14
[Urate oxidase deficiency] (1)|UOX|191540|1p22
[Uric acid concentration, serum, QTL1], 138900 (3)|ABCG2, BCRP, ABCP, UAQTL1, GOUT1|603756|4q22.1
[Uric acid concentration, serum, QTL4] (2)|UAQTL4, GOUT4|612671|6p21
[Uric acid concentration, serum, QTL4], 612671 (3)|SLC17A3, NPT4|611034|6p22.2
[Uric acid concentration, serum, QTL5] (2)|UAQTL5|614746|19q13
[Uric acid concentration, serum, QTL6] (2)|UAQTL6|614747|1q21.1
[Visuospatial/perceptual abilities] (2)|VSPA|313000|Xp22.33
[White blood cell count QTL], 611862 (3)|DARC, FY, GPD, WBCQ1|613665|1q23.2
van Buchem disease, type 2, 607636 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
van der Woude syndrome, 119300 (3)|IRF6, VWS, LPS, PIT, PPS1, OFC6|607199|1q32.2
von Hippel-Lindau syndrome, 193300 (3)|VHL|608537|3p25.3
von Willebrand disease, platelet-type, 177820 (3)|GP1BA, BSS, BDPLT1, VWDP, BDPLT3|606672|17p13.2
von Willebrand disease, type 1, 193400 (3)|VWF, F8VWF|613160|12p13.31
von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 (3)|VWF, F8VWF|613160|12p13.31
von Willibrand disease, type 3, 277480 (3)|VWF, F8VWF|613160|12p13.31
{46XY sex reversal 8, modifier of}, 614279 (3)|AKR1C4, CHDR, CDR, HAKRA, DD4|600451|10p15.1
{?Allergy and asthma susceptibility} (2)|IGES|147061|5q31.1
{?Amyloidosis, secondary, susceptibility to} (1)|APCS, SAP|104770|1q23.2
{?Bladder cancer susceptibility}, 109800 (2)|TACC3|605303|4p16.3
{?Breast cancer susceptibility}, 114480 (1)|NQO2, NMOR2|160998|6p25.2
{?Hearing loss, cisplatin-induced, susceptibility to} (2)|CIHL|613290|6p22.3
{?Hypertension, essential} (1)|ACSM3, SAH|145505|16p12.3
{?Macular degeneration, age-related}, 603075 (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
{?Major affective disorder 2} (2)|MAFD2, MDX|309200|Xq28
{?Membranous nephropathy, susceptibility to} (2)|MBNP|614692|6p21.3
{?SLE susceptibility} (1)|CR1, C3BR|120620|1q32.2
{?Schizophrenia susceptibility 18}, 615232 (3)|SLC1A1, EAAC1, SCZD18|133550|9p24.2
{?Schizophrenia, susceptibility to}, 603013 (1)|NRG1, HGL, HRGA, ARIA|142445|8p12
{?Schizophrenia}, 181500 (2)|SCZD2|603342|11q14-q21
{AIDS, delayed/rapid progression to}, 609423 (3)|KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1|604946|19q13.42
{AIDS, rapid progression to}, 609423 (3)|IFNG, IFG, IFI|147570|12q15
{AIDS, resistance to}, 609423 (3)|CXCL12, SDF1|600835|10q11.21
{AIDS, slow progression to}, 609423 (3)|CXCR1, IL8RA|146929|2q35
{AIDS, slow progression to}, 609423 (3)|IL4R, IL4RA|147781|16p12.1
{Abacavir hypersensitivity, susceptibility to} (3)|HLA-B, SPDA1|142830|6p21.33
{Abruptio placentae, susceptibility to} (3)|MTHFD, MTHFC|172460|14q23.3
{Accelerated tumor formation, susceptibility to}, 614401 (3)|MDM2, ACTFS|164785|12q15
{Adiponectin, serum level of, QTL2} (2)|ADIPQTL2, CAQ5|606770|5p15.2-p14
{Adiponectin, serum level of, QTL3} (2)|ADIPQTL3, CAQ14|606771|14p11.2-q13
{Adiponectin, serum level of, QTL4} (2)|ADIPQTL4|612629|11q23-q24
{Adiponectin, serum level of, QTL5] (2)|ADIPQTL5|613836|16q23.3
{Aerodigestive tract cancer, squamous cell, alcohol-related, protection against} (3)|ADH1B, ADH2|103720|4q23
{Age-related hearing impairment 1} (2)|ARHI1|612448|8q24.13-q24.22
{Age-related hearing impairment 2} (2)|ARHI2|612976|3p26.1-p25.1
{Age-related maculopathy, susceptibility to}, 603075 (2)|PLEKHA1, TAPP1|607772|10q26.13
{Albinism, oculocutaneous, type II, modifier of}, 203200 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
{Alcohol dependence, protection against}, 103780 (3)|ADH1B, ADH2|103720|4q23
{Alcohol dependence, protection against}, 103780 (3)|ADH1C, ADH3|103730|4q23
{Alcohol dependence, susceptibility to}, 103780 (3)|GABRA2|137140|4p12
{Alcohol dependence, susceptibility to}, 103780 (3)|HTR2A|182135|13q14.2
{Alcohol dependence, susceptibility to}, 103780 (3)|RCBTB1, CLLD7, GLP|607867|13q14.2
{Alcohol dependence}, 103780 (3)|TAS2R16, T2R16|604867|7q31.32
{Alkaline phosphatase, plasma level of, QTL 2} (2)|ALPQTL2|612367|1p36
{Alkaline phosphatase, plasma level of, QTL1} (2)|ALPQTL1|171720|9q34.13
{Alkaline phosphatase, plasma level of, QTL3} (2)|ALPQTL3|612368|6p22
{Alkaline phosphatase, plasma level of, QTL4} (2)|ALPQTL4|612369|10q21
{Allergic rhinitis, susceptibility to}, 607154 (3)|IL13, ALRH, BHR1|147683|5q31.1
{Alzheimer disease 12} (2)|AD12|611073|8p12-q22
{Alzheimer disease 16} (2)|AD16|300756|Xq21.3
{Alzheimer disease 18, susceptibility to}, 615590 (3)|ADAM10, MADM, RAK, AD18|602192|15q21.3
{Alzheimer disease 9, late onset, susceptibility to}, 104300 (2)|AD9|608907|19p13.2
{Alzheimer disease, late-onset, susceptibility to}, 104300 (3)|NOS3|163729|7q36.1
{Alzheimer disease, late-onset, susceptibility to}, 104300 (3)|PLAU, URK, QPD, BDPLT5|191840|10q22.2
{Alzheimer disease, late-onset}, 104300 (3)|APBB2, FE65L1|602710|4p14-p13
{Alzheimer disease, pathogenesis, association with}, 104300 (3)|SORL1, LR11, SORLA|602005|11q24.1
{Alzheimer disease, susceptibility to}, 104300 (3)|A2M , A2MD|103950|12p13.31
{Alzheimer disease, susceptibility to}, 104300 (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
{Alzheimer disease, susceptibility to}, 104300 (3)|BLMH, BMH|602403|17q11.2
{Alzheimer disease, susceptibility to}, 104300 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
{Alzheimer disease, susceptibility to}, 104300 (3)|MPO|606989|17q22
{Alzheimer disease, susceptibility to}, 104300 (3)|PACIP1, PAXIP1L, PTIP|608254|7q36.2
{Alzheimer disease-13} (2)|AD13|611152|1q21
{Alzheimer disease-14} (2)|AD14|611154|1q25
{Alzheimer disease-15} (2)|AD15|611155|3q22-q24
{Amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3)|ATXN2, ATX2, SCA2, ASL13|601517|12q24.12
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)|DCTN1, HMN7B|601143|2p13.1
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)|NEFH|162230|22q12.2
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)|PRPH|170710|12q13.12
{Amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3)|TRPM7, LTRPC7, CHAK, ALSPDC|605692|15q21.2
{Aneurysm, familial abdominal 3} (2)|AAA3|611891|9p21
{Aneurysm, intracranial berry, 10} (2)|ANIB10|612587|8q12.1
{Aneurysm, intracranial berry, 6} (2)|ANIB6|611892|9p21
{Aneurysm, intracranial berry, 9} (2)|ANIB9|612586|2q33.1
{Angioedema induced by ACE inhibitors, susceptibility to}, 300909 (3)|XPNPEP2, AEACEI|300145|Xq26.1
{Anorexia nervosa, susceptibility to, 1} (2)|ANON1|606788|1p
{Anorexia nervosa, susceptibility to}, 606788 (3)|HTR2A|182135|13q14.2
{Anorexia nervosa, susceptibility to}, 610269 (3)|BDNF, BULN2, ANON2|113505|11p14.1
{Anxiety-related personality traits}, 607834 (3)|SLC6A4, HTT, OCD1|182138|17q11.2
{Aplastic anemia}, 609135 (3)|IFNG, IFG, IFI|147570|12q15
{Aplastic anemia}, 614743 (3)|TERC, TRC3, TR, DKCA1, PFBMFT2|602322|3q26.2
{Asperger syndrome susceptibility 1} (2)|ASPG1|608638|3q25-q27
{Asperger syndrome susceptibility 2} (2)|ASPG2|608631|17p13
{Asperger syndrome susceptibility 3} (2)|ASPG3|608781|1q21-q22
{Asperger syndrome susceptibility 4} (2)|ASPG4|609954|3p24-p21
{Asperger syndrome susceptibility, X-linked 1}, 300494 (3)|NLGN3, ASPGX1, AUTSX1|300336|Xq13.1
{Asperger syndrome susceptibility, X-linked 2}, 300497 (3)|NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.32-p22.31
{Aspergillosis, susceptibility to}, 614079 (3)|CLEC7A, CLECSF12, DECTIN1, CANDF4|606264|12p13.2
{Asthma susceptibility 5}, 611064 (3)|IRAK3, IRAKM, ASRT5|604459|12q14.3
{Asthma, aspirin-induced, susceptibility to}, 208550 (3)|PTGER2|176804|14q22.1
{Asthma, aspirin-induced, susceptibility to}, 208550 (3)|TBX21, TBET|604895|17q21.32
{Asthma, diminished response to antileukotriene treatment in}, 600807 (3)|ALOX5|152390|10q11.21
{Asthma, nocturnal, susceptibility to}, 600807 (3)|ADRB2|109690|5q32
{Asthma, protection against}, 600807 (3)|MUC7|158375|4q13.3
{Asthma, susceptibility to, 1}, 607277 (3)|PTGDR, AS1, ASRT1|604687|14q22.1
{Asthma, susceptibility to, 2}, 608584 (3)|NPSR1, GPR154, GPRA, VRR1, PGR14, ASRT2|608595|7p14.3
{Asthma, susceptibility to}, 600807 (2)|HLA-G|142871|6p22.1
{Asthma, susceptibility to}, 600807 (3)|CCL11, SCYA11|601156|17q12
{Asthma, susceptibility to}, 600807 (3)|HNMT|605238|2q22.1
{Asthma, susceptibility to}, 600807 (3)|IL12B, NKSF2|161561|5q33.3
{Asthma, susceptibility to}, 600807 (3)|IL13, ALRH, BHR1|147683|5q31.1
{Asthma, susceptibility to}, 600807 (3)|PLA2G7, PAFAH, PAFAD|601690|6p12.3
{Asthma, susceptibility to}, 600807 (3)|SCGB1A1, UGB, CC10, CCSP, SCGB1A1|192020|11q12.3
{Asthma, susceptibility to}, 600807 (3)|SCGB3A2, UGRP1|606531|5q32
{Asthma, susceptibility to}, 600807 (3)|TNF, TNFA|191160|6p21.33
{Asthma-related traits, susceptibility to, 3} (2)|ASRT3|609958|2p16
{Asthma-related traits, susceptibility to, 4} (2)|ASRT4|610906|1p31
{Asthma-related traits, susceptibility to, 6} (2)|ASRT6|611403|17q21
{Asthma-related traits, susceptibility to, 7}, 611960 (3)|CHI3L1, GP39, YKL40, ASRT7|601525|1q32.1
{Asthma-related traits, susceptibility to, 8} (2)|ASRT8|613207|9q33
{Asthma}, 600807 (3)|PHF11, NYREN34|607796|13q14.2
{Atherosclerosis, susceptibility to} (2)|ATHS, ALP|108725|19p13.3-p13.2
{Atherosclerosis, susceptibility to} (3)|ALOX5|152390|10q11.21
{Atherosclerosis, susceptibility to} (3)|ESR1, ESR, ESTRR|133430|6q25.1
{Atopy, resistance to}, 147050 (3)|HAVCR1, HAVCR|606518|5q33.3
{Atopy, susceptibility to}, 147050 (3)|IL4R, IL4RA|147781|16p12.1
{Atopy, susceptibility to}, 147050 (3)|MS4A2, FCER1B|147138|11q12.1
{Atopy, susceptibility to}, 147050 (3)|PLA2G7, PAFAH, PAFAD|601690|6p12.3
{Atopy, susceptibility to}, 147050 (3)|SELP, GRMP|173610|1q24.2
{Atrial fibrillation, familial, 5} (2)|ATFB5|611494|4q25
{Atrioventricular septal defect, susceptibility to, 1} (2)|AVSD1, AVCD|606215|1p31-p21
{Atrioventricular septal defect, susceptibility to, 2}, 606217 (3)|CRELD1, AVSD2|607170|3p25.3
{Attention deficit-hyperactivity disorder, susceptibility to, 5} (2)|ADHD5|612311|2q21.1
{Attention deficit-hyperactivity disorder, susceptibility to, 6} (2)|ADHD6|612312|13q12.11
{Attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3)|TPH2, NTPH, ADHD7|607478|12q21.1
{Attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3)|DRD5, DRD1B, DRD1L2|126453|4p16.1
{Attention deficit-hyperactivity disorder}, 143465 (2)|ADHD1|608903|16p13
{Attention deficit-hyperactivity disorder}, 143465 (2)|ADHD2|608904|17p11
{Attention deficit-hyperactivity disorder}, 143465 (2)|ADHD3|608905|6q12
{Attention deficit-hyperactivity disorder}, 143465 (2)|ADHD4|608906|5p13
{Attention deficit-hyperactivity disorder}, 143465 (3)|DRD4|126452|11p15.5
{Atypical mycobacteriosis, familial}, 300636 (3)|IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
{Autism susceptibility 11} (2)|AUTS11|610836|1q41-q42
{Autism susceptibility 12} (2)|AUTS12|610838|21p13-q11
{Autism susceptibility 13} (2)|AUTS13|610908|12q14.2
{Autism susceptibility 14A} (2)|DEL16p11.2, C16DELp11.2, AUTS14A|611913|16p11.2
{Autism susceptibility 15}, 612100 (3)|CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
{Autism susceptibility 17}, 613436 (3)|SHANK2, CORTBP1, AUTS17|603290|11q13.3-q13.4
{Autism susceptibility 1} (2)|AUTS1|209850|7q22
{Autism susceptibility 3} (2)|AUTS3|608049|13q14.2-q14.1
{Autism susceptibility 4} (2)|AUTS4|608636|15q11
{Autism susceptibility 5} (2)|AUTS5|606053|2q
{Autism susceptibility 6} (2)|AUTS6|609378|17q11
{Autism susceptibility 7} (2)|AUTS7|610676|17q21
{Autism susceptibility 8} (2)|AUTS8|607373|3q25-q27
{Autism susceptibility, X-linked 1}, 300425 (3)|NLGN3, ASPGX1, AUTSX1|300336|Xq13.1
{Autism susceptibility, X-linked 2}, 300495 (3)|NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.32-p22.31
{Autism susceptibility, X-linked 3}, 300496 (3)|MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
{Autism susceptibility, X-linked 4} (4)|DELXp22.11, CXDELp22.11, AUTSX4|300830|Xp22.11
{Autism, susceptibility to, 10} (2)|AUTS10|611016|7q36
{Autism, susceptibility to, 14B} (2)|DUP16p11.2, C16DUPp11.2, AUTS14B|614671|16p11.2
{Autism, susceptibility to, 18}, 615032 (3)|CHD8, DUPLIN, KIAA1564, AUTS18|610528|14q11.2
{Autism, susceptibility to, 19}, 615091 (3)|EIF4E, EIF4EL1, AUTS19|133440|4q23
{Autism, susceptibility to, 9} (2)|AUTS9|611015|7q31
{Autism, susceptibility to, X-linked 5}, 300847 (3)|RPL10, DXS648, QM, AUTSX5|312173|Xq28
{Autoimmune disease, susceptibility to, 1}, 607836 (3)|FOXD3, AIS1, VAMAS2|611539|1p31.3
{Autoimmune disease, susceptibility to, 2} (2)|AIS2, VAMAS3|608391|Chr.7
{Autoimmune disease, susceptibility to, 3} (2)|AIS3, VAMAS4|608392|Chr.8
{Autoimmune disease, susceptibility to, 4} (2)|AIS4, VAMAS5|609400|4q13-q21
{Autoimmune disease, susceptibility to, 5} (2)|CELIAC6, AIS5|611598|4q27
{Autoimmune disease, susceptibility to, 6}, 613551 (3)|SIAE, AIS6|610079|11q24.2
{Autoimmune lymphoproliferative syndrome}, 601859 (3)|TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q23.31
{Autoimmune thyroid disease, susceptibility to, 1} (2)|AITD1|608173|6p11
{Autoimmune thyroid disease, susceptibility to, 2} (2)|AITD2|608174|5q31-q33
{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)|TG, AITD3, TDH3|188450|8q24.22
{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)|ZFAT1, ZNF406, AITD3|610931|8q24.22
{Autoimmune thyroid disease, susceptibility to, 4} (2)|AITD4|608176|10q
{Bacteremia, protection against}, 614382 (3)|TIRAP, BACTS1|606252|11q24.2
{Bacteremia, susceptibility to}, 614383 (3)|CISH, BACTS2|602441|3p21.2
{Bardet-Biedl syndrome 1, modifier of}, 209900 (3)|ARL6, BBS3, RP55|608845|3q11.2
{Bardet-Biedl syndrome 14, modifier of}, 209900 (3)|TMEM67, MKS3, JBTS6, NPHP11|609884|8q22.1
{Bardet-Biedl syndrome, modifier of}, 209900 (3)|CCDC28B, MGC1203|610162|1p35.1
{Basal cell carcinoma 7}, 614740 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
{Basal cell carcinoma, susceptibility to, 1} (2)|BCC1|605462|1p36
{Basal cell carcinoma, susceptibility to, 2} (2)|BCC2|613058|1q42
{Basal cell carcinoma, susceptibility to, 3} (2)|BCC3|613059|5p15.33
{Basal cell carcinoma, susceptibility to, 4} (2)|BCC4|613061|12q13
{Basal cell carcinoma, susceptibility to, 5} (2)|BCC5|613062|9p21
{Basal cell carcinoma, susceptibility to, 6} (2)|BCC6|613063|7q32
{Benzene toxicity, susceptibility to} (3)|NQO1, DIA4, NMOR1|125860|16q22.1
{Beryllium disease, chronic, susceptibility to} (3)|HLA-DPB1|142858|6p21.32
{Biliary cirrhosis, primary, 2} (2)|PBC2|613007|6p21.3
{Biliary cirrhosis, primary, 3} (2)|PBC3|613008|1p31.2
{Bladder cancer, somatic}, 109800 (3)|HRAS|190020|11p15.5
{Bleeding disorder, platelet-type, 13, susceptibility to}, 614009 (3)|TBXA2R, BDPLT13|188070|19p13.3
{Blepharospasm, primary benign}, 606798 (3)|DRD5, DRD1B, DRD1L2|126453|4p16.1
{Bone marrow failure, telomere-related, 1}, 614742 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Bone mineral density QTL 12, osteoporosis}, 612560 (3)|UGT2B17, BMND12|601903|4q13.2
{Bone mineral density, low, susceptibility to}, 615311 (3)|LGR4, GPR48, BNMD17|606666|11p14.1
{Bone size QTL} (2)|BSZQTL2|609657|5q
{Bone size QTL} (2)|BSZQTL|609656|17q23
{Breast and colorectal cancer, susceptibility to} (3)|CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Breast cancer, invasive ductal}, 114480 (3)|RAD54L, HR54, HRAD54|603615|1p34.1
{Breast cancer, lobular}, 114480 (3)|CDH1, UVO, LCAM, ECAD|192090|16q22.1
{Breast cancer, male, susceptibility to}, 114480 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
{Breast cancer, poor survival after chemotherapy for} (3)|NQO1, DIA4, NMOR1|125860|16q22.1
{Breast cancer, protection against}, 114480 (3)|CASP8, MCH5, ALPS2B|601763|2q33.1
{Breast cancer, susceptibility to}, 114480 (3)|ATM, ATA, AT1|607585|11q22.3
{Breast cancer, susceptibility to}, 114480 (3)|BARD1|601593|2q35
{Breast cancer, susceptibility to}, 114480 (3)|CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Breast cancer, susceptibility to}, 114480 (3)|HMMR|600936|5q34
{Breast cancer, susceptibility to}, 114480 (3)|PALB2, FANCN, PNCA3|610355|16p12.2
{Breast cancer, susceptibility to}, 114480 (3)|PHB|176705|17q21.33
{Breast cancer, susceptibility to}, 114480 (3)|RAD51A, RECA, MRMV2|179617|15q15.1
{Breast cancer, susceptibility to}, 114480 (3)|XRCC3, CMM6|600675|14q32.33
{Breast cancer}, 114480 (1)|ESR1, ESR, ESTRR|133430|6q25.1
{Breast-ovarian cancer, familial, 1}, 604370 (3)|BRCA1, PSCP, BROVCA1, PNCA4|113705|17q21.31
{Breast-ovarian cancer, familial, 2}, 612555 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
{Breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3)|RAD51C, FANCO, BROVCA3|602774|17q22
{Breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3)|RAD51L3, RAD51D, BROVCA4|602954|17q12
{Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Budd-Chiari syndrome}, 600880 (3)|F5, THPH2, RPRGL1|612309|1q24.2
{Budd-Chiari syndrome}, 600880 (3)|JAK2, THCYT3|147796|9p24.1
{Bulimia nervosa, age of onset of weight loss in}, 607499 (3)|BDNF, BULN2, ANON2|113505|11p14.1
{Bulimia nervosa, susceptibility to} (2)|BULN|607499|10p
{Buruli ulcer, susceptibility to}, 610446 (3)|NRAMP1, NRAMP, SLC11A1|600266|2q35
{Calcium, serum level of} (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
{Cancer progression/metastasis} (3)|FGFR4|134935|5q35.2
{Cardiac conduction defect, susceptibility to}, 115080 (3)|AKAP10|604694|17p11.2
{Carotid stenosis, susceptibility to} (3)|HABP2, PHBP, HGFAL, FSAP|603924|10q25.3
{Cataract 28, age-related cortical, susceptibility to} (2)|CTRCT28, ARCC1|609026|6p12-q12
{Celiac disease, susceptibility to, 10} (2)|CELIAC10|612008|3q25-q26
{Celiac disease, susceptibility to, 11} (2)|CELIAC11|612009|3q28
{Celiac disease, susceptibility to, 12} (2)|CELIAC12|612010|6q25.3
{Celiac disease, susceptibility to, 13} (2)|CELIAC13|612011|12q24
{Celiac disease, susceptibility to, 2} (2)|CELIAC2|609754|5q31-q33
{Celiac disease, susceptibility to, 3}, 609755 (3)|CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33.2
{Celiac disease, susceptibility to, 4}, 609753 (3)|MYO9B, MYR5, CELIAC4|602129|19p13.11
{Celiac disease, susceptibility to, 5} (2)|CELIAC5, GSES|607202|15q11-q13
{Celiac disease, susceptibility to, 6} (2)|CELIAC6, AIS5|611598|4q27
{Celiac disease, susceptibility to, 7} (2)|CELIAC7|612005|1q31
{Celiac disease, susceptibility to, 8} (2)|CELIAC8|612006|2q11-q12
{Celiac disease, susceptibility to, 9} (2)|CELIAC9|612007|3p21
{Celiac disease, susceptibility to}, 212750 (3)|HLA-DQA1, CELIAC1|146880|6p21.32
{Celiac disease, susceptibility to}, 212750 (3)|HLA-DQB1, CELIAC1|604305|6p21.32
{Centronuclear myopathy, autosomal, modifier of}, 160150 (3)|MTMR14, C3orf29, HJUMPY|611089|3p25.3
{Cerebral infarction, susceptibility to}, 601367 (3)|PRKCH, PKCL, PRKCL|605437|14q23.1
{Chordoma, susceptibility to} (4)|CHDM|215400|7q33
{Chronic infections, due to MBL deficiency}, 614372 (3)|MBL2, MBL, MBP1, MBL2D, MBPD|154545|10q21.1
{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3)|KRT18|148070|12q13.13
{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3)|KRT8|148060|12q13.13
{Codeine sensitivity}, 608902 (3)|CYP2D6, CPD6, P450DB1|124030|22q13.2
{Colchicine resistance}, 120080 (3)|ABCB1, PGY1, MDR1, IBD13, CLCs|171050|7q21.12
{Colon cancer, susceptibility to}, 114500 (3)|AURKA, STK15, AURORA2, BTAK, ARK1, STK6, AIK|603072|20q13.2
{Colonic adenoma recurrence, reduced risk of}, 114500 (3)|ODC1|165640|2p25.1
{Colorectal cancer, susceptibility to, 10}, 612591 (3)|POLD1, CRCS10, MDPL|174761|19q13.33
{Colorectal cancer, susceptibility to, 11} (2)|CRCS11|612592|20p12.3
{Colorectal cancer, susceptibility to, 12}, 615083 (3)|POLE1, CRCS12, FILS|174762|12q24.33
{Colorectal cancer, susceptibility to, 1}, 608812 (3)|GALNT12, CRCS1|610290|9q22.33
{Colorectal cancer, susceptibility to, 2} (2)|CRCS2|611469|8q24
{Colorectal cancer, susceptibility to, 3}, 612229 (3)|SMAD7, MADH7, CRCS3|602932|18q21.1
{Colorectal cancer, susceptibility to, 4} (4)|HMPS1, CRAC1, CRCS4, DUP15q, C15DUPq|601228|15q15.3-q22.1
{Colorectal cancer, susceptibility to, 5} (2)|CRCS5|612230|10p14
{Colorectal cancer, susceptibility to, 6} (2)|CRCS6|612231|8q23
{Colorectal cancer, susceptibility to, 7} (2)|CRCS7|612232|11q23
{Colorectal cancer, susceptibility to, 8} (2)|CRCS8|612589|14q22.2
{Colorectal cancer, susceptibility to, 9} (2)|CRCS9|612590|16q22.1
{Colorectal cancer, susceptibility to}, 114500 (3)|CCND1, PRAD1, BCL1|168461|11q13.3
{Colorectal cancer, susceptibility to}, 114500 (3)|TLR2, TIL4|603028|4q31.3
{Colorectal cancer, susceptibility to}, 114500 (3)|TLR4, ARMD10|603030|9q33.1
{Colorectal cancer}, 114500 (3)|PLA2G2A, PLA2B, PLA2L, MOM1|172411|1p36.13
{Congenital anomalies of kidney and urinary tract, susceptibility to}, 610805 (3)|DSTYK, KIAA0472, RIP5, DUSTYPK, CAKUT1|612666|1q32.1
{Congestive heart failure and beta-blocker response, modifier of} (3)|ADRA2C, ADRA2L2|104250|4p16.3
{Congestive heart failure and beta-blocker response, modifier of} (3)|ADRB1, ADRB1R, RHR|109630|10q25.3
{Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 (3)|ABCA1, ABC1, HDLDT1, TGD|600046|9q31.1
{Coronary artery disease, autosomal dominant, 1}, 608320 (3)|MEF2A, ADCAD1|600660|15q26.3
{Coronary artery disease, autosomal dominant, 2}, 610947 (3)|LRP6, ADCAD2|603507|12p13.2
{Coronary artery disease, modifier of} (3)|CCL2, SCYA2, MCP1, MCAF|158105|17q12
{Coronary artery disease, resistance to}, 607339 (3)|CX3CR1, GPR13, V28|601470|3p22.2
{Coronary artery disease, susceptibility to} (1)|LPA|152200|6q25-q26
{Coronary artery disease, susceptibility to} (3)|IRS1|147545|2q36.3
{Coronary artery disease, susceptibility to} (3)|KL, KLOTHO|604824|13q13.1
{Coronary artery disease, susceptibility to} (3)|PON1, PON, ESA, MVCD5|168820|7q21.3
{Coronary artery disease, susceptibility to} (3)|PON2|602447|7q21.3
{Coronary artery disease} (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Coronary artery spasm 1, susceptibility to} (3)|NOS3|163729|7q36.1
{Coronary artery spasm 2, susceptibility to (3)|PON1, PON, ESA, MVCD5|168820|7q21.3
{Coronary heart disease, susceptibility to, 2} (2)|CHDS2|608316|2q21.1-q22
{Coronary heart disease, susceptibility to, 3} (2)|CHDS3|300464|Xq23-q26
{Coronary heart disease, susceptibility to, 4} (2)|CHDS4|608318|14q32
{Coronary heart disease, susceptibility to, 5}, 608901 (3)|KALRN, HAPIP, DUO, CHDS5|604605|3q21.2
{Coronary heart disease, susceptibility to, 6}, 614466 (3)|MMP3, STMY1, CHDS6|185250|11q22.2
{Coronary heart disease, susceptibility to, 7}, 610938 (3)|CD36, CHDS7, BDPLT10|173510|7q21.11
{Coronary heart disease, susceptibility to, 8} (2)|CHDS8|611139|9p21
{Coronary heart disease, susceptibility to, 9} (2)|CHDS9|612030|8p22
{Coronary heart disease, susceptibility to} (2)|CHDS1|607339|16pter-p13
{Craniosynostosis 5, susceptibility to}, 615529 (3)|ALX4, PFM2, FPP, FND2, CRS5|605420|11p11.2
{Creutzfeldt-Jakob disease, variant, resistance to}, 123400 (3)|HLA-DQB1, CELIAC1|604305|6p21.32
{Crohn disease-associated growth failure}, 266600 (3)|IL6, IFNB2, BSF2, HSF, HGF|147620|7p15.3
{Cystic fibrosis lung disease, modifier of}, 219700 (3)|TGFB1, DPD1, CED|190180|19q13.2
{Deafness, autosomal recessive 12, modifier of}, 601386 (3)|ATP2B2, PMCA2|108733|3p25.3
{Deafness, mitochondrial, modifier of}, 580000 (3)|TRMU, MTO2, TRNT1|610230|22q13.31
{Deafness, nonsyndromic, modifier 1} (2)|DFNM1|605429|1q24
{Debrisoquine sensitivity}, 608902 (3)|CYP2D6, CPD6, P450DB1|124030|22q13.2
{Deep venous thrombosis, protection against}, 300807 (3)|F9, HEMB, THPH8|300746|Xq27.1
{Delayed sleep phase syndrome, susceptibility to}, 614163 (3)|AANAT, SNAT, DSPS|600950|17q25.1
{Dementia, vascular, susceptibility to} (3)|TNF, TNFA|191160|6p21.33
{Dengue fever, protection against}, 614371 (3)|CD209, CDSIGN|604672|19p13.2
{Dermatitis, atopic, susceptibility to, 1} (2)|ATOD1|603165|3q21
{Dermatitis, atopic, susceptibility to, 2}, 605803 (3)|FLG, ATOD2|135940|1q21.3
{Dermatitis, atopic, susceptibility to, 3} (2)|ATOD3|605804|20p
{Dermatitis, atopic, susceptibility to, 4} (2)|ATOD4|605805|17q25.3
{Dermatitis, atopic, susceptibility to, 5} (2)|ATOD5|605844|13q12-q14
{Dermatitis, atopic, susceptibility to, 6} (2)|ATOD6|605845|5q31-q33
{Dermatitis, atopic, susceptibility to, 7} (2)|ATOD7|613064|11q13.5
{Diabetes mellitus, insulin-dependent, 11} (2)|IDDM11|601208|14q24.3-q31
{Diabetes mellitus, insulin-dependent, 13} (2)|IDDM13|601318|2q34
{Diabetes mellitus, insulin-dependent, 15} (2)|IDDM15|601666|6q21
{Diabetes mellitus, insulin-dependent, 17} (2)|IDDM17|603266|10q25
{Diabetes mellitus, insulin-dependent, 18} (2)|IDDM18|605598|5q31.1-q33.1
{Diabetes mellitus, insulin-dependent, 19} (2)|IDDM19|610155|2q24.3
{Diabetes mellitus, insulin-dependent, 21} (2)|IDDM21|612521|6q25
{Diabetes mellitus, insulin-dependent, 22}, 612522 (3)|CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21.31
{Diabetes mellitus, insulin-dependent, 23} (2)|IDDM23|612622|4q27
{Diabetes mellitus, insulin-dependent, 24} (2)|IDDM24|613006|10q23.31
{Diabetes mellitus, insulin-dependent, 3} (2)|IDDM3|600318|15q26
{Diabetes mellitus, insulin-dependent, 4} (2)|IDDM4|600319|11q13
{Diabetes mellitus, insulin-dependent, 5}, 600320 (3)|SUMO4, IDDM5|608829|6q25.1
{Diabetes mellitus, insulin-dependent, 6} (2)|IDDM6|601941|18q21
{Diabetes mellitus, insulin-dependent, 7} (2)|IDDM7|600321|2q31
{Diabetes mellitus, insulin-dependent, 8} (2)|IDDM8|600883|6q25-q27
{Diabetes mellitus, insulin-dependent, X-linked} (2)|IDDMX|300136|Xp11
{Diabetes mellitus, insulin-dependent, susceptibility to}, 601388 (3)|CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33.2
{Diabetes mellitus, insulin-dependent-1} (2)|IDDM1|222100|6p21.3
{Diabetes mellitus, insulin-dependent}, 222100 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
{Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
{Diabetes mellitus, noninsulin-dependent 1}, 601283 (3)|CAPN10, NIDDM1|605286|2q37.3
{Diabetes mellitus, noninsulin-dependent, 2}, 125853 (3)|HNF1A, TCF1, MODY3, IDDM20|142410|12q24.31
{Diabetes mellitus, noninsulin-dependent, association with}, 125853 (3)|WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41|606201|4p16.1
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)|CDKAL1|611259|6p22.3
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)|HMGA1, HMGIY|600701|6p21.31
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)|IGF2BP2, IMP2|608289|3q27.2
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)|RETN, RSTN, FIZZ3|605565|19p13.2
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)|SLC30A8, ZNT8|611145|8q24.11
{Diabetes mellitus, noninsulin-dependent}, 125853 (2)|NIDDM3|603694|20q12-q13.1
{Diabetes mellitus, noninsulin-dependent}, 125853 (2)|NIDDM4|608036|5q34-q35.2
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|GCGR|138033|17q25.3
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|HNF4A, TCF14, MODY1|600281|20q13.12
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|IRS1|147545|2q36.3
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|IRS2|600797|13q34
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|LIPC, HL, LIPH, HDLCQ12|151670|15q21.3
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|MAPK8IP1, IB1|604641|11p11.2
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|NEUROD1, NIDDM|601724|2q31.3
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)|SLC2A4, GLUT4|138190|17p13.1
{Diabetes mellitus, noninsulin-dependent}, 135853 (3)|SLC2A2, GLUT2|138160|3q26.2
{Diabetes mellitus, transient neonatal}, 601410 (1)|PLAGL1, ZAC, LOT1|603044|6q24.2
{Diabetes mellitus, type 1, susceptibility to}, 222100 (3)|OAS1, OIAS|164350|12q24.13
{Diabetes mellitus, type 2, susceptibility to}, 125853 (3)|KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
{Diabetes mellitus, type 2, susceptibility to}, 125853 (3)|TCF7L2, TCF4|602228|10q25.2-q25.3
{Diabetes mellitus, type 2, susceptiblity to}, 125853 (3)|MTNR1B|600804|11q14.3
{Diabetes mellitus, type I, susceptibility to}, 222100 (3)|FOXP3, IPEX, AIID, XPID, PIDX|300292|Xp11.23
{Diabetes mellitus, type II, susceptibility to}, 125853 (3)|IPF1, MODY4|600733|13q12.2
{Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)|IL2RA, IL2R, IDDM10|147730|10p15.1
{Diabetes, susceptibility to}, 222100, 125853 (3)|IL6, IFNB2, BSF2, HSF, HGF|147620|7p15.3
{Diabetes, type 1, susceptibility to}, 222100 (2)|ITPR3|147267|6p21.31
{Diabetes, type 1, susceptibility to}, 222100 (3)|PTPN22, PEP, PTPN8, LYP|600716|1p13.2
{Diabetes, type 2, susceptibility to}, 125853 (3)|GPD2|138430|2q24.1
{Diabetes, type 2}, 125853 (3)|PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25.2
{Diphtheria, susceptibility to} (1)|HBEGF, DTR, DTSF, HEGFL|126150|5q31.3
{Dravet syndrome, modifier of}, 607208 (3)|SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP|603415|2q24.3
{Drug addiction, susceptibility to}, 606581 (3)|FAAH|602935|1p33
{Drug-induced liver injury due to flucloxacillin} (3)|HLA-B, SPDA1|142830|6p21.33
{Dyskeratosis congenita, autosomal dominant 2}, 613989 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Dyskeratosis congenita, autosomal recessive 4}, 613989 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Dyslexia, susceptibility to, 1}, 127700 (3)|DYX1C1, DYXC1, DYX1, CILD25|608706|15q21.3
{Dyslexia, susceptibility to, 2}, 600202 (3)|KIAA0319, DYX2, DYLX2, DLX2|609269|6p22.3
{Dyslexia, susceptibility to, 3} (2)|DYX3|604254|2p16-p15
{Dyslexia, susceptibility to, 5} (2)|DYX5|606896|3p12-q13
{Dyslexia, susceptibility to, 6} (2)|DYX6, DYXQTL18|606616|18p11.2
{Dyslexia, susceptibility to, 8} (2)|DYX8|608995|1p36-p34
{Dyslexia, susceptibility to, 9} (2)|DYX9|300509|Xq27.3
{Dystonia-1, modifier of} (3)|DYT1, TOR1A|605204|9q34.11
{Efavirenz central nervous system toxicity, susceptibility to}, 614546 (3)|CYP2B6, CYP2B, EFVM|123930|19q13.2
{Encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3)|RANBP2, NUP358, ANE1, IIAE3|601181|2q12.3
{Encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3)|CPT2, IIAE4|600650|1p32.3
{Encephalopathy, acute, infection-induced, susceptibility to, 6}, 614850 (3)|TICAM1, TRIF, IIAE6|607601|19p13.3
{End-stage renal disease, nondiabetic, susceptibility to}, 612551 (3)|APOL1, FSGS4|603743|22q12.3
{Endometriosis, susceptibility to, 1} (2)|ENDO1|131200|10q26
{Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 (3)|MMP1, CLG|120353|11q22.2
{Epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3)|CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1|601199|3q21.1
{Epilepsy, childhood absence, susceptibility to, 2}, 607681 (3)|GABRG2, GEFSP3, CAE2, ECA2|137164|5q34
{Epilepsy, childhood absence, susceptibility to, 4}, 611136 (3)|GABRA1, EJM5, ECA4|137160|5q34
{Epilepsy, childhood absence, susceptibility to, 5}, 612269 (3)|GABRB3, ECA5|137192|15q12
{Epilepsy, childhood absence, susceptibility to, 6}, 611942 (3)|CACNA1H, EIG6, ECA6|607904|16p13.3
{Epilepsy, generalized, with febrile seizures plus, type 5, susceptibility to}, 613060 (3)|GABRD, GEFSP5, EIG10, EJM7|137163|1p36.33
{Epilepsy, idiopathic generalized, 10}, 613060 (3)|GABRD, GEFSP5, EIG10, EJM7|137163|1p36.33
{Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3)|CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT|600570|3q27.1
{Epilepsy, idiopathic generalized, susceptibility to, 1} (2)|EIG1|600669|8q24
{Epilepsy, idiopathic generalized, susceptibility to, 2} (2)|EIG2|606972|14q23
{Epilepsy, idiopathic generalized, susceptibility to, 3} (2)|EIG3|608762|9q32-q33
{Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3)|CACNA1H, EIG6, ECA6|607904|16p13.3
{Epilepsy, idiopathic generalized, susceptibility to, 7} (2)|EIG7, EJM2|604827|15q14
{Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3)|CACNB4, EJM6, EA5, EIG9|601949|2q23.3
{Epilepsy, idiopathic generalized, susceptibility to}, 600669 (3)|ME2, ODS1|154270|18q21.2
{Epilepsy, idiopathic generalized, suscpetibility to, 12}, 614847 (3)|SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9|138140|1p34.2
{Epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3)|EFHC1, FLJ10466, EJM1, JAE, EJA1|608815|6p12.2
{Epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3)|CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT|600570|3q27.1
{Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3)|GABRA1, EJM5, ECA4|137160|5q34
{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3)|CACNB4, EJM6, EA5, EIG9|601949|2q23.3
{Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3)|CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT|600570|3q27.1
{Epilepsy, juvenile myoclonic, susceptibility to}, 613060 (3)|GABRD, GEFSP5, EIG10, EJM7|137163|1p36.33
{Epilepsy, juvenile myoclonic, susceptiblity to, 9} (2)|EJM9|614280|2q33-q36
{Esophageal cancer, alcohol-related, susceptibility to} (3)|ALDH2|100650|12q24.12
{Esophagitis, eosinophilic, 1} (2)|EOE1, EE|610247|7q11.2
{Esophagitis, eosinophilic, 2} (2)|EOE2|613412|5q22
{Essential tremor, susceptibility to}, 190300 (3)|DRD3, ETM1, FET1|126451|3q13.31
{Exfoliation syndrome, susceptibility to}, 177650 (3)|LOXL1, LOXL|153456|15q24.1
{Fatty liver disease, nonalcoholic, susceptibility to, 1} (2)|NAFLD1|613282|22q13
{Fatty liver disease, nonalcoholic, susceptibility to, 2} (2)|NAFLD2|613387|11q23
{Fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3)|SPINK1, PSTI, PCTT, TATI, TCP|167790|5q32
{Follicular lymphoma, susceptibility to, 1} (2)|FL1|613024|6p21.33
{Gastric cancer risk after H. pylori infection}, 137215 (3)|IL1B|147720|2q13
{Gastric cancer risk after H. pylori infection}, 137215 (3)|IL1RN, MVCD4, DIRA|147679|2q13
{Gene expression, variation in, QTL} (2)|GEVQ1|608875|14q32
{Gene expression, variation in, QTL} (2)|GEVQ2|608878|20q13
{Gilles de la Tourette syndrome, susceptibility to}, 137580 (3)|HDC|142704|15q21.2
{Glaucoma, normal tension, susceptibility to}, 606657 (3)|OPA1, NTG, NPG|605290|3q29
{Glaucoma, normal tension, susceptibility to}, 606657 (3)|OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p13
{Glioblastoma 3}, 613029 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
{Glioma susceptibility 1}, 137800 (3)|TP53, P53, LFS1 , BCC7|191170|17p13.1
{Glioma susceptibility 2}, 613028 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
{Glioma susceptibility 4} (2)|GLM4|607248|15q23-q26.3
{Glioma susceptibility 5} (2)|GLM5|613030|9p21.3
{Glioma susceptibility 6} (2)|GLM6|613031|20q13.33
{Glioma susceptibility 7} (2)|GLM7|613032|8q24.21
{Glioma susceptibility 8} (2)|GLM8|613033|5p15.33
{Glioma, susceptibility to, somatic}, 137800 (3)|IDH1|147700|2q34
{Glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3)|APOL1, FSGS4|603743|22q12.3
{Glucocorticoid therapy, response to}, 614400 (3)|GLCCI1, TSSN1, GCTR|614283|7p21.3
{Gout susceptibility 4}, 612671 (3)|SLC17A3, NPT4|611034|6p22.2
{Graft-versus-host disease, protection against}, 614395 (3)|IL10, CSIF, GVHDS|124092|1q32.1
{Graves disease, susceptibility to, 1} (2)|GRD1|275000|14q31
{Graves disease, susceptibility to, 2} (2)|GRD2|603388|20q13.11
{Graves disease, susceptibility to, 3} (3)|GC, DBP, GRD3|139200|4q13.3
{Graves disease, susceptibility to, 4} (3)|CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33.2
{Graves disease, susceptibility to, X-linked} (2)|GRDX, GD3|300351|Xp11
{H. pylori infection, susceptibility to}, 600263 (1)|PTPRZ1, PTP18|176891|7q31.32
{H. pylori infection, susceptibility to}, 600263 (3)|IFNGR1|107470|6q23.3
{HDL response to hormone replacement, augmented} (3)|ESR1, ESR, ESTRR|133430|6q25.1
{HFE hemochromatosis, modifier of}, 235200 (3)|BMP2, BMP2A, BDA2|112261|20p12.3
{HIV infection, resistance to}, 609423 (2)|CCL3, SCYA3, MIP1A|182283|17q12
{HIV infection, susceptibility/resistance to} (3)|CCR2, CMKBR2|601267|3p21.31
{HIV infection, susceptibility/resistance to} (3)|CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21.31
{HIV type 1, susceptibility to}, 609423 (3)|CD209, CDSIGN|604672|19p13.2
{HIV-1 disease, delayed progression of} (3)|CCL5, SCYA5, D17S136E, TCP228|187011|17q12
{HIV-1 disease, rapid progression of} (3)|CCL5, SCYA5, D17S136E, TCP228|187011|17q12
{HIV-1 viremia, susceptibility to}, 609423 (3)|HLA-C, PSORS1|142840|6p21.33
{HIV-1, resistance to}, 609423 (3)|CCL2, SCYA2, MCP1, MCAF|158105|17q12
{HIV-1, susceptibility to}, 609423 (3)|IL10, CSIF, GVHDS|124092|1q32.1
{HIV/AIDS, susceptibility to}, 609423 (3)|CCL3L1, SCYA3L1, LD78|601395|17q12
{HIV1 infection, resistance to}, 609423 (3)|TLR3, IIAE2|603029|4q35.1
{HIV1, resistance to}, 609423 (3)|CCL11, SCYA11|601156|17q12
{Hangover, susceptibility to}, 610251 (3)|ALDH2|100650|12q24.12
{Hemangioma, capillary infantile, susceptibility to}, 602089 (3)|ANTXR1, TEM8, ATR, GAPO|606410|2p13.3
{Hemangioma, capillary infantile, susceptibility to}, 602089 (3)|KDR|191306|4q12
{Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3)|HF1, CFH, HUS, ARMD4, AHUS1|134370|1q31.3
{Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3)|MCP, CD46, AHUS2|120920|1q32.2
{Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3)|CFI, FI, AHUS3, ARMD13|217030|4q25
{Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3)|CFB, BF, GBG, AHUS4, ARMD14, CFBD|138470|6p21.33
{Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3)|C3, ARMD9, AHUS5|120700|19p13.3
{Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3)|THBD, THRM, AHUS6, THPH12|188040|20p11.21
{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)|CFHR1, FHR1, HFL1, CFHL1|134371|1q31.3
{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)|CFHR3, FHR3, HLF4, CFHL3|605336|1q31.3
{Hemorrhage, intracerebral, susceptibility to}, 614519 (3)|COL4A1, POREN1, HANAC, ICH|120130|13q34
{Hemorrhage, intracerebral, susceptibility to}, 614519 (3)|COL4A2, POREN2, ICH|120090|13q34
{Hepatic fibrosis susceptibility due to Schistosoma mansoni infection} (2)|SM2|604201|6q22-q23
{Hepatitic C virus, susceptibility to}, 609532 (3)|PTPRC, CD45, LCA|151460|1q31.3-q32.1
{Hepatitis B virus infection, susceptibility to}, 610424 (3)|IFNGR1|107470|6q23.3
{Hepatitis B virus, susceptibility to}, 610424 (3)|CRFB4, IBD25|123889|21q22.11
{Hepatitis B virus, susceptibility to}, 610424 (3)|IFNAR2|602376|21q22.11
{Hepatitis C virus infection, response to therapy of}, 609532 (3)|IFNL3, IL28B|607402|19q13.2
{Hepatitis C virus, resistance to}, 609532 (3)|CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21.31
{Hepatitis C virus, response to therapy of}, 609532 (3)|IFNG, IFG, IFI|147570|12q15
{Herpes simplex encephalitis, susceptibility to, 2} 613002 (3)|TLR3, IIAE2|603029|4q35.1
{Herpes simplex encephalitis, susceptibility to, 3}, 614849 (3)|TRAF3, CD40BP, LAP1, CAP1, CRAF1, IIAE5|601896|14q32.32
{High density lipoprotein cholesterol, low serum, 3} (2)|HDLC3|607687|16q24.1
{Hirschsprung disease, susceptibility to, 1}, 142623 (3)|RET, MEN2A, HSCR1|164761|10q11.21
{Hirschsprung disease, susceptibility to, 2}, 600155 (3)|EDNRB, HSCR2, ABCDS, WS4A|131244|13q22.3
{Hirschsprung disease, susceptibility to, 3}, 613711 (3)|GDNF, HSCR3|600837|5p13.2
{Hirschsprung disease, susceptibility to, 4}, 613712 (3)|EDN3, WS4B, HSCR4|131242|20q13.32
{Hirschsprung disease, susceptibility to, 5} (2)|HSCR5|600156|9q31
{Hirschsprung disease, susceptibility to, 6} (2)|HSCR6|606874|3p21
{Hirschsprung disease, susceptibility to, 7} (2)|HSCR7|606875|19q12
{Hirschsprung disease, susceptibility to, 8} (2)|HSCR8|608462|16q23
{Hirschsprung disease, susceptibility to, 9} (2)|HSCR9|611644|4q31.3-q32.3
{Hodgkin disease susceptibility, pseudoautosomal} (2)|HDPA|300221|Xpter-p22.32
{Human herpesvirus 8, susceptibility to} (2)|HHV8S|614836|3p22
{Hyperapobetalipoproteinemia, susceptibility to} (3)|PPARA, PPAR|170998|22q13.31
{Hypercalciuria, absorptive, susceptibility to}, 143870 (3)|SAC, HCA2|605205|1q24.2
{Hypercholesterolemia, familial, due to LDLR defect, modifier of}, 143890 (3)|EPHX2|132811|8p21.2-p21.1
{Hypercholesterolemia, familial, modification of}, 143890 (3)|APOA2|107670|1q23.3
{Hypercholesterolemia, familial, modification of}, 143890 (3)|GHR|600946|5p13-p12
{Hypercholesterolemia, susceptibility to}, 143890 (3)|GSBS|604088|7p14.3
{Hypercholesterolemia, susceptibility to}, 143890 (3)|ITIH4, PK120, ITIHL1|600564|3p21.1
{Hyperlipidemia, familial combined, susceptibility to}, 602491 (3)|USF1, HYPLIP1|191523|1q23.3
{Hypersensitivity syndrome, carbamazepine-induced, susceptibility to}, 608579 (3)|HLA-A|142800|6p22.1
{Hypertension, diastolic, resistance to}, 608622 (3)|KCNMB1|603951|5q35.1
{Hypertension, essential, salt-sensitive}, 145500 (3)|ADD1|102680|4p16.3
{Hypertension, essential, susceptibility to, 1}, 145500 (2)|HYT1|603918|17q
{Hypertension, essential, susceptibility to, 2}, 145500 (2)|HYT2|604329|15q
{Hypertension, essential, susceptibility to, 3}, 145500 (2)|HYT3|607329|2p25-p24
{Hypertension, essential, susceptibility to, 4}, 145500 (2)|HYT4|608742|12p12.2-p12.1
{Hypertension, essential, susceptibility to, 5}, 145500 (2)|HYT5|610261|20q11-q13
{Hypertension, essential, susceptibility to, 6}, 145500 (2)|HYT6|610262|5p13-q12
{Hypertension, essential, susceptibility to, 7} (2)|HYT7|610948|3p14.1-q12.3
{Hypertension, essential, susceptibility to, 8} (2)|HYT8|611014|18q21.2
{Hypertension, essential, susceptibility to}, 145500 (3)|AGT, SERPINA8|106150|1q42.2
{Hypertension, essential, susceptibility to}, 145500 (3)|ECE1|600423|1p36.12
{Hypertension, essential, susceptibility to}, 145500 (3)|GNB3|139130|12p13.31
{Hypertension, insulin resistance-related, susceptibility to}, 125853 (3)|RETN, RSTN, FIZZ3|605565|19p13.2
{Hypertension, pregnancy-induced}, 189800 (3)|NOS3|163729|7q36.1
{Hypertension, salt-sensitive essential, susceptibility to}, 145500 (3)|CYP3A5, P450PCN3|605325|7q22.1
{Hypertension, susceptibility to}, 145500 (2)|NOS2A, NOS2|163730|17q11.2
{Hypertension, susceptibility to}, 145500 (3)|NOS3|163729|7q36.1
{Hypertriglyceridemia, susceptibility to} (2)|HTGS|145750|15q11.2-q13.1
{Hypertriglyceridemia, susceptibility to}, 145750 (3)|APOA5|606368|11q23.3
{Hypertriglyceridemia, susceptibility to}, 145750 (3)|LIPI, LPDL, PRED5|609252|21q11.2
{Hypertriglyceridemia, susceptibility to}, 145750 (3)|RP1, ORP1|603937|8q12.1
{Hypertrypsinemia, neonatal} (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Hypogonadotropic hypogonadism 15 with or without anosmia}, 614880 (3)|HS6ST1, HS6ST, HH15|604846|2q14.3
{Hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3)|SEMA3A, SEMAD, COLL1, HH16|603961|7q21.11
{Hypospadias 4, X-linked, susceptibilty to} (2)|HYSP4|300856|Xp11.22
{Hypothalamic hamartomas, somatic}, 241800 (3)|GLI3, PAPA, PAPB|165240|7p14.1
{Hypothyroidism, autoimmune}, 140300 (3)|CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33.2
{IgA nephropathy, susceptibility to, 2} (2)|IGAN2|613944|2q36
{Inflammatory bowel disease 10}, 611081 (3)|ATG16L1, APG16L, IBD10|610767|2q37.1
{Inflammatory bowel disease 11} (2)|IBD11|191390|7q22
{Inflammatory bowel disease 12} (2)|IBD12|612241|3p21.3
{Inflammatory bowel disease 13}, 612244 (3)|ABCB1, PGY1, MDR1, IBD13, CLCs|171050|7q21.12
{Inflammatory bowel disease 14}, 612245 (3)|IRF5, IBD14, SLEB10|607218|7q32.1
{Inflammatory bowel disease 15} (2)|IBD15|612255|10q21
{Inflammatory bowel disease 16} (2)|IBD16|612259|9q32
{Inflammatory bowel disease 17, protection against}, 612261 (3)|IL23R, IBD17|607562|1p31.3
{Inflammatory bowel disease 18} (2)|IBD18|612262|5p13.1
{Inflammatory bowel disease 1}, 266600 (3)|NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12.1
{Inflammatory bowel disease 20} (2)|IBD20|612288|10q23-q24
{Inflammatory bowel disease 21} (2)|IBD21|612354|18p11
{Inflammatory bowel disease 22} (2)|IBD22|612380|17q21.2
{Inflammatory bowel disease 23} (2)|IBD23|612381|1q32.1
{Inflammatory bowel disease 24} (2)|IBD24|612566|20q13
{Inflammatory bowel disease 26} (2)|IBD26|612639|12q15
{Inflammatory bowel disease 27} (2)|IBD27|612796|13q13.3
{Inflammatory bowel disease 2} (2)|IBD2|601458|12p13.2-q24.1
{Inflammatory bowel disease 3} (2)|IBD3|604519|6p21.3
{Inflammatory bowel disease 4} (2)|IBD4|606675|14q11-q12
{Inflammatory bowel disease 5} (2)|IBD5|606348|5q31
{Inflammatory bowel disease 6} (2)|IBD6|606674|19p13
{Inflammatory bowel disease 7} (2)|IBD7|605225|1p36
{Inflammatory bowel disease 8} (2)|IBD8|606668|16p
{Inflammatory bowel disease 9} (2)|IBD9|608448|3p26
{Influenza, severe, susceptibility to}, 614680 (3)|IFITM3|605579|11p15.5
{Insulin resistance, susceptibility to}, 125853 (3)|PTPN1, PTP1B|176885|20q13.13
{Intelligence QTL1} (2)|INTLQ1|603783|4p16-q34
{Intelligence QTL3} (2)|INTLQ2|610295|2q24.1-q31.1
{Intelligence QTL3} (2)|INTLQ3|610294|6p25.3-p22.3
{Intervertebral disc disease, susceptibility to}, 603932 (3)|COL9A2, EDM2, STL5|120260|1p34.2
{Intervertebral disc disease, susceptibility to}, 603932 (3)|COL9A3, EDM3, IDD|120270|20q13.33
{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3)|IL6, IFNB2, BSF2, HSF, HGF|147620|7p15.3
{Ischemic stroke, susceptibility to}, 601367 (3)|NOS3|163729|7q36.1
{Kala-azar, susceptibility to, 1} (2)|KAZA1|608207|22q12
{Kala-azar, susceptibility to, 2} (2)|KAZA2|611381|1p22
{Kala-azar, susceptibility to, 3} (2)|KAZA3|611382|6q27
{Kaposi sarcoma, susceptibility to}, 148000 (3)|IL6, IFNB2, BSF2, HSF, HGF|147620|7p15.3
{Kawasaki disease, susceptibility to}, 611775 (3)|ITPKC|606476|19q13.2
{Kuru, susceptibility to}, 245300 (3)|PRNP, PRIP, KURU, CJD|176640|20p13
{Lead poisoning, susceptibility to}, 612740 (3)|ALAD, ALADH, PBGS|125270|9q32
{Leanness, inherited} (3)|AGRP, ART, AGRT|602311|16q22.1
{Leber optic atrophy, susceptibility to} (2)|LOAS|308905|Xp11
{Legionaire disease, susceptibility to}, 608556 (3)|TLR5, TIL3, SLEB1, MELIOS|603031|1q41
{Leprosy, paucibacillary type, susceptibility to} (2)|LPRS|609888|10p13
{Leprosy, protection against}, 613223 (3)|TLR1, TIL. LPRS5|601194|4p14
{Leprosy, susceptibility to, 4}, 610988 (3)|LTA, TNFB|153440|6p21.33
{Leprosy, susceptibility to, 5}, 613223 (3)|TLR1, TIL. LPRS5|601194|4p14
{Leprosy, susceptibility to}, 246300 (3)|TLR2, TIL4|603028|4q31.3
{Leprosy, susceptibility to}, 607572 (3)|PRKN, PARK2, PDJ, LPRS2|602544|6q26
{Leprosy, susceptiblity to, 6} (2)|LPRS6|613407|13q14.11
{Leukemia, acute lymphoblastic, susceptibility to, 2} (2)|ALL2|613067|7p12.2
{Leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3)|PAX5, BSAP, ALL3|167414|9p13.2
{Leukemia, acute lymphoblastic, susceptibility to} (3)|HOXD4, HOX4B|142981|2q31.1
{Leukemia, acute lymphocytic, susceptibility to, 1} (2)|ALL1|613065|10q21
{Leukemia, acute myeloid, susceptibility to}, 601626 (3)|GATA2, DCML, MONOMAC|137295|3q21.3
{Leukemia, acute myeloid}, 601626 (3)|CHIC2, BTL|604332|4q12
{Leukemia, acute myeloid}, 601626 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Leukemia, chronic lymphocytic susceptibility to, 4} (2)|CLLS4|612558|6p25
{Leukemia, chronic lymphocytic susceptibility to, 5} (2)|CLLS5|612559|11q24.1
{Leukemia, chronic lymphocytic, susceptibility to, 1} (2)|CLLS1|609630|11q13.3
{Leukemia, chronic lymphocytic, susceptibility to, 2} (2)|CLLS2, D13S25, DBM|109543|13q14
{Leukemia, chronic lymphocytic, susceptibility to, 3} (2)|CLLS3|612557|9q34.1
{Leukemia, post-chemotherapy, susceptibility to} (3)|NQO1, DIA4, NMOR1|125860|16q22.1
{Lewy body dementia, susceptibility to}, 127750 (3)|GBA|606463|1q22
{Lipodystrophy, partial, acquired, susceptibility to}, 608709 (3)|LMNB2, LMN2|150341|19p13.3
{Long QT syndrome 1, acquired, susceptibility to}, 192500 (3)|KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5-p15.4
{Long QT syndrome 2, acquired, susceptibility to}, 613688 (3)|KCNH2, LQT2, HERG, SQT1|152427|7q36.1
{Long QT syndrome, acquired, reduced susceptibility to}, 613688 (3)|ALG10, KCR1|603313|12p11.1
{Low density lipoprotein cholesterol level QTL 1}, 603776 (3)|PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1|607786|1p32.3
{Low renin hypertension, susceptibility to} (3)|CYP11B2|124080|8q24.3
{Lumbar disc degeneration}, 603932 (3)|ASPN, PLAP1, OS3|608135|9q22.31
{Lumbar disc disease, susceptibility to}, 603932 (3)|CILP|603489|15q22.31
{Lumbar disc herniation, susceptibility to}, 603932 (3)|COL11A1, STL2|120280|1p21.1
{Lumbar disc herniation, susceptibility to}, 603932 (3)|THBS2|188061|6q27
{Lung cancer susceptibility 2}, 612052 (3)|CHRNA3, LNCR2, PAOD2|118503|15q25.1
{Lung cancer susceptibility 2}, 612052 (3)|CHRNA5, LNCR2|118505|15q25.1
{Lung cancer susceptibility 3} (2)|LNCR3|612571|5p15.33
{Lung cancer susceptibility 4} (2)|LNCR4|612593|6p21.33
{Lung cancer susceptibility 5} (2)|LNCR5|614210|3q28
{Lung cancer susceptibility} (2)|LNCR1|608935|6q23-q25
{Lung cancer, protection against, in smokers} (3)|MPO|606989|17q22
{Lung cancer, protection against}, 211980 (3)|CASP8, MCH5, ALPS2B|601763|2q33.1
{Lung cancer, resistance to}, 211980 (3)|CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
{Lung cancer, susceptibility to}, 211980 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
{Lung cancer, susceptibility to}, 211980 (3)|TNFSF6, APT1LG1, FASL, ALPS1B|134638|1q24.3
{Lupus nephritis, susceptibility to} (3)|FCGR2A, IGFR2, CD32|146790|1q23.3
{Lymphoma, follicular, somatic}, 613024 (3)|BCL10|603517|1p22.3
{Macroglobulinemia, Waldenstrom, susceptibility to, 1} (2)|WM1|153600|6p21.3
{Macroglobulinemia, Waldenstrom, susceptibility to, 2} (2)|WM2|610430|4q
{Macular degeneration, age-related, 10}, 611488 (3)|TLR4, ARMD10|603030|9q33.1
{Macular degeneration, age-related, 12}, 613784 (3)|CX3CR1, GPR13, V28|601470|3p22.2
{Macular degeneration, age-related, 13, susceptibility to}, 615439 (3)|CFI, FI, AHUS3, ARMD13|217030|4q25
{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3)|C2, ARMD14|613927|6p21.33
{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3)|CFB, BF, GBG, AHUS4, ARMD14, CFBD|138470|6p21.33
{Macular degeneration, age-related, 1}, 603075 (3)|HMCN1, FBLN6, FIBL6, ARMD1|608548|1q25.3-q31.1
{Macular degeneration, age-related, 4}, 610698 (3)|HF1, CFH, HUS, ARMD4, AHUS1|134370|1q31.3
{Macular degeneration, age-related, 7}, 610149 (3)|HTRA1, PRSS11, ARMD7, CARASIL|602194|10q26.13
{Macular degeneration, age-related, 8}, 613778 (3)|LOC387715, ARMD8|611313|10q26.13
{Macular degeneration, age-related, 9}, 611378 (3)|C3, ARMD9, AHUS5|120700|19p13.3
{Macular degeneration, age-related, neovascular type}, 610149 (3)|HTRA1, PRSS11, ARMD7, CARASIL|602194|10q26.13
{Macular degeneration, age-related, reduced risk of}, 603075 (3)|CFHR1, FHR1, HFL1, CFHL1|134371|1q31.3
{Macular degeneration, age-related, reduced risk of}, 603075 (3)|CFHR3, FHR3, HLF4, CFHL3|605336|1q31.3
{Macular degeneration, age-related, susceptibility to 5}, 613761 (3)|ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1|609413|10q11.23
{Major affective disorder 1} (2)|MAFD1, BPAD, MD1|125480|18p
{Major affective disorder 3, early onset} (2)|MAFD3, BPEO|609633|21q22.13
{Major affective disorder 5} (2)|MAFD5|611535|2q22-q24
{Major affective disorder 6} (2)|MAFD6, BPAD|611536|6q23-q24
{Major affective disorder-7, susceptibility to}, 612371 (3)|XBP1, XBP2|194355|22q12.1
{Major affective disorder-8, susceptibility to} (2)|MAFD8|612357|10q21
{Major affective disorder-9, susceptibility to} (2)|MAFD9|612372|12p13.3
{Major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)|FKBP5, FKBP51|602623|6p21.31
{Major depressive disorder, response to citalopram therapy in}, 608516 (3)|HTR2A|182135|13q14.2
{Malaria, cerebral, reduced risk of}, 611162 (3)|CD36, CHDS7, BDPLT10|173510|7q21.11
{Malaria, cerebral, susceptibility to}, 611162 (3)|CD36, CHDS7, BDPLT10|173510|7q21.11
{Malaria, cerebral, susceptibility to}, 611162 (3)|ICAM1|147840|19p13.2
{Malaria, cerebral, susceptibility to}, 611162 (3)|TNF, TNFA|191160|6p21.33
{Malaria, intensity of infection} (2)|PFBI|248310|5q31-q33
{Malaria, mild, susceptibility to}, 609148 (3)|NCR3, 1C7, NKP30, CD337, MALS|611550|6p21.33
{Malaria, protection against}, 611162 (3)|TIRAP, BACTS1|606252|11q24.2
{Malaria, resistance to}, 611162 (3)|FCGR2B, CD32|604590|1q23.3
{Malaria, resistance to}, 611162 (3)|GYPA, MN, GPA|111300|4q31.21
{Malaria, resistance to}, 611162 (3)|GYPB, SS, MNS|111740|4q31.21
{Malaria, resistance to}, 611162 (3)|GYPC, GE, GPC|110750|2q14.3
{Malaria, resistance to}, 611162 (3)|HBB|141900|11p15.4
{Malaria, resistance to}, 611162 (3)|NOS2A, NOS2|163730|17q11.2
{Malaria, severe, resistance to}, 611162 (3)|CR1, C3BR|120620|1q32.2
{Malaria, severe, susceptibility to}, 611162 (3)|FCGR2A, IGFR2, CD32|146790|1q23.3
{Malaria, susceptibility to}, 611162 (3)|CISH, BACTS2|602441|3p21.2
{Malaria, vivax, protection against}, 611162 (3)|DARC, FY, GPD, WBCQ1|613665|1q23.2
{Male germ cell tumor, somatic}, 273300, (3)|BCL10|603517|1p22.3
{Malignant hyperthermia susceptibility 1}, 145600 (3)|RYR1, MHS, CCO|180901|19q13.2
{Malignant hyperthermia susceptibility 2} (2)|MHS2|154275|17q11.2-q24
{Malignant hyperthermia susceptibility 3} (2)|MHS3|154276|7q21-q22
{Malignant hyperthermia susceptibility 4} (2)|MHS4|600467|3q13.1
{Malignant hyperthermia susceptibility 5}, 601887 (3)|CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32.1
{Malignant hyperthermia susceptibility 6} (2)|MHS6|601888|5p
{Malignant mesothelioma, susceptibility to} (2)|MMS|156240|9p
{Meconium ileus in cystic fibrosis, susceptibility to} (2)|CFM1|603855|19q13.2-q13.4
{Medulloblastoma}, 155255 (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
{Melanoma, cutaneous malignant, 1} (2)|CMM, MLM, DNS|155600|1p36
{Melanoma, cutaneous malignant, 2}, 155601 (3)|CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21.3
{Melanoma, cutaneous malignant, 3}, 609048 (3)|CDK4, CMM3|123829|12q14.1
{Melanoma, cutaneous malignant, 4} (2)|CMM4|608035|1p22
{Melanoma, cutaneous malignant, 5}, 613099 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
{Melanoma, cutaneous malignant, 6}, 613972 (3)|XRCC3, CMM6|600675|14q32.33
{Melanoma, cutaneous malignant, 7} (2)|CMM7|612263|20q11.2
{Melanoma, cutaneous malignant, 9}, 615134 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3)|TYR, SHEP3, CMM8, OCA1A, ATN|606933|11q14.3
{Melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3)|MITF, WS2A, CMM8|156845|3p14-p13
{Melanoma, uveal, susceptibility to, 1} (2)|UVM1|606660|3q24-q26
{Melanoma, uveal, susceptibility to, 2} (2)|UVM2|606661|3p25.2-p25.1
{Melioidosis, susceptibilty to}, 615557 (3)|TLR5, TIL3, SLEB1, MELIOS|603031|1q41
{Memory impairment, susceptibility to} (3)|BDNF, BULN2, ANON2|113505|11p14.1
{Menarche, age at, QTL2} (2)|MENAQ2|612882|6q21
{Menarche, age at, QTL3} (2)|MENAQ3|612883|9q31.2
{Menarche, age at, QTL} (2)|MENAQ1|610873|22q13
{Meningioma, familial, susceptibility to}, 607174 (3)|SMARCE1, BAF57|603111|17q21.2
{Meningioma, familial, susceptibility to}, 607174 (3)|SUFU, SUFUXL, SUFUH|607035|10q24.32
{Meningioma}, 607174 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
{Menopause, natural, age at, QTL1} (2)|MENOQ1|300488|Xp21.3
{Menopause, natural, age at, QTL2} (2)|MENOQ2|612884|19q13.4
{Menopause, natural, age at, QTL3} (2)|MENOQ3|612885|20p12.3
{Menopause, natural, age at, QTL4} (2)|MENOQ4|612886|5q35.2
{Mental health wellness-1} (2)|MHW1|603663|4p
{Mental health wellness-2} (2)|MHW2|603664|4q
{Mesothelioma, somatic}, 156240 (3)|BCL10|603517|1p22.3
{Metabolic syndrome, protection against}, 605552 (3)|MTP|157147|4q23
{Microvascular complications of diabetes 1}, 603933 (3)|VEGF, MVCD1|192240|6p21.1
{Microvascular complications of diabetes 2}, 612623 (3)|EPO, MVCD2|133170|7q22.1
{Microvascular complications of diabetes 3}, 612624 (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
{Microvascular complications of diabetes 4}, 612628 (3)|IL1RN, MVCD4, DIRA|147679|2q13
{Microvascular complications of diabetes 5}, 612633 (3)|PON1, PON, ESA, MVCD5|168820|7q21.3
{Microvascular complications of diabetes 6}, 612634 (3)|SOD2, MNSOD, MVCD6|147460|6q25.3
{Microvascular complications of diabetes 7}, 612635 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
{Migraine with aura, susceptibility to, 7} (2)|MGR7|609179|15q11.2-q12
{Migraine with aura, susceptibility to, 9} (2)|MGR9|609670|11q24
{Migraine with or without aura, susceptibility to, 1} (2)|MGR1, MA|157300|4q24
{Migraine with or without aura, susceptibility to, 3} (2)|MGR3|607498|6p21.1-p12.2
{Migraine with or without aura, susceptibility to, 5} (2)|MGR5|607508|19p13
{Migraine without aura, susceptibility to, 4} (2)|MGR4, MGOA|607501|14q21.2-q22.3
{Migraine without aura, susceptibility to}, 157300 (3)|TNF, TNFA|191160|6p21.33
{Migraine, familial typical, susceptibility to, 2} (2)|MGR2|300125|Xq
{Migraine, susceptibility to, 8} (2)|MGR8|609570|5q21
{Migraine, susceptibility to}, 157300 (3)|ESR1, ESR, ESTRR|133430|6q25.1
{Migraine, with or without aura, susceptibility to, 12} (2)|MGR12|611706|10q22-q23
{Migraine, with or without aura, susceptibility to, 13}, 613656 (3)|KCNK18, TRESK, TRIK, MGR13|613655|10q25.3
{Moyamoya disease 2, susceptibility to}, 607151 (3)|RNF213, ALO17, KIAA1618, MYMY2|613768|17q25.3
{Multiple myeloma, resistance to}, 254500 (3)|LIG4|601837|13q33.3
{Multiple myeloma, susceptibility to}, 254500 (3)|CCND1, PRAD1, BCL1|168461|11q13.3
{Multiple sclerosis, disease progression, modifier of}, 126200 (3)|PDCD1, SLEB2|600244|2q37.3
{Multiple sclerosis, susceptibility to, 1}, 126200 (3)|HLA-DQB1, CELIAC1|604305|6p21.32
{Multiple sclerosis, susceptibility to, 1}, 126200 (3)|HLA-DRB1, SS1|142857|6p21.32
{Multiple sclerosis, susceptibility to, 2} (2)|MS2|612594|10p15.1
{Multiple sclerosis, susceptibility to, 3} (2)|MS3|612595|5p13.2
{Multiple sclerosis, susceptibility to, 4} (2)|MS4|612596|1p36
{Multiple sclerosis, susceptibility to, 5}, 614810 (3)|TNFRSF1A, TNFR1, TNFAR, FPF, MS5|191190|12p13.31
{Multiple self-healing squamous epithelioma, susceptiblity to}, 132800 (3)|TGFBR1, ALK5, AAT5, LDS2A, LDS1A, MSSE|190181|9q22.33
{Multiple system atrophy, susceptibility to}, 146500 (3)|COQ2, COQ10D1, MSA1|609825|4q21.23
{Mycobacerium tuberculosis, susceptibility, X-linked} (2)|MTBSX|300259|Xq
{Mycobacterial and salmonella infections, susceptibility to}, 209950 (3)|IL12RB1|601604|19p13.11
{Mycobacterial infection, atypical, familial disseminated}, 209950 (3)|IFNGR2, IFNGT1, IFGR2|147569|21q22.11
{Mycobacterium tuberculosis infection, protection against}, 607948 (3)|IFNGR1|107470|6q23.3
{Mycobacterium tuberculosis, protection against}, 607948 (3)|IRGM, LRG47, IFI1, IBD19|608212|5q33.1
{Mycobacterium tuberculosis, protection against}, 607948 (3)|MC3R, BMIQ9|155540|20q13.2
{Mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3)|NRAMP1, NRAMP, SLC11A1|600266|2q35
{Mycobacterium tuberculosis, susceptibility to, 2} (2)|MTBS2|611046|8q12-q13
{Mycobacterium tuberculosis, susceptibility to, 3} (2)|MTBS3|612929|20q13.31-q13.33
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)|CCL2, SCYA2, MCP1, MCAF|158105|17q12
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)|CD209, CDSIGN|604672|19p13.2
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)|SP110, IFI41, IFI75, VODI|604457|2q37.1
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)|TLR2, TIL4|603028|4q31.3
{Myelodysplastic syndrome, susceptibility to}, 614286 (3)|GATA2, DCML, MONOMAC|137295|3q21.3
{Myocardial infarcation, susceptibility to}, 608446 (3)|PSMA6, PROS27, P27K|602855|14q13.2
{Myocardial infarction susceptibility} (3)|APOE, AD2, LPG, LDLCQ5|107741|19q13.32
{Myocardial infarction, decreased susceptibility to}, 608446 (3)|F7|613878|13q34
{Myocardial infarction, protection against}, 608446 (3)|F13A1, F13A|134570|6p25.1
{Myocardial infarction, susceptibility to, 2} (2)|MCI2|608557|13q12
{Myocardial infarction, susceptibility to} (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
{Myocardial infarction, susceptibility to}, 608446 (3)|ESR1, ESR, ESTRR|133430|6q25.1
{Myocardial infarction, susceptibility to}, 608446 (3)|GCLC, GLCLC|606857|6p12.1
{Myocardial infarction, susceptibility to}, 608446 (3)|GCLM, GLCLR|601176|1p22.1
{Myocardial infarction, susceptibility to}, 608446 (3)|ITGB3, GP3A, GT, BDPLT2, BDPLT16|173470|17q21.32
{Myocardial infarction, susceptibility to}, 608446 (3)|LGALS2|150571|22q13.1
{Myocardial infarction, susceptibility to}, 608446 (3)|LRP8, APOER2, MCI1|602600|1p32.3
{Myocardial infarction, susceptibility to}, 608446 (3)|LTA, TNFB|153440|6p21.33
{Myocardial infarction, susceptibility to}, 608446 (3)|MIAT, C22orf35|611082|22q12.1
{Myocardial infarction, susceptibility to}, 608446 (3)|OLR1, LOX1|602601|12p13.2
{Myocardial infarction, susceptibility to}, 608446 (3)|TNFSF4, GP34, OX4OL|603594|1q25.1
{Myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3)|EFHC1, FLJ10466, EJM1, JAE, EJA1|608815|6p12.2
{Narcolepsy 4} (2)|NRCLP4|612417|22q13
{Narcolepsy 5} (2)|NRCLP5|612851|14q11.2
{Nasopharyngeal carcinoma 1} (2)|NPC1, NPCA1|607107|4p15.1-q12
{Nasopharyngeal carcinoma, susceptibility to, 2} (2)|NPCA2|161550|6p21.3
{Natural teeth remaining intact} (2)|MGP, NTI|154870|12p12.3
{Nephrolithiasis, uric acid, susceptibility to}, 605990 (3)|ZNF365, UAN|607818|10q21.2
{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3)|MTR, HMAG|156570|1q43
{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3)|MTRR|602568|5p15.31
{Neural tube defects, susceptibility to}, 182940 (3)|T, TFT|601397|6q27
{Neural tube defects, susceptibility to}, 601634 (3)|MTHFR|607093|1p36.22
{Neuroblastoma, susceptibility to, 1}, 256700 (3)|KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.22
{Neuroblastoma, susceptibility to, 2}, 613013 (3)|PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p13
{Neuroblastoma, susceptibility to, 3}, 613014 (3)|ALK, NBLST3|105590|2p23.2-p23.1
{Neuroblastoma, susceptibility to, 4} (2)|NBLST4|613015|6p22
{Neuroblastoma, susceptibility to, 5} (2)|NBLST5|613016|2q35
{Neuroblastoma, susceptibility to, 6} (2)|NBLST6|613017|1q21.1
{Nevus sebaceous, somatic}, 162900 (3)|HRAS|190020|11p15.5
{Nicotine addiction, protection from}, 188890 (3)|CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
{Nicotine addiction, susceptibility to}, 188890 (3)|CHRNA4, ENFL1|118504|20q13.33
{Nicotine dependence, protection against}, 188890 (3)|GPR51, GABBR2|607340|9q22.33
{Nicotine dependence, protection against}, 188890 (3)|SLC6A3, DAT1, PKDYS|126455|5p15.33
{Nicotine dependence, susceptibility to}, 188890 (3)|GPR51, GABBR2|607340|9q22.33
{Nicotine dependence, susceptibility to}, 612052 (3)|CHRNA5, LNCR2|118505|15q25.1
{Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3)|GP1BA, BSS, BDPLT1, VWDP, BDPLT3|606672|17p13.2
{Nonsmall cell lung cancer, susceptibility to}, 211980 (3)|EGFR|131550|7p11.2
{Nonsmall cell lung cancer} (2)|DDX26, DICE1|604331|13q14.3
{Nonsmall cell lung cancer} (2)|TSG11|603040|11q23
{Norwalk virus infection, resistance to} (3)|FUT2, SE, B12QTL1|182100|19q13.33
{Obesity, association with}, 601665 (3)|SDC3, SYND3, SDCN|186357|1p35.2
{Obesity, early-onset, susceptibility to}, 601665 (3)|POMC|176830|2p23.3
{Obesity, late-onset}, 601665 (3)|AGRP, ART, AGRT|602311|16q22.1
{Obesity, severe, and type II diabetes}, 601665 (3)|UCP3|602044|11q13.4
{Obesity, severe, susceptibility to, BMIQ9}, 602025 (3)|MC3R, BMIQ9|155540|20q13.2
{Obesity, susceptibility to, BMIQ10} (2)|BMIQ10|607514|10q
{Obesity, susceptibility to, BMIQ11}, 300306 (3)|SLC6A14, OBX, BMIQ11|300444|Xq23
{Obesity, susceptibility to, BMIQ12}, 612362 (3)|PCSK1, NEC1, PC1, PC3, BMIQ12|162150|5q15
{Obesity, susceptibility to, BMIQ18}, 615457 (3)|MRAP2, C6orf117, BMIQ18|615410|6q14.2
{Obesity, susceptibility to, BMIQ4}, 607447 (3)|UCP2, BMIQ4|601693|11q13.4
{Obesity, susceptibility to, BMIQ7} (2)|BMIQ7|608410|4p15-p14
{Obesity, susceptibility to, BMIQ8} (2)|BMIQ8|603188|10p
{Obesity, susceptibility to}, 601665 (3)|ADRB2|109690|5q32
{Obesity, susceptibility to}, 601665 (3)|ADRB3|109691|8p11.23
{Obesity, susceptibility to}, 601665 (3)|CART|602606|5q13.2
{Obesity, susceptibility to}, 601665 (3)|ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED|173335|6q23.2
{Obesity, susceptibility to}, 601665 (3)|GHRL|605353|3p25.3
{Obesity, susceptibility to}, 601665 (3)|UCP1|113730|4q31.1
{Obesity, susceptibility to}, 607514 (3)|FFAR4, O3FAR1, GPR120, PGR4, BMIQ10|609044|10q23.33
{Obesity, variation in}, 601665 (3)|PPARGC1B, PGC1B, PERC|608886|5q32
{Obesity}, 601665 (3)|PYY|600781|17q21.31
{Obsessive-compulsive disorder, protection against}, 164230 (3)|BDNF, BULN2, ANON2|113505|11p14.1
{Obsessive-compulsive disorder, susceptibility to}, 164230 (3)|HTR2A|182135|13q14.2
{Obsessive-compulsive disorder}, 164230 (3)|SLC6A4, HTT, OCD1|182138|17q11.2
{Opioid dependence, susceptibility to, 1} (2)|ODS1|610064|Chr.17
{Opioid dependence, susceptibility to}, 610064 (3)|ME2, ODS1|154270|18q21.2
{Organophosphate poisoning, sensitivity to} (3)|PON1, PON, ESA, MVCD5|168820|7q21.3
{Ossification of the posterior longitudinal spinal ligaments}, 602475 (2)|COL6A1, OPLL|120220|21q22.3
{Osteoarthritis susceptibility 1}, 165720 (3)|FRZB, FRZB1, SRFP3, OS1|605083|2q32.1
{Osteoarthritis susceptibility 2}, 140600 (3)|MATN3, EDM5, HOA, OS2|602109|2p24.1
{Osteoarthritis susceptibility 3}, 607850 (3)|ASPN, PLAP1, OS3|608135|9q22.31
{Osteoarthritis susceptibility 4} (2)|OS4, GOA1|610839|2q33.3
{Osteoarthritis susceptibility 6} (2)|OS6|612401|3p24.3
{Osteoarthritis-5}, 612400 (3)|GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B|601146|20q11.22
{Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 (3)|WNT1, INT1, OI15, BMND16|164820|12q13.12
{Osteoporosis, postmenopausal, susceptibility}, 166710 (3)|CALCR, CRT|114131|7q21.3
{Osteoporosis, postmenopausal}, 166710 (3)|COL1A2|120160|7q21.3
{Osteoporosis, susceptibility to}, 166710 (3)|RIL|603422|5q31.1
{Osteoporosis}, 166710 (2)|BMND7|611738|20p12.3
{Osteoporosis}, 166710 (2)|BMND8|611739|11p12
{Osteoporosis}, 166710 (3)|COL1A1|120150|17q21.33
{Osteoporosis}, 166710 (3)|LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.2
{Otitis media, susceptibility to} (2)|OMS|166760|10q26.3
{Otosclerosis 4} (2)|OTSC4|611571|16q22.1-q23.1
{Ovarian cancer, somatic}, 167000 (3)|OPCML|600632|11q25
{Ovarian cancer, susceptibility to} (2)|OVCAS1|607893|3p25-p22
{Pancreatic cancer, susceptibility to, 1}, 606856 (3)|PALLD, KIAA0992, PNCA1|608092|4q32.3
{Pancreatic cancer, susceptibility to, 3}, 613348 (3)|PALB2, FANCN, PNCA3|610355|16p12.2
{Pancreatic cancer, susceptibility to, 4}, 614320 (3)|BRCA1, PSCP, BROVCA1, PNCA4|113705|17q21.31
{Pancreatitis, chronic, protection against}, 167800 (3)|PRSS2, TRY2|601564|7q35
{Pancreatitis, chronic, susceptibility to}, 167800 (3)|CTRC, CLCR|601405|1p36.21
{Pancreatitis, idiopathic}, 167800 (3)|CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Panic disorder, susceptibility to}, 167870 (3)|COMT|116790|22q11.21
{Parkinson disease 16} (2)|PARK16|613164|1q32
{Parkinson disease, late-onset, susceptibility to}, 168600 (3)|GBA|606463|1q22
{Parkinson disease, susceptibility to}, 168600 (3)|ADH1C, ADH3|103730|4q23
{Parkinson disease, susceptibility to}, 168600 (3)|MAPT, MTBT1, DDPAC, MSTD|157140|17q21.31
{Parkinson disease, susceptibility to}, 168600 (3)|TBP, SCA17, HDL4|600075|6q27
{Patent ductus arteriosus, susceptibility to} (2)|PDA1|607411|12q24
{Pelvic organ prolapse, susceptibility to, 1} (2)|PVOP1|176780|1q31
{Pelvic organ prolapse, susceptibility to, 2} (2)|PVOP2|613088|9q21
{Pemphigoid, susceptibility to} (2)|HLA-DRB1, SS1|142857|6p21.32
{Pheochromocytoma, modifier of}, 171300 (3)|GDNF, HSCR3|600837|5p13.2
{Pheochromocytoma, susceptibility to}, 171300 (3)|MAX|154950|14q23.3
{Pheochromocytoma, susceptibility to}, 171300 (3)|TMEM127|613403|2q11.2
{Placental abruption} (3)|NOS3|163729|7q36.1
{Plasmodium falciparum fever episodes QTL1} (2)|PFFE1|611384|10p15
{Pneumococcal disease, invasive, protection against}, 610799 (3)|TIRAP, BACTS1|606252|11q24.2
{Podoconiosis, susceptibility to} (2)|PDCOS|614590|6p21.3
{Porphyria cutanea tarda, susceptibility to}, 176100 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
{Porphyria variegata, susceptibility to}, 176200 (3)|HFE, HLA-H, HFE1, MVCD7, TFQTL2|613609|6p22.2
{Pre-B-cell acute lymphoblastic leukemia} (3)|BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q13.1
{Preeclampsia, susceptibility to} (3)|AGT, SERPINA8|106150|1q42.2
{Preeclampsia, susceptibility to}, 189800 (3)|EPHX1|132810|1q42.12
{Pregnancy loss, recurrent, susceptibility to, 1}, 614389 (3)|F5, THPH2, RPRGL1|612309|1q24.2
{Pregnancy loss, recurrent, susceptibility to, 2}, 614390 (3)|F2, THPH1, RPRGL2|176930|11p11.2
{Pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3)|ANXA5, ENX2, RPRGL3|131230|4q27
{Pregnancy loss, susceptibility to} (3)|SYCP3, SCP3, COR1, SPGF4|604759|12q23.2
{Preterm premature rupture of the membranes, susceptibility to}, 610504 (3)|SERPINH1, SERPINH2, PPROM, CBP2, CBP1, OI10|600943|11q13.5
{Prostate cancer aggressiveness QTL}, 176807 (2)|HPCQTL19|607592|19q
{Prostate cancer, familial, susceptibility to}, 176807 (3)|CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Prostate cancer, hereditary, 10} (2)|HPC10|611100|8q24
{Prostate cancer, hereditary, 11} (2)|HPC11|611955|17q12
{Prostate cancer, hereditary, 12}, 611868 (3)|EHBP1, KIAA0903, HPC12|609922|2p15
{Prostate cancer, hereditary, 13}, 611928 (3)|MSMB, HPC13|157145|10q11.23
{Prostate cancer, hereditary, 14} (2)|HPC14|611958|11q13
{Prostate cancer, hereditary, 15} (2)|HPC15|611959|19q13.4
{Prostate cancer, hereditary, 2, susceptibility to}, 614731 (3)|ELAC2, HPC2, COXPD17|605367|17p12
{Prostate cancer, hereditary, 5}, 176807 (2)|HPC5|609299|3p26
{Prostate cancer, hereditary, 7} (2)|HPC7|610321|15q12
{Prostate cancer, hereditary, 9} (2)|HPC9|610997|17q21-q22
{Prostate cancer, hereditary, X-linked 1} (2)|HPCX1|300147|Xq27-q28
{Prostate cancer, hereditary, X-linked 2} (2)|HPCX2|300704|Xp11.22
{Prostate cancer, progression of}, 176807 (1)|HIP1|601767|7q11.23
{Prostate cancer, somatic}, 176807 (3)|PTEN, MMAC1, GLM2, CWS1|601728|10q23.31
{Prostate cancer, susceptibility to, 3}, 176807 (2)|HPC3|608656|20q13
{Prostate cancer, susceptibility to, 4}, 176807 (2)|HPC4|608658|7p11-q21
{Prostate cancer, susceptibility to}, 176807 (2)|CD82, SAR2, KAI1, ST6|600623|11p11.2
{Prostate cancer, susceptibility to}, 176807 (2)|HPC6|609558|22q12.3
{Prostate cancer, susceptibility to}, 176807 (2)|PCAP|602759|1q42.2-q43
{Prostate cancer, susceptibility to}, 176807 (3)|AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq12
{Prostate cancer, susceptibility to}, 176807 (3)|CDH1, UVO, LCAM, ECAD|192090|16q22.1
{Prostate cancer, susceptibility to}, 176807 (3)|MXI1|600020|10q25.2
{Prostate cancer, susceptibility to}, 176807 (3)|ZFHX3, ATBF1|104155|16q22.2-q22.3
{Pseudofolliculitis barbae, susceptibility to}, 612318 (3)|KRT75, K6HF, PFB|609025|12q13.13
{Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3)|FCGR2A, IGFR2, CD32|146790|1q23.3
{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3)|XYLT1, XT1|608124|16p12.3
{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3)|XYLT2, XT2|608125|17q21.33
{Psoraisis susceptibility 9} (2)|PSORS9|607857|4q31-q34
{Psoriasis susceptibility 10} (3)|PSORS10|612410|18p11.23
{Psoriasis susceptibility 11} (2)|PSORS11|612599|5q31.1-q33.1
{Psoriasis susceptibility 12} (2)|PSORS12|612950|20q13
{Psoriasis susceptibility 13}, 614070 (3)|TRAF3IP2, C6orf5, ACT1, CIKS, C6orf4, C6orf6, PSORS13, CANDF8|607043|6q21
{Psoriasis susceptibility 1}, 177900 (3)|HLA-C, PSORS1|142840|6p21.33
{Psoriasis susceptibility 2}, 602723 (3)|CARD14, CARMA2, BIMP2, PSORS2, PSS1, PRP|607211|17q25.3
{Psoriasis susceptibility 3} (2)|PSORS3|601454|4q
{Psoriasis susceptibility 4} (2)|PSORS4|603935|1q21
{Psoriasis susceptibility 5} (2)|PSORS5|604316|3q21
{Psoriasis susceptibility 6} (3)|PSORS6|605364|19p13
{Psoriasis susceptibility 7} (2)|PSORS7|605606|1p
{Psoriasis susceptibility 8} (2)|PSORS8|610707|16q
{Psoriasis, protection against}, 605606 (3)|IL23R, IBD17|607562|1p31.3
{Psoriatic arthritis, susceptibility to}, 607507 (3)|LTA, TNFB|153440|6p21.33
{Psoriatic arthritis, susceptibility to}, 607507 (3)|NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12.1
{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (1)|SERPINA1, PI, AAT|107400|14q32.13
{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3)|HMOX1, HMOX1D|141250|22q12.3
{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3)|MUC5B|600770|11p15.5
{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3)|SFTPA1, SFTP1|178630|10q22.3
{Pulmonary fibrosis, idiopathic, susceptibility to}, 614743 (3)|TERC, TRC3, TR, DKCA1, PFBMFT2|602322|3q26.2
{Pulmonary fibrosis, telomere-related, 1}, 614742 (3)|TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9|187270|5p15.33
{Pulmonary function} (2)|PLF|608852|6q21-q22
{Pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to} (2)|CTEPH1|612862|6p21.3
{Pulmonary hypertension, neonatal, susceptibility to}, 615371 (3)|CPS1, PHN|608307|2q34
{Rapid progression to AIDS from HIV1 infection}, 609423 (3)|CX3CR1, GPR13, V28|601470|3p22.2
{Reduced triglycerides, susceptibility to} (3)|ANGPTL4, PGAR, HFARP, FIAF|605910|19p13.2
{Renal cell carcinoma}, 144700 (3)|HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
{Renal dysplasia, cystic, susceptibility to}, 601331 (3)|BICC1, BICC, CYSRD|614295|10q21.1
{Resistance to malaria due to G6PD deficiency}, 611162 (3)|G6PD, G6PD1|305900|Xq28
{Restless legs syndrome 1} (2)|RLS1|102300|12q12-q21
{Restless legs syndrome 2} (2)|RLS2|608831|14q13-q21
{Restless legs syndrome 3} (2)|RLS3|610438|9p24-p22
{Restless legs syndrome 4} (2)|RLS4|610439|2q33
{Restless legs syndrome 5} (2)|RLS5|611242|20p13
{Restless legs syndrome 6} (2)|RLS6|611185|6p21
{Restless legs syndrome 7} (2)|RLS7|612853|2p14-p13
{Retinal disease in Usher syndrome type IIA, modifier of}, 276901 (3)|PDZD7|612971|10q24.31
{Rheumatoid arthritis, progression of}, 180300 (3)|IL10, CSIF, GVHDS|124092|1q32.1
{Rheumatoid arthritis, susceptibility to} (2)|RA|180300|6q23
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|CD244, NAIL, NKR2B4, SLAMF4|605554|1q23.3
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|HLA-DRB1, SS1|142857|6p21.32
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|MHC2TA, C2TA|600005|16p13.13
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|NFKBIL1|601022|6p21.33
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|PADI4, PADI5, PAD|605347|1p36.13
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|PTPN22, PEP, PTPN8, LYP|600716|1p13.2
{Rheumatoid arthritis, susceptibility to}, 180300 (3)|SLC22A4, OCTN1|604190|5q31.1
{Rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)|MIF|153620|22q11.23
{Rheumatoid arthritis, systemic juvenile}, 604302 (3)|IL6, IFNB2, BSF2, HSF, HGF|147620|7p15.3
{SARS, progression of} (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
{Sarcoidosis, susceptibility to, 1}, 181000 (3)|HLA-DRB1, SS1|142857|6p21.32
{Sarcoidosis, susceptibility to, 2}, 612387 (3)|BTNL2, SS2|606000|6p21.32
{Sarcoidosis, susceptibility to, 3} (2)|SS3|612388|10q22.3
{Schistosoma mansoni infection, susceptibility/resistance to} (2)|SM1|181460|5q31-q33
{Schizoaffective disorder, susceptibility to}, 181500 (3)|DISC1, SCZD9|605210|1q42.2
{Schizophrenia 10} (2)|SCZD10|605419|15q15
{Schizophrenia 12}, 181500 (2)|SCZD12|608543|1p36.2
{Schizophrenia 15}, 613950 (3)|SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3, SCZD15|606230|22q13.33
{Schizophrenia, susceptibility to, 13} (2)|SCZD13|613025|15q13
{Schizophrenia, susceptibility to, 14} (2)|SCZD14|612361|2q32.1
{Schizophrenia, susceptibility to, 17}, 614332 (3)|NRXN1, PTHSL2, SCZD17|600565|2p16.3
{Schizophrenia, susceptibility to, 4}, 600850 (3)|PRODH, PRODH2, SCZD4|606810|22q11.21
{Schizophrenia, susceptibility to}, 181500 (2)|AKT1, CWS6|164730|14q32.33
{Schizophrenia, susceptibility to}, 181500 (3)|CHI3L1, GP39, YKL40, ASRT7|601525|1q32.1
{Schizophrenia, susceptibility to}, 181500 (3)|COMT|116790|22q11.21
{Schizophrenia, susceptibility to}, 181500 (3)|DRD3, ETM1, FET1|126451|3q13.31
{Schizophrenia, susceptibility to}, 181500 (3)|HTR2A|182135|13q14.2
{Schizophrenia, susceptibility to}, 181500 (3)|MTHFR|607093|1p36.22
{Schizophrenia, susceptibility to}, 181500 (3)|RTN4R, NOGOR|605566|22q11.21
{Schizophrenia, susceptibility to}, 181500 (3)|SYN2|600755|3p25.2
{Schizophrenia, susceptibility to}, 604906 (3)|DISC1, SCZD9|605210|1q42.2
{Schizophrenia}, 181500 (1)|APOL2|607252|22q12.3
{Schizophrenia}, 181500 (1)|APOL4|607254|22q12.3
{Schizophrenia}, 181500 (2)|DAO, DAMOX|124050|12q24.11
{Schizophrenia}, 181500 (2)|DAOA, G72|607408|13q33.2
{Schizophrenia}, 181500 (2)|DTNBP1, HPS7|607145|6p22.3
{Schizophrenia}, 181500 (2)|SCZD11|608078|10q22.3
{Schizophrenia}, 181500 (2)|SCZD1|181510|5q23-q35
{Schizophrenia}, 181500 (2)|SCZD3|600511|6p23
{Schizophrenia}, 181500 (2)|SCZD5|603175|6q13-q26
{Schizophrenia}, 181500 (2)|SCZD6|603013|8p21
{Schizophrenia}, 181500 (2)|SCZD7|603176|13q32
{Schizophrenia}, 181500 (2)|SCZD8|603206|18p
{Schwannomatosis-1, susceptibility to}, 162091 (3)|SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1|601607|22q11.23
{Schwannomatosis-2, susceptibility to}, 615670 (3)|LZTR1, SWNTS2|600574|22q11.21
{Scoliosis, idiopathic 3}, 608765 (3)|CHD7, IS3, HH5|608892|8q12.1-q12.2
{Scoliosis, idiopathic, susceptibility to, 4} (2)|IS4|612238|9q31.2-q34.2
{Seasonal affective disorder, susceptibility to}, 608516 (3)|HTR2A|182135|13q14.2
{Sepsis, susceptibility to} (3)|CASP12, CASP12P1|608633|11q22.3
{Septic shock, susceptibility to} (3)|TNF, TNFA|191160|6p21.33
{Sezary syndrome, somatic}, (3)|BCL10|603517|1p22.3
{Sick sinus syndrome 3}, 614090 (3)|MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3|160710|14q11.2
{Smoking as a quantitative trait locus 1} (2)|SQTL1|611003|10q22
{Smoking as a quantitative trait locus 2} (2)|SQTL2|611004|22q12
{Specific language impairment 4} (2)|SLI4|612514|7q35-q36
{Specific language impairment 5}, 615432 (3)|TM4SF20, SLI5|615404|2q36.3
{Speech-sound disorder} (2)|SSD|608445|3p12-q13
{Spermatogenic failure, susceptibility to} (3)|DAZL, DAZH, SPGYLA|601486|3p24.3
{Spina bifida, folate-sensitive, susceptibility to}, 601634 (3)|MTHFD, MTHFC|172460|14q23.3
{Spina bifida, susceptibility to}, 182940 (3)|CCL2, SCYA2, MCP1, MCAF|158105|17q12
{Spinal muscular atrophy, type III, modifier of}, 253400 (3)|SMN2|601627|5q13.2
{Spondyloarthropathy, susceptibility to, 1}, 106300 (3)|HLA-B, SPDA1|142830|6p21.33
{Spondyloarthropathy, susceptibility to, 2} (2)|SPDA2|183840|9q31-q34
{Spondyloarthropathy, susceptibility to, 3} (2)|SPDA3|613238|2q36.1-q36.3
{Stature QTL 10} (2)|STQTL10|612221|3q23
{Stature QTL 11} (2)|STQTL11|612223|7q21
{Stature QTL 12} (2)|STQTL12|612224|4q31
{Stature QTL 13} (2)|STQTL13|612226|4p15.3
{Stature QTL 14} (2)|STQTL14|612228|20q11.22
{Stature QTL 15} (2)|STQTL15|612578|8q21.13
{Stature QTL 16} (2)|STQTL16|612579|15q22.32
{Stature QTL 17} (2)|STQTL17|612737|7p15
{Stature QTL 18} (2)|STQTL18|612892|6p22.1
{Stature QTL 19} (2)|STQTL19|612893|6p21.31
{Stature QTL 1} (2)|STQTL1|606255|6q24-q25
{Stature QTL 20} (2)|STQTL20|612894|13q14.3
{Stature QTL 21} (2)|STQTL21|613440|2q37.1
{Stature QTL 22} (2)|STQTL22|613547|16q24
{Stature QTL 23} (2)|STQTL23|613548|1p32
{Stature QTL 24} (2)|STQTL24|613549|2p16
{Stature QTL 2} (2)|STQTL2|606256|7q31.3
{Stature QTL 3} (2)|STQTL3|606257|12p11.2-q14
{Stature QTL 4} (2)|STQTL4|606258|13q32-q33
{Stature QTL 5} (2)|STQTL5|608982|3p26
{Stature QTL 6} (2)|STQTL6|300591|Xq24-q25
{Stature QTL 7} (2)|STQTL7|609822|1p21
{Stature QTL 8} (2)|STQTL8|610114|9q22
{Stature QTL 9} (2)|STQTL9|611547|12q14.3
{Stevens-Johnson syndrome, susceptibility to}, 608579 (3)|HLA-B, SPDA1|142830|6p21.33
{Strabismus, susceptibility to, 1} (2)|STBMS1|185100|7p22.1
{Stroke, hemorrhagic}, 614519 (3)|ACE, DCP1, ACE1, MVCD3, ICH|106180|17q23.3
{Stroke, ischemic, susceptibility to}, 601367 (3)|F2, THPH1, RPRGL2|176930|11p11.2
{Stroke, ischemic, susceptibility to}, 601367 (3)|F5, THPH2, RPRGL1|612309|1q24.2
{Stroke, susceptibility to, 1}, 606799 (3)|PDE4D, DPDE3, STRK1, ACRDYS2|600129|5q11.2-q12.1
{Stroke, susceptibility to}, 601367 (3)|ALOX5AP, FLAP|603700|13q12.3
{Sublingual nitroglycerin, susceptibility to poor response to} (3)|ALDH2|100650|12q24.12
{Sudden infant death syndrome, susceptibility to}, 272120 (3)|SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p22.2
{Synovitis, chronic, susceptibility to} (3)|HLA-B, SPDA1|142830|6p21.33
{Systemic lupus erthematosus, susceptibility to, 15} (2)|SLEB15|300809|Xq28
{Systemic lupus erythematosus susceptibility to}, 152700 (3)|PTPN22, PEP, PTPN8, LYP|600716|1p13.2
{Systemic lupus erythematosus with hemolytic anemia} (2)|SLEH1|607279|11q14
{Systemic lupus erythematosus with nephritis, susceptibility to, 1} (2)|SLEN1|607965|10q22.3
{Systemic lupus erythematosus with nephritis, susceptibility to, 2} (2)|SLEN2|607966|2q34-q35
{Systemic lupus erythematosus with nephritis, susceptibility to, 3} (2)|SLEN3|607967|11p15.5
{Systemic lupus erythematosus, association with}, 152700 (3)|BANK1, FLJ20706, BANK|610292|4q24
{Systemic lupus erythematosus, resistance to}, 601744 (3)|TLR5, TIL3, SLEB1, MELIOS|603031|1q41
{Systemic lupus erythematosus, susceptibility to, 10}, 612251 (3)|IRF5, IBD14, SLEB10|607218|7q32.1
{Systemic lupus erythematosus, susceptibility to, 12} (2)|SLEB12|612254|8p23.1
{Systemic lupus erythematosus, susceptibility to, 13} (2)|SLEB13|612378|6q23
{Systemic lupus erythematosus, susceptibility to, 14} (2)|SLEB14|613145|1q21-q23
{Systemic lupus erythematosus, susceptibility to, 1}, 601744 (2)|TLR5, TIL3, SLEB1, MELIOS|603031|1q41
{Systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)|PDCD1, SLEB2|600244|2q37.3
{Systemic lupus erythematosus, susceptibility to, 3} (2)|SLEB3|605480|4p16-p15.2
{Systemic lupus erythematosus, susceptibility to, 4} (2)|SLEB4|608437|12q24
{Systemic lupus erythematosus, susceptibility to, 5} (2)|SLEB5|609903|13q32
{Systemic lupus erythematosus, susceptibility to, 7} (2)|SLEB7|610065|20p12
{Systemic lupus erythematosus, susceptibility to, 8} (2)|SLEB8|610066|20q13
{Systemic lupus erythematosus, susceptibility to, 9}, 610927 (3)|CR2, C3DR, SLEB9, CVID7|120650|1q32.2
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)|DNASE1, DNL1|125505|16p13.3
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)|FCGR2B, CD32|604590|1q23.3
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)|TREX1, AGS1, CRV, HERNS|606609|3p21.31
{Systemic lupus erythematosus, susceptitbility to, 11}, 612253 (3)|STAT4, SLEB11|600558|2q32.2-q32.3
{Systemic lupus erythematous, association with susceptibility to, 6}, 609939 (3)|ITGAM, CR3A, CD11B, MAC1A, SLEB6|120980|16p11.2
{T-cell acute lymphoblastic leukemia} (3)|MYB|189990|6q23.3
{TSC2 angiomyolipomas, renal, modifier of}, 613254 (3)|IFNG, IFG, IFI|147570|12q15
{Thromboembolism, susceptibility to}, 188050 (3)|MTHFR|607093|1p36.22
{Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 (3)|F5, THPH2, RPRGL1|612309|1q24.2
{Thyroid carcinoma, Hurthle cell}, 607464 (3)|NDUFA13, GRIM19|609435|19p13.11
{Thyroid carcinoma, follicular, somatic}, 188470 (3)|HRAS|190020|11p15.5
{Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3)|CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32.1
{Thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3)|KCNJ18, KIR2.6, TTPP2|613236|17p11.2
{Toxic epidermal necrolysis, susceptibility to}, 608579 (3)|HLA-B, SPDA1|142830|6p21.33
{Transcription of plasminogen activator inhibitor, modulator of} (3)|PAI1, PLANH1, SERPINE1|173360|7q22.1
{Tuberculosis, protection against}, 607948 (3)|IFNG, IFG, IFI|147570|12q15
{Tuberculosis, protection against}, 607948 (3)|TIRAP, BACTS1|606252|11q24.2
{Tuberculosis, susceptibility to} (2)|MTBS1|607949|2q35
{Tuberculosis, susceptibility to}, 607948 (3)|CISH, BACTS2|602441|3p21.2
{Tuberculosis, susceptibility to}, 607948 (3)|IFNGR1|107470|6q23.3
{UV-induced skin damage}, 266300 (3)|MC1R, SHEP2, CMM5|155555|16q24.3
{Unipolar depression, susceptibility to}, 608516 (3)|TPH2, NTPH, ADHD7|607478|12q21.1
{Uric acid concentration, serum, QTL 2}, 612076 (3)|SLC2A9, GLUT9, UAQTL2|606142|4p16.1
{Vascular disease, susceptibility to} (3)|MTHFR|607093|1p36.22
{Venoocclusive disease after bone marrow transplantation} (3)|CPS1, PHN|608307|2q34
{Venous thromboembolism, susceptibility to}, 188050 (3)|HABP2, PHBP, HGFAL, FSAP|603924|10q25.3
{Venous thrombosis, protection against}, 188050 (3)|F13A1, F13A|134570|6p25.1
{Venous thrombosis, susceptibility to} (3)|SERPINA10, ZPI|605271|14q32.13
{Viral infection, susceptibility to} (3)|OAS1, OIAS|164350|12q24.13
{Viral infections, recurrent} (3)|FCGR3A, CD16, IGFR3|146740|1q23.3
{Vitamin B12 plasma level QTL1}, 612542 (3)|FUT2, SE, B12QTL1|182100|19q13.33
{Vitamin B6 plasma level QTL 1} (2)|B6QTL1|612957|1p36.12
{Vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3)|NLRP1, NALP1, KIAA0926, DEFCAP, CARD7, SLEV1, VAMAS1, CIDED|606636|17p13.2
{Vitiligo-associated multiple autoimmune disease susceptiblity 6} (2)|VAMAS6|193200|6p21.3
{Warfarin sensitivity}, 122700 (3)|F9, HEMB, THPH8|300746|Xq27.1
{West nile virus, susceptibility to}, 610379 (3)|CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21.31
{Wilms tumor susceptibility-5}, 601583 (3)|POU6F2, WTSL, WT5|609062|7p14.1
{von Hippel-Lindau syndrome, modifier of}, 193300 (3)|CCND1, PRAD1, BCL1|168461|11q13.3
